

**August 2015**

**Volume 22 Number 2**

**Editor:** Kaye Wilson

email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

Telephone +64 4 460 4990

Facsimile +64 4 460 4995

Level 9, 40 Mercer Street

PO Box 10 254 Wellington

**Freephone Information Line**

**0800 66 00 50** (9am – 5pm weekdays)

**Circulation**

Published each April, August and December. Changes to the contents are published in monthly updates.

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website [www.schedule.co.nz](http://www.schedule.co.nz).

**Production**

Typeset automatically from XML and T<sub>E</sub>X.

XML version of the Schedule available from [www.pharmac.govt.nz/schedule/archive/](http://www.pharmac.govt.nz/schedule/archive/)

**Programmers**

Anrik Drenth & John Geering

email: [texschedule@pharmac.govt.nz](mailto:texschedule@pharmac.govt.nz)

©Pharmaceutical Management Agency



ISSN 1179-3686 pdf

ISSN 1172-9376 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

[creativecommons.org/licenses/by/3.0/nz/](http://creativecommons.org/licenses/by/3.0/nz/).

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

**Introducing PHARMAC** **2**

**Section A** **General Rules** **6**

**Section B**

Alimentary Tract & Metabolism	20
Blood & Blood Forming Organs	40
Cardiovascular System	49
Dermatologicals	62
Genito Urinary System	73
Hormone Preparations – Systemic	79
Infections – Agents For Systemic Use	91
Musculoskeletal System	115
Nervous System	124
Oncology Agents & Immunosuppressants	157
Respiratory System & Allergies	193
Sensory Organs	200
Various	204

**Section C** **Extemporaneous Compounds (ECPs)** **206**

**Section D** **Special Foods** **213**

**Section E**

Practitioner's Supply Orders	235
Rural Areas	239

**Section F** **Dispensing Period Exemptions** **240**

**Section G** **Safety Cap Medicines** **242**

**Section I** **National Immunisation Schedule** **245**

**Index** **252**

# Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

## PHARMAC's role:

***"Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided."***

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at <http://www.pharmac.health.nz/about>.

## Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The Schedule does not show the final cost to Government of subsidising each Community Pharmaceutical or to DHB Hospitals in purchasing each Pharmaceutical, since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for Pharmaceuticals used in DHB Hospitals, on any logistics arrangements put in place.

This book contains sections A through to G and Section I of the Pharmaceutical Schedule and lists the Pharmaceuticals funded for use in the community, including vaccines, as well as haemophilia and cancer treatments given in DHB hospitals. Section H lists the Pharmaceuticals that can be used in DHB hospitals and is a separate publication.

The Pharmaceuticals in this book are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. The listings are displayed alphabetically under each heading.

The index lists both chemical entities and product brand names.

# Explaining pharmaceutical entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the subsidy, the supplier's price and the access conditions that may apply.

## Example

ANATOMICAL HEADING			
		Subsidy (Manufacturer's Price) \$	Fully Brand or Subsidised Generic Per ✓ Manufacturer
THERAPEUTIC HEADING			
CHEMICAL			
▲ Presentation, form and strength .....	10.00	100	Brand A ✓ Brand B
Presentation - Available on a PSO .....	15.00	50	✓ Brand C
⊕ Presentation - Retail pharmacy-specialist .....	18.00	250 ml OP	✓ Brand D
a) Prescriptions must be written by a paediatrician or paediatric cardiologist; or b) on the recommendation of a paediatrician or a paediatric cardiologist			
CHEMICAL			
* Presentation, form and strength .....	26.53	100	Brand E
(35.27)			
Sole Supply ✓ Fully Subsidised			
▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.			

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Practitioner's Supply Order

Safety cap

Conditions of and restrictions on prescribing (including Special Authority where it applies)

Three months or six months, as applicable, dispensed all-at-once

Brand or manufacturer's name

Sole subsidised supply product

Fully subsidised product

Original Pack - Subsidy is rounded up to a multiple of whole packs

Quantity the Subsidy applies to

Subsidy paid on a product before mark-ups and GST

Manufacturer's Price if different from Subsidy

# Glossary

## Units of Measure

gram .....	g	microgram.....	mcg	millimole.....	mmol
kilogram.....	kg	milligram .....	mg	unit.....	u
international unit.....	iu	millilitre.....	ml		

## Abbreviations

Ampoule .....	Amp	Gelatinous .....	Gel	Solution.....	Soln
Capsule .....	Cap	Granules .....	Gran	Suppository .....	Supp
Cream.....	Crn	Infusion .....	Inf	Tablet .....	Tab
Device.....	Dev	Injection .....	Inj	Tincture.....	Tinc
Dispersible.....	Disp	Liquid .....	Liq	Trans Dermal Delivery	
Effervescent.....	Eff	Long Acting.....	LA	System.....	TTDS
Emulsion.....	Emul	Ointment .....	Oint		
Enteric Coated.....	EC	Sachet .....	Sach		

BSO Bulk Supply Order.

CBS Cost Brand Source.

ECP Extemporaneously Compounded Preparation.

OP Original Pack – subsidy is rounded up to a multiple at whole packs.

PSO Practitioner's Supply Order.

### Sole Subsidised

Supplier Only brand of this medicine subsidised.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

▲ Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner or pharmacist.

\* Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless the medicine meets the Dispensing Frequency Rule criteria.

‡ Safety cap required for oral liquid formulations, including extemporaneously compounded preparations.

✓ Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a manufacturer's surcharge.

Ⓢ29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981.

HP3 Subsidised when dispensed from a pharmacy that has a contract to dispense Special Foods.

HP4 Subsidised when dispensed from a pharmacy that has a contract to dispense from the Monitored Therapy Variation (for Clozapine Services).

## Community Pharmaceutical costs met by the Government

Most of the cost of a subsidised prescription for a Community Pharmaceutical is met by the Government through the Combined Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to pharmacies, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to pharmacies does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a ✓ in the product's Schedule listing.

## Patient costs

Everyone who is eligible for publicly funded health and disability services should in most circumstances pay only a \$5 co-payment for subsidised medicines, although co-payments can vary from \$0 to \$15. Where the price of a Pharmaceutical is higher than the subsidy, a patient may pay a manufacturer's surcharge in addition to the co-payment. A patient may also pay additional fees for services such as after-hours dispensing and special packaging.

Patients can check whether they are eligible for publicly funded health and disability services by referring to the Guide to eligibility on the Ministry of Health's website.

DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not specifically listed by a DHB as an approved provider/prescriber should be regarded as not approved.

For more information on patient co-payments or eligibility please visit <http://www.moh.govt.nz>.

## Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person.

### Subsidy

Once approved, the applicant will be provided a Special Authority number which must appear on the prescription.

The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical.

Some approvals are dependent on the availability of funding from the Combined Pharmaceutical Budget.

### Criteria

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website. For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised.

### Making a Special Authority application

Application forms can be found at <http://www.pharmac.govt.nz>. Except where stated on the application form, applications are processed by the Ministry of Health, and are sent to:

Ministry of Health Sector Services, Fax: (06) 349 1983 or free fax 0800 100 131  
Private Bag 3015, WANGANUI 4540

To register for submission of applications on-line - Contact the Ministry of Health on 0800 505 125 or email at [onlinehelpdesk@moh.govt.nz](mailto:onlinehelpdesk@moh.govt.nz). For Special Authority approval numbers, applicants can phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666.

## Named Patient Pharmaceutical Assessment policy

Named Patient Pharmaceutical Assessment (NPPA) provides a mechanism for individual patients to receive funding for medicines not listed in the Pharmaceutical Schedule (either at all or for their clinical circumstances). PHARMAC will assess applications that meet the prerequisites according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions.

For more information on NPPA, or to apply, visit the PHARMAC website at

<http://www.pharmac.health.nz/link/nppa>, or call the Panel Coordinators at 0800 660 050 Option 2.

### INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 August 2015 and is to be referred to as the Pharmaceutical Schedule Volume 22 Number 2, 2015. Distribution will be from 20 August 2015. This Schedule comes into force on 1 August 2015.

### PART I INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

**"90 Day Lot"**, means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

**"180 Day Lot"**, means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

**"Access Exemption Criteria"**, means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

- a) have limited physical mobility;
- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.

**"Act"**, means the New Zealand Public Health and Disability Act 2000.

**"Advisory Committee"**, means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

**"Alternate Subsidy"**, means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

**"Annotation"**, means written annotation of a prescription by a dispensing pharmacist in the pharmacist's own handwriting following confirmation from the Prescriber if required, and "Annotated" has a corresponding meaning. The Annotation must include the details specified in the Schedule, including the date the prescriber was contacted (if applicable) and be initialised by the dispensing pharmacist.

**"Authority to Substitute"**, means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

**"Bulk Supply Order"**, means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be

required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

**“Class B Controlled Drug”**, means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975.

**“Community Pharmaceutical”**, means a Pharmaceutical listed in Sections A to G and Section I of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

**“Contractor”**, means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

**“Controlled Drug”**, means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

**“Cost, Brand, Source of Supply”**, means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor’s annotated purchase price, brand, and source of supply. Alternatively a copy of the invoice for the purchase of the Pharmaceutical may be attached to the prescription, in the place of an annotation, in order to be eligible for Subsidy.

**“Dentist”**, means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

**“Diabetes Nurse Prescriber”**, means a nurse who is a Designated Prescriber—Registered Nurses Practising in Diabetes Health as determined by the Nursing Council of New Zealand to practice in diabetes health and has authority to prescribe specified diabetes medicines in accordance with regulations made under the Medicines Act 1981.

**“Dietitian”**, means a person registered as a dietitian with the Dietitians Board, and who holds a current annual practicing certificate under the HPCA Act 2003.

**“DHB”**, means an organisation established as a District Health Board by or under Section 19 of the Act.

**“DHB Hospital”**, means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

**“Dispensing Frequency Rule”**, means the rule in Part IV, Section A of the Pharmaceutical Schedule that defines patient groups or medicines eligible for more frequent dispensing periods.

**“Doctor”**, means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

**“DV Limit”**, means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

**“DV Pharmaceutical”**, means a discretionary variance Pharmaceutical, that does not have HSS and which:

- a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or
- b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

**“Endorsements”**, - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as “certified condition”, or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes “certified condition” as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

**“Funder”**, means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

**“GST”**, means goods and services tax under the Goods and Services Tax Act 1985.

**“Hospital Care Operator”**, means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

**“Hospital Pharmaceuticals”**, means the list of pharmaceuticals set out in Section H part II of the Schedule which includes some National Contract Pharmaceuticals.

**“Hospital Pharmacy”**, means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to a person on the Prescription of a Practitioner.

**“Hospital Pharmacy-Specialist”**, means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either:

- a) on a Prescription signed by a Specialist, or
- b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either:
  - i) endorsed with the words "recommended by [name of specialist and year of authorisation]" and signed by the Practitioner, or
  - ii) endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol",
  - iii) annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and date of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as either:

- i) follows a substantive consultation with an appropriate Specialist;
  - ii) the consultation to relate to the Patient for whom the Prescription is written;
  - iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
  - iv) except in emergencies consultation to precede annotation of the Prescription; and
  - v) both the specialist and the General Practitioner must keep a written record of the consultation; or
- a) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital.

**"Hospital Pharmacy-Specialist Prescription"**, means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

**"HSS"**, means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

**"In Combination"**, means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

**"Individual DV Limit"**, means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

**"Licensed Hospital"**, means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

**"Lot"**, means a quantity of a Community Pharmaceutical supplied in one dispensing.

**"Manufacturer's Price"**, means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

**"Maternity hospital"**, means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

**"Midwife"**, means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

**"Month"**, means a period of 30 consecutive days.

**"Monthly Lot"**, means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 30 consecutive days' treatment;

**"Named Patient Pharmaceutical Assessment Advisory Panel"**, means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising, within its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and Exceptional Circumstances renewal applications submitted after 1 March 2012 (EC renewal application form located at <http://www.pharmac.govt.nz/healthpros/EC/ECForms>)

**"National Contract Pharmaceutical"**, means a Hospital Pharmaceutical for which PHARMAC has negotiated a



national contract and the Price.

**“National DV Limit”**, means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

**“National Immunisation Schedule”**, means Section I of the Pharmaceutical Schedule, which is a schedule administered by PHARMAC, being a schedule specifying a programme of vaccinations to promote immunity against the diseases specified in the schedule.

**“Not In Combination”**, means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

**“Nurse Prescriber”**, means a person who is a nurse practitioner in terms of the Medicines Act 1981, or a Diabetes Nurse Prescriber

**“Optional Pharmaceuticals”**, means the list of National Contract Pharmaceuticals set out in Section H Part II of the Schedule

**“Optometrist”**, means a person registered with the Optometrists and Dispensing Opticians Board with a scope of practice that includes prescribing medicines (TPA endorsement)

**“Outpatient”**, in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person's home.

**“PCT”**, means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

**“PCT only”**, means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.

**“Penal Institution”**, means a penal institution, as that term is defined in The Penal Institutions Act 1954;

**“PHARMAC”**, means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC).

**“Pharmaceutical”**, means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

**“Pharmaceutical Benefits”**, means the right of:

- a) a person; and
- b) any member under 16 years of age of that person's family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

**“Pharmaceutical Budget”**, means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

**“Pharmaceutical Cancer Treatment”**, means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must provide access to, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

**“Pharmacist Prescriber”**, means a person registered with the Pharmacy Council of New Zealand, who holds a current annual practising certificate under the HPCA Act 2003, and is approved by the Pharmacy Council of New Zealand to prescribe specified prescription medicines relating to his/her scope of practice.

**“Pharmacist”**, means a person registered with the Pharmacy Council of New Zealand and who holds a current annual practicing certificate under the HPCA Act 2003.

**“Practitioner”**, means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber, an Optometrist, a Quitcard Provider, or a Pharmacist Prescriber as those terms are defined in the Pharmaceutical Schedule.

**“Practitioner's Supply Order”**, means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

**“Prescription”**, means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

**“Prescription Medicine”**, means any Pharmaceutical listed in Part I of Schedule 1 of the Medicines Regulations

1984.

**“Private Hospital”**, means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

**“Quitcard Provider”**, means a person registered with the Ministry of Health as a Quitcard Provider.

**“Residential Disability Care Institution”**, means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

**“Rest Home”**, means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

**“Restricted Medicine”**, means any Pharmaceutical listed in Part II of Schedule 1 of the Medicines Regulations 1984.

**“Retail Pharmacy-Specialist”**, means that the Community Pharmaceutical is only eligible for Subsidy if it is either:

- a) supplied on a Prescription or Practitioner's Supply Order signed by a Specialist, or
- b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner's Supply Order and either:
  - i) endorsed with the words “recommended by [name of Specialist and year of authorisation]” and signed by the Practitioner, or
  - ii) endorsed with the word ‘protocol’ which means “initiated in accordance with DHB hospital approved protocol”, or
  - iii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words “recommended by [name of specialist and year of authorisation], confirmed by [practitioner]”. Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

“As recommended by a Specialist” to be interpreted as either:

- a)
  - i) follows a substantive consultation with an appropriate Specialist;
  - ii) the consultation to relate to the Patient for whom the Prescription is written;
  - iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
  - iv) except in emergencies consultation to precede annotation of the Prescription; and
  - v) both the Specialist and the General Practitioner must keep a written record of consultation; or
- b) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

**“Retail Pharmacy-Specialist Prescription”**, means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner's Supply Order, signed by a Specialist.

For the purposes of this definition, a “specialist” means a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

**“Safety Medicine”**, means a Community Pharmaceutical defined in Section A, Part IV of the Pharmaceutical Schedule.

**“Schedule”**, means this Pharmaceutical Schedule and all its sections and appendices.

**“Special Authority”**, means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

**“Specialist”**, in relation to a Prescription, means a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below:

- a) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; or
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that prescription in the course of practising in that area of competency; or
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of competency; or
- d) the doctor writes the prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

**“Subsidy”**, means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

**“Supply Order”**, means a Bulk Supply Order or a Practitioner’s Supply Order.

**“Unapproved Indication”**, means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 5.5.

**“Unlisted Pharmaceutical”**, means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical but is not listed in Section H part II

**“Unusual Clinical Circumstances (UCC)”**, means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule.

**“Urgent Assessment (UA)”**, means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient’s clinical circumstances justify urgent assessment, prior to a decision on Schedule listing.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
  - a) the singular includes the plural; and
  - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

## PART II COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G and I of the Schedule subject to:
  - 2.1.1 clauses 2.2 of the Schedule; and
  - 2.1.2 clauses 3.1 to 5.4 of the Schedule; and
  - 2.1.3 the conditions (if any) specified in Sections B to G and I of the Schedule;
- 2.2 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless the Community Pharmaceuticals so supplied:
  - 2.2.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or
  - 2.2.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
  - 2.2.3 in the absence of the standards prescribed in clauses 2.2.1 and 2.2.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
  - 2.2.4 in the absence of the standards prescribed in clauses 2.2.1, 2.2.2 and 2.2.3 are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

## PART III PERIOD AND QUANTITY OF SUPPLY

- 3.1 **Doctors’, Dentists’, Dietitians’, Midwives’, Nurse Prescribers’, Optometrists and Pharmacist Prescribers’ Prescriptions (other than oral contraceptives)**

## SECTION A: GENERAL RULES

The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dentist, Dietitian, Midwife, Nurse Prescriber, an Optometrist, or a Pharmacist Prescriber unless specifically excluded:

- 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity sufficient to provide treatment for a period not exceeding three Months will be subsidised.
- 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate (except for Dentist prescriptions), only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
- 3.1.3 For a Class B Controlled Drug:
  - a) other than Dentist prescriptions and methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity:
    - i) sufficient to provide treatment for a period not exceeding 10 days; and
    - ii) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
  - b) for a Dentist prescription only such quantity as is necessary to provide treatment for a period not exceeding five days will be subsidised.
- 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dentist, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:
  - A) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
  - B) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
    - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
    - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
      - a) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
      - b) both:
        - 1) the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
        - 2) every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
- 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
  - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
  - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
- 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
  - a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
  - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.
- 3.1.7 If a Community Pharmaceutical:
  - a) is stable for a limited period only, and the Practitioner has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that may be dispensed at any one time; or
  - b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
  - c) is under the Dispensing Frequency Rule,

The actual quantity dispensed will be subsidised in accordance with any such specification.

### 3.2 Oral Contraceptives

The following provisions apply to all Prescriptions written by a Doctor, Midwife, Nurse Prescriber or a Pharmacist Prescriber for an oral contraceptive:

- 3.2.1 The prescribing Doctor, Midwife, Nurse Prescriber or a Pharmacist Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed six Months.
- 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:
  - a) in Lots as specified in the Prescription if the Community Pharmaceutical is under the Dispensing Frequency Rule; or
  - b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.
- 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.
- 3.2.4 Where a Community Pharmaceutical on a Prescription is under the Dispensing Frequency Rule and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.

### 3.3 Original Packs, Certain Antibiotics and Unapproved Medicines

- 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference:
  - a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
  - b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
- 3.3.2 If a Community Pharmaceutical is either:
  - a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or
  - b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981, but excluding any medicine listed as Cost, Brand, Source of Supply, or
  - c) any other pharmaceutical that PHARMAC determines, from time to time and notes in the Pharmaceutical Schedule

and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:

- a) the difference between the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and
- b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

### 3.4 Pharmacist Prescribers' Prescriptions

The following apply to every prescription written by a Pharmacist Prescriber

- 3.4.1 Prescriptions written by a Pharmacist Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
  - a) a Community Pharmaceutical classified as a Prescription Medicine and which a Pharmacist Prescriber is permitted under regulations to prescribe; or

- b) any other Community Pharmaceutical that is a Restricted Medicine (Pharmacist Only Medicine), a Pharmacy Only Medicine or a General Sales Medicine.
  - 3.4.2 Any Pharmacist Prescribers' prescriptions for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).
  - 3.5 **Dietitians' Prescriptions**

The following provisions apply to every Prescription written by a Dietitian:

  - 3.5.1 Prescriptions written by a Dietitian for a Community Pharmaceutical will only be subsidised where they are for either:
    - a) special foods, as listed in Section D; or
    - b) any other Pharmaceutical that has been identified in Section D of the Pharmaceutical Schedule as being able to be prescribed by a Dietitian, providing that the products being prescribed are not classified as Prescription Medicines or Restricted Medicines.
  - 3.5.2 For the purposes of Dietitians prescribing pursuant to this clause 3.5, the prescribing and dispensing of these products is required to be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.
- 3.6 **Diabetes Nurse Prescribers' Prescriptions**

The following provisions apply to every Prescription written by a Diabetes Nurse Prescriber:

- 3.6.1 Prescriptions written by a Diabetes Nurse Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
  - a) a Community Pharmaceutical classified as a Prescription Medicine or a Restricted Medicine and which a Diabetes Nurse Prescribers is permitted under regulations to prescribe; or
  - b) any other Community Pharmaceutical listed below:  
aspirin, blood glucose diagnostic test meter, blood glucose diagnostic test strip, blood ketone diagnostic test meter, glucagon hydrochloride inj 1 mg syringe kit, insulin pen needles, insulin syringes disposable with attached needle, insulin pump accessories, insulin pump infusion set, insulin pump reservoir, ketone blood beta-ketone electrodes test strip, nicotine, sodium nitroprusside test strip,
- 3.6.2 Any Diabetes Nurse Prescribers' prescription for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).
- 3.7 **Quitcard Providers' Prescriptions**

Prescriptions written by a Quitcard Provider will only be subsidised where they are:

  - a) for any of the following Community Pharmaceuticals: nicotine patches, nicotine lozenges or nicotine gum; and
  - b) written on a Quitcard.

## **PART IV**

### **DISPENSING FREQUENCY RULE**

Rule 3.1.4 of the Pharmaceutical Schedule specifies, for community patients, a default period of supply for each Community Pharmaceutical (a Monthly Lot, 90 Day Lot or for oral contraceptives 180 Day Lot). This Dispensing Frequency Rule defines patient groups or medicines eligible for more frequent dispensing periods for Community Pharmaceuticals; and the conditions that must be met to enable any pharmacy to claim for payment of handling fees for the additional dispensings made. This Dispensing Frequency Rule relates to the circumstances in which a subsidy is payable for the Community Pharmaceutical; it does not override alternative dispensing frequencies as expressly stated in the Medicines Act, Medicines Regulations, Pharmacy Services Agreement or Pharmaceutical Schedule.

For the purposes of this Dispensing Frequency Rule:

"Frequent Dispensing" means:

- i) for a Community Pharmaceutical referred to in Section F Part I, (the Stat exemption) dispensing in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot); or
- ii) for any other Community Pharmaceutical dispensing in quantities less than a Monthly Lot

"Safety Medicine"

- i) an antidepressant listed under the "Cyclic and Related Agents" subheading;
- ii) an antipsychotic;

- iii) a benzodiazepine;
- iv) a Class B Controlled Drug;
- v) codeine (includes combination products);
- vi) buprenorphine with naloxone; or
- vii) zopiclone.

The Dispensing Frequency Rule covers 5 different circumstances where Frequent Dispensing for patients may be clinically or otherwise appropriate. These are:

- 1) Long Term Condition (LTC) patients and Core patients, or
- 2) Persons in residential care, or
- 3) Trial periods, or
- 4) Safety and co-prescribed medicines, or
- 5) Pharmaceutical Supply Management.

#### 4.1 Frequent Dispensing for patients registered as Long Term Condition (LTC) or Core patients

If a Pharmacist considers Frequent Dispensing is required, then:

- 4.1.1 For LTC registered patients, Frequent Dispensing can occur as often as the dispensing Pharmacist deems appropriate to meet that patient's compliance and adherence needs;
- 4.1.2 For Core (non-LTC) patients, Frequent Dispensing should be no more often than a Monthly Lot. Pharmacists may authorise monthly dispensing on a Stat exemption Community Pharmaceutical without prescriber authority. If the Pharmacist considers more frequent (than monthly) dispensing is necessary, prescriber approval is required. Verbal approval from the prescriber is acceptable provided it is annotated by the Pharmacist on the Prescription and dated.

#### 4.2 Frequent Dispensings for persons in residential care

4.2.1 Community Pharmaceuticals can be dispensed to:

- any person whose placement in a Residential Disability Care Institution is funded by the Ministry of Health or a DHB; or
- a person assessed as requiring long term residential care services and residing in an age related residential care facility;

on the request of the person, their agent or caregiver or community residential service provider via Frequent Dispensing, provided the following conditions are met:

- a) the quantity or period of supply to be dispensed at any one time is not less than:
  - i) 7 days' supply for a Class B Controlled Drug; or
  - ii) 7 days' supply for clozapine in accordance with a Clozapine Dispensing Protocol; or
  - iii) 28 days' supply for any other Community Pharmaceutical (except under conditions outlined in 4.3 (Trial periods) below); and
- b) the prescribing Practitioner or dispensing Pharmacist has
  - i) included the name of the patient's residential placement or facility on the Prescription; and
  - ii) included the patient's NHI number on the Prescription; and
  - iii) specified the maximum quantity or period of supply to be dispensed at any one time.

4.2.2 Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changed is able to have their medicine dispensed in accordance with 4.3 (Trial periods) below.

#### 4.3 Frequent Dispensings for Trial Periods

Frequent Dispensing can occur when a Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient's first changed Prescription only) and the prescribing Practitioner has:

- endorsed each Community Pharmaceutical on the Prescription clearly with the words "Trial Period", or "Trial"; and
- specified the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time.

Patients who reside in Penal Institutions are not eligible for Trial Periods.

**4.4 Frequent Dispensing for Safety and co-prescribed medicines**

4.4.1 For a Safety Medicine to be dispensed via Frequent Dispensing, both of the following conditions must be met:

- a) The patient is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.2 on the previous page; and
- b) The prescribing Practitioner has:
  - i) Assessed clinical risk and determined the patient requires increased Frequent Dispensing; and
  - ii) Specified the maximum quantity or period of supply to be dispensed for each Safety Medicine at each dispensing.

4.4.2 A Community Pharmaceutical that is co-prescribed with a Safety Medicine, which can be dispensed in accordance with rule 4.4.1 above, may be dispensed at the same frequency as the Safety Medicine if the dispensing pharmacist has:

- Assessed clinical risk and determined the patient requires Frequent Dispensing of their co-dispensed medicines; and
- Annotated the Prescription with the amended dispensing quantity and frequency.

**4.5 Frequent Dispensing for Pharmaceutical Supply Management**

4.5.1 Frequent Dispensing may be required from time to time to manage stock supply issues or emergency situations. Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met:

- a) PHARMAC has approved and notified pharmacists to annotate Prescriptions for a specified Community Pharmaceutical(s) "out of stock" without prescriber endorsement for a specified time; and
- b) the dispensing pharmacist has:
  - i) clearly annotated each of the approved Community Pharmaceuticals that appear on the Prescription with the words "out of stock" or "OOS"; and
  - ii) initialled the annotation in their own handwriting; and
  - iii) has complied with maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

Note – no claim shall be made to any DHB for subsidised dispensing under this rule where dispensing occurs more frequently than specified by PHARMAC to manage the supply management issue.

**PART V****MISCELLANEOUS PROVISIONS****5.1 Bulk Supply Orders**

The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:

- 5.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
- 5.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
- 5.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
- 5.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 and:
  - a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
  - b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
- 5.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.
- 5.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders



with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.

## 5.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

- 5.2.1 Subject to clause 5.2.3 and 5.2.6, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.
- 5.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:
  - a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.
  - b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)
- 5.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:
  - a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which:
    - i) is personally signed and dated by the Practitioner; and
    - ii) sets out the Practitioner's address; and
    - iii) sets out the Community Pharmaceuticals and quantities; and;
  - b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.
- 5.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.
- 5.2.6 A Practitioner working in the Rheumatic Fever Prevention Programme (RFPP) may order under a Practitioner's Supply Order such Community Pharmaceuticals (identified below) as he or she requires to ensure medical supplies are available for patients with suspected or confirmed Group A Streptococcal throat infections for the purposes of the RFPP in the following circumstances:
  - a) the RFPP provider name is written on the Practitioner's Supply Order; and
  - b) the total quantity ordered does not exceed a multiple of:
    - i) ten times the Practitioner's Supply Order current maximum listed in Section E Part I for amoxicillin grans for oral liq 250 mg per 5 ml, amoxicillin cap 250 mg and amoxicillin cap 500 mg; or
    - ii) two times the Practitioner's Supply Order current maximum listed in Section E Part I for phenoxymethyl penicillin grans for oral liquid 250 mg per 5 ml, phenoxymethyl penicillin cap 500 mg, erythromycin ethyl succinate grans for oral liq 200 mg per 5 ml and erythromycin ethyl succinate tab 400 mg; and
  - c) the practitioner must specify the order quantity in course-specific amounts on the Practitioner's Supply Order (e.g. 10 x 300 ml amoxicillin grans for oral liq 250 mg per 5 ml). This will enable the pharmacy to dispense each course separately and claim multiple service fees as per the Community Pharmacy Services Agreement.

## 5.3 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

### 5.3.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

### 5.3.2 **Expiry**

The recommendation expires at the end of two years and can be renewed by a further consultation.

5.3.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 5.3.1 and 5.3.2, for the individual Patient.

5.3.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.

5.3.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the Ministry of Health's routine auditing procedures.

## 5.4 **Pharmaceutical Cancer Treatments**

5.4.1 DHBs must provide access to Pharmaceutical Cancer Treatments for the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.

5.4.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:

- a) has Named Patient Pharmaceutical Assessment (NPPA) approval;
- b) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
- c) is being used and funded as part of a paediatric oncology service; or
- d) was being used to treat the patient in question prior to 1 July 2005.

5.4.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatments with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:

- a) Part 1;
- b) clauses 2.1 to 2.2;
- c) clauses 3.1 to 3.4; and
- d) clause 5.4,

of Section A of the Schedule

5.4.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.

5.4.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 decision by the Minister of Health as to pharmaceuticals and indications for which DHBs must provide access. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.

5.4.6 Applications to add pharmaceuticals, and add or amend indications for Pharmaceutical Cancer Treatments, may be made in writing by pharmaceutical suppliers and/or clinicians to PHARMAC. Applications should follow the Guidelines for Funding Applications to PHARMAC 2010 and Recommended methods to derive clinical inputs for proposals to PHARMAC, copies of which are available from PHARMAC or PHARMAC's website.

## 5.5 **Practitioners prescribing unapproved Pharmaceuticals**

Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

- a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under

- the Medicines Act 1981 or for an Unapproved Indication; or
- b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;

Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

#### 5.6 **Substitution**

Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, unless either or both of the following circumstances apply:

- a) there is a clinical reason why substitution should not occur; or
- b) the prescriber has marked the prescription with a statement such as 'no brand substitution permitted'

Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and sign the prescription and inform the patient of the brand change.

#### 5.7 **Alteration to Presentation of Pharmaceutical Dispensed**

A Contractor, when dispensing a subsidised Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed to another subsidised presentation but may not alter the dose, frequency and/or total daily dose. This may only occur when it is not practicable for the contractor to dispense the requested presentation. If the change will result in additional cost to the DHBs, then annotation of the prescription by the dispensing pharmacist must occur stating the reason for the change, and the Contractor must initial the change for the purposes of Audit.

#### 5.8 **Other DHB Funding**

A DHB may fund a Community Pharmaceutical outside of the mechanisms established in the Pharmaceutical Schedule, provided that:

- a) specific prior agreement is obtained from PHARMAC for such funding;
- b) any funding restrictions set out in the Pharmaceutical Schedule for those Community Pharmaceuticals are applied; and
- c) a Contractor (including a DHB Hospital Pharmacy) may not claim a Subsidy for a Community Pharmaceutical dispensed and funded by the DHB via such an alternate mechanism.

#### 5.9 **Conflict in Provisions**

If any rules in Sections B-G and Section I of this Schedule conflict with the rules in Section A, the rules in Sections B-G and Section I apply.

## SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Antacids and Antiflatulants</b>				
<b>Antacids and Reflux Barrier Agents</b>				
<b>ALGINIC ACID</b>				
Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet .....	4.50	30	✓	Gaviscon Infant
<b>SIMETHICONE</b>				
* Oral liq aluminium hydroxide 200 mg with magnesium hydrox- ide 200 mg and activated simethicone 20 mg per 5 ml .....	1.50 (4.26)	500 ml		Mylanta P
<b>SODIUM ALGINATE</b>				
* Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour .....	1.80 (8.60)	60		Gaviscon Double Strength
* Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml .....	1.50 (4.95)	500 ml		Acidex
<b>Phosphate Binding Agents</b>				
<b>ALUMINIUM HYDROXIDE</b>				
* Tab 600 mg .....	12.56	100	✓	Alu-Tab
<b>CALCIUM CARBONATE</b>				
Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement .....	39.00	500 ml	✓	Roxane
Only when prescribed for children under 12 years of age for use as a phosphate binding agent and the prescription is endorsed accordingly.				
<b>Antidiarrhoeals</b>				
<b>Agents Which Reduce Motility</b>				
<b>LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a PSO</b>				
* Tab 2 mg .....	8.95	400	✓	Nodia
* Cap 2 mg .....	7.84	400	✓	Diamide Relief
<b>Rectal and Colonic Anti-inflammatories</b>				
<b>BUDESONIDE</b>				
Cap 3 mg – Special Authority see SA1155 below – Retail pharmacy .....	166.50	90	✓	Entocort CIR
<b>►SA1155 Special Authority for Subsidy</b> <b>Initial application — (Crohn's disease)</b> from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: <ol style="list-style-type: none"> <li>1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and</li> <li>2 Any of the following:</li> </ol>				
				continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 2.1 Diabetes; or
- 2.2 Cushingoid habitus; or
- 2.3 Osteoporosis where there is significant risk of fracture; or
- 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
- 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
- 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

**Initial application — (collagenous and lymphocytic colitis (microscopic colitis))** from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

**Initial application — (gut Graft versus Host disease)** from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation\*.

Note: Indication marked with \* is an Unapproved Indication.

**Renewal** from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

#### HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications) .....	26.55	21.1 g OP	✓ Colifoam
Colifoam to be Sole Supply on 1 November 2015			

#### MESALAZINE

Tab 400 mg .....	49.50	100	✓ Asacol
Tab EC 500 mg .....	49.50	100	✓ Asamax
Tab long-acting 500 mg .....	59.05	100	✓ Pentasa
Modified release granules, 1 g .....	141.72	120 OP	✓ Pentasa
Enema 1 g per 100 ml .....	41.30	7	✓ Pentasa
Pentasa to be Sole Supply on 1 October 2015			
Suppos 500 mg .....	22.80	20	✓ Asacol
Suppos 1 g .....	54.60	30	✓ Pentasa

#### OLSALAZINE

Tab 500 mg .....	59.86	100	✓ Dipentum
Cap 250 mg .....	31.51	100	✓ Dipentum

#### SODIUM CROMOGLYCATE

Cap 100 mg .....	89.21	100	✓ Nalcrom
------------------	-------	-----	-----------

#### SULPHASALAZINE

* Tab 500 mg – For sulphasalazine oral liquid formulation refer, page 207 .....	11.68	100	✓ Salazopyrin
* Tab EC 500 mg .....	12.89	100	✓ Salazopyrin EN

## Local preparations for Anal and Rectal Disorders

### Antihæmorrhoidal Preparations

#### FLUCORTOLONE CAPROATE WITH FLUCORTOLONE PIVALATE AND CINCHOCAINE

Oint 950 mcg, with flucortolone pivalate 920 mcg, and cin- chocaine hydrochloride 5 mg per g .....	6.35	30 g OP	✓ Ultraproct
Suppos 630 mcg, with flucortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg .....	2.66	12	✓ Ultraproct

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time  
if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>HYDROCORTISONE WITH CINCHOCAINE</b>				
Oint 5 mg with cinchocaine hydrochloride 5 mg per g .....	15.00	30 g OP	✓	<b>Proctosedyl</b>
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g .....	9.90	12	✓	<b>Proctosedyl</b>

## Management of Anal Fissures

GLYCERYL TRINITRATE – Special Authority see SA1329 below – Retail pharmacy

\* Oint 0.2% ..... 22.00 30 g OP ✓ **Rectogesic**

### ►SA1329 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has a chronic anal fissure that has persisted for longer than three weeks.

## Antispasmodics and Other Agents Altering Gut Motility

GLYCOPYRRONIUM BROMIDE

Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available on  
a PSO ..... 28.56 10 ✓ **Max Health**

HYOSCINE N-BUTYLBROMIDE

\* Tab 10 mg ..... 2.18 20 ✓ **Gastrosoothe**  
\* Inj 20 mg, 1 ml – Up to 5 inj available on a PSO ..... 9.57 5 ✓ **Buscopan**

MEBEVERINE HYDROCHLORIDE

\* Tab 135 mg ..... 18.00 90 ✓ **Colofac**

## Antiulcerants

### Antisecretory and Cytoprotective

MISOPROSTOL

\* Tab 200 mcg ..... 56.92 120 ✓ **Cytotec**

### Helicobacter Pylori Eradication

CLARITHROMYCIN

Tab 500 mg – Subsidy by endorsement ..... 10.40 14 ✓ **Apo-Clarithromycin**  
a) Maximum of 14 tab per prescription  
b) Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly.

Note: the prescription is considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxicillin or metronidazole.

### H2 Antagonists

CIMETIDINE – Only on a prescription

\* Tab 200 mg ..... 5.00 100  
(7.50) Apo-Cimetidine  
\* Tab 400 mg ..... 10.00 100  
(12.00) Apo-Cimetidine

(Apo-Cimetidine Tab 200 mg to be delisted 1 February 2016)

(Apo-Cimetidine Tab 400 mg to be delisted 1 February 2016)

RANITIDINE – Only on a prescription

\* Tab 150 mg ..... 10.30 500 ✓ **Ranitidine Relief**  
\* Tab 300 mg ..... 14.73 500 ✓ **Ranitidine Relief**  
\* Oral liq 150 mg per 10 ml ..... 4.92 300 ml ✓ **Peptisoothe**  
\* Inj 25 mg per ml, 2 ml ..... 8.75 5 ✓ **Zantac**

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Proton Pump Inhibitors

### LANSOPRAZOLE

* Cap 15 mg	2.00	28	✓ Solox
* Cap 30 mg	2.32	28	✓ Solox

### OMEPRAZOLE

For omeprazole suspension refer Standard Formulae, page 210

* Cap 10 mg	2.23	90	✓ Omezol Relief
* Cap 20 mg	2.91	90	✓ Omezol Relief
* Cap 40 mg	4.42	90	✓ Omezol Relief
* Powder – Only in combination	42.50	5 g	✓ Midwest
Only in extemporaneously compounded omeprazole suspension.			
* Inj 40 mg	28.65	5	✓ Dr Reddy's Omeprazole

### PANTOPRAZOLE

* Tab EC 20 mg	2.68	100	✓ Pantoprazole Actavis 20
* Tab EC 40 mg	3.54	100	✓ Pantoprazole Actavis 40

## Site Protective Agents

### BISMUTH TRIOXIDE

Tab 120 mg	32.50	112	✓ De Nol <sup>S29</sup>
------------	-------	-----	-------------------------

### SUCRALFATE

Tab 1 g	35.50 (48.28)	120	Carafate
---------	------------------	-----	----------

## Bile and Liver Therapy

RIFAXIMIN – Special Authority see SA1461 below – Retail pharmacy

Tab 550 mg	625.00	56	✓ Xifaxan
------------	--------	----	-----------

### ▶SA1461 Special Authority for Subsidy

**Initial application** only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid for 6 months where the patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

**Renewal** only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

## Diabetes

## Hyperglycaemic Agents

DIAZOXIDE – Special Authority see SA1320 on the next page – Retail pharmacy

Cap 25 mg	110.00	100	✓ Proglycem <sup>S29</sup>
Cap 100 mg	280.00	100	✓ Proglycem <sup>S29</sup>
Oral liq 50 mg per ml	620.00	30 ml OP	✓ Proglycem <sup>S29</sup>

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>►SA1320 Special Authority for Subsidy</b> <b>Initial application</b> from any relevant practitioner. Approvals valid for 12 months where used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism. <b>Renewal</b> from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.				
<b>GLUCAGON HYDROCHLORIDE</b>				
Inj 1 mg syringe kit – Up to 5 kit available on a PSO.....	32.00	1	✓	Glucagen Hypokit
<b>Insulin - Short-acting Preparations</b>				
<b>INSULIN NEUTRAL</b>				
▲ Inj human 100 u per ml .....	25.26	10 ml OP	✓	Actrapid
			✓	Humulin R
▲ Inj human 100 u per ml, 3 ml .....	42.66	5	✓	Actrapid Penfill
			✓	Humulin R
<b>Insulin - Intermediate-acting Preparations</b>				
<b>INSULIN ASPART WITH INSULIN ASPART PROTAMINE</b>				
▲ Inj 100 iu per ml, 3 ml prefilled pen .....	52.15	5	✓	NovoMix 30 FlexPen
<b>INSULIN ISOPHANE</b>				
▲ Inj human 100 u per ml .....	17.68	10 ml OP	✓	Humulin NPH
			✓	Protaphane
▲ Inj human 100 u per ml, 3 ml .....	29.86	5	✓	Humulin NPH
			✓	Protaphane Penfill
<b>INSULIN ISOPHANE WITH INSULIN NEUTRAL</b>				
▲ Inj human with neutral insulin 100 u per ml .....	25.26	10 ml OP	✓	Humulin 30/70
			✓	Mixtard 30
▲ Inj human with neutral insulin 100 u per ml, 3 ml .....	42.66	5	✓	Humulin 30/70
			✓	PenMix 30
			✓	PenMix 40
			✓	PenMix 50
<b>INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE</b>				
▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml .....	42.66	5	✓	Humalog Mix 25
▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml .....	42.66	5	✓	Humalog Mix 50
<b>Insulin - Long-acting Preparations</b>				
<b>INSULIN GLARGINE</b>				
▲ Inj 100 u per ml, 10 ml .....	63.00	1	✓	Lantus
▲ Inj 100 u per ml, 3 ml .....	94.50	5	✓	Lantus
▲ Inj 100 u per ml, 3 ml disposable pen .....	94.50	5	✓	Lantus SoloStar
<b>Insulin - Rapid Acting Preparations</b>				
<b>INSULIN ASPART</b>				
▲ Inj 100 u per ml, 3 ml syringe .....	51.19	5	✓	NovoRapid FlexPen
▲ Inj 100 u per ml, 3 ml .....	51.19	5	✓	NovoRapid Penfill
▲ Inj 100 u per ml, 10 ml .....	30.03	1	✓	NovoRapid



	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>INSULIN GLULISINE</b>				
▲ Inj 100 u per ml, 10 ml .....	27.03	1	✓	<b>Apidra</b>
▲ Inj 100 u per ml, 3 ml .....	46.07	5	✓	<b>Apidra</b>
▲ Inj 100 u per ml, 3 ml disposable pen .....	46.07	5	✓	<b>Apidra SoloStar</b>
<b>INSULIN LISPRO</b>				
▲ Inj 100 u per ml, 10 ml .....	34.92	10 ml OP	✓	<b>Humalog</b>
▲ Inj 100 u per ml, 3 ml .....	59.52	5	✓	<b>Humalog</b>
<b>Alpha Glucosidase Inhibitors</b>				
<b>ACARBOSE</b>				
* Tab 50 mg .....	4.28	90	✓	<b>Glucobay</b>
	9.82		✓	<b>Accarb</b>
* Tab 100 mg .....	7.78	90	✓	<b>Glucobay</b>
	15.83		✓	<b>Accarb</b>
<b>Oral Hypoglycaemic Agents</b>				
<b>GLIBENCLAMIDE</b>				
* Tab 5 mg .....	5.00	100	✓	<b>Daonil</b>
<b>GLICLAZIDE</b>				
* Tab 80 mg .....	11.50	500	✓	<b>Glizide</b>
<b>GLIPIZIDE</b>				
* Tab 5 mg .....	2.85	100	✓	<b>Minidiab</b>
Minidiab to be Sole Supply on 1 October 2015				
<b>METFORMIN HYDROCHLORIDE</b>				
* Tab immediate-release 500 mg .....	12.30	1,000	✓	<b>Apotex</b>
* Tab immediate-release 850 mg .....	10.10	500	✓	<b>Apotex</b>
<b>PIOGLITAZONE</b>				
* Tab 15 mg .....	1.50	28	✓	<b>Pizaccord</b>
* Tab 30 mg .....	2.50	28	✓	<b>Pizaccord</b>
* Tab 45 mg .....	3.50	28	✓	<b>Pizaccord</b>
<b>Diabetes Management</b>				
<b>Ketone Testing</b>				
<b>BLOOD KETONE DIAGNOSTIC TEST METER – Up to 1 meter available on a PSO</b>				
Meter funded for the purposes of blood ketone diagnostics only. Patient has had one or more episodes of ketoacidosis and is at risk of future episodes or patient is on an insulin pump. Only one meter per patient will be subsidised every 5 years.				
Meter .....	40.00	1	✓	<b>Freestyle Optium</b>
<b>KETONE BLOOD BETA-KETONE ELECTRODES</b>				
a) Maximum of 20 strip per prescription				
b) Up to 10 strip available on a PSO				
Test strip – Not on a BSO .....	15.50	10 strip OP	✓	<b>Freestyle Optium Ketone</b>
<b>SODIUM NITROPRUSSIDE – Maximum of 50 strip per prescription</b>				
* Test strip – Not on a BSO .....	6.00	50 strip OP	✓	<b>Accu-Chek Ketur-Test</b>
	14.14		✓	<b>Ketostix</b>

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## Blood Glucose Testing

### BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement

- Maximum of 1 pack per prescription
- Up to 1 pack available on a PSO
- A diagnostic blood glucose test meter is subsidised for a patient who:
  - is receiving insulin or sulphonylurea therapy; or
  - is pregnant with diabetes; or
  - is on home TPN at risk of hypoglycaemia or hyperglycaemia; or
  - has a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome.

Only one CareSens meter per patient. No further prescriptions will be subsidised for patients who already have a CareSens meter. For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a CareSens meter. The prescription must be endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylureas.

Meter with 50 lancets, a lancing device and 10 diagnostic test

strips .....	20.00	1 OP	✓ CareSens II ✓ CareSens N ✓ CareSens N POP
--------------	-------	------	---

Note: Only 1 meter available per PSO

### BLOOD GLUCOSE DIAGNOSTIC TEST STRIP – Up to 50 test available on a PSO

The number of test strips available on a prescription is restricted to 50 unless:

- Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
- Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
- Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
- Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Blood glucose test strips – Note differing brand requirements

below .....	10.56	50 test OP	✓ CareSens ✓ CareSens N ✓ Accu-Chek Performa ✓ Freestyle Optium
	28.75		

a) Accu-Chek Performa brand: Special Authority see SA1294 below – Retail pharmacy

b) Freestyle Optium brand: Special Authority see SA1291 below – Retail pharmacy

c) Note: Accu-Chek Performa and Freestyle Optium are not available on a PSO

#### ►SA1294 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> and can be sent to:

PHARMAC

PO Box 10 254

Wellington

Facsimile: (04) 974 4788

Email: [bgstrips@pharmac.govt.nz](mailto:bgstrips@pharmac.govt.nz)

#### ►SA1291 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> and can be sent to:

PHARMAC

PO Box 10 254

Wellington

Facsimile: (04) 974 4788

Email: [bgstrips@pharmac.govt.nz](mailto:bgstrips@pharmac.govt.nz)

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

**BLOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)**

The number of test strips available on a prescription is restricted to 50 unless:

- 1) Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
- 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
- 4) Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
- 5) Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Blood glucose test strips .....26.20      50 test OP      ✓ **SensoCard**

**Insulin Syringes and Needles**

Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or when prescribed for an insulin patient and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin.

**INSULIN PEN NEEDLES – Maximum of 100 dev per prescription**

* 29 g × 12.7 mm .....	3.15	30	✓ <b>B-D Micro-Fine</b>
	10.50	100	✓ <b>B-D Micro-Fine</b>
* 31 g × 5 mm .....	11.75	100	✓ <b>B-D Micro-Fine</b>
* 31 g × 6 mm .....	10.50	100	✓ <b>ABM</b>
* 31 g × 8 mm .....	3.15	30	✓ <b>B-D Micro-Fine</b>
	10.50	100	✓ <b>B-D Micro-Fine</b>
			✓ <b>ABM</b>
* 32 g × 4 mm .....	10.50	100	✓ <b>B-D Micro-Fine</b>

(ABM 31 g × 8 mm to be delisted 1 September 2015)

**INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription**

* Syringe 0.3 ml with 29 g × 12.7 mm needle .....	1.30	10	
	(1.99)		B-D Ultra Fine
	13.00	100	✓ <b>B-D Ultra Fine</b>
* Syringe 0.3 ml with 31 g × 8 mm needle .....	1.30	10	
	(1.99)		B-D Ultra Fine II
	13.00	100	✓ <b>B-D Ultra Fine II</b>
* Syringe 0.5 ml with 29 g × 12.7 mm needle .....	1.30	10	
	(1.99)		B-D Ultra Fine
	13.00	100	✓ <b>B-D Ultra Fine</b>
* Syringe 0.5 ml with 31 g × 8 mm needle .....	1.30	10	
	(1.99)		B-D Ultra Fine II
	13.00	100	✓ <b>B-D Ultra Fine II</b>
* Syringe 1 ml with 29 g × 12.7 mm needle .....	13.00	100	✓ <b>ABM</b>
	1.30	10	
	(1.99)		B-D Ultra Fine
	13.00	100	✓ <b>B-D Ultra Fine</b>
* Syringe 1 ml with 31 g × 8 mm needle .....	13.00	100	✓ <b>ABM</b>
	1.30	10	
	(1.99)		B-D Ultra Fine II
	13.00	100	✓ <b>B-D Ultra Fine II</b>

(ABM Syringe 1 ml with 29 g × 12.7 mm needle to be delisted 1 September 2015)

(ABM Syringe 1 ml with 31 g × 8 mm needle to be delisted 1 September 2015)

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Insulin Pumps

INSULIN PUMP – Special Authority see SA1237 below – Retail pharmacy

a) Maximum of 1 dev per prescription			
b) Only on a prescription			
c) Maximum of 1 insulin pump per patient each four year period.			
Min basal rate 0.025 U/h; black colour .....	4,500.00	1	✓ Animas Vibe
Min basal rate 0.025 U/h; blue colour .....	4,500.00	1	✓ Animas Vibe
Min basal rate 0.025 U/h; green colour .....	4,500.00	1	✓ Animas Vibe
Min basal rate 0.025 U/h; pink colour .....	4,500.00	1	✓ Animas Vibe
Min basal rate 0.025 U/h; silver colour .....	4,500.00	1	✓ Animas Vibe
Min basal rate 0.05 U/h; blue colour .....	4,400.00	1	✓ Paradigm 522
			✓ Paradigm 722
Min basal rate 0.05 U/h; clear colour .....	4,400.00	1	✓ Paradigm 522
			✓ Paradigm 722
Min basal rate 0.05 U/h; pink colour .....	4,400.00	1	✓ Paradigm 522
			✓ Paradigm 722
Min basal rate 0.05 U/h; purple colour .....	4,400.00	1	✓ Paradigm 522
			✓ Paradigm 722
Min basal rate 0.05 U/h; smoke colour .....	4,400.00	1	✓ Paradigm 522
			✓ Paradigm 722

### ►SA1237 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The IPP Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 974 7806
PO Box 10 254	Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a>
Wellington	

## Insulin Pump Consumables

### ►SA1240 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The IPP Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 974 7806
PO Box 10 254	Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a>
Wellington	

INSULIN PUMP ACCESSORIES – Special Authority see SA1240 above – Retail pharmacy

a) Maximum of 1 cap per prescription			
b) Only on a prescription			
c) Maximum of 1 prescription per 180 days.			
Battery cap .....	32.00	1	✓ Animas Battery Cap

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## INSULIN PUMP INFUSION SET (STEEL CANNULA) – Special Authority see SA1240 on the previous page – Retail pharmacy

a) Maximum of 3 sets per prescription

b) Only on a prescription

c) Maximum of 13 infusion sets will be funded per year.

10 mm steel needle; 29 G; manual insertion; 60 cm tubing ×

10 with 10 needles .....	130.00	1 OP	✓ <b>Paradigm Sure-T MMT-884</b>
--------------------------	--------	------	--------------------------------------

10 mm steel needle; 29 G; manual insertion; 60 cm tubing ×

10 with 10 needles; luer lock .....	130.00	1 OP	✓ <b>Sure-T MMT-883</b>
-------------------------------------	--------	------	-------------------------

10 mm steel needle; 29 G; manual insertion; 80 cm tubing ×

10 with 10 needles .....	130.00	1 OP	✓ <b>Paradigm Sure-T MMT-886</b>
--------------------------	--------	------	--------------------------------------

10 mm steel needle; 29 G; manual insertion; 80 cm tubing ×

10 with 10 needles; luer lock .....	130.00	1 OP	✓ <b>Sure-T MMT-885</b>
-------------------------------------	--------	------	-------------------------

6 mm steel cannula; straight insertion; 60 cm grey line × 10

with 10 needles .....	130.00	1 OP	✓ <b>Contact-D</b>
-----------------------	--------	------	--------------------

6 mm steel needle; 29 G; manual insertion; 60 cm tubing ×

10 with 10 needles .....	130.00	1 OP	✓ <b>Paradigm Sure-T MMT-864</b>
--------------------------	--------	------	--------------------------------------

6 mm steel needle; 29 G; manual insertion; 60 cm tubing ×

10 with 10 needles; luer lock .....	130.00	1 OP	✓ <b>Sure-T MMT-863</b>
-------------------------------------	--------	------	-------------------------

6 mm steel needle; 29 G; manual insertion; 80 cm tubing ×

10 with 10 needles .....	130.00	1 OP	✓ <b>Paradigm Sure-T MMT-866</b>
--------------------------	--------	------	--------------------------------------

6 mm steel needle; 29 G; manual insertion; 80 cm tubing ×

10 with 10 needles; luer lock .....	130.00	1 OP	✓ <b>Sure-T MMT-865</b>
-------------------------------------	--------	------	-------------------------

8 mm steel cannula; straight insertion; 110 cm grey line × 10

with 10 needles .....	130.00	1 OP	✓ <b>Contact-D</b>
-----------------------	--------	------	--------------------

8 mm steel cannula; straight insertion; 60 cm grey line × 10

with 10 needles .....	130.00	1 OP	✓ <b>Contact-D</b>
-----------------------	--------	------	--------------------

8 mm steel needle; 29 G; manual insertion; 60 cm tubing ×

10 with 10 needles .....	130.00	1 OP	✓ <b>Paradigm Sure-T MMT-874</b>
--------------------------	--------	------	--------------------------------------

8 mm steel needle; 29 G; manual insertion; 60 cm tubing ×

10 with 10 needles; luer lock .....	130.00	1 OP	✓ <b>Sure-T MMT-873</b>
-------------------------------------	--------	------	-------------------------

8 mm steel needle; 29 G; manual insertion; 80 cm tubing ×

10 with 10 needles .....	130.00	1 OP	✓ <b>Paradigm Sure-T MMT-876</b>
--------------------------	--------	------	--------------------------------------

8 mm steel needle; 29 G; manual insertion; 80 cm tubing ×

10 with 10 needles; luer lock .....	130.00	1 OP	✓ <b>Sure-T MMT-875</b>
-------------------------------------	--------	------	-------------------------

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE INSERTION WITH INSERTION DEVICE) – Special Authority see SA1240 on page 28 – Retail pharmacy			
a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
13 mm teflon cannula; angle insertion; insertion device; 110 cm grey line × 10 with 10 needles .....	140.00	1 OP	✓ Inset 30
13 mm teflon cannula; angle insertion; insertion device; 60 cm blue line × 10 with 10 needles .....	140.00	1 OP	✓ Inset 30
13 mm teflon cannula; angle insertion; insertion device; 60 cm grey line × 10 with 10 needles .....	140.00	1 OP	✓ Inset 30
13 mm teflon cannula; angle insertion; insertion device; 60 cm pink line × 10 with 10 needles .....	140.00	1 OP	✓ Inset 30
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE INSERTION) – Special Authority see SA1240 on page 28 – Retail pharmacy			
a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
13 mm teflon cannula; angel insertion; 60 cm grey line × 5 with 10 needles .....	120.00	1 OP	✓ Comfort Short
13 mm teflon cannula; angle insertion; 120 cm line × 10 with 10 needles .....	130.00	1 OP	✓ Paradigm Silhouette MMT-382
13 mm teflon cannula; angle insertion; 45 cm line × 10 with 10 needles .....	130.00	1 OP	✓ Paradigm Silhouette MMT-368
13 mm teflon cannula; angle insertion; 60 cm line × 10 with 10 needles .....	130.00	1 OP	✓ Paradigm Silhouette MMT-381
13 mm teflon cannula; angle insertion; 80 cm line × 10 with 10 needles .....	130.00	1 OP	✓ Paradigm Silhouette MMT-383
17 mm teflon cannula; angle insertion; 110 cm grey line × 5 with 10 needles .....	120.00	1 OP	✓ Comfort
17 mm teflon cannula; angle insertion; 110 cm line × 10 with 10 needles .....	130.00	1 OP	✓ Paradigm Silhouette MMT-377
17 mm teflon cannula; angle insertion; 110 cm line × 10 with 10 needles; luer lock .....	130.00	1 OP	✓ Silhouette MMT-371
17 mm teflon cannula; angle insertion; 60 cm grey line × 5 with 10 needles .....	120.00	1 OP	✓ Comfort
17 mm teflon cannula; angle insertion; 60 cm line × 10 with 10 needles .....	130.00	1 OP	✓ Paradigm Silhouette MMT-378
17 mm teflon cannula; angle insertion; 60 cm line × 10 with 10 needles; luer lock .....	130.00	1 OP	✓ Silhouette MMT-373
17 mm teflon cannula; angle insertion; 80 cm line × 10 with 10 needles .....	130.00	1 OP	✓ Paradigm Silhouette MMT-384

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION WITH INSERTION DEVICE) – Special Authority  
see SA1240 on page 28 – Retail pharmacy

a) Maximum of 3 sets per prescription

b) Only on a prescription

c) Maximum of 13 infusion sets will be funded per year.

6 mm teflon cannula; straight insertion; insertion device; 110

cm grey line × 10 with 10 needles ..... 140.00 1 OP ✓ Inset II

6 mm teflon cannula; straight insertion; insertion device; 45

cm blue tubing × 10 with 10 needles ..... 130.00 1 OP ✓ Paradigm Mio  
MMT-941

6 mm teflon cannula; straight insertion; insertion device; 45

cm pink tubing × 10 with 10 needles ..... 130.00 1 OP ✓ Paradigm Mio  
MMT-921

6 mm teflon cannula; straight insertion; insertion device; 60

cm blue tubing × 10 with 10 needles ..... 130.00 1 OP ✓ Paradigm Mio  
MMT-943

6 mm teflon cannula; straight insertion; insertion device; 60

cm pink tubing × 10 with 10 needles ..... 130.00 1 OP ✓ Paradigm Mio  
MMT-923

6 mm teflon cannula; straight insertion; insertion device; 80

cm blue tubing × 10 with 10 needles ..... 130.00 1 OP ✓ Paradigm Mio  
MMT-945

6 mm teflon cannula; straight insertion; insertion device; 80

cm clear tubing × 10 with 10 needles ..... 130.00 1 OP ✓ Paradigm Mio  
MMT-965

6 mm teflon cannula; straight insertion; insertion device; 80

cm pink tubing × 10 with 10 needles ..... 130.00 1 OP ✓ Paradigm Mio  
MMT-925

6 mm teflon cannula; straight insertion; insertion device; 60

cm blue line × 10 with 10 needles ..... 140.00 1 OP ✓ Inset II

6 mm teflon cannula; straight insertion; insertion device; 60

cm grey line × 10 with 10 needles ..... 140.00 1 OP ✓ Inset II

6 mm teflon cannula; straight insertion; insertion device; 60

cm pink line × 10 with 10 needles ..... 140.00 1 OP ✓ Inset II

9 mm teflon cannula; straight insertion; insertion device; 60

cm blue line × 10 with 10 needles ..... 140.00 1 OP ✓ Inset II

9 mm teflon cannula; straight insertion; insertion device; 60

cm grey line × 10 with 10 needles ..... 140.00 1 OP ✓ Inset II

9 mm teflon cannula; straight insertion; insertion device; 60

cm pink line × 10 with 10 needles ..... 140.00 1 OP ✓ Inset II

9 mm teflon cannula; straight insertion; insertion device; 80

cm clear tubing × 10 with 10 needles ..... 130.00 1 OP ✓ Paradigm Mio  
MMT-975

9 mm teflon cannula; straight insertion; insertion device; 110

cm grey line × 10 with 10 needles ..... 140.00 1 OP ✓ Inset II

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION) – Special Authority see SA1240 on page 28 –</b>				
Retail pharmacy				
a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
6 mm teflon cannula; straight insertion; 110 cm tubing × 10 with 10 needles .....	130.00	1 OP	✓	Paradigm Quick-Set MMT-398
6 mm teflon cannula; straight insertion; 110 cm tubing × 10 with 10 needles; luer lock .....	130.00	1 OP	✓	Quick-Set MMT-391
6 mm teflon cannula; straight insertion; 60 cm tubing × 10 with 10 needles .....	130.00	1 OP	✓	Paradigm Quick-Set MMT-399
6 mm teflon cannula; straight insertion; 60 cm tubing × 10 with 10 needles; luer lock .....	130.00	1 OP	✓	Quick-Set MMT-393
6 mm teflon cannula; straight insertion; 80 cm tubing × 10 with 10 needles .....	130.00	1 OP	✓	Paradigm Quick-Set MMT-387
9 mm teflon cannula; straight insertion; 106 cm tubing × 10 with 10 needles .....	130.00	1 OP	✓	Paradigm Quick-Set MMT-396
9 mm teflon cannula; straight insertion; 110 cm tubing × 10 with 10 needles; luer lock .....	130.00	1 OP	✓	Quick-Set MMT-390
9 mm teflon cannula; straight insertion; 60 cm tubing × 10 with 10 needles .....	130.00	1 OP	✓	Paradigm Quick-Set MMT-397
9 mm teflon cannula; straight insertion; 60 cm tubing × 10 with 10 needles; luer lock .....	130.00	1 OP	✓	Quick-Set MMT-392
9 mm teflon cannula; straight insertion; 80 cm tubing × 10 with 10 needles .....	130.00	1 OP	✓	Paradigm Quick-Set MMT-386
<b>INSULIN PUMP RESERVOIR – Special Authority see SA1240 on page 28 – Retail pharmacy</b>				
a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 packs of reservoir sets will be funded per year.				
10 × luer lock conversion cartridges 1.8 ml for Paradigm pumps .....	50.00	1 OP	✓	ADR Cartridge 1.8
10 × luer lock conversion cartridges 3.0 ml for Paradigm pumps .....	50.00	1 OP	✓	ADR Cartridge 3.0
Cartridge 200 U, luer lock × 10 .....	50.00	1 OP	✓	Animas Cartridge
Cartridge for 5 and 7 series pump; 1.8 ml × 10 .....	50.00	1 OP	✓	Paradigm 1.8 Reservoir
Cartridge for 7 series pump; 3.0 ml × 10 .....	50.00	1 OP	✓	Paradigm 3.0 Reservoir
Syringe and cartridge for 50X pump, 3.0 ml × 10 .....	50.00	1 OP	✓	50X 3.0 Reservoir



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Digestives Including Enzymes

### PANCREATIC ENZYME

Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease .....	34.93	100	✓ Creon 10000
Creon 10000 to be Sole Supply on 1 November 2015			
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease .....	94.38	100	✓ Creon 25000
Creon 25000 to be Sole Supply on 1 November 2015			
Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease .....	94.40	100	✓ Panzytrat

### URSODEOXYCHOLIC ACID – Special Authority see SA1383 below – Retail pharmacy

Cap 250 mg – For ursodeoxycholic acid oral liquid formula- tion refer, page 207.....	53.40	100	✓ <u>Ursosan</u>
---	-------	-----	------------------

#### ►SA1383 Special Authority for Subsidy

**Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis)** from any relevant practitioner.

Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

**Initial application — (Chronic severe drug induced cholestatic liver injury)** from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

**Initial application — (Cirrhosis)** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

**Initial application — (Pregnancy)** from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

**Initial application — (Haematological Transplant)** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

**Initial application — (Total parenteral nutrition induced cholestasis)** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
- 2 Liver function has not improved with modifying the TPN composition.

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

**Renewal — (Chronic severe drug induced cholestatic liver injury)** from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.

**Renewal — (Pregnancy/Cirrhosis)** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**Renewal — (Total parenteral nutrition induced cholestasis)** from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 100 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

## Laxatives

### Bulk-forming Agents

ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription

* Powder for oral soln .....	5.51	500 g OP	✓ <u>Konsyl-D</u>
------------------------------	------	----------	-------------------

MUCILAGINOUS LAXATIVES WITH STIMULANTS

* Dry .....	2.41	200 g OP	
	(8.72)		Normacol Plus
	6.02	500 g OP	
	(17.32)		Normacol Plus

### Faecal Softeners

DOCUSATE SODIUM – Only on a prescription

* Tab 50 mg .....	2.31	100	✓ <u>Coloxyl</u>
* Tab 120 mg .....	3.13	100	✓ <u>Coloxyl</u>
* Enema conc 18% .....	5.40	100 ml OP	✓ <u>Coloxyl</u>

DOCUSATE SODIUM WITH SENNOSIDES

* Tab 50 mg with sennosides 8 mg .....	4.40	200	✓ <u>Laxsol</u>
--	------	-----	-----------------

POLOXAMER – Only on a prescription

Not funded for use in the ear.

* Oral drops 10% .....	3.78	30 ml OP	✓ <u>Coloxyl</u>
------------------------	------	----------	------------------

### Osmotic Laxatives

GLYCEROL

* Suppos 3.6 g – Only on a prescription .....	6.50	20	✓ <u>PSM</u>
---	------	----	--------------

PSM to be Sole Supply on 1 October 2015

LACTULOSE – Only on a prescription

* Oral liq 10 g per 15 ml .....	3.84	500 ml	✓ <u>Laevolac</u>
---------------------------------	------	--------	-------------------

MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE – Special Authority see SA1473 on the next page – Retail pharmacy

Powder for oral soln 13.125 g with potassium chloride

46.6 mg, sodium bicarbonate 178.5 mg and sodium chlo-

ride 350.7 mg – Maximum of 90 sach per prescription .....	7.65	30	✓ <u>Lax-Sachets</u>
---	------	----	----------------------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

### ►SA1473 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has problematic constipation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated; and
- 2 The patient would otherwise require a per rectal preparation.

**Renewal** from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gain benefit from treatment.

**SODIUM ACID PHOSPHATE** – Only on a prescription

Enema 16% with sodium phosphate 8% .....	2.50	1	✓ <b>Fleet Phosphate Enema</b>
--	------	---	--------------------------------

**SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE** – Only on a prescription

Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml .....	19.95	50	✓ <b>Micolette</b>
---	-------	----	--------------------

### Stimulant Laxatives

**BISACODYL** – Only on a prescription

* Tab 5 mg .....	5.99	200	✓ <b>Lax-Tab</b>
Lax-Tab to be Sole Supply on 1 November 2015			
* Suppos 5 mg .....	3.00	6	✓ <b>Dulcolax</b>
* Suppos 10 mg .....	3.00	6	✓ <b>Dulcolax</b>

**SENNA** – Only on a prescription

* Tab, standardised .....	0.43	20	
	(1.72)		Senokot
	2.17	100	
	(6.84)		Senokot

### Metabolic Disorder Agents

#### Gaucher's Disease

**IMIGLUCERASE** – Special Authority see SA0473 below – Retail pharmacy

Inj 40 iu per ml, 200 iu vial .....	1,072.00	1	✓ <b>Cerezyme</b>
Inj 40 iu per ml, 400 iu vial .....	2,144.00	1	✓ <b>Cerezyme</b>

### ►SA0473 Special Authority for Subsidy

Special Authority approved by the Gaucher's Treatment Panel

Notes: Subject to a budgetary cap. Applications will be considered and approved subject to funding availability.

Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Co-ordinator, Gaucher's Treatment Panel	Phone: (04) 460 4990
PHARMAC, PO Box 10 254	Facsimile: (04) 916 7571
Wellington	Email: <a href="mailto:gaucherpanel@pharmac.govt.nz">gaucherpanel@pharmac.govt.nz</a>

Subsidy  
(Manufacturer's Price)  
\$

Fully  
Subsidised  
✓

Brand or  
Generic  
Manufacturer

## Mouth and Throat

### Agents Used in Mouth Ulceration

#### BENZYDAMINE HYDROCHLORIDE

Soln 0.15% – Higher subsidy of up to \$17.01 per 500 ml with

Endorsement .....	3.60	200 ml	
	(8.50)		Difflam
	9.00	500 ml	
	(17.01)		Difflam

Additional subsidy by endorsement for a patient who has oral mucositis as a result of treatment for cancer, and the prescription is endorsed accordingly.

#### CHLORHEXIDINE GLUCONATE

Mouthwash 0.2% .....	2.57	200 ml OP	✓ healthE
healthE to be Sole Supply on 1 October 2015			

#### CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE

* Adhesive gel 8.7% with cetalkonium chloride 0.01% .....	2.06	15 g OP	
	(6.00)		Bonjela

#### SODIUM CARBOXYMETHYLCELLULOSE

With pectin and gelatin paste .....	17.20	56 g OP	✓ Stomahesive
	1.52	5 g OP	
	(3.60)		Orabase
	4.55	15 g OP	
	(7.90)		Orabase
With pectin and gelatin powder .....	8.48	28 g OP	
	(10.95)		Stomahesive

#### TRIAMCINOLONE ACETONIDE

Paste 0.1% .....	5.33	5 g OP	✓ Kenalog in Orabase
------------------	------	--------	----------------------

### Oropharyngeal Anti-infectives

#### AMPHOTERICIN B

Lozenges 10 mg .....	5.86	20	✓ Fungilin
----------------------	------	----	------------

#### MICONAZOLE

Oral gel 20 mg per g .....	4.79	40 g OP	✓ Decozol
Decozol to be Sole Supply on 1 October 2015			

#### NYSTATIN

Oral liq 100,000 u per ml .....	3.35	24 ml OP	✓ Nilstat
---------------------------------	------	----------	-----------

### Other Oral Agents

For folinic mouthwash, pilocarpine oral liquid or saliva substitute formula refer Standard Formulae, page 210

#### HYDROGEN PEROXIDE

* Soln 10 vol – Maximum of 200 ml per prescription.....	1.28	100 ml	✓ PSM
---	------	--------	-------

#### THYMOL GLYCERIN

* Compound, BPC .....	9.15	500 ml	✓ PSM
-----------------------	------	--------	-------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Vitamins

### Vitamin A

#### VITAMIN A WITH VITAMINS D AND C

* Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops .....	4.50	10 ml OP	✓ Vitadol C
--	------	----------	-------------

### Vitamin B

#### HYDROXOCOBALAMIN

* Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a PSO .....	2.31	3	✓ Neo-B12
	5.10		✓ ABM Hydroxocobalamin

#### PYRIDOXINE HYDROCHLORIDE

- a) No more than 100 mg per dose  
b) Only on a prescription

* Tab 25 mg – No patient co-payment payable .....	2.15	90	✓ Vitamin B6 25
* Tab 50 mg .....	11.55	500	✓ Apo-Pyridoxine

#### THIAMINE HYDROCHLORIDE – Only on a prescription

* Tab 50 mg .....	5.62	100	✓ Apo-Thiamine
-------------------	------	-----	----------------

#### VITAMIN B COMPLEX

* Tab, strong, BPC .....	4.30	500	✓ Bplex
--------------------------	------	-----	---------

### Vitamin C

#### ASCORBIC ACID

- a) No more than 100 mg per dose  
b) Only on a prescription

* Tab 100 mg .....	7.00	500	✓ Cvite
--------------------	------	-----	---------

### Vitamin D

#### ALFACALCIDOL

* Cap 0.25 mcg .....	26.32	100	✓ One-Alpha
* Cap 1 mcg .....	87.98	100	✓ One-Alpha
* Oral drops 2 mcg per ml .....	60.68	20 ml OP	✓ One-Alpha

#### CALCITRIOL

* Cap 0.25 mcg .....	3.03	30	✓ Airflow
	10.10	100	✓ Calcitriol-AFT
* Cap 0.5 mcg .....	5.62	30	✓ Airflow
	18.73	100	✓ Calcitriol-AFT

#### CHOLECALCIFEROL

* Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescription .....	7.76	12	✓ Cal-d-Forte
--	------	----	---------------

### Multivitamin Preparations

#### MULTIVITAMINS – Special Authority see SA1036 on the next page – Retail pharmacy

* Powder .....	72.00	200 g OP	✓ Paediatric Seravit
----------------	-------	----------	----------------------

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time  
if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
<b>►SA1036 Special Authority for Subsidy</b>			
<b>Initial application</b> from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism.			
<b>Renewal</b> from any relevant practitioner. Approvals valid without further renewal unless notified where patient has had a previous approval for multivitamins.			
<b>VITAMINS</b>			
* Tab (BPC cap strength) .....	7.60	1,000	✓ <u>Mvite</u>
* Cap (fat soluble vitamins A, D, E, K) – Special Authority see SA1002 below – Retail pharmacy .....	23.40	60	✓ <u>Vitabdeck</u>
<b>►SA1002 Special Authority for Subsidy</b>			
<b>Initial application</b> from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:			
Either:			
1 Patient has cystic fibrosis with pancreatic insufficiency; or			
2 Patient is an infant or child with liver disease or short gut syndrome.			
<b>Minerals</b>			
<b>Calcium</b>			
<b>CALCIUM CARBONATE</b>			
* Tab eff 1.75 g (1 g elemental) .....	6.21	30	✓ <u>Calsource</u>
* Tab 1.25 g (500 mg elemental) .....	5.38	250	✓ <u>Arrow-Calcium</u>
<b>CALCIUM GLUCONATE</b>			
* Inj 10%, 10 ml ampoule .....	34.24	10	✓ <u>Hospira</u>
<b>Fluoride</b>			
<b>SODIUM FLUORIDE</b>			
* Tab 1.1 mg (0.5 mg elemental) .....	5.00	100	✓ <u>PSM</u>
<b>Iodine</b>			
<b>POTASSIUM IODATE</b>			
* Tab 253 mcg (150 mcg elemental iodine) .....	3.65	90	✓ <u>NeuroTabs</u>
<b>Iron</b>			
<b>FERROUS FUMARATE</b>			
* Tab 200 mg (65 mg elemental) .....	2.89	100	✓ <u>Ferro-tab</u>
<b>FERROUS FUMARATE WITH FOLIC ACID</b>			
* Tab 310 mg (100 mg elemental) with folic acid 350 mcg .....	4.75	60	✓ <u>Ferro-F-Tabs</u>
<b>FERROUS SULPHATE</b>			
* Tab long-acting 325 mg (105 mg elemental) .....	2.06	30	✓ <u>Ferrograd</u>
* ‡ Oral liq 30 mg (6 mg elemental) per 1 ml .....	10.28	500 ml	✓ <u>Ferodan</u>
<b>FERROUS SULPHATE WITH FOLIC ACID</b>			
* Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg .....	1.80 (4.29)	30	Ferrograd F
<b>IRON POLYMALTOSE</b>			
* Inj 50 mg per ml, 2 ml ampoule .....	15.22	5	✓ <u>Ferrum H</u>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Magnesium</b>				
For magnesium hydroxide mixture refer Standard Formulae, page 210				
MAGNESIUM SULPHATE				
* Inj 2 mmol per ml, 5 ml ampoule .....	12.65	10	✓	<u>DBL</u>
<b>Zinc</b>				
ZINC SULPHATE				
* Cap 137.4 mg (50 mg elemental) .....	11.00	100	✓	<u>Zincaps</u>

## Antianaemics

### Hypoplastic and Haemolytic

#### ►SA1469 Special Authority for Subsidy

**Initial application — (chronic renal failure)** from any specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin  $\leq$  100g/L; and
- 3 Any of the following:
  - 3.1 Both:
    - 3.1.1 Patient does not have diabetes mellitus; and
    - 3.1.2 Glomerular filtration rate  $\leq$  30ml/min; or
  - 3.2 Both:
    - 3.2.1 Patient has diabetes mellitus; and
    - 3.2.2 Glomerular filtration rate  $\leq$  45ml/min; or
  - 3.3 Patient is on haemodialysis or peritoneal dialysis.

Note: Erythropoietin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

**Initial application — (myelodysplasia)** from any specialist. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS)\*; and
- 2 Has had symptomatic anaemia with haemoglobin  $<$ 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum erythropoietin level of  $<$ 500 IU/L; and
- 6 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with \* is an Unapproved Indication

**Renewal — (chronic renal failure)** from any specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Erythropoietin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

**Renewal — (myelodysplasia)** from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with \* is an Unapproved Indication



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

EPOETIN ALFA [ERYTHROPOIETIN ALFA] – Special Authority see SA1469 on the previous page – Retail pharmacy

Wastage claimable – see rule 3.3.2 on page 13

Inj 1,000 iu in 0.5 ml, syringe .....	48.68	6	✓ <b>Eprex</b>
Inj 2,000 iu in 0.5 ml, syringe .....	120.18	6	✓ <b>Eprex</b>
Inj 3,000 iu in 0.3 ml, syringe .....	166.87	6	✓ <b>Eprex</b>
Inj 4,000 iu in 0.4 ml, syringe .....	193.13	6	✓ <b>Eprex</b>
Inj 5,000 iu in 0.5 ml, syringe .....	243.26	6	✓ <b>Eprex</b>
Inj 6,000 iu in 0.6 ml, syringe .....	291.92	6	✓ <b>Eprex</b>
Inj 8,000 iu in 0.8 ml, syringe .....	352.69	6	✓ <b>Eprex</b>
Inj 10,000 iu in 1 ml, syringe .....	395.18	6	✓ <b>Eprex</b>
Inj 40,000 iu in 1 ml, syringe .....	263.45	1	✓ <b>Eprex</b>

## Megaloblastic

FOLIC ACID

* Tab 0.8 mg .....	20.60	1,000	✓ <b>Apo-Folic Acid</b>
Apo-Folic Acid to be Sole Supply on 1 November 2015			
* Tab 5 mg .....	10.92	500	✓ <b>Apo-Folic Acid</b>
Apo-Folic Acid to be Sole Supply on 1 November 2015			
Oral liq 50 mcg per ml .....	24.00	25 ml OP	✓ <b>Biomed</b>

## Antifibrinolytics, Haemostatics and Local Sclerosants

ELTROMBOPAG – Special Authority see SA1418 below – Retail pharmacy

Wastage claimable – see rule 3.3.2 on page 13

Tab 25 mg .....	1,771.00	28	✓ <b>Revolade</b>
Tab 50 mg .....	3,542.00	28	✓ <b>Revolade</b>

### ▶SA1418 | Special Authority for Subsidy

**Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy)** only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
  - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
  - 3.2 Patient has a platelet count of  $\leq$  20,000 platelets per microlitre and has evidence of active bleeding; or
  - 3.3 Patient has a platelet count of  $\leq$  10,000 platelets per microlitre.

**Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy)** only from a haematologist. Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

**Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy)** only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of  $>30,000$  platelets per microlitre.

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – [Xpharm]

For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Inj 1 mg syringe .....	1,163.75	1	✓ <b>NovoSeven RT</b>
Inj 2 mg syringe .....	2,327.50	1	✓ <b>NovoSeven RT</b>
Inj 5 mg syringe .....	5,818.75	1	✓ <b>NovoSeven RT</b>
Inj 8 mg syringe .....	9,310.00	1	✓ <b>NovoSeven RT</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

# BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>FACTOR EIGHT INHIBITORS BYPASSING AGENT – [Xpharm]</b>				
For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.				
Inj 500 U .....	1,640.00	1	✓	FEIBA
Inj 1,000 U .....	3,280.00	1	✓	FEIBA
<b>MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – [Xpharm]</b>				
For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.				
Inj 250 iu vial .....	225.00	1	✓	Xyntha
Inj 500 iu vial .....	450.00	1	✓	Xyntha
Inj 1,000 iu vial .....	900.00	1	✓	Xyntha
Inj 2,000 iu vial .....	1,800.00	1	✓	Xyntha
Inj 3,000 iu vial .....	2,700.00	1	✓	Xyntha
<b>NONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpharm]</b>				
For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.				
Inj 250 iu vial .....	310.00	1	✓	BeneFIX
Inj 500 iu vial .....	620.00	1	✓	BeneFIX
Inj 1,000 iu vial .....	1,240.00	1	✓	BeneFIX
Inj 2,000 iu vial .....	2,480.00	1	✓	BeneFIX
<b>OCTOCOG ALFA [RECOMBINANT FACTOR VIII] – [Xpharm]</b>				
For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.				
Inj 250 iu vial .....	237.50	1	✓	Advate
	250.00		✓	Kogenate FS
Inj 500 iu vial .....	475.00	1	✓	Advate
	500.00		✓	Kogenate FS
Inj 1,000 iu vial .....	950.00	1	✓	Advate
	1,000.00		✓	Kogenate FS
Inj 1,500 iu vial .....	1,425.00	1	✓	Advate
Inj 2,000 iu vial .....	1,900.00	1	✓	Advate
	2,000.00		✓	Kogenate FS
Inj 3,000 iu vial .....	2,850.00	1	✓	Advate
	3,000.00		✓	Kogenate FS
<b>SODIUM TETRADECYL SULPHATE</b>				
* Inj 3% 2 ml .....	28.50	5		
	(73.00)			Fibro-vein
<b>TRANEXAMIC ACID</b>				
Tab 500 mg .....	23.00	100	✓	Cyklokapron
<b>Vitamin K</b>				
<b>PHYTOMENADIONE</b>				
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO .....	8.00	5	✓	Konakion MM
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	9.21	5	✓	Konakion MM

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## Antithrombotic Agents

### Antiplatelet Agents

#### ASPIRIN

\* Tab 100 mg ..... 10.50 990 ✓ **Ethics Aspirin EC**

#### CLOPIDOGREL

\* Tab 75 mg – For clopidogrel oral liquid formulation refer, page 207 ..... 5.48 84 ✓ **Arrow - Clopid**

#### DIPYRIDAMOLE

\* Tab 25 mg – For dipyridamole oral liquid formulation refer, page 207 ..... 8.36 84 ✓ **Persantin**  
\* Tab long-acting 150 mg ..... 11.52 60 ✓ **Pytazen SR**

#### PRASUGREL – Special Authority see SA1201 below – Retail pharmacy

Tab 5 mg ..... 108.00 28 ✓ **Effient**  
Tab 10 mg ..... 120.00 28 ✓ **Effient**

#### ►SA1201 Special Authority for Subsidy

**Initial application — (coronary angioplasty and bare metal stent)** from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic\*.

**Initial application — (drug eluting stent)** from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic\*.

**Initial application — (stent thrombosis)** from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

**Renewal — (coronary angioplasty and bare metal stent)** from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic\*.

**Renewal — (drug eluting stent)** from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic\*.

Note: \* Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

#### TICAGRELOR – Special Authority see SA1382 below – Retail pharmacy

\* Tab 90 mg ..... 90.00 56 ✓ **Brilinta**

#### ►SA1382 Special Authority for Subsidy

**Initial application — (acute coronary syndrome)** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

**Renewal — (subsequent acute coronary syndrome)** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

## Heparin and Antagonist Preparations

DALTEPARIN SODIUM – Special Authority see SA1270 below – Retail pharmacy

Inj 2,500 iu per 0.2 ml prefilled syringe .....	19.97	10	✓	Fragmin
Inj 5,000 iu per 0.2 ml prefilled syringe .....	39.94	10	✓	Fragmin
Inj 7,500 iu per 0.75 ml graduated syringe .....	60.03	10	✓	Fragmin
Inj 10,000 iu per 1 ml graduated syringe .....	77.55	10	✓	Fragmin
Inj 12,500 iu per 0.5 ml prefilled syringe .....	99.96	10	✓	Fragmin
Inj 15,000 iu per 0.6 ml prefilled syringe .....	120.05	10	✓	Fragmin
Inj 18,000 iu per 0.72 ml prefilled syringe .....	158.47	10	✓	Fragmin

### ►SA1270 Special Authority for Subsidy

**Initial application — (Pregnancy or Malignancy)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

**Initial application — (Venous thromboembolism other than in pregnancy or malignancy)** from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

**Renewal — (Pregnancy or Malignancy)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

**Renewal — (Venous thromboembolism other than in pregnancy or malignancy)** from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, Acute Coronary Syndrome, cardioversion, or prior to oral anti-coagulation).

ENOXAPARIN SODIUM – Special Authority see SA1174 on the next page – Retail pharmacy

Inj 20 mg .....	37.24	10	✓	Clexane
Inj 40 mg .....	49.69	10	✓	Clexane
Inj 60 mg .....	74.91	10	✓	Clexane
Inj 80 mg .....	99.86	10	✓	Clexane
Inj 100 mg .....	125.06	10	✓	Clexane
Inj 120 mg .....	155.40	10	✓	Clexane
Inj 150 mg .....	177.60	10	✓	Clexane

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

►SA1174 Special Authority for Subsidy

**Initial application — (Pregnancy or Malignancy)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

**Initial application — (Venous thromboembolism other than in pregnancy or malignancy)** from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

**Renewal — (Pregnancy or Malignancy)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

**Renewal — (Venous thromboembolism other than in pregnancy or malignancy)** from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml .....	13.36	10	✓ Hospira
	66.80	50	✓ Hospira
	61.04		✓ Pfizer
Inj 1,000 iu per ml, 35 ml .....	16.00	1	✓ Hospira
Inj 5,000 iu per ml, 1 ml .....	14.20	5	✓ Hospira
Inj 5,000 iu per ml, 5 ml .....	236.60	50	✓ Pfizer
Inj 25,000 iu per ml, 0.2 ml .....	9.50	5	✓ Hospira

HEPARINISED SALINE

* Inj 10 iu per ml, 5 ml .....	39.00	50	✓ Pfizer
--------------------------------	-------	----	----------

PROTAMINE SULPHATE

* Inj 10 mg per ml, 5 ml .....	22.40	10	
	(119.23)		Artex

Oral Anticoagulants

DABIGATRAN

Cap 75 mg – No more than 2 cap per day .....	148.00	60	✓ Pradaxa
Cap 110 mg .....	148.00	60	✓ Pradaxa
Cap 150 mg .....	148.00	60	✓ Pradaxa

RIVAROXABAN – Special Authority see SA1066 on the next page – Retail pharmacy

Tab 10 mg .....	153.00	15	✓ Xarelto
-----------------	--------	----	-----------

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

## ►SA1066 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 5 weeks for applications meeting the following criteria:  
Either:

- 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or
- 2 For the prophylaxis of venous thromboembolism following a total knee replacement.

Note: Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.

**Renewal** from any relevant practitioner. Approvals valid for 5 weeks where prophylaxis for venous thromboembolism is required for patients following a subsequent total hip or knee replacement.

## WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

* Tab 1 mg .....	3.46	50	✓ Coumadin
	6.86	100	✓ Marevan
* Tab 2 mg .....	4.31	50	✓ Coumadin
* Tab 3 mg .....	9.70	100	✓ Marevan
* Tab 5 mg .....	5.93	50	✓ Coumadin
	11.75	100	✓ Marevan

## Blood Colony-stimulating Factors

FILGRASTIM – Special Authority see SA1259 below – Retail pharmacy

Inj 300 mcg per 0.5 ml prefilled syringe .....	540.00	5	✓ <u>Zarzio</u>
Inj 480 mcg per 0.5 ml prefilled syringe .....	864.00	5	✓ <u>Zarzio</u>

## ►SA1259 Special Authority for Subsidy

**Initial application** only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk  $\geq 20\%$ ); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia ( $ANC < 0.5 \times 10^9/L$ ); or
- 5 Treatment of drug-induced prolonged neutropenia ( $ANC < 0.5 \times 10^9/L$ ).

Note: \*Febrile neutropenia risk  $\geq 20\%$  after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM – Special Authority see SA1384 below – Retail pharmacy

Inj 6 mg per 0.6 ml syringe .....	1,080.00	1	✓ Neulastim
-----------------------------------	----------	---	-------------

## ►SA1384 Special Authority for Subsidy

**Initial application** only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk  $\geq 20\%$ ).

Note: \*Febrile neutropenia risk  $\geq 20\%$  after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Fluids and Electrolytes

### Intravenous Administration

#### GLUCOSE [DEXTROSE]

* Inj 50%, 10 ml ampoule – Up to 5 inj available on a PSO .....	27.50	5	✓ <b>Biomed</b>
* Inj 50%, 90 ml bottle – Up to 5 inj available on a PSO .....	14.50	1	✓ <b>Biomed</b>

#### POTASSIUM CHLORIDE

* Inj 75 mg per ml, 10 ml .....	55.00	50	✓ <b>AstraZeneca</b>
---------------------------------	-------	----	----------------------

#### SODIUM BICARBONATE

Inj 8.4%, 50 ml .....	19.95	1	✓ <b>Biomed</b>
a) Up to 5 inj available on a PSO			
b) Not in combination			
Inj 8.4%, 100 ml .....	20.50	1	✓ <b>Biomed</b>
a) Up to 5 inj available on a PSO			
b) Not in combination			

#### SODIUM CHLORIDE

Not funded for use as a nasal drop. Only funded for nebuliser use when in conjunction with an antibiotic intended for nebuliser use.

Inj 0.9% – Up to 2000 ml available on a PSO .....	3.06	500 ml	✓ <b>Baxter</b>
	4.06	1,000 ml	✓ <b>Baxter</b>

Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs)

Inj 23.4%, 20 ml ampoule .....	31.25	5	✓ <b>Biomed</b>
For Sodium chloride oral liquid formulation refer Standard Formulae, page 210			
Inj 0.9%, 5 ml – Up to 5 inj available on a PSO .....	10.85	50	✓ <b>Multichem</b>
	15.50		✓ <b>Pfizer</b>
Inj 0.9%, 10 ml – Up to 5 inj available on a PSO .....	11.50	50	✓ <b>Multichem</b>
	15.50		✓ <b>Pfizer</b>
Inj 0.9%, 20 ml .....	4.72	6	✓ <b>Pharmacia</b>
	11.79	30	✓ <b>Pharmacia</b>
	8.41	20	✓ <b>Multichem</b>

#### TOTAL PARENTERAL NUTRITION (TPN) – Retail pharmacy-Specialist

Infusion .....	CBS	1 OP	✓ <b>TPN</b>
----------------	-----	------	--------------

#### WATER

- 1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or
- 2) On a bulk supply order; or
- 3) When used in the extemporaneous compounding of eye drops.

Purified for inj, 5 ml – Up to 5 inj available on a PSO .....	10.25	50	✓ <b>Multichem</b>
Purified for inj, 10 ml – Up to 5 inj available on a PSO .....	11.25	50	✓ <b>Multichem</b>
Purified for inj, 20 ml – Up to 5 inj available on a PSO .....	6.50	20	✓ <b>Multichem</b>

### Oral Administration

#### CALCIUM POLYSTYRENE SULPHONATE

Powder .....	169.85	300 g OP	✓ <b>Calcium Resonium</b>
--------------	--------	----------	---------------------------

#### COMPOUND ELECTROLYTES

Powder for oral soln – Up to 10 sach available on a PSO .....	1.80	10	✓ <b>Enerlyte</b>
---	------	----	-------------------

## BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>DEXTROSE WITH ELECTROLYTES</b>				
Soln with electrolytes .....	6.55	1,000 ml OP	✓	<b>Pedialyte - Bubblegum</b>
<b>PHOSPHORUS</b>				
Tab eff 500 mg (16 mmol) .....	82.50	100	✓	<b>Phosphate-Sandoz</b>
<b>POTASSIUM CHLORIDE</b>				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq) .....	5.26 (11.85)	60		Chlorvescent
* Tab long-acting 600 mg (8 mmol) .....	7.42	200	✓	<b>Span-K</b>
Span-K to be Sole Supply on 1 October 2015				
<b>SODIUM BICARBONATE</b>				
Cap 840 mg .....	8.52	100	✓	<b>Sodibic</b>
<b>SODIUM POLYSTYRENE SULPHONATE</b>				
Powder .....	84.65	454 g OP	✓	<b>Resonium-A</b>
Resonium-A to be Sole Supply on 1 October 2015				



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Alpha Adrenoceptor Blockers

### DOXAZOSIN

* Tab 2 mg .....	6.75	500	✓ <u>Apo-Doxazosin</u>
* Tab 4 mg .....	9.67	500	✓ <u>Apo-Doxazosin</u>

### PHENOXYBENZAMINE HYDROCHLORIDE

* Cap 10 mg .....	65.00	30	✓ <u>BNM S29</u>
-------------------	-------	----	------------------

### PAZOSIN

* Tab 1 mg .....	5.53	100	✓ <u>Apo-Prazosin</u>
* Tab 2 mg .....	7.00	100	✓ <u>Apo-Prazosin</u>
* Tab 5 mg .....	11.70	100	✓ <u>Apo-Prazosin</u>

### TERAZOSIN

* Tab 1 mg .....	0.50	28	✓ <u>Arrow</u>
* Tab 2 mg .....	0.45	28	✓ <u>Arrow</u>
* Tab 5 mg .....	0.68	28	✓ <u>Arrow</u>

## Agents Affecting the Renin-Angiotensin System

### ACE Inhibitors

#### CAPTOPRIL

* ‡ Oral liq 5 mg per ml .....	94.99	95 ml OP	✓ <u>Capoten</u>
Oral liquid restricted to children under 12 years of age.			

#### CILAZAPRIL

* Tab 0.5 mg .....	2.00	90	✓ <u>Zapril</u>
* Tab 2.5 mg .....	4.31	90	✓ <u>Zapril</u>
* Tab 5 mg .....	6.98	90	✓ <u>Zapril</u>

#### ENALAPRIL MALEATE

* Tab 5 mg .....	0.96	100	✓ <u>Ethics Enalapril</u>
Ethics Enalapril to be Sole Supply on 1 October 2015			
* Tab 10 mg .....	1.24	100	✓ <u>Ethics Enalapril</u>
Ethics Enalapril to be Sole Supply on 1 October 2015			
* Tab 20 mg – For enalapril maleate oral liquid formulation re- fer, page 207.....	1.78	100	✓ <u>Ethics Enalapril</u>
Ethics Enalapril to be Sole Supply on 1 October 2015			

#### LISINAPRIL

* Tab 5 mg .....	3.58	90	✓ <u>Arrow-Lisinopril</u>
* Tab 10 mg .....	4.08	90	✓ <u>Arrow-Lisinopril</u>
* Tab 20 mg .....	4.88	90	✓ <u>Arrow-Lisinopril</u>

#### PERINDOPRIL

* Tab 2 mg .....	3.75	30	✓ <u>Apo-Perindopril</u>
* Tab 4 mg .....	4.80	30	✓ <u>Apo-Perindopril</u>

#### QUINAPRIL

* Tab 5 mg .....	4.31	90	✓ <u>Arrow-Quinapril 5</u>
Arrow-Quinapril 5 to be Sole Supply on 1 October 2015			
* Tab 10 mg .....	3.15	90	✓ <u>Arrow-Quinapril 10</u>
Arrow-Quinapril 10 to be Sole Supply on 1 October 2015			
* Tab 20 mg .....	5.97	90	✓ <u>Arrow-Quinapril 20</u>
Arrow-Quinapril 20 to be Sole Supply on 1 October 2015			

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>TRANDOLAPRIL</b>				
Higher subsidy by endorsement is available for patients who were taking trandolapril for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". For the purposes of this endorsement, congestive heart failure includes patients post myocardial infarction with an ejection fraction of less than 40%. Patients who started on trandolapril after 1 June 1998 are not eligible for full subsidy by endorsement.				
* Cap 1 mg – Higher subsidy of \$18.67 per 28 cap with Endorsement.....	3.06 (18.67)	28		Gopten
* Cap 2 mg – Higher subsidy of \$27.00 per 28 cap with Endorsement.....	4.43 (27.00)	28		Gopten

## ACE Inhibitors with Diuretics

<b>CILAZAPRIL WITH HYDROCHLOROTHIAZIDE</b>				
* Tab 5 mg with hydrochlorothiazide 12.5 mg .....	10.72	100	✓ Apo-	<u>Cilazapril/Hydrochlorothiazide</u>
<b>ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE</b>				
* Tab 20 mg with hydrochlorothiazide 12.5 mg .....	3.32 (8.70)	30		Co-Renitec
<b>QUINAPRIL WITH HYDROCHLOROTHIAZIDE</b>				
* Tab 10 mg with hydrochlorothiazide 12.5 mg .....	3.65	30	✓ Accuretic 10	
Accuretic 10 to be Sole Supply on 1 November 2015				
* Tab 20 mg with hydrochlorothiazide 12.5 mg .....	4.78	30	✓ Accuretic 20	
Accuretic 20 to be Sole Supply on 1 November 2015				

## Angiotensin II Antagonists

<b>CANDESARTAN CILEXETIL – Special Authority see SA1223 below – Retail pharmacy</b>				
* Tab 4 mg .....	2.50	90	✓ Candestar	
Candestar to be Sole Supply on 1 October 2015				
* Tab 8 mg .....	3.68	90	✓ Candestar	
Candestar to be Sole Supply on 1 October 2015				
* Tab 16 mg .....	6.12	90	✓ Candestar	
Candestar to be Sole Supply on 1 October 2015				
* Tab 32 mg .....	10.66	90	✓ Candestar	
Candestar to be Sole Supply on 1 October 2015				

### ►SA1223 Special Authority for Subsidy

**Initial application — (ACE inhibitor intolerance)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or
- 2 Patient has a history of angioedema.

**Initial application — (Unsatisfactory response to ACE inhibitor)** from any relevant practitioner. Approvals valid without further renewal unless notified where patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>LOSARTAN POTASSIUM</b>				
* Tab 12.5 mg .....	1.55	84	✓	<u>Losartan Actavis</u>
* Tab 25 mg .....	1.90	84	✓	<u>Losartan Actavis</u>
* Tab 50 mg .....	2.25	84	✓	<u>Losartan Actavis</u>
* Tab 100 mg .....	2.60	84	✓	<u>Losartan Actavis</u>
<b>Angiotensin II Antagonists with Diuretics</b>				
<b>LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE</b>				
Tab 50 mg with hydrochlorothiazide 12.5 mg .....	2.18	30	✓	<u>Arrow-Losartan &amp; Hydrochlorothiazide</u>
<b>Antiarrhythmics</b>				
For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesthetics, Local, page 124				
<b>AMIODARONE HYDROCHLORIDE</b>				
▲ Tab 100 mg – Retail pharmacy-Specialist .....	18.65	30	✓	<u>Aratac</u>
▲ Tab 200 mg – Retail pharmacy-Specialist .....	30.52	30	✓	<u>Cordarone-X</u>
Inj 50 mg per ml, 3 ml ampoule – Up to 6 inj available on a PSO .....	22.80	6	✓	<u>Aratac</u>
			✓	<u>Cordarone-X</u>
<b>ATROPINE SULPHATE</b>				
* Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO .....	71.00	50	✓	<u>AstraZeneca</u>
<b>DIGOXIN</b>				
* Tab 62.5 mcg – Up to 30 tab available on a PSO .....	6.67	240	✓	<u>Lanoxin PG</u>
* Tab 250 mcg – Up to 30 tab available on a PSO .....	14.52	240	✓	<u>Lanoxin</u>
*‡ Oral liq 50 mcg per ml .....	16.60	60 ml	✓	<u>Lanoxin</u>
<b>DISOPYRAMIDE PHOSPHATE</b>				
▲ Cap 100 mg .....	15.00	100		Rythmodan
	(23.87)		✓	<u>Rythmodan</u>
▲ Cap 150 mg .....	26.21	100		
<b>FLECAINIDE ACETATE – Retail pharmacy-Specialist</b>				
▲ Tab 50 mg .....	38.95	60	✓	<u>Tambocor</u>
▲ Tab 100 mg – For flecainide acetate oral liquid formulation refer, page 207 .....	68.78	60	✓	<u>Tambocor</u>
▲ Cap long-acting 100 mg .....	38.95	30	✓	<u>Tambocor CR</u>
▲ Cap long-acting 200 mg .....	68.78	30	✓	<u>Tambocor CR</u>
Inj 10 mg per ml, 15 ml ampoule .....	52.45	5	✓	<u>Tambocor</u>
<b>MEXILETINE HYDROCHLORIDE</b>				
▲ Cap 150 mg .....	162.00	100	✓	<u>Mexiletine Hydrochloride USP</u> <sup>S29</sup>
▲ Cap 250 mg .....	202.00	100	✓	<u>Mexiletine Hydrochloride USP</u> <sup>S29</sup>
<b>PROPAFENONE HYDROCHLORIDE – Retail pharmacy-Specialist</b>				
▲ Tab 150 mg .....	40.90	50	✓	<u>Rytmonorm</u>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Antihypotensives</b>				
MIDODRINE – Special Authority see SA1474 below – Retail pharmacy				
Tab 2.5 mg .....	53.00	100	✓	Gutron
Tab 5 mg .....	79.00	100	✓	Gutron
<b>SA1474 Special Authority for Subsidy</b> <b>Initial application</b> from any relevant practitioner. Approvals valid for 2 years where patient has disabling orthostatic hypotension not due to drugs. Note: Treatment should be started with small doses and titrated upwards as necessary. Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. <b>Renewal</b> from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.				
<b>Beta Adrenoceptor Blockers</b>				
ATENOLOL				
* Tab 50 mg .....	4.61	500	✓	Mylan Atenolol
Mylan Atenolol to be Sole Supply on 1 October 2015				
* Tab 100 mg .....	7.67	500	✓	Mylan Atenolol
Mylan Atenolol to be Sole Supply on 1 October 2015				
* Oral liq 25 mg per 5 ml .....	21.25	300 ml OP	✓	Atenolol AFT
Restricted to children under 12 years of age.				
BISOPROLOL FUMARATE				
Tab 2.5 mg .....	2.40	30	✓	Bosvate
Tab 5 mg .....	3.50	30	✓	Bosvate
Tab 10 mg .....	6.40	30	✓	Bosvate
CARVEDILOL				
* Tab 6.25 mg .....	1.95	30	✓	Dilatrend
	3.90	60	✓	Dicarz
Dicarz to be Sole Supply on 1 September 2015				
* Tab 12.5 mg .....	2.55	30	✓	Dilatrend
	5.10	60	✓	Dicarz
Dicarz to be Sole Supply on 1 September 2015				
* Tab 25 mg – For carvedilol oral liquid formulation refer, page 207 .....	3.15	30	✓	Dilatrend
	6.30	60	✓	Dicarz
Dicarz to be Sole Supply on 1 September 2015				
(Dilatrend Tab 6.25 mg to be delisted 1 September 2015)				
(Dilatrend Tab 12.5 mg to be delisted 1 September 2015)				
(Dilatrend Tab 25 mg to be delisted 1 September 2015)				
CELIPROLOL				
* Tab 200 mg .....	21.40	180	✓	Celol
LABETALOL				
* Tab 50 mg .....	8.23	100	✓	Hybloc
* Tab 100 mg – For labetalol oral liquid formulation refer, page 207 .....	10.06	100	✓	Hybloc
* Tab 200 mg .....	17.55	100	✓	Hybloc
* Inj 5 mg per ml, 20 ml ampoule .....	59.06	5		
	(88.60)			Trandate

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>METOPROLOL SUCCINATE</b>				
* Tab long-acting 23.75 mg .....	0.96	30	✓	Metoprolol - AFT CR
* Tab long-acting 47.5 mg .....	1.41	30	✓	Metoprolol - AFT CR
* Tab long-acting 95 mg .....	2.42	30	✓	Metoprolol - AFT CR
* Tab long-acting 190 mg .....	4.66	30	✓	Metoprolol - AFT CR
<b>METOPROLOL TARTRATE</b>				
* Tab 50 mg – For metoprolol tartrate oral liquid formulation refer, page 207 .....	16.00	100	✓	Lopresor
* Tab 100 mg .....	21.00	60	✓	Lopresor
* Tab long-acting 200 mg .....	18.00	28	✓	Slow-Lopresor
* Inj 1 mg per ml, 5 ml vial .....	24.00	5	✓	Lopresor
<b>NADOLOL</b>				
* Tab 40 mg .....	16.05	100	✓	Apo-Nadolol
Apo-Nadolol to be Sole Supply on 1 November 2015				
* Tab 80 mg .....	24.70	100	✓	Apo-Nadolol
Apo-Nadolol to be Sole Supply on 1 November 2015				
<b>PINDOLOL</b>				
* Tab 5 mg .....	9.72	100	✓	Apo-Pindolol
* Tab 10 mg .....	15.62	100	✓	Apo-Pindolol
* Tab 15 mg .....	23.46	100	✓	Apo-Pindolol
<b>PROPRANOLOL</b>				
* Tab 10 mg .....	3.65	100	✓	Apo- Propranolol <sup>\$29</sup>
* Tab 40 mg .....	4.65	100	✓	Apo- Propranolol <sup>\$29</sup>
* Cap long-acting 160 mg .....	18.17	100	✓	Cardinol LA
* Oral liq 4 mg per ml – Special Authority see SA1327 below – Retail pharmacy .....	CBS	500 ml	✓	Roxane <sup>\$29</sup>
<b>▶SA1327 Special Authority for Subsidy</b>				
<b>Initial application</b> from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:				
Either:				
1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or				
2 For the treatment of a child under 12 years with cardiac arrhythmias or congenital cardiac abnormalities.				
<b>Renewal</b> from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:				
Either:				
1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or				
2 For the treatment of a child under 12 years with cardiac arrhythmias or congenital cardiac abnormalities.				
<b>SOTALOL</b>				
* Tab 80 mg – For sotalol oral liquid formulation refer, page 207 .....	27.50	500	✓	Mylan
* Tab 160 mg .....	10.50	100	✓	Mylan
* Inj 10 mg per ml, 4 ml ampoule .....	65.39	5	✓	Sotacor
<b>TIMOLOL</b>				
* Tab 10 mg .....	10.55	100	✓	Apo-Timol

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## Calcium Channel Blockers

### Dihydropyridine Calcium Channel Blockers

#### AMLODIPINE

* Tab 2.5 mg .....	2.21	100	✓ <u>Apo-Amlodipine</u>
* Tab 5 mg – For amlodipine oral liquid formulation refer, page 207 .....	5.04	250	✓ <u>Apo-Amlodipine</u>
* Tab 10 mg .....	7.21	250	✓ <u>Apo-Amlodipine</u>

#### FELODIPINE

* Tab long-acting 2.5 mg .....	1.45	30	✓ <u>Plendil ER</u>
Plendil ER to be Sole Supply on 1 October 2015			
* Tab long-acting 5 mg .....	1.55	30	✓ <u>Plendil ER</u>
Plendil ER to be Sole Supply on 1 October 2015			
* Tab long-acting 10 mg .....	2.30	30	✓ <u>Plendil ER</u>
Plendil ER to be Sole Supply on 1 October 2015			

#### ISRADIPINE

* Cap long-acting 2.5 mg .....	7.50	30	✓ <u>Dynacirc-SRO</u>
* Cap long-acting 5 mg .....	7.85	30	✓ <u>Dynacirc-SRO</u>

#### NIFEDIPINE

* Tab long-acting 10 mg .....	17.72	60	✓ <u>Adalat 10</u>
* Tab long-acting 20 mg .....	9.59	100	✓ <u>Nyefax Retard</u>
* Tab long-acting 30 mg .....	3.75	30	✓ <u>Adefin XL</u>
* Tab long-acting 60 mg .....	5.75	30	✓ <u>Adefin XL</u>

### Other Calcium Channel Blockers

#### DILTIAZEM HYDROCHLORIDE

* Tab 30 mg .....	4.60	100	✓ <u>Dilzem</u>
* Tab 60 mg – For diltiazem hydrochloride oral liquid formula- tion refer, page 207 .....	8.50	100	✓ <u>Dilzem</u>
* Cap long-acting 120 mg .....	1.91	30	✓ <u>Cardizem CD</u>
	31.83	500	✓ <u>Apo-Diltiazem CD</u>
* Cap long-acting 180 mg .....	7.56	30	✓ <u>Cardizem CD</u>
	47.67	500	✓ <u>Apo-Diltiazem CD</u>
* Cap long-acting 240 mg .....	10.22	30	✓ <u>Cardizem CD</u>
	63.58	500	✓ <u>Apo-Diltiazem CD</u>

#### PERHEXILINE MALEATE

* Tab 100 mg .....	62.90	100	✓ <u>Pexsig</u>
--------------------	-------	-----	-----------------

#### VERAPAMIL HYDROCHLORIDE

* Tab 40 mg .....	7.01	100	✓ <u>Isoptin</u>
* Tab 80 mg – For verapamil hydrochloride oral liquid formula- tion refer, page 207 .....	11.74	100	✓ <u>Isoptin</u>
* Tab long-acting 120 mg .....	15.20	250	✓ <u>Verpamil SR</u>
* Tab long-acting 240 mg .....	25.00	250	✓ <u>Verpamil SR</u>
* Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO .....	7.54	5	✓ <u>Isoptin</u>

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## Centrally-Acting Agents

### CLONIDINE

* Patch 2.5 mg, 100 mcg per day – Only on a prescription.....	12.80	4	✓ Catapres-TTS-1
* Patch 5 mg, 200 mcg per day – Only on a prescription.....	18.04	4	✓ Catapres-TTS-2
* Patch 7.5 mg, 300 mcg per day – Only on a prescription.....	22.68	4	✓ Catapres-TTS-3

### CLONIDINE HYDROCHLORIDE

* Tab 25 mcg .....	10.53	112	✓ Clonidine BNM
Clonidine BNM to be Sole Supply on 1 October 2015			
* Tab 150 mcg .....	34.32	100	✓ Catapres
* Inj 150 mcg per ml, 1 ml ampoule .....	16.07	5	✓ Catapres

### METHYLDOPA

* Tab 125 mg .....	14.25	100	✓ Prodopa
* Tab 250 mg .....	15.10	100	✓ Prodopa
* Tab 500 mg .....	23.15	100	✓ Prodopa

## Diuretics

### Loop Diuretics

#### BUMETANIDE

* Tab 1 mg .....	16.36	100	✓ Burinex
* Inj 500 mcg per ml, 4 ml vial .....	7.95	5	✓ Burinex

#### FUROSEMIDE [FRUSEMIDE]

* Tab 40 mg – Up to 30 tab available on a PSO.....	8.00	1,000	✓ Diurin 40
Diurin 40 to be Sole Supply on 1 October 2015			
* Tab 500 mg .....	25.00	50	✓ Urex Forte
Urex Forte to be Sole Supply on 1 October 2015			
*† Oral liq 10 mg per ml .....	10.66	30 ml OP	✓ Lasix
* Inj 10 mg per ml, 25 ml ampoule .....	48.14	5	✓ Lasix
* Inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO.....	1.30	5	✓ Frusemide-Claris

### Potassium Sparing Diuretics

#### AMILORIDE HYDROCHLORIDE

* Tab 5 mg .....	17.50	100	✓ Apo-Amiloride
† Oral liq 1 mg per ml .....	30.00	25 ml OP	✓ Biomed

#### METOLAZONE – Special Authority see SA1349 below – Retail pharmacy

Tab 5 mg .....	CBS	1	✓ Metolazone <sup>S29</sup>
		50	✓ Zaroxolyn <sup>S29</sup>

#### ►SA1349 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified where used for the treatment of patients with refractory heart failure who are intolerant or have not responded to loop diuretics and/or loop-thiazide combination therapy.

#### SPIRONOLACTONE

* Tab 25 mg .....	3.65	100	✓ Spiractin
* Tab 100 mg .....	11.80	100	✓ Spiractin
† Oral liq 5 mg per ml .....	30.00	25 ml OP	✓ Biomed

† safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Potassium Sparing Combination Diuretics</b>				
AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE				
* Tab 5 mg with furosemide 40 mg .....	8.63	28	✓	<b>Frumil</b>
AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE				
* Tab 5 mg with hydrochlorothiazide 50 mg .....	5.00	50	✓	<b>Moduretic</b>
<b>Thiazide and Related Diuretics</b>				
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]				
* Tab 2.5 mg – Up to 150 tab available on a PSO.....	5.48	500	✓	<b>Arrow- Bendrofluazide</b>
May be supplied on a PSO for reasons other than emergency.				
* Tab 5 mg .....	8.95	500	✓	<b>Arrow- Bendrofluazide</b>
CHLOROTHIAZIDE				
‡ Oral liq 50 mg per ml .....	26.00	25 ml OP	✓	<b>Biomed</b>
CHLORTALIDONE [CHLORTHALIDONE]				
* Tab 25 mg .....	8.00	50	✓	<b>Hygroton</b>
INDAPAMIDE				
* Tab 2.5 mg .....	2.25	90	✓	<b>Dapa-Tabs</b>
<b>Lipid-Modifying Agents</b>				
<b>Fibrates</b>				
BEZAFIBRATE				
* Tab 200 mg .....	9.05	90	✓	<b>Bezalip</b>
Bezalip to be Sole Supply on 1 November 2015				
* Tab long-acting 400 mg .....	6.78	30	✓	<b>Bezalip Retard</b>
Bezalip Retard to be Sole Supply on 1 November 2015				
GEMFIBROZIL				
* Tab 600 mg .....	17.60	60	✓	<b>Lipazil</b>
<b>Other Lipid-Modifying Agents</b>				
ACIPIMOX				
* Cap 250 mg .....	18.75	30	✓	<b>Olbetam</b>
NICOTINIC ACID				
* Tab 50 mg .....	3.96	100	✓	<b>Apo-Nicotinic Acid</b>
* Tab 500 mg .....	17.37	100	✓	<b>Apo-Nicotinic Acid</b>
<b>Resins</b>				
CHOLESTYRAMINE				
Powder for oral liq 4 g .....	19.25 (52.68)	50		Questran-Lite
COLESTIPOL HYDROCHLORIDE				
Grans for oral liq 5 g .....	22.00	30	✓	<b>Colestid</b>



Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## HMG CoA Reductase Inhibitors (Statins)

### Prescribing Guidelines

Treatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater.

ATORVASTATIN – See prescribing guideline above

* Tab 10 mg	0.84	30	✓ Lipitor ✓ Pfizer atorvastatin
	2.52	90	✓ Zarator
* Tab 20 mg	1.39	30	✓ Lipitor ✓ Pfizer atorvastatin
	4.17	90	✓ Zarator
* Tab 40 mg	2.44	30	✓ Lipitor ✓ Pfizer atorvastatin
	7.32	90	✓ Zarator
* Tab 80 mg	5.41	30	✓ Lipitor ✓ Pfizer atorvastatin
	16.23	90	✓ Zarator

(Lipitor Tab 10 mg to be delisted 1 November 2015)

(Pfizer atorvastatin Tab 10 mg to be delisted 1 November 2015)

(Lipitor Tab 20 mg to be delisted 1 November 2015)

(Pfizer atorvastatin Tab 20 mg to be delisted 1 November 2015)

(Lipitor Tab 40 mg to be delisted 1 November 2015)

(Pfizer atorvastatin Tab 40 mg to be delisted 1 November 2015)

(Lipitor Tab 80 mg to be delisted 1 November 2015)

(Pfizer atorvastatin Tab 80 mg to be delisted 1 November 2015)

PRAVASTATIN – See prescribing guideline above

* Tab 20 mg	3.45	30	✓ Cholvastin
* Tab 40 mg	6.36	30	✓ Cholvastin

SIMVASTATIN – See prescribing guideline above

* Tab 10 mg	0.95	90	✓ Arrow-Simva 10mg
* Tab 20 mg	1.61	90	✓ Arrow-Simva 20mg
* Tab 40 mg	2.83	90	✓ Arrow-Simva 40mg
* Tab 80 mg	7.91	90	✓ Arrow-Simva 80mg

## Selective Cholesterol Absorption Inhibitors

EZETIMIBE – Special Authority see SA1045 below – Retail pharmacy

Tab 10 mg	3.35 (34.43)	30	✓ Ezemibe Ezetrol
-----------	-----------------	----	----------------------

Ezemibe to be Sole Supply on 1 November 2015

(Ezetrol Tab 10 mg to be delisted 1 November 2015)

### SA1045 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:

continued...

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than  $10 \times$  normal) when treated with one statin; or
- 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
- 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to  $< 2.0$  mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**EZETIMIBE WITH SIMVASTATIN** – Special Authority see SA1046 below – Retail pharmacy

Tab 10 mg with simvastatin 10 mg .....	5.15 (36.68)	30	✓ <b>Zimybe</b> Vytorin
Zimybe to be Sole Supply on 1 November 2015			
Tab 10 mg with simvastatin 20 mg .....	6.15 (38.70)	30	✓ <b>Zimybe</b> Vytorin
Zimybe to be Sole Supply on 1 November 2015			
Tab 10 mg with simvastatin 40 mg .....	7.15 (41.40)	30	✓ <b>Zimybe</b> Vytorin
Zimybe to be Sole Supply on 1 November 2015			
Tab 10 mg with simvastatin 80 mg .....	8.15 (45.45)	30	✓ <b>Zimybe</b> Vytorin

Zimybe to be Sole Supply on 1 November 2015

*(Vytorin Tab 10 mg with simvastatin 10 mg to be delisted 1 November 2015)*

*(Vytorin Tab 10 mg with simvastatin 20 mg to be delisted 1 November 2015)*

*(Vytorin Tab 10 mg with simvastatin 40 mg to be delisted 1 November 2015)*

*(Vytorin Tab 10 mg with simvastatin 80 mg to be delisted 1 November 2015)*

## ►SA1046 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to  $\leq 2.0$  mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Nitrates

### GLYCERYL TRINITRATE

* Tab 600 mcg – Up to 100 tab available on a PSO .....	8.00	100 OP	✓ <b>Lycinate</b>
* Oral pump spray, 400 mcg per dose – Up to 250 dose available on a PSO .....	4.45	250 dose OP	✓ <b>Nitrolingual Pump Spray</b>
* Oral spray, 400 mcg per dose – Up to 250 dose available on a PSO .....	4.45	250 dose OP	✓ <b>Glytrin</b>
* Patch 25 mg, 5 mg per day .....	15.73	30	✓ <b>Nitroderm TTS</b>
* Patch 50 mg, 10 mg per day .....	18.62	30	✓ <b>Nitroderm TTS</b>

### ISOSORBIDE MONONITRATE

* Tab 20 mg .....	17.10	100	✓ <b>Ismo 20</b>
* Tab long-acting 40 mg .....	7.50	30	✓ <b>Ismo 40 Retard</b>
* Tab long-acting 60 mg .....	3.94	90	✓ <b>Duride</b>

## Sympathomimetics

### ADRENALINE

Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO .....	4.98	5	✓ <b>Aspen Adrenaline</b>
	5.25		✓ <b>Hospira</b>
Inj 1 in 10,000, 10 ml ampoule – Up to 5 inj available on a PSO .....	27.00	5	✓ <b>Hospira</b>
	49.00	10	✓ <b>Aspen Adrenaline</b>

### ISOPRENALINE

* Inj 200 mcg per ml, 1 ml ampoule .....	36.80	25	
	(164.20)		Isuprel

## Vasodilators

### AMYL NITRITE

* Liq 98% in 0.3 ml cap .....	62.92	12	
	(73.40)		Baxter

### HYDRALAZINE HYDROCHLORIDE

* Tab 25 mg – Special Authority see SA1321 below – Retail pharmacy .....	CBS	1	✓ <b>Hydralazine</b>
		56	✓ <b>Onelink</b> <small>\$29</small>
* Inj 20 mg ampoule .....	25.90	5	✓ <b>Apresoline</b>

#### ►SA1321 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 For the treatment of refractory hypertension; or
- 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

### MINOXIDIL – Special Authority see SA1271 below – Retail pharmacy

▲ Tab 10 mg .....	70.00	100	✓ <b>Loniten</b>
-------------------	-------	-----	------------------

#### ►SA1271 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid without further renewal unless notified where patient has severe refractory hypertension which has failed to respond to extensive multiple therapies.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time

if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>NICORANDIL</b>				
▲ Tab 10 mg .....	27.95	60	✓	Ikorel
▲ Tab 20 mg .....	33.28	60	✓	Ikorel
<b>PAPAVERINE HYDROCHLORIDE</b>				
* Inj 12 mg per ml, 10 ml ampoule .....	217.90	5	✓	Hospira
<b>PENTOXIFYLLINE [OXPENTIFYLLINE]</b>				
Tab 400 mg .....	36.94 (42.26)	50		Trental 400

## Endothelin Receptor Antagonists

### ►SA0967 Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: [PAH@pharmac.govt.nz](mailto:PAH@pharmac.govt.nz)

**AMBRISENTAN** – Special Authority see SA0967 above – Retail pharmacy

Tab 5 mg .....	4,585.00	30	✓	Volibris
Tab 10 mg .....	4,585.00	30	✓	Volibris

**BOSENTAN** – Special Authority see SA0967 above – Retail pharmacy

Tab 62.5 mg .....	375.00	56	✓	Mylan-Bosentan
	1,500.00	60	✓	pms-Bosentan
	4,585.00		✓	Tracleer
Tab 125 mg .....	375.00	56	✓	Mylan-Bosentan
	1,500.00	60	✓	pms-Bosentan
	4,585.00		✓	Tracleer

## Phosphodiesterase Type 5 Inhibitors

### ►SA1293 Special Authority for Subsidy

**Initial application — (Raynaud's Phenomenon\* - for Pulmonary Arterial Hypertension see note below)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has Raynaud's Phenomenon\*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) ; and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Notes: Sildenafil is also funded for patients with Pulmonary Arterial Hypertension who are approved by the Pulmonary Arterial Hypertension Panel (an application must be made using form [SA1293-PAH](#)).

Application details may be obtained from:

The Coordinator, PAH Panel

PHARMAC, PO Box 10 254, Wellington

Phone: (04) 916 7561 Facsimile: (04) 974 4858 Email: [PAH@pharmac.govt.nz](mailto:PAH@pharmac.govt.nz)

Indications marked with \* are Unapproved Indications.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SILDENAFIL – Special Authority see SA1293 on the previous page – Retail pharmacy				
Tab 25 mg .....	0.75	4	✓	Vedafil
	1.85		✓	Silagra
Tab 50 mg .....	0.75	4	✓	Vedafil
	1.85		✓	Silagra
Tab 100 mg – For sildenafil oral liquid formulation refer, page				
207 .....	2.75	4	✓	Vedafil
	7.45		✓	Silagra

## Prostacyclin Analogues

### ►SA0969 Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: [PAH@pharmac.govt.nz](mailto:PAH@pharmac.govt.nz)

ILOPROST – Special Authority see SA0969 above – Retail pharmacy

Nebuliser soln 10 mcg per ml, 2 ml .....	1,185.00	30	✓	Ventavis
--	----------	----	---	----------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Antiacne Preparations

For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 91

### ADAPALENE

a) Maximum of 30 g per prescription

b) Only on a prescription

Crm 0.1% .....	22.89	30 g OP	✓ Differin
----------------	-------	---------	------------

Gel 0.1% .....	22.89	30 g OP	✓ Differin
----------------	-------	---------	------------

### ISOTRETINOIN – Special Authority see SA1475 below – Retail pharmacy

Cap 10 mg .....	18.71	120	✓ Oratane
-----------------	-------	-----	-----------

Cap 20 mg .....	28.91	120	✓ Oratane
-----------------	-------	-----	-----------

### ►SA1475 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 3 Either:
  - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
  - 3.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

**Renewal** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
- 2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

### TRETINOIN

Crm 0.5 mg per g – Maximum of 50 g per prescription .....	13.90	50 g OP	✓ ReTrieve
---	-------	---------	------------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Antibacterials Topical

For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 91

### FUSIDIC ACID

Crm 2% .....	2.52	15 g OP	✓ <u>DP Fusidic Acid Cream</u>
--------------	------	---------	--------------------------------

- a) Maximum of 15 g per prescription
- b) Only on a prescription
- c) Not in combination

Oint 2% .....	3.45	15 g OP	✓ <u>Foban</u>
---------------	------	---------	----------------

- a) Maximum of 15 g per prescription
- b) Only on a prescription
- c) Not in combination

### HYDROGEN PEROXIDE

* Crm 1% .....	8.56	15 g OP	✓ <u>Crystaderm</u>
----------------	------	---------	---------------------

### MUPIROCIN

Oint 2% .....	6.60 (9.26)	15 g OP	Bactroban
---------------	----------------	---------	-----------

- a) Only on a prescription
- b) Not in combination

### SILVER SULPHADIAZINE

Crm 1% .....	12.30	50 g OP	✓ <u>Flamazine</u>
--------------	-------	---------	--------------------

- a) Up to 250 g available on a PSO
- b) Not in combination

## Antifungals Topical

For systemic antifungals, refer to INFECTIONS, Antifungals, page 98

### AMOROLFINE

- a) Only on a prescription
- b) Not in combination

Nail soln 5% .....	19.95	5 ml OP	✓ <u>MycoNail</u>
--------------------	-------	---------	-------------------

### CICLOPIROX OLAMINE

- a) Only on a prescription
- b) Not in combination

Nail-soln 8% .....	6.50	7 ml OP	✓ <u>Apo-Ciclopirox</u>
--------------------	------	---------	-------------------------

Apo-Ciclopirox to be Sole Supply on 1 October 2015

### CLOTRIMAZOLE

* Crm 1% .....	0.52	20 g OP	✓ <u>Clomazol</u>
----------------	------	---------	-------------------

- a) Only on a prescription
- b) Not in combination

* Soln 1% .....	4.36 (7.55)	20 ml OP	Canesten
-----------------	----------------	----------	----------

- a) Only on a prescription
- b) Not in combination

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ECONAZOLE NITRATE</b>				
Crm 1% .....	1.00 (7.48)	20 g OP		Pevaryl
a) Only on a prescription				
b) Not in combination				
Foaming soln 1%, 10 ml sachets .....	9.89 (17.23)	3		Pevaryl
a) Only on a prescription				
b) Not in combination				
<b>MICONAZOLE NITRATE</b>				
* Crm 2% .....	0.55	15 g OP	✓	<b>Multichem</b>
a) Only on a prescription				
b) Not in combination				
* Lotn 2% .....	4.36 (10.03)	30 ml OP		Daktarin
a) Only on a prescription				
b) Not in combination				
* Tinct 2% .....	4.36 (12.10)	30 ml OP		Daktarin
a) Only on a prescription				
b) Not in combination				
<b>NYSTATIN</b>				
Crm 100,000 u per g .....	1.00 (7.90)	15 g OP		Mycostatin
a) Only on a prescription				
b) Not in combination				
<b>Antipruritic Preparations</b>				
<b>CALAMINE</b>				
a) Only on a prescription				
b) Not in combination				
Crm, aqueous, BP .....	1.77	100 g	✓	<b>Pharmacy Health</b>
Lotn, BP .....	13.45	2,000 ml	✓	<b>PSM</b>
<b>CROTAMITON</b>				
a) Only on a prescription				
b) Not in combination				
Crm 10% .....	3.37	20 g OP	✓	<b>Itch-Soothe</b>
Itch-Soothe to be Sole Supply on 1 October 2015				
<b>MENTHOL – Only in combination</b>				
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, refer dermatological base, page 206				
2) With or without other dermatological galenicals.				
Crystals .....	6.50 6.92 29.60	25 g  100 g	✓ ✓ ✓	<b>PSM</b> <b>MidWest</b> <b>MidWest</b>



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Corticosteroids Topical

For systemic corticosteroids, refer to CORTICOSTEROIDS AND RELATED AGENTS, page 79

### Corticosteroids - Plain

#### BETAMETHASONE DIPROPIONATE

Crm 0.05% .....	2.96	15 g OP	✓ <b>Diprosone</b>
	8.97	50 g OP	✓ <b>Diprosone</b>
Crm 0.05% in propylene glycol base .....	4.33	30 g OP	✓ <b>Diprosone OV</b>
Oint 0.05% .....	2.96	15 g OP	✓ <b>Diprosone</b>
	8.97	50 g OP	✓ <b>Diprosone</b>
Oint 0.05% in propylene glycol base .....	4.33	30 g OP	✓ <b>Diprosone OV</b>

#### BETAMETHASONE VALERATE

* Crm 0.1% .....	3.15	50 g OP	✓ <b>Beta Cream</b>
* Oint 0.1% .....	3.15	50 g OP	✓ <b>Beta Ointment</b>
* Lotn 0.1% .....	10.05	50 ml OP	✓ <b>Betnovate</b>

#### CLOBETASOL PROPIONATE

* Crm 0.05% .....	3.20	30 g OP	✓ <b>Clobetasol BNM</b>
			✓ <b>Dermol</b>
Clobetasol BNM to be Sole Supply on 1 October 2015			
* Oint 0.05% .....	3.20	30 g OP	✓ <b>Clobetasol BNM</b>
			✓ <b>Dermol</b>

Clobetasol BNM to be Sole Supply on 1 October 2015

(Dermol Crm 0.05% to be delisted 1 October 2015)

(Dermol Oint 0.05% to be delisted 1 October 2015)

#### CLOBETASONE BUTYRATE

Crm 0.05% .....	5.38	30 g OP	
	(7.09)		Eumovate
	16.13	100 g OP	
	(22.00)		Eumovate

#### DIFLUCORTOLONE VALERATE

Crm 0.1% .....	8.97	50 g OP	
	(15.86)		Nerisone
Fatty oint 0.1% .....	8.97	50 g OP	
	(15.86)		Nerisone

#### HYDROCORTISONE

* Crm 1% – Only on a prescription .....	3.75	100 g	✓ <b>Pharmacy Health</b>
	14.00	500 g	✓ <b>Pharmacy Health</b>
* Powder – Only in combination .....	59.50	25 g	✓ <b>ABM</b>
Up to 5% in a dermatological base (not proprietary Topical Corticosteroid – Plain) with or without other dermatological galenicals. Refer, page 206			

#### HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN

Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – Only on a prescription .....	10.57	250 ml	✓ <b>DP Lotn HC</b>
--	-------	--------	---------------------

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>HYDROCORTISONE BUTYRATE</b>				
Lipocream 0.1% .....	2.30	30 g OP	✓	Locoid Lipocream
	6.85	100 g OP	✓	Locoid Lipocream
Oint 0.1% .....	6.85	100 g OP	✓	Locoid
Milky emul 0.1% .....	6.85	100 ml OP	✓	Locoid Crelo
<b>METHYLPREDNISOLONE ACEPONATE</b>				
Crm 0.1% .....	4.95	15 g OP	✓	Advantan
Oint 0.1% .....	4.95	15 g OP	✓	Advantan
<b>MOMETASONE FUROATE</b>				
Crm 0.1% .....	1.78	15 g OP	✓	m-Mometasone
	3.42	45 g OP	✓	m-Mometasone
Oint 0.1% .....	1.78	15 g OP	✓	m-Mometasone
	3.42	45 g OP	✓	m-Mometasone
Lotn 0.1% .....	7.35	30 ml OP	✓	Elocon
Elocon to be Sole Supply on 1 October 2015				
<b>TRIAMCINOLONE ACETONIDE</b>				
Crm 0.02% .....	6.30	100 g OP	✓	Aristocort
Oint 0.02% .....	6.35	100 g OP	✓	Aristocort
<b>Corticosteroids - Combination</b>				
<b>BETAMETHASONE VALERATE WITH CLIOQUINOL – Only on a prescription</b>				
Crm 0.1% with clioquinol 3% .....	3.49	15 g OP		Betnovate-C
	(4.90)			
<b>BETAMETHASONE VALERATE WITH FUSIDIC ACID</b>				
Crm 0.1% with fusidic acid 2% .....	3.49	15 g OP		Fucicort
	(10.45)			
a) Maximum of 15 g per prescription				
b) Only on a prescription				
<b>HYDROCORTISONE WITH MICONAZOLE – Only on a prescription</b>				
* Crm 1% with miconazole nitrate 2% .....	2.00	15 g OP	✓	Micreme H
Micreme H to be Sole Supply on 1 October 2015				
<b>HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – Only on a prescription</b>				
Crm 1% with natamycin 1% and neomycin sulphate 0.5% .....	2.79	15 g OP	✓	Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5% .....	2.79	15 g OP	✓	Pimafucort
<b>TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN</b>				
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g – Only on a prescription .....	3.49	15 g OP		Viaderm KC
	(6.60)			
<b>Disinfecting and Cleansing Agents</b>				
<b>CHLORHEXIDINE GLUCONATE – Subsidy by endorsement</b>				
a) No more than 500 ml per month				
b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly.				
* Handrub 1% with ethanol 70% .....	4.29	500 ml	✓	healthE
healthE to be Sole Supply on 1 October 2015				
* Soln 4% wash .....	3.98	500 ml	✓	healthE
	5.90		✓	Orion

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## TRICLOSAN – Subsidy by endorsement

- a) Maximum of 500 ml per prescription  
b)

- a) Only if prescribed for a patient identified with Methicillin-resistant Staphylococcus aureus (MRSA) prior to elective surgery in hospital and the prescription is endorsed accordingly; or  
b) Only if prescribed for a patient with recurrent Staphylococcus aureus infection and the prescription is endorsed accordingly

Soln 1% .....	4.50	500 ml OP	✓ <b>Pharmacy Health</b>
	5.90		✓ <b>healthE</b>

## Barrier Creams and Emollients

## Barrier Creams

## DIMETHICONE

* Crm 5% pump bottle .....	4.73	500 ml OP	✓ <b>healthE</b> <u>Dimethicone 5%</u>
----------------------------	------	-----------	---

## ZINC AND CASTOR OIL

* Oint BP .....	3.83	500 g	✓ <b>Multichem</b>
-----------------	------	-------	--------------------

## Emollients

## AQUEOUS CREAM

* Crm .....	1.96	500 g	✓ <b>AFT</b>
-------------	------	-------	--------------

## CETOMACROGOL

* Crm BP .....	3.15	500 g	✓ <b>PSM</b>
----------------	------	-------	--------------

## CETOMACROGOL WITH GLYCEROL

Crm 90% with glycerol 10% .....	4.50	500 ml OP	✓ <b>Pharmacy Health</b> <b>Sorbolene with Glycerin</b>
	6.50	1,000 ml OP	✓ <b>Pharmacy Health</b> <b>Sorbolene with Glycerin</b>

## EMULSIFYING OINTMENT

* Oint BP .....	2.73	500 g	✓ <b>AFT</b>
-----------------	------	-------	--------------

## OIL IN WATER EMULSION

* Crm .....	2.63	500 g	✓ <b>healthE Fatty Cream</b>
-------------	------	-------	------------------------------

## UREA

* Crm 10% .....	1.65	100 g OP	✓ <b>healthE Urea Cream</b>
-----------------	------	----------	-----------------------------

## WOOL FAT WITH MINERAL OIL – Only on a prescription

* Lotn hydrous 3% with mineral oil .....	1.40	250 ml OP	
	(4.53)		DP Lotion
	5.60	1,000 ml	
	(11.95)		DP Lotion
	(20.53)		Alpha-Keri Lotion
	1.40	250 ml OP	
	(7.73)		BK Lotion
	5.60	1,000 ml	
	(23.91)		BK Lotion

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Other Dermatological Bases</b>				
<b>PARAFFIN</b>				
White soft – Only in combination .....	3.58 (7.78)	500 g		IPW
	20.20	2,500 g	✓	IPW
	3.58 (8.69)	500 g		PSM
Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain.				
<b>Minor Skin Infections</b>				
<b>POVIDONE IODINE</b>				
Oint 10% .....	3.27	25 g OP	✓	Betadine
a) Maximum of 100 g per prescription				
b) Only on a prescription				
Antiseptic soln 10% .....	0.19 (4.45)	15 ml		Betadine
	1.28 (8.25)	100 ml		Betadine
	6.20	500 ml	✓	Betadine
	1.28 (4.20)	100 ml		Riodine
	6.20	500 ml	✓	Riodine
Skin preparation, povidone iodine 10% with 30% alcohol .....	1.63 (3.65)	100 ml		Betadine Skin Prep
	10.00	500 ml	✓	Betadine Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol .....	1.63 (6.04)	100 ml		Orion
	8.13 (18.63)	500 ml		Orion

## Parasiticial Preparations

<b>GAMMA BENZENE HEXACHLORIDE</b>				
Crm 1% .....	3.50	50 g OP	✓	Benhex
<i>(Benhex Crm 1% to be delisted 1 January 2016)</i>				
<b>IVERMECTIN – Special Authority see SA1225 on the next page – Retail pharmacy</b>				
Tab 3 mg – Up to 100 tab available on a PSO.....	17.20	4	✓	Stromectol
1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and a valid Special Authority for patient of that institution.				
2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution.				
3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or penal institutions.				

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

### ►SA1225 | Special Authority for Subsidy

**Initial application — (Scabies)** from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:

2.1 Both:

2.1.1 The patient is in the community; and

2.1.2 Any of the following:

2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or

2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or

2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or

2.2 All of the following:

2.2.1 The Patient is a resident in an institution; and

2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and

2.2.3 Any of the following:

2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or

2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or

2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

**Initial application — (Other parasitic infections)** only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

**Renewal — (Scabies)** from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:

2.1 Both:

2.1.1 The patient is in the community; and

2.1.2 Any of the following:

2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or

2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or

2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or

2.2 All of the following:

2.2.1 The Patient is a resident in an institution; and

2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and

2.2.3 Any of the following:

continued...

continued...

- 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
- 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
- 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

**Renewal — (Other parasitic infections)** only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

#### MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE

Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2% .....11.15      90 g OP      ✓ **Para Plus**

#### PERMETHRIN

Crm 5% .....4.20      30 g OP      ✓ **Lyderm**  
 Lotn 5% .....3.19      30 ml OP      ✓ **A-Scabies**

### Psoriasis and Eczema Preparations

ACITRETIN – Special Authority see SA1476 below – Retail pharmacy

Cap 10 mg .....17.86      60      ✓ **Novatretin**  
 Cap 25 mg .....41.36      60      ✓ **Novatretin**

#### ►SA1476 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
  - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
  - 3.2 Patient is male.

**Renewal** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
- 2 Patient is male.

#### BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Gel 500 mcg with calcipotriol 50 mcg per g .....26.12      30 g OP      ✓ **Daivobet**  
 Daivobet to be Sole Supply on 1 October 2015  
 Oint 500 mcg with calcipotriol 50 mcg per g .....26.12      30 g OP      ✓ **Daivobet**  
 Daivobet to be Sole Supply on 1 October 2015

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>CALCIPOTRIOL</b>				
Crm 50 mcg per g .....	16.00	30 g OP	✓	<b>Daivonex</b>
	45.00	100 g OP	✓	<b>Daivonex</b>
Oint 50 mcg per g .....	45.00	100 g OP	✓	<b>Daivonex</b>
Soln 50 mcg per ml .....	16.00	30 ml OP	✓	<b>Daivonex</b>
<b>COAL TAR</b>				
Soln – Only in combination .....	12.55	200 ml	✓	<b>Midwest</b>
1) Up to 10% only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, refer dermatological base, page 206				
2) With or without other dermatological galenicals.				
<b>COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR</b>				
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and allantoin crm 2.5% .....	3.43 (4.35) 6.59 (8.00)	30 g OP  75 g OP		Egopsoryl TA  Egopsoryl TA
<b>COAL TAR WITH SALICYLIC ACID AND SULPHUR</b>				
Soln 12% with salicylic acid 2% and sulphur 4% oint .....	7.95	40 g OP	✓	<b>Coco-Scalp</b>
<b>SALICYLIC ACID</b>				
Powder – Only in combination .....	18.88	250 g	✓	<b>PSM</b>
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain or collodion flexible, refer dermatological base, page 206				
2) With or without other dermatological galenicals.				
<b>SULPHUR</b>				
Precipitated – Only in combination .....	6.35	100 g	✓	<b>Midwest</b>
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, refer dermatological base, page 206				
2) With or without other dermatological galenicals.				
<b>TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCIN – Only on a prescription</b>				
* Soln 2.3% with triethanolamine lauryl sulphate and fluores- cein sodium .....	3.36	500 ml	✓	<b>Pinetarsol</b>
Pinetarsol to be Sole Supply on 1 October 2015				
<b>Scalp Preparations</b>				
<b>BETAMETHASONE VALERATE</b>				
* Scalp app 0.1% .....	7.75	100 ml OP	✓	<b>Beta Scalp</b>
<b>CLOBETASOL PROPIONATE</b>				
* Scalp app 0.05% .....	6.96	30 ml OP	✓	<b>Dermol</b>
<b>HYDROCORTISONE BUTYRATE</b>				
Scalp lotn 0.1% .....	3.65	100 ml OP	✓	<b>Locoid</b>
<b>KETOCONAZOLE</b>				
Shampoo 2% .....	2.99	100 ml OP	✓	<b>Sebizole</b>
a) Maximum of 100 ml per prescription				
b) Only on a prescription				

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## Sunscreens

### SUNSCREENS, PROPRIETARY – Subsidy by endorsement

Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly.

Crm .....	3.30 (5.89)	100 g OP	
Lotn, .....	3.30	100 g OP	✓ <b>Hamilton Sunscreen</b> <b>Marine Blue Lotion</b> <b>SPF 50+</b>
	5.10	200 g OP	✓ <b>Marine Blue Lotion</b> <b>SPF 50+</b>
Lotn .....	4.13 (6.94)	125 ml OP	Aquasun 30+

## Wart Preparations

For salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, page 70

### IMIQUIMOD

Crm 5%, 250 mg sachet .....	17.98	12	✓ <b><u>Apo-Imiquimod</u></b> <b><u>Cream 5%</u></b>
-----------------------------	-------	----	---

### PODOPHYLLOTOXIN

Soln 0.5% .....	33.60	3.5 ml OP	✓ <b>Condyline</b>
a) Maximum of 3.50 ml per prescription			
b) Only on a prescription			

## Other Skin Preparations

### Antineoplastics

### FLUOROURACIL SODIUM

Crm 5% .....	8.95	20 g OP	✓ <b>Efudix</b>
Efudix to be Sole Supply on 1 October 2015			



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Contraceptives - Non-hormonal

### Condoms

#### CONDOMS

* 49 mm – Up to 144 dev available on a PSO.....	13.36	144	✓ MarquisTantiliza ✓ Shield 49
* 52 mm – Up to 144 dev available on a PSO.....	13.36	144	✓ Marquis Selecta ✓ Marquis Sensolite ✓ Marquis Supalite ✓ Marquis Protecta
* 52 mm extra strength – Up to 144 dev available on a PSO.....	13.36	144	✓ Gold Knight ✓ Shield Blue
* 53 mm – Up to 144 dev available on a PSO.....	1.11	12	✓ Shield Blue ✓ Shield Blue ✓ Marquis Black ✓ Marquis Titillata
	13.36	144	✓ Gold Knight ✓ Gold Knight ✓ Gold Knight ✓ Gold Knight
* 53 mm (chocolate) – Up to 144 dev available on a PSO.....	1.11	12	
	13.36	144	
* 53 mm (strawberry) – Up to 144 dev available on a PSO.....	1.11	12	
	13.36	144	
* 54 mm, shaped – Up to 144 dev available on a PSO.....	1.12	12	
	(1.24)		Lifestyles Flared
	13.36	144	
	(14.84)		Lifestyles Flared
* 55 mm – Up to 144 dev available on a PSO.....	13.36	144	✓ Marquis Conform
* 56 mm – Up to 144 dev available on a PSO.....	1.11	12	✓ Gold Knight ✓ Gold Knight ✓ Durex Extra Safe ✓ Durex Select Flavours
	13.36	144	✓ Durex Confidence ✓ Durex Confidence ✓ Shield XL
* 56 mm, shaped – Up to 144 dev available on a PSO.....	1.11	12	
	13.36	144	
* 60 mm – Up to 144 dev available on a PSO.....	13.36	144	

### Contraceptive Devices

#### DIAPHRAGM – Up to 1 dev available on a PSO

One of each size is permitted on a PSO.

* 65 mm .....	42.90	1	✓ Ortho All-flex
* 70 mm .....	42.90	1	✓ Ortho All-flex
* 75 mm .....	42.90	1	✓ Ortho All-flex
* 80 mm .....	42.90	1	✓ Ortho All-flex

#### INTRA-UTERINE DEVICE

a) Up to 40 dev available on a PSO

b) Only on a PSO

* IUD 29.1 mm length × 23.2 mm width .....	31.60	1	✓ Choice TT380 Short
* IUD 33.6 mm length × 29.9 mm width .....	31.60	1	✓ Choice TT380 Standard

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## Contraceptives - Hormonal

### Combined Oral Contraceptives

#### ►SA0500 Special Authority for Alternate Subsidy

**Initial application** from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
  - 1.1 Patient is on a Social Welfare benefit; or
  - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

**Renewal** from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

#### ETHINYLOESTRADIOL WITH DESOGESTREL

* Tab 20 mcg with desogestrel 150 mcg and 7 inert tab .....	6.62	84	
	(19.80)		Mercilon 28
a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 above			
b) Up to 84 tab available on a PSO			
* Tab 30 mcg with desogestrel 150 mcg and 7 inert tab .....	6.62	84	
	(19.80)		Marvelon 28
a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 above			
b) Up to 84 tab available on a PSO			

#### ETHINYLOESTRADIOL WITH LEVONORGESTREL

* Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab – Up			
to 84 tab available on a PSO .....	2.65	84	✓ Ava 20 ED
* Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab – Up			
to 84 tab available on a PSO .....	9.45	84	✓ Microgynon 50 ED
* Tab 30 mcg with levonorgestrel 150 mcg .....	6.62	63	
	(16.50)		Microgynon 30
a) Higher subsidy of \$15.00 per 63 tab with Special Authority see SA0500 above			
b) Up to 63 tab available on a PSO			
* Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab – Up			
to 84 tab available on a PSO .....	2.30	84	✓ Ava 30 ED

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ETHINYLOESTRADIOL WITH NORETHISTERONE</b>				
* Tab 35 mcg with norethisterone 1 mg – Up to 63 tab available on a PSO .....	6.62	63	✓	<b>Brevinor 1/21</b>
* Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO .....	6.62	84	✓	<b>Brevinor 1/28</b>
* Tab 35 mcg with norethisterone 500 mcg – Up to 63 tab available on a PSO .....	6.62	63	✓	<b>Brevinor 21</b>
* Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – Up to 84 tab available on a PSO .....	6.62	84	✓	<b>Norimin</b>

### Progestogen-only Contraceptives

#### ►SA0500 | Special Authority for Alternate Subsidy

**Initial application** from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
  - 1.1 Patient is on a Social Welfare benefit; or
  - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

**Renewal** from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

#### LEVONORGESTREL

* Tab 30 mcg .....	6.62	84		
	(16.50)			Microlut
a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 above				
b) Up to 84 tab available on a PSO				

* Subdermal implant (2 × 75 mg rods) .....	133.65	1	✓	<b>Jadelle</b>
--	--------	---	---	----------------

#### MEDROXYPROGESTERONE ACETATE

* Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO .....	7.00	1	✓	<b>Depo-Provera</b>
--	------	---	---	---------------------

#### NORETHISTERONE

* Tab 350 mcg – Up to 84 tab available on a PSO .....	6.25	84	✓	<b>Noriday 28</b>
Noriday 28 to be Sole Supply on 1 November 2015				

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Emergency Contraceptives</b>				
<b>LEVONORGESTREL</b>				
* Tab 1.5 mg .....	3.50	1	✓	<b>Postinor-1</b>
a) Up to 5 tab available on a PSO				
b) Maximum of 2 tab per prescription				
<b>Antiandrogen Oral Contraceptives</b>				
Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows:				
• \$5.00 prescription charge (patient co-payment) will apply.				
• prescription may be written for up to six months supply.				
Prescriptions coded in any other way are subject to the non contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.				
<b>CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL</b>				
* Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs – Up to 168 tab available on a PSO .....	5.36	168	✓	<b>Ginet</b>
<b>Gynaecological Anti-infectives</b>				
<b>ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID</b>				
Jelly with glacial acetic acid 0.94%, hydroxyquinoline sul- phate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator .....	8.43 (24.00)	100 g OP		Aci-Jel
<b>CLOTRIMAZOLE</b>				
* Vaginal crm 1% with applicators .....	1.45	35 g OP	✓	<b>Clomazol</b>
* Vaginal crm 2% with applicators .....	2.20	20 g OP	✓	<b>Clomazol</b>
<b>MICONAZOLE NITRATE</b>				
* Vaginal crm 2% with applicator .....	3.95	40 g OP	✓	<b>Micreme</b>
<b>NYSTATIN</b>				
Vaginal crm 100,000 u per 5 g with applicator(s) .....	4.71	75 g OP	✓	<b>Nilstat</b>
<b>Myometrial and Vaginal Hormone Preparations</b>				
<b>ERGOMETRINE MALEATE</b>				
Inj 500 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO .....	94.70	5	✓	<b>DBL Ergometrine</b>
<b>OESTRIOL</b>				
* Crm 1 mg per g with applicator .....	6.30	15 g OP	✓	<b>Ovestin</b>
* Pessaries 500 mcg .....	6.53	15	✓	<b>Ovestin</b>
<b>OXYTOCIN – Up to 5 inj available on a PSO</b>				
Inj 5 iu per ml, 1 ml ampoule .....	4.75	5	✓	<b>Oxytocin BNM</b>
Inj 10 iu per ml, 1 ml ampoule .....	5.98	5	✓	<b>BNM</b>
<b>OXYTOCIN WITH ERGOMETRINE MALEATE – Up to 5 inj available on a PSO</b>				
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml .....	11.13	5	✓	<b>Syntometrine</b>
Syntometrine to be Sole Supply on 1 October 2015				

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## Pregnancy Tests - hCG Urine

### PREGNANCY TESTS - HCG URINE

- a) Up to 200 test available on a PSO  
b) Only on a PSO

Cassette .....	17.60	40 test OP	✓ EasyCheck
	22.80		✓ Innovacon hCG One Step Pregnancy Test

## Urinary Agents

For urinary tract Infections refer to INFECTIONS, Antibacterials, page 112

## 5-Alpha Reductase Inhibitors

FINASTERIDE – Special Authority see SA0928 below – Retail pharmacy

* Tab 5 mg .....	1.95	28	✓ <u>Finpro</u>
------------------	------	----	-----------------

### SA0928 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
  - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
  - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

Note: Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.

## Alpha-1A Adrenoreceptor Blockers

TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 below – Retail pharmacy

* Cap 400 mcg .....	13.51	100	✓ <u>Tamsulosin-Rex</u>
---------------------	-------	-----	-------------------------

### SA1032 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

## Other Urinary Agents

### OXYBUTYNIN

* Tab 5 mg .....	11.20	500	✓ <u>Apo-Oxybutynin</u>
* Oral liq 5 mg per 5 ml .....	56.45	473 ml	✓ <u>Apo-Oxybutynin</u>

### POTASSIUM CITRATE

Oral liq 3 mmol per ml – Special Authority see SA1083 on the next page – Retail pharmacy .....	30.00	200 ml OP	✓ Biomed
---	-------	-----------	----------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## ►►SA1083 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:  
Both:

- 1 The patient has recurrent calcium oxalate urolithiasis; and
- 2 The patient has had more than two renal calculi in the two years prior to the application.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

### SODIUM CITRO-TARTRATE

* Grans eff 4 g sachets .....	2.93	28	✓ <u>Ural</u>
SOLIFENACIN SUCCINATE – Special Authority see SA0998 below – Retail pharmacy			
Tab 5 mg .....	37.50	30	✓ <u>Vesicare</u>
Tab 10 mg .....	37.50	30	✓ <u>Vesicare</u>

## ►►SA0998 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin.

### TOLTERODINE – Special Authority see SA1272 below – Retail pharmacy

Tab 1 mg .....	14.56	56	✓ <u>Arrow-Tolterodine</u>
Tab 2 mg .....	14.56	56	✓ <u>Arrow-Tolterodine</u>

## ►►SA1272 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified where patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin.

## Detection of Substances in Urine

### ORTHO-TOLIDINE

* Compound diagnostic sticks .....	7.50 (8.25)	50 test OP	Hemastix
------------------------------------	----------------	------------	----------

### TETRABROMOPHENOL

* Blue diagnostic strips .....	7.02 (13.92)	100 test OP	Albustix
--------------------------------	-----------------	-------------	----------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Calcium Homeostasis

### CALCITONIN

\* Inj 100 iu per ml, 1 ml ampoule ..... 121.00      5      ✓ Miacalcic

### ZOLEDRONIC ACID

Inj 4 mg per 5 ml, vial – Special Authority see SA1512 below

– Retail pharmacy ..... 550.00      1      ✓ Zometa

#### ►SA1512 | Special Authority for Subsidy

**Initial application** only from an oncologist, haematologist or palliative care specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Patient has hypercalcaemia of malignancy; or
- 2 Both:
  - 2.1 Patient has bone metastases or involvement; and
  - 2.2 Patient has severe bone pain resistant to standard first-line treatments; or
- 3 Both:
  - 3.1 Patient has bone metastases or involvement; and
  - 3.2 Patient is at risk of skeletal-related events pathological fracture, spinal cord compression, radiation to bone or surgery to bone).

## Corticosteroids and Related Agents for Systemic Use

### BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

\* Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ..... 19.20      5  
(33.60)      Celestone  
Chronodose

### DEXAMETHASONE

\* Tab 1 mg – Retail pharmacy-Specialist ..... 5.87      100      ✓ Douglas  
Up to 30 tab available on a PSO

\* Tab 4 mg – Retail pharmacy-Specialist ..... 8.16      100      ✓ Douglas  
Up to 30 tab available on a PSO

Oral liq 1 mg per ml – Retail pharmacy-Specialist ..... 45.00      25 ml OP      ✓ Biomed

Oral liq prescriptions:

- 1) Must be written by a Paediatrician or Paediatric Cardiologist; or
- 2) On the recommendation of a Paediatrician or Paediatric Cardiologist.

### DEXAMETHASONE PHOSPHATE

Dexamethasone phosphate injection will not be funded for oral use.

\* Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO ..... 25.80      10      ✓ Dexamethasone-  
hameln

\* Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO ..... 17.98      5      ✓ Dexamethasone-  
hameln

### FLUDROCORTISONE ACETATE

\* Tab 100 mcg ..... 14.32      100      ✓ Florinef

# HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>HYDROCORTISONE</b>				
* Tab 5 mg .....	8.10	100	✓	<b>Douglas</b>
Douglas to be Sole Supply on 1 October 2015				
* Tab 20 mg – For hydrocortisone oral liquid formulation refer, page 207 .....	20.32	100	✓	<b>Douglas</b>
Douglas to be Sole Supply on 1 October 2015				
* Inj 100 mg vial .....	4.99	1	✓	<b>Solu-Cortef</b>
a) Up to 5 inj available on a PSO				
b) Only on a PSO				
<b>METHYLPREDNISOLONE – Retail pharmacy-Specialist</b>				
* Tab 4 mg .....	80.00	100	✓	<b>Medrol</b>
Medrol to be Sole Supply on 1 November 2015				
* Tab 100 mg .....	180.00	20	✓	<b>Medrol</b>
Medrol to be Sole Supply on 1 November 2015				
<b>METHYLPREDNISOLONE (AS SODIUM SUCCINATE) – Retail pharmacy-Specialist</b>				
Inj 40 mg vial .....	10.50	1	✓	<b>Solu-Medrol</b>
Solu-Medrol to be Sole Supply on 1 November 2015				
Inj 125 mg vial .....	22.25	1	✓	<b>Solu-Medrol</b>
Solu-Medrol to be Sole Supply on 1 November 2015				
Inj 500 mg vial .....	9.00	1	✓	<b>Solu-Medrol</b>
Solu-Medrol to be Sole Supply on 1 November 2015				
Inj 1 g vial .....	16.00	1	✓	<b>Solu-Medrol</b>
Solu-Medrol to be Sole Supply on 1 November 2015				
<b>METHYLPREDNISOLONE ACETATE</b>				
Inj 40 mg per ml, 1 ml vial .....	40.00	5	✓	<b>Depo-Medrol</b>
Depo-Medrol to be Sole Supply on 1 November 2015				
<b>METHYLPREDNISOLONE ACETATE WITH LIDOCAINE [LIGNOCAINE]</b>				
Inj 40 mg per ml with lidocaine [lignocaine] 1 ml vial .....	9.25	1	✓	<b>Depo-Medrol with Lidocaine</b>
Depo-Medrol with Lidocaine to be Sole Supply on 1 November 2015				
<b>PREDNISOLONE</b>				
* Oral liq 5 mg per ml – Up to 30 ml available on a PSO .....	7.50	30 ml OP	✓	<b>Redipred</b>
Restricted to children under 12 years of age.				
<b>PREDNISONE</b>				
* Tab 1 mg .....	2.13	100	✓	<b>Apo-Prednisone</b>
S29 <sup>S29</sup>				
	10.68	500	✓	<b>Apo-Prednisone</b>
* Tab 2.5 mg .....	12.09	500	✓	<b>Apo-Prednisone</b>
* Tab 5 mg – Up to 30 tab available on a PSO .....	11.09	500	✓	<b>Apo-Prednisone</b>
* Tab 20 mg .....	29.03	500	✓	<b>Apo-Prednisone</b>
<b>TETRACOSACTRIN</b>				
* Inj 250 mcg per ml, 1 ml ampoule .....	17.71	1	✓	<b>Synacthen</b>
	177.18	10	✓	<b>Synacthen</b>
* Inj 1 mg per ml, 1 ml .....	29.56	1	✓	<b>Synacthen Depot</b>
<b>TRIAMCINOLONE ACETONIDE</b>				
Inj 10 mg per ml, 1 ml ampoule .....	20.80	5	✓	<b>Kenacort-A 10</b>
Inj 40 mg per ml, 1 ml ampoule .....	51.10	5	✓	<b>Kenacort-A 40</b>



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Sex Hormones Non Contraceptive

### Androgen Agonists and Antagonists

#### CYPROTERONE ACETATE – Retail pharmacy-Specialist

Tab 50 mg .....	15.87	50	✓ <b>Procur</b>
	18.80		✓ <b>Siterone</b>
Tab 100 mg .....	30.40	50	✓ <b>Procur</b>
	34.25		✓ <b>Siterone</b>

#### TESTOSTERONE

Transdermal patch, 2.5 mg per day .....	80.00	60	✓ <b>Androderm</b>
---	-------	----	--------------------

#### TESTOSTERONE CYPIONATE – Retail pharmacy-Specialist

Inj 100 mg per ml, 10 ml vial .....	76.50	1	✓ <b><u>Depo-Testosterone</u></b>
-------------------------------------	-------	---	-----------------------------------

#### TESTOSTERONE ESTERS – Retail pharmacy-Specialist

Inj 250 mg per ml, 1 ml .....	12.98	1	✓ <b>Sustanon Ampoules</b>
-------------------------------	-------	---	----------------------------

#### TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist

Cap 40 mg .....	16.80	60	✓ <b>Andriol Testocaps</b>
Andriol Testocaps to be Sole Supply on 1 October 2015			
Inj 250 mg per ml, 4 ml vial .....	86.00	1	✓ <b>Reandron 1000</b>

## Hormone Replacement Therapy - Systemic

### ▶SA1018 | Special Authority for Alternate Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria:  
Any of the following:

- 1 acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 × normal triglyceride levels post oral oestrogens; or
- 4 Somatropin co-therapy - patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

**Renewal** from any relevant practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment, or the patient remains on subsidised somatropin co-therapy.

### Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

# HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Oestrogens</b>				
OESTRADIOL – See prescribing guideline on the previous page				
* Tab 1 mg .....	4.12 (11.10)	28 OP		Estrofem
* Tab 2 mg .....	4.12 (11.10)	28 OP		Estrofem
* TDDS 25 mcg per day .....	3.01 (10.86)	8		Estradot
a) Higher subsidy of \$10.86 per 8 patch with Special Authority see SA1018 on the previous page				
b) No more than 2 patch per week				
c) Only on a prescription				
* TDDS 3.9 mg (releases 50 mcg of oestradiol per day) .....	4.12 (13.18)	4		Climara 50
a) Higher subsidy of \$13.18 per 4 patch with Special Authority see SA1018 on the previous page				
b) No more than 1 patch per week				
c) Only on a prescription				
* TDDS 50 mcg per day .....	4.12 (13.18)	8		Estradot 50 mcg
a) Higher subsidy of \$13.18 per 8 patch with Special Authority see SA1018 on the previous page				
b) No more than 2 patch per week				
c) Only on a prescription				
* TDDS 7.8 mg (releases 100 mcg of oestradiol per day) .....	7.05 (16.14)	4		Climara 100
a) Higher subsidy of \$16.14 per 4 patch with Special Authority see SA1018 on the previous page				
b) No more than 1 patch per week				
c) Only on a prescription				
* TDDS 100 mcg per day .....	7.05 (16.14)	8		Estradot
a) Higher subsidy of \$16.14 per 8 patch with Special Authority see SA1018 on the previous page				
b) No more than 2 patch per week				
c) Only on a prescription				
OESTRADIOL VALERATE – See prescribing guideline on the previous page				
* Tab 1 mg .....	12.36	84	✓	<u>Progynova</u>
* Tab 2 mg .....	12.36	84	✓	<u>Progynova</u>
OESTROGENS – See prescribing guideline on the previous page				
* Conjugated, equine tab 300 mcg .....	3.01 (11.48)	28		Premarin
* Conjugated, equine tab 625 mcg .....	4.12 (11.48)	28		Premarin
<b>Progestogens</b>				
MEDROXYPROGESTERONE ACETATE – See prescribing guideline on the previous page				
* Tab 2.5 mg .....	3.09	30	✓	<u>Provera</u>
* Tab 5 mg .....	13.06	100	✓	<u>Provera</u>
* Tab 10 mg .....	6.85	30	✓	<u>Provera</u>

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Progestogen and Oestrogen Combined Preparations

OESTRADIOL WITH NORETHISTERONE – See prescribing guideline on page 81

* Tab 1 mg with 0.5 mg norethisterone acetate .....	5.40 (18.10)	28 OP	Kliovance
* Tab 2 mg with 1 mg norethisterone acetate .....	5.40 (18.10)	28 OP	Kliogest
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6) .....	5.40 (18.10)	28 OP	Trisequens

OESTROGENS WITH MEDROXYPROGESTERONE – See prescribing guideline on page 81

* Tab 625 mcg conjugated equine with 2.5 mg medroxyproges- terone acetate tab (28) .....	5.40 (22.96)	28 OP	Premia 2.5 Continuous
* Tab 625 mcg conjugated equine with 5 mg medroxyproges- terone acetate tab (28) .....	5.40 (22.96)	28 OP	Premia 5 Continuous

## Other Oestrogen Preparations

ETHINYLOESTRADIOL

* Tab 10 mcg .....	17.60	100	✓ NZ Medical and Scientific
--------------------	-------	-----	--------------------------------

NZ Medical and Scientific to be Sole Supply on 1 October 2015

OESTRIOL

* Tab 2 mg .....	7.00	30	✓ Ovestin
------------------	------	----	-----------

## Other Progestogen Preparations

LEVONORGESTREL

* Levonorgestrel - releasing intrauterine system 20 mcg/24 hr – Special Authority see SA0782 below – Retail pharmacy .....	269.50	1	✓ Mirena
---	--------	---	----------

### ►SA0782 Special Authority for Subsidy

**Initial application — (No previous use)** only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and
- 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
- 3 Either:
  - 3.1 serum ferritin level < 16 mcg/l (within the last 12 months); or
  - 3.2 haemoglobin level < 120 g/l.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

**Initial application — (Previous use before 1 October 2002)** only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and
- 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and

continued...

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

# HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3 Applicant to state date of the previous insertion.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

**Renewal** only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
  - 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or
  - 1.2 Previous insertion was removed or expelled within 3 months of insertion; and

- 2 Applicant to state date of the previous insertion.

## MEDROXYPROGESTERONE ACETATE

\* Tab 100 mg – Retail pharmacy-Specialist ..... 96.50      100      ✓ **Provera**

## NORETHISTERONE

\* Tab 5 mg – Up to 30 tab available on a PSO ..... 18.29      100      ✓ **Primolut N**

## PROGESTERONE

Cap 100 mg – Special Authority see SA1392 below – Retail

pharmacy ..... 16.50      30      ✓ **Utrogestan**

### ►SA1392 Special Authority for Subsidy

**Initial application** only from an obstetrician or gynaecologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 For the prevention of pre-term labour\*; and
- 2 Either:
  - 2.1 The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or
  - 2.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with \* are Unapproved Indications (refer to Interpretations and Definitions).

## Thyroid and Antithyroid Agents

### CARBIMAZOLE

\* Tab 5 mg ..... 10.80      100      ✓ **Neo-Mercazole**

### LEVOTHYROXINE

\* Tab 25 mcg ..... 3.89      90      ✓ **Synthroid**

‡ Safety cap for extemporaneously compounded oral liquid preparations.

\* Tab 50 mcg ..... 4.05      90      ✓ **Synthroid**

64.28      1,000

✓ **Eltroxin**

‡ Safety cap for extemporaneously compounded oral liquid preparations.

\* Tab 100 mcg ..... 4.21      90      ✓ **Synthroid**

66.78      1,000

✓ **Eltroxin**

‡ Safety cap for extemporaneously compounded oral liquid preparations.

### LEVOTHYROXINE (MERCURY PHARMA)

\* Tab 50 mcg ..... 1.71      28      ✓ **Mercury Pharma**

‡ Safety cap for extemporaneously compounded oral liquid preparations.

\* Tab 100 mcg ..... 1.78      28      ✓ **Mercury Pharma**

‡ Safety cap for extemporaneously compounded oral liquid preparations.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

PROPYLTHIOURACIL – Special Authority see SA1199 below – Retail pharmacy

Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

Tab 50 mg .....	35.00	100	✓ PTU <del>\$29</del>
-----------------	-------	-----	-----------------------

## ▶SA1199 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

## Trophic Hormones

### Growth Hormones

SOMATROPIN (OMNITROPE) – Special Authority see SA1451 below – Retail pharmacy

* Inj 5 mg cartridge .....	109.50	1	✓ <u>Omnitrope</u>
* Inj 10 mg cartridge .....	219.00	1	✓ <u>Omnitrope</u>
* Inj 15 mg cartridge .....	328.50	1	✓ <u>Omnitrope</u>

## ▶SA1451 Special Authority for Subsidy

**Initial application — (growth hormone deficiency in children)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or
- 2 All of the following:
  - 2.1 Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
  - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
  - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
  - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
  - 2.5 Appropriate imaging of the pituitary gland has been obtained.

**Renewal — (growth hormone deficiency in children)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 A current bone age is ≤ 14 years (female patients) or ≤ 16 years (male patients); and
- 2 Height velocity is ≥ 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is ≥ 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

**Initial application — (Turner syndrome)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

**Renewal — (Turner syndrome)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity  $\geq$  50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is  $\geq$  2 cm per year, calculated over six months; and
- 3 A current bone age is  $\leq$  14 years; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

**Initial application — (short stature without growth hormone deficiency)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

**Renewal — (short stature without growth hormone deficiency)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is  $\geq$  50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is  $\geq$  2 cm per year as calculated over six months; and
- 3 A current bone age is  $\leq$  14 years (female patients) or  $\leq$  16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

**Initial application — (short stature due to chronic renal insufficiency)** only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is  $\leq$  to 14 years (female patients) or  $\leq$  to 16 years (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 6.1 The patient has a GFR  $\leq 30$  ml/min/1.73m<sup>2</sup> as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l)  $\times 40$  = corrected GFR (ml/min/1.73m<sup>2</sup> in a child who may or may not be receiving dialysis; or
- 6.2 The patient has received a renal transplant and has received  $< 5$ mg/ m<sup>2</sup>/day of prednisone or equivalent for at least 6 months..

**Renewal — (short stature due to chronic renal insufficiency)** only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is  $\geq 50$ th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is  $\geq 2$  cm per year as calculated over six months; and
- 3 A current bone age is  $\leq 14$  years (female patients) or  $\leq 16$  years (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

**Initial application — (Prader-Willi syndrome)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient's height velocity is  $< 25$ th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 Either:
  - 3.1 The patient is under two years of age and height velocity has been assessed over a minimum six month period from the age of 12 months, with at least three supine length measurements over this period demonstrating clear and consistent evidence of linear growth failure (with height velocity  $< 25$ th percentile); or
  - 3.2 The patient is aged two years or older; and
- 4 A current bone age is  $< 14$  years (female patients) or  $< 16$  years (male patients); and
- 5 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 6 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by  $\geq 0.5$  standard deviations in the preceding 12 months.

**Renewal — (Prader-Willi syndrome)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is  $\geq 50$ th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is  $\geq 2$  cm per year as calculated over six months; and
- 3 A current bone age is  $\leq 14$  years (female patients) or  $\leq 16$  years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

continued...

- The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by  $\geq 0.5$  standard deviations in the preceding 12 months.

**Initial application — (adults and adolescents)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- The patient has severe growth hormone deficiency (see notes); and
- The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA<sup>®</sup>).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of  $\leq 3$  mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of  $\leq 0.4$  mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

**Renewal — (adults and adolescents)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- All of the following:
  - The patient has been treated with somatropin for  $< 12$  months; and
  - There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA<sup>®</sup>) score from baseline; and
  - Serum IGF-I levels have been increased within  $\pm 1SD$  of the mean of the normal range for age and sex; and
  - The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- All of the following:
  - The patient has been treated with somatropin for more than 12 months; and
  - The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA<sup>®</sup> score on treatment (other than due to obvious external factors such as external stressors); and
  - Serum IGF-I levels have continued to be maintained within  $\pm 1SD$  of the mean of the normal range for age and sex (other than for obvious external factors); and
  - The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

## GnRH Analogues

### GOSERELIN ACETATE

Inj 3.6 mg .....	166.20	1	✓ Zoladex
Inj 10.8 mg .....	443.76	1	✓ Zoladex



	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>LEUPRORELIN</b>				
Inj 3.75 mg prefilled syringe .....	221.60	1	✓	Lucrin Depot PDS
Inj 7.5 mg .....	166.20	1	✓	Eligard
Inj 11.25 mg prefilled syringe .....	591.68	1	✓	Lucrin Depot PDS
Inj 22.5 mg .....	443.76	1	✓	Eligard
Inj 30 mg .....	591.68	1	✓	Eligard
Inj 30 mg prefilled syringe .....	1,109.40	1	✓	Lucrin Depot PDS
Inj 45 mg .....	832.05	1	✓	Eligard

## Vasopressin Agonists

### DESMOPRESSIN ACETATE

Tab 100 mcg – Special Authority see SA1401 below – Retail pharmacy .....	36.40	30	✓	Minirin
Tab 200 mcg – Special Authority see SA1401 below – Retail pharmacy .....	93.60	30	✓	Minirin
▲ Nasal drops 100 mcg per ml – Retail pharmacy-Specialist .....	39.03	2.5 ml OP	✓	Minirin
▲ Nasal spray 10 mcg per dose – Retail pharmacy-Specialist .....	22.95	6 ml OP	✓	Desmopressin-PH&T
Inj 4 mcg per ml, 1 ml – Special Authority see SA1401 below – Retail pharmacy .....	67.18	10	✓	Minirin

#### ►SA1401 Special Authority for Subsidy

**Initial application — (Desmopressin tablets for Nocturnal enuresis)** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has primary nocturnal enuresis; and
- 2 The nasal forms of desmopressin are contraindicated; and
- 3 An enuresis alarm is contraindicated.

**Initial application — (Desmopressin tablets for Diabetes insipidus)** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has cranial diabetes insipidus; and
- 2 The nasal forms of desmopressin are contraindicated.

**Renewal — (Desmopressin tablets)** from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from the treatment.

**Initial application — (Desmopressin injection)** only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

**Renewal — (Desmopressin injection)** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

## Other Endocrine Agents

### CABERGOLINE

Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA1370 on the next page .....	4.75	2	✓	Dostinex
	19.00	8	✓	Dostinex
Dostinex to be Sole Supply on 1 October 2015				

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

# HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>►SA1370 Special Authority for Waiver of Rule</b>				
<b>Initial application</b> from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:				
Either:				
1 pathological hyperprolactinemia; or				
2 acromegaly*.				
<b>Renewal — (for patients who have previously been funded under Special Authority form SA1031)</b> from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment.				
Note: Indication marked with * is an Unapproved indication.				
<b>CLOMIPHENE CITRATE</b>				
Tab 50 mg .....	29.84	10	✓	<u>Serophene</u>
<b>DANAZOL</b>				
Cap 100 mg .....	68.33	100	✓	<u>Azol</u>
Cap 200 mg .....	97.83	100	✓	<u>Azol</u>
<b>METYRAPONE</b>				
Cap 250 mg – Retail pharmacy-Specialist .....	520.00	50	✓	<u>Metopirone</u>

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Anthelmintics

ALBENDAZOLE – Special Authority see SA1318 below – Retail pharmacy

Tab 400 mg .....	469.20	60	✓ Eskazole S29
------------------	--------	----	----------------

### ►SA1318 Special Authority for Subsidy

**Initial application** only from an infectious disease specialist or clinical microbiologist. Approvals valid for 6 months where the patient has hydatids.

**Renewal** only from an infectious disease specialist or clinical microbiologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.

MEBENDAZOLE – Only on a prescription

Tab 100 mg .....	24.19	24	✓ De-Worm
Oral liq 100 mg per 5 ml .....	2.18	15 ml	
	(7.17)		Vermox

PRAZIQUANTEL

Tab 600 mg .....	68.00	8	✓ Biltricide
------------------	-------	---	--------------

## Antibacterials

a) For topical antibacterials, refer to DERMATOLOGICALS, page 63

b) For anti-infective eye preparations, refer to SENSORY ORGANS, page 200

## Cephalosporins and Cephamycins

CEFACLOR MONOHYDRATE

Cap 250 mg .....	26.00	100	✓ <u>Ranbaxy-Cefaclor</u>
Grans for oral liq 125 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 13 .....	3.53	100 ml	✓ <u>Ranbaxy-Cefaclor</u>

CEFALEXIN

Cap 500 mg .....	5.70	20	✓ <u>Cephalexin ABM</u>
Grans for oral liq 25 mg per ml – Wastage claimable – see rule 3.3.2 on page 13 .....	8.00	100 ml	✓ <u>Cefalexin Sandoz</u>

a) Note: Cefalexin grans for oral liq will not be funded in amounts more than 14 days treatment per dispensing.

b) Cefalexin Sandoz to be Sole Supply on 1 October 2015

Grans for oral liq 50 mg per ml – Wastage claimable – see rule 3.3.2 on page 13 .....	11.00	100 ml	✓ <u>Cefalexin Sandoz</u>
--	-------	--------	---------------------------

a) Note: Cefalexin grans for oral liq will not be funded in amounts more than 14 days treatment per dispensing.

b) Cefalexin Sandoz to be Sole Supply on 1 October 2015

CEFAZOLIN – Subsidy by endorsement

Only if prescribed for dialysis or cellulitis in accordance with a DHB approved protocol and the prescription is endorsed accordingly.

Inj 500 mg vial .....	3.99	5	✓ <u>AFT</u>
Inj 1 g vial .....	3.38	5	✓ <u>AFT</u>

CEFTRIAXONE – Subsidy by endorsement

a) Up to 5 inj available on a PSO

b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of gonorrhoea, or the treatment of pelvic inflammatory disease, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly.

Inj 500 mg vial .....	1.50	1	✓ <u>Ceftriaxone-AFT</u>
Inj 1 g vial .....	5.22	5	✓ <u>Ceftriaxone-AFT</u>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time  
if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>CEFUROXIME AXETIL – Subsidy by endorsement</b>				
Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
Tab 250 mg .....	29.40	50	✓	Zinnat
<b>Macrolides</b>				
<b>AZITHROMYCIN – Maximum of 5 days treatment per prescription; can be waived by endorsement</b>				
For Endorsement, patient has either:				
1) Received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome*; or				
2) Cystic fibrosis and has chronic infection with <i>Pseudomonas aeruginosa</i> or <i>Pseudomonas</i> related gram negative organisms*.				
Indications marked with * are Unapproved Indications				
Tab 250 mg .....	9.00	30	✓	Apo-Azithromycin
Apo-Azithromycin to be Sole Supply on 1 October 2015				
Tab 500 mg – Up to 8 tab available on a PSO.....	1.05	2	✓	Apo-Azithromycin
Apo-Azithromycin to be Sole Supply on 1 October 2015				
Grans for oral liq 200 mg per 5 ml (40 mg per ml) – Wastage claimable – see rule 3.3.2 on page 13.....	12.50	15 ml	✓	Zithromax
Zithromax to be Sole Supply on 1 November 2015				
<b>CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA1131 below</b>				
Tab 250 mg .....	3.98	14	✓	Apo-Clarithromycin
Grans for oral liq 125 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 13 .....	23.12	70 ml	✓	Klacid
<b>►SA1131 Special Authority for Waiver of Rule</b>				
<b>Initial application — (Mycobacterial infections)</b> only from a respiratory specialist, infectious disease specialist or paediatrician.				
Approvals valid for 2 years for applications meeting the following criteria:				
Either:				
1 Atypical mycobacterial infection; or				
2 Mycobacterium tuberculosis infection where there is drug-resistance or intolerance to standard pharmaceutical agents.				
<b>Renewal — (Mycobacterial infections)</b> only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.				
<b>ERYTHROMYCIN ETHYL SUCCINATE</b>				
Tab 400 mg .....	16.95	100	✓	E-Mycin
a) Up to 20 tab available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP – see rule 5.2.6 on page 17				
Grans for oral liq 200 mg per 5 ml .....	5.00	100 ml	✓	E-Mycin
a) Up to 300 ml available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP – see rule 5.2.6 on page 17				
c) Wastage claimable – see rule 3.3.2 on page 13				
Grans for oral liq 400 mg per 5 ml .....	6.77	100 ml	✓	E-Mycin
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 13				
<b>ERYTHROMYCIN LACTOBIONATE</b>				
Inj 1 g .....	16.00	1	✓	Erythrocin IV
<b>ERYTHROMYCIN STEARATE</b>				
Tab 250 mg – Up to 30 tab available on a PSO.....	14.95 (22.29)	100		ERA
Tab 500 mg .....	29.90 (44.58)	100		ERA

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ROXITHROMYCIN</b>				
Tab 150 mg .....	7.48	50	✓	Arrow-Roxithromycin
Tab 300 mg .....	14.40	50	✓	Arrow-Roxithromycin
<b>Penicillins</b>				
<b>AMOXICILLIN</b>				
Cap 250 mg .....	16.18	500	✓	Apo-Amoxi
a) Up to 30 cap available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP – see rule 5.2.6 on page 17				
Cap 500 mg .....	20.94	500	✓	Apo-Amoxi
a) Up to 30 cap available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP – see rule 5.2.6 on page 17				
Grans for oral liq 125 mg per 5 ml .....	0.88	100 ml	✓	Alphamox
			✓	Amoxicillin Actavis
			✓	Ranmoxy
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 13				
Grans for oral liq 250 mg per 5 ml .....	0.97	100 ml	✓	Alphamox
			✓	Amoxicillin Actavis
			✓	Ranmoxy
a) Up to 300 ml available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP – see rule 5.2.6 on page 17				
c) Wastage claimable – see rule 3.3.2 on page 13				
Inj 250 mg vial .....	10.67	10	✓	Ibiamox
Inj 500 mg vial .....	12.41	10	✓	Ibiamox
Inj 1 g vial – Up to 5 inj available on a PSO .....	17.29	10	✓	Ibiamox
<i>(Ranmoxy Grans for oral liq 125 mg per 5 ml to be delisted 1 October 2015)</i>				
<i>(Ranmoxy Grans for oral liq 250 mg per 5 ml to be delisted 1 October 2015)</i>				
<b>AMOXICILLIN WITH CLAVULANIC ACID</b>				
Tab 500 mg with clavulanic acid 125 mg – Up to 30 tab available on a PSO .....	1.95	20	✓	Augmentin
	9.75	100	✓	Curam Duo
Grans for oral liq amoxicillin 125 mg with clavulanic acid 31.25 mg per 5 ml .....	1.61	100 ml	✓	Augmentin
			✓	Curam
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 13				
Grans for oral liq amoxicillin 250 mg with clavulanic acid 62.5 mg per 5 ml .....	2.19	100 ml	✓	Augmentin
			✓	Curam
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 13				
<b>BENZATHINE BENZYL PENICILLIN</b>				
Inj 900 mg (1.2 million units) in 2.3 ml syringe – Up to 5 inj available on a PSO .....	315.00	10	✓	Bicillin LA
Bicillin LA to be Sole Supply on 1 October 2015				

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

# INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>BENZYLPENICILLIN SODIUM (PENICILLIN G)</b>				
Inj 600 mg (1 million units) vial – Up to 5 inj available on a PSO .....	10.35	10	✓	<b>Sandoz</b>
<b>FLUCLOXACILLIN</b>				
Cap 250 mg – Up to 30 cap available on a PSO .....	18.70	250	✓	<b>Staphlex</b>
Staphlex to be Sole Supply on 1 October 2015				
Cap 500 mg .....	62.90	500	✓	<b>Staphlex</b>
Staphlex to be Sole Supply on 1 October 2015				
Grans for oral liq 25 mg per ml .....	2.29	100 ml	✓	<b>AFT</b>
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 13				
c) AFT to be Sole Supply on 1 October 2015				
Grans for oral liq 50 mg per ml .....	3.08	100 ml	✓	<b>AFT</b>
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 13				
c) AFT to be Sole Supply on 1 October 2015				
Inj 250 mg vial .....	8.80	10	✓	<b>Flucloxin</b>
Inj 500 mg vial .....	9.20	10	✓	<b>Flucloxin</b>
Inj 1 g vial – Up to 10 inj available on a PSO .....	5.80	5	✓	<b>DBL Flucloxacillin</b>
	11.60	10	✓	<b>Flucloxin</b>
<b>PHENOXYMETHYLPENICILLIN (PENICILLIN V)</b>				
Cap 250 mg – Up to 30 cap available on a PSO .....	2.88	50	✓	<b>Cilicaine VK</b>
Cap 500 mg .....	4.73	50	✓	<b>Cilicaine VK</b>
a) Up to 20 cap available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP – see rule 5.2.6 on page 17				
Grans for oral liq 125 mg per 5 ml .....	1.64	100 ml	✓	<b>AFT</b>
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 13				
Grans for oral liq 250 mg per 5 ml .....	1.74	100 ml	✓	<b>AFT</b>
a) Up to 300 ml available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP – see rule 5.2.6 on page 17				
c) Wastage claimable – see rule 3.3.2 on page 13				
<b>PROCAINE PENICILLIN</b>				
Inj 1.5 g in 3.4 ml syringe – Up to 5 inj available on a PSO .....	123.50	5	✓	<b>Cilicaine</b>
<b>Tetracyclines</b>				
<b>DOXYCYCLINE</b>				
* Tab 50 mg – Up to 30 tab available on a PSO .....	2.90	30		
	(6.00)			Doxy-50
* Tab 100 mg – Up to 30 tab available on a PSO .....	6.75	250	✓	<b>Doxine</b>
<b>MINOCYCLINE HYDROCHLORIDE</b>				
* Tab 50 mg – Additional subsidy by Special Authority see SA1355 below – Retail pharmacy .....	5.79	60		
	(12.05)			Mino-tabs
* Cap 100 mg .....	19.32	100		
	(52.04)			Minomycin

## ►SA1355 Special Authority for Manufacturers Price

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has rosacea.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TETRACYCLINE – Special Authority see SA1332 below – Retail pharmacy				
Cap 500 mg .....	46.00	30	✓	<b>Tetracyclin Wolff S29</b>

►SA1332 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:  
Both:

- 1 For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy; and
- 2 For use only in combination with bismuth as part of a quadruple therapy regimen.

## Other Antibiotics

For topical antibiotics, refer to DERMATOLOGICALS, page 63

### CIPROFLOXACIN

Recommended for patients with any of the following:

- i) microbiologically confirmed and clinically significant pseudomonas infection; or
- ii) prostatitis; or
- iii) pyelonephritis; or
- iv) gonorrhoea.

Tab 250 mg – Up to 5 tab available on a PSO.....	1.75	28	✓	<b>Cipflox</b>
Tab 500 mg – Up to 5 tab available on a PSO.....	2.00	28	✓	<b>Cipflox</b>
Tab 750 mg .....	3.75	28	✓	<b>Cipflox</b>

### CLINDAMYCIN

Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement - Retail pharmacy -

Specialist .....	5.80	16	✓	<b>Clindamycin ABM</b>
------------------	------	----	---	------------------------

Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy -  
Specialist .....

100.00	10	✓	<b>Dalacin C</b>
--------	----	---	------------------

### CO-TRIMOXAZOLE

\* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg –

Up to 30 tab available on a PSO .....	22.90	500	✓	<b>Trisul</b>
---------------------------------------	-------	-----	---	---------------

\* Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg

per 5 ml – Up to 200 ml available on a PSO.....	2.15	100 ml	✓	<b>Deprim</b>
---	------	--------	---	---------------

### COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – Subsidy by endorsement

Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.

Inj 150 mg .....	65.00	1	✓	<b>Colistin-Link</b>
------------------	-------	---	---	----------------------

### FUSIDIC ACID

Tab 250 mg – Retail pharmacy-Specialist .....	34.50	12	✓	<b>Fucidin</b>
---	-------	----	---	----------------

Prescriptions must be written by, or on the recommendation of, an infectious disease physician or a clinical microbiologist

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>GENTAMICIN SULPHATE</b>				
Inj 10 mg per ml, 1 ml – Subsidy by endorsement .....	8.56	5	✓	<b>Hospira</b>
Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.				
Inj 10 mg per ml, 2 ml – Subsidy by endorsement .....	175.10	25	✓	<b>APP</b>
<b>Pharmaceuticals</b> <small>S29</small>				
Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.				
Inj 40 mg per ml, 2 ml ampoule – Subsidy by endorsement.....	6.00	10	✓	<b>Pfizer</b>
a) Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.				
b) Pfizer to be Sole Supply on 1 October 2015				
<b>MOXIFLOXACIN</b> – Special Authority see SA1358 below – Retail pharmacy				
No patient co-payment payable				
Tab 400 mg .....	52.00	5	✓	<b>Avelox</b>
<b>SA1358 Special Authority for Subsidy</b>				
<b>Initial application — (Tuberculosis)</b> only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:				
Either:				
1 Both:				
1.1 Active tuberculosis*; and				
1.2 Any of the following:				
1.2.1 Documented resistance to one or more first-line medications; or				
1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or				
1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or				
1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or				
1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications;				
or				
2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*.				
Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).				
<b>Renewal</b> only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.				
<b>Initial application — (Mycoplasma genitalium)</b> from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:				
All of the following:				
1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium*; and				
2 Has tried and failed to clear infection using azithromycin; and				
3 Treatment is only for 7 days.				
<b>Initial application — (Penetrating eye injury)</b> only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only.				
Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).				
<b>PAROMOMYCIN</b> – Special Authority see SA1324 on the next page – Retail pharmacy				
Cap 250 mg .....	126.00	16	✓	<b>Humatin</b> <small>S29</small>



Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

►SA1324 Special Authority for Subsidy

**Initial application** only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month where the patient has confirmed cryptosporidium infection.

**Renewal** only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month where the patient has confirmed cryptosporidium infection.

PYRIMETHAMINE – Special Authority see SA1328 below – Retail pharmacy

Tab 25 mg .....	26.14	30	✓ Daraprim <sup>\$29</sup>
	36.95	50	✓ Daraprim <sup>\$29</sup>

►SA1328 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
- 2 For pregnant patients for the term of the pregnancy; or
- 3 For infants with congenital toxoplasmosis until 12 months of age.

SULFADIAZINE SODIUM – Special Authority see SA1331 below – Retail pharmacy

Tab 500 mg .....	238.20	56	✓ Wockhardt <sup>\$29</sup>
------------------	--------	----	-----------------------------

►SA1331 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
- 2 For pregnant patients for the term of the pregnancy; or
- 3 For infants with congenital toxoplasmosis until 12 months of age.

TOBRAMYCIN

Inj 40 mg per ml, 2 ml – Subsidy by endorsement .....	29.32	5	✓ DBL Tobramycin
---	-------	---	------------------

Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.

Solution for inhalation 60 mg per ml, 5 ml – Subsidy by endorsement.....	2,200.00	56 dose	✓ TOBI
--	----------	---------	--------

a) Wastage claimable – see rule 3.3.2 on page 13

b) Only if prescribed for a cystic fibrosis patient and the prescription is endorsed accordingly.

TRIMETHOPRIM

* Tab 300 mg – Up to 30 tab available on a PSO.....	15.00	50	✓ TMP
---	-------	----	-------

TMP to be Sole Supply on 1 November 2015

VANCOMYCIN – Subsidy by endorsement

Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis or for treatment of Clostridium difficile following metronidazole failure and the prescription is endorsed accordingly.

Inj 500 mg .....	2.64	1	✓ Mylan
------------------	------	---	---------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Antifungals

a) For topical antifungals refer to DERMATOLOGICALS, page 63

b) For topical antifungals refer to GENITO URINARY, page 76

### FLUCONAZOLE

Cap 50 mg – Retail pharmacy-Specialist .....	3.49	28	✓ <b>Ozole</b>
Cap 150 mg – Subsidy by endorsement .....	0.71	1	✓ <b>Ozole</b>
a) Maximum of 1 cap per prescription; can be waived by endorsement - Retail pharmacy - Specialist			
b) Patient has vaginal candida albicans and the practitioner considers that a topical imidazole (used intra-vaginally) is not recommended and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist.			
Cap 200 mg – Retail pharmacy-Specialist .....	9.69	28	✓ <b>Ozole</b>
Powder for oral suspension 10 mg per ml – Special Authority			
see SA1359 below – Retail pharmacy .....	34.56	35 ml	✓ <b>Diffucan S29</b> <small>S29</small>
	98.50		✓ <b>Diffucan</b>

Wastage claimable – see rule 3.3.2 on page 13

### ►SA1359 Special Authority for Subsidy

**Initial application — (Systemic candidiasis)** from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

**Initial application — (Immunocompromised)** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient is at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

**Renewal — (Systemic candidiasis)** from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

**Renewal — (Immunocompromised)** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient remains immunocompromised; and
- 2 Patient remains at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

### ITRACONAZOLE

Cap 100 mg – Subsidy by endorsement .....	2.99	15	✓ <b>Itrazole</b>
Funded for tinea vesicolor where topical treatment has not been successful and diagnosis has been confirmed by mycology, or for tinea unguium where terbinafine has not been successful in eradication or the patient is intolerant to terbinafine and diagnosis has been confirmed by mycology and the prescription is endorsed accordingly. Can be waived by endorsement - Retail pharmacy - Specialist Specialist must be an infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist.			
Oral liq 10 mg per ml – Special Authority see SA1322 on the next page – Retail pharmacy .....	141.80	150 ml OP	✓ <b>Sporanox</b>

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1322 | Special Authority for Subsidy

**Initial application** only from an infectious disease specialist, clinical microbiologist, clinical immunologist or any relevant practitioner on the recommendation of a infectious disease physician, clinical microbiologist or clinical immunologist. Approvals valid for 6 months where the patient has a congenital immune deficiency.

**Renewal** from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.

KETOCONAZOLE

Tab 200 mg – PCT – Retail pharmacy-Specialist – Subsidy by endorsement.....CBS	30	✓ Link Healthcare S29
		✓ Nizoral S29

Prescriptions must be written by, or on the recommendation of an oncologist

NYSTATIN

Tab 500,000 u .....	14.16	50	
	(17.09)		Nilstat
Cap 500,000 u .....	12.81	50	
	(15.47)		Nilstat

POSACONAZOLE – Special Authority see SA1285 below – Retail pharmacy

Oral liq 40 mg per ml .....	761.13	105 ml OP	✓ Noxafil
-----------------------------	--------	-----------	-----------

►SA1285 | Special Authority for Subsidy

**Initial application** only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy\*.

**Renewal** only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression\* and requires on going posaconazole treatment.

Note: \* Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids ( $\geq 1$  mg per kilogram of body weight per day for patients with acute GVHD or  $\geq 0.8$  mg per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

TERBINAFINE

* Tab 250 mg – For terbinafine oral liquid formulation refer, page 207 .....	1.50	14	✓ Dr Reddy's Terbinafine
---	------	----	-----------------------------

VORICONAZOLE – Special Authority see SA1273 on the next page – Retail pharmacy

Tab 50 mg .....	730.00	56	✓ Vfend
Tab 200 mg .....	2,930.00	56	✓ Vfend
Powder for oral suspension 40 mg per ml – Wastage claimable – see rule 3.3.2 on page 13.....	730.00	70 ml	✓ Vfend

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

## ►SA1273 Special Authority for Subsidy

**Initial application — (invasive fungal infection)** only from a haematologist, infectious disease specialist or clinical microbiologist.

Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
  - 3.1 Patient has proven or probable invasive aspergillus infection; or
  - 3.2 Patient has possible invasive aspergillus infection; or
  - 3.3 Patient has fluconazole resistant candidiasis; or
  - 3.4 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp.

**Renewal — (invasive fungal infection)** only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
  - 3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
  - 3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
  - 3.3 Patient has fluconazole resistant candidiasis; or
  - 3.4 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp.

## Antimalarials

PRIMAQUINE PHOSPHATE – Special Authority see SA1326 below – Retail pharmacy

Tab 7.5 mg .....	117.00	56	✓ Primacin <sup>\$29</sup>
------------------	--------	----	----------------------------

## ►SA1326 Special Authority for Subsidy

**Initial application** only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has vivax or ovale malaria; and
- 2 Primaquine is to be given for a maximum of 21 days.

## Antiparasitics

### Antiprotozoals

QUININE SULPHATE

* Tab 300 mg .....	54.06	500	✓ Q 300
--------------------	-------	-----	---------

‡ Safety cap for extemporaneously compounded oral liquid preparations.

## Antitrichomonal Agents

METRONIDAZOLE

Tab 200 mg – Up to 30 tab available on a PSO.....	10.45	100	✓ Trichazole
Tab 400 mg .....	18.15	100	✓ Trichazole
Oral liq benzoate 200 mg per 5 ml .....	25.00	100 ml	✓ Flagyl-S
Suppos 500 mg .....	24.48	10	✓ Flagyl

ORNIDAZOLE

Tab 500 mg .....	16.50	10	✓ Arrow-Ornidazole
------------------	-------	----	--------------------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Antituberculosics and Antileprotics

Note: There is no co-payment charge for all pharmaceuticals listed in the Antituberculosics and Antileprotics group regardless of immigration status.

### CLOFAZIMINE – Retail pharmacy-Specialist

a) No patient co-payment payable

b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist.

* Cap 50 mg .....	351.54	100	✓ <b>Lamprene</b> <small>S29</small>
-------------------	--------	-----	--------------------------------------

### CYCLOSERINE – Retail pharmacy-Specialist

a) No patient co-payment payable

b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician.

Cap 250 mg .....	1,294.50	100	✓ <b>King</b> <small>S29</small>
------------------	----------	-----	----------------------------------

### DAPSONE – Retail pharmacy-Specialist

a) No patient co-payment payable

b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist

Tab 25 mg .....	95.00	100	✓ <b>Dapsone</b>
Tab 100 mg .....	110.00	100	✓ <b>Dapsone</b>

### ETHAMBUTOL HYDROCHLORIDE – Retail pharmacy-Specialist

a) No patient co-payment payable

b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician

Tab 100 mg .....	48.01	56	✓ <b>Myambutol</b>
Tab 400 mg .....	49.34	56	✓ <b>Myambutol</b>

### ISONIAZID – Retail pharmacy-Specialist

a) No patient co-payment payable

b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician

* Tab 100 mg .....	20.00	100	✓ <b>PSM</b>
PSM to be Sole Supply on 1 October 2015			
* Tab 100 mg with rifampicin 150 mg .....	85.54	100	✓ <b>Rifinah</b>
Rifinah to be Sole Supply on 1 October 2015			
* Tab 150 mg with rifampicin 300 mg .....	170.60	100	✓ <b>Rifinah</b>
Rifinah to be Sole Supply on 1 October 2015			

### PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist

a) No patient co-payment payable

b) Specialist must be an infectious disease specialist, clinical microbiologist or respiratory specialist.

Grans for oral liq 4 g sachet .....	280.00	30	✓ <b>Paser</b> <small>S29</small>
-------------------------------------	--------	----	-----------------------------------

### PROTIONAMIDE – Retail pharmacy-Specialist

a) No patient co-payment payable

b) Specialist must be an infectious disease specialist, clinical microbiologist or respiratory specialist.

Tab 250 mg .....	305.00	100	✓ <b>Peteha</b> <small>S29</small>
------------------	--------	-----	------------------------------------

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
<b>PYRAZINAMIDE – Retail pharmacy-Specialist</b>			
a) No patient co-payment payable			
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician			
* Tab 500 mg – For pyrazinamide oral liquid formulation refer, page 207 .....	59.00	100	✓ <b>AFT-Pyrazinamide</b>
<b>RIFABUTIN – Retail pharmacy-Specialist</b>			
a) No patient co-payment payable			
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, respiratory physician or gastroenterologist			
* Cap 150 mg – For rifabutin oral liquid formulation refer, page 207 .....	213.19	30	✓ <b>Mycobutin</b>
<b>RIFAMPICIN – Subsidy by endorsement</b>			
a) No patient co-payment payable			
b) For confirmed recurrent <i>Staphylococcus aureus</i> infection in combination with other effective anti-staphylococcal antimicrobial based on susceptibilities and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist. Specialist must be an internal medicine physician, clinical microbiologist, dermatologist, paediatrician, or public health physician.			
* Tab 600 mg .....	108.70	30	✓ <b>Rifadin</b>
* Cap 150 mg .....	55.75	100	✓ <b>Rifadin</b>
* Cap 300 mg .....	116.25	100	✓ <b>Rifadin</b>
* Oral liq 100 mg per 5 ml .....	12.00	60 ml	✓ <b>Rifadin</b>

## Antivirals

For eye preparations refer to Eye Preparations, Anti-Infective Preparations, page 200

## Hepatitis B Treatment

<b>ADEFOVIR DIPVOXIL – Special Authority see SA0829 below – Retail pharmacy</b>			
Tab 10 mg .....	670.00	30	✓ <b>Hepsera</b>

### ►SA0829 Special Authority for Subsidy

**Initial application** only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as:
- 2 Patient has raised serum ALT ( $> 1 \times \text{ULN}$ ); and
- 3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load  $\geq 10$  fold over nadir; and
- 4 Detection of M204I or M204V mutation; and
- 5 Either:
  - 5.1 Both:
    - 5.1.1 Patient is cirrhotic; and
    - 5.1.2 adefovir dipivoxil to be used in combination with lamivudine; or
  - 5.2 Both:
    - 5.2.1 Patient is not cirrhotic; and
    - 5.2.2 adefovir dipivoxil to be used as monotherapy.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

**Renewal** only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment.

Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as:

- i) raised serum ALT ( $> 1 \times \text{ULN}$ ); and
- ii) HBV DNA greater than 100,000 copies per mL, or viral load  $\geq 10$  fold over nadir; and
- iii) Detection of N236T or A181T/V mutation.

Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil.

The recommended dose of adefovir dipivoxil is no more than 10mg daily.

In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines.

Adefovir dipivoxil should be avoided in pregnant women and children.

ENTECAVIR – Special Authority see SA1361 below – Retail pharmacy

Tab 0.5 mg .....	400.00	30	✓ Baraclude
------------------	--------	----	-------------

►SA1361 Special Authority for Subsidy

**Initial application** only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naïve; and
- 3 Entecavir dose 0.5 mg/day; and
- 4 Either:
  - 4.1 ALT greater than upper limit of normal; or
  - 4.2 Bridging fibrosis (Metavir stage 3 or greater or moderate fibrosis) or cirrhosis on liver histology; and
- 5 Either:
  - 5.1 HBeAg positive; or
  - 5.2 patient has  $\geq 2,000$  IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and
- 6 No continuing alcohol abuse or intravenous drug use; and
- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

Notes:

- Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4).
- Entecavir should be taken on an empty stomach to improve absorption.

LAMIVUDINE – Special Authority see SA1360 on the next page – Retail pharmacy

Tab 100 mg .....	6.00	28	✓ Zeffix
Oral liq 5 mg per ml .....	270.00	240 ml	✓ Zeffix

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

## ►SA1360 Special Authority for Subsidy

**Initial application** only from a gastroenterologist, infectious disease specialist, paediatrician, general physician or medical practitioner on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 HBV DNA positive cirrhosis prior to liver transplantation; or
- 2 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
- 3 Hepatitis B virus naive patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or
- 4 Hepatitis B surface antigen (HbsAg) positive patient who is receiving chemotherapy for a malignancy, or high dose steroids (at least 20mg/day for at least 7 days), or who has received such treatment within the previous two months; or
- 5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or
- 6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).

**Renewal** only from a gastroenterologist, infectious disease specialist, paediatrician, general physician or medical practitioner on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

Renewal for patients who have maintained continuous treatment and response to lamivudine

- 1 All of the following:
  - 1.1 Have maintained continuous treatment with lamivudine; and
  - 1.2 Most recent test result shows continuing biochemical response (normal ALT); and
  - 1.3 HBV DNA <100,000 copies per ml by quantitative PCR at a reference laboratory; or

Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine

- 2 All of the following:
  - 2.1 Lamivudine to be used in combination with adefovir dipivoxil; and
  - 2.2 Patient is cirrhotic; and  
Documented resistance to lamivudine, defined as:
  - 2.3 Patient has raised serum ALT ( $> 1 \times \text{ULN}$ ); and
  - 2.4 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
  - 2.5 Detection of M204I or M204V mutation; or

Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil

- 3 All of the following:
  - 3.1 Lamivudine to be used in combination with adefovir dipivoxil; and  
Documented resistance to adefovir, defined as:
  - 3.2 Patient has raised serum ALT ( $> 1 \times \text{ULN}$ ); and
  - 3.3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
  - 3.4 Detection of N236T or A181T/V mutation.

## Herpesvirus Treatments

### ACICLOVIR

* Tab dispersible 200 mg .....	1.78	25	✓ <u>Lovir</u>
* Tab dispersible 400 mg .....	5.98	56	✓ <u>Lovir</u>
* Tab dispersible 800 mg .....	6.64	35	✓ <u>Lovir</u>

VALACICLOVIR – Special Authority see SA1363 on the next page – Retail pharmacy

Tab 500 mg .....	102.72	30	✓ <u>Valtrex</u>
------------------	--------	----	------------------



Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1363 Special Authority for Subsidy

**Initial application — (recurrent genital herpes)** from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.

**Renewal — (recurrent genital herpes)** from any medical practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

**Initial application — (ophthalmic zoster)** from any medical practitioner. Approvals valid without further renewal unless notified where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.

**Initial application — (CMV prophylaxis)** from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation.

**Initial application — (immunocompromised patients)** from any medical practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patients is immunocompromised; and
- 2 Patient has herpes zoster; and
- 3 Valaciclovir is to be given for a maximum of 7 days per course.

VALGANCICLOVIR – Special Authority see SA1404 below – Retail pharmacy

Tab 450 mg .....	1,050.00	60	✓ <b>Valcyte</b>
------------------	----------	----	------------------

►SA1404 Special Authority for Subsidy

**Initial application — (transplant cytomegalovirus prophylaxis)** only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

**Renewal — (transplant cytomegalovirus prophylaxis)** only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
- 2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin.

**Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin)** only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

**Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin)** only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

**Initial application — (Lung transplant cytomegalovirus prophylaxis)** only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
  - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
  - 2.2 The recipient is cytomegalovirus positive.

**Initial application — (Cytomegalovirus in immunocompromised patients)** only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued. . .

- 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
- 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
- 2.3 Patient has cytomegalovirus retinitis.

**Renewal — (Cytomegalovirus in immunocompromised patients)** only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
  - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
  - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
  - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

## Hepatitis B/ HIV/AIDS Treatment

**TENOFOVIR DISOPROXIL FUMARATE** – Subsidy by endorsement; can be waived by Special Authority see SA1362 below

Endorsement for treatment of HIV: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1364 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Tenofovir disoproxil fumarate prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1364, page 108

Tab 300 mg .....	531.00	30	✓ Viread
------------------	--------	----	----------

### ►SA1362 Special Authority for Waiver of Rule

**Initial application — (Chronic Hepatitis B)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
  - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
  - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
  - 1.3 HBV DNA greater than 20,000 IU/mL or increased  $\geq 10$  fold over nadir; and
  - 1.4 Any of the following:
    - 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or
    - 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or
    - 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV; or
- 3 Patient has decompensated cirrhosis with a Mayo score  $>20$ .

**Initial application — (Pregnant, Active hepatitis B)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA  $> 20,000$  IU/mL and ALT  $> \text{ULN}$ .

**Renewal — (Confirmed Hepatitis B following funded tenofovir treatment for pregnancy within the previous two years)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

continued. . .

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

1 All of the following:

- 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
- 1.3 HBV DNA greater than 20,000 IU/mL or increased  $\geq 10$  fold over nadir; and
- 1.4 Any of the following:
  - 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or
  - 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or
  - 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or

2 Patient is either listed or has undergone liver transplantation for HBV.

**Renewal — (Subsequent pregnancy or Breastfeeding, Active hepatitis B)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient is HBsAg positive and pregnant or breastfeeding; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

**Initial application — (Pregnant, prevention of vertical transmission)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

**Renewal — (Subsequent pregnancy, prevention of vertical transmission)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Notes:

- Tenofovir disoproxil fumarate should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg positive prior to commencing this agent and 6 months following HBsAg seroconversion for patients who were HBeAg negative prior to commencing this agent.
- The recommended dose of Tenofovir disoproxil fumarate for the treatment of all three indications is 300 mg once daily.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Tenofovir disoproxil fumarate dose should be reduced in accordance with the approved Medsafe datasheet guidelines.
- Tenofovir disoproxil fumarate is not approved for use in children.

## Hepatitis C Treatment

BOCEPREVIR – Special Authority see SA1402 below – Retail pharmacy

Cap 200 mg – Wastage claimable – see rule 3.3.2 on page

13 ..... 5,015.00 336 ✓ **Victrelis**

### ►SA1402| Special Authority for Subsidy

**Initial application — (chronic hepatitis C - genotype 1, first-line)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has not received prior pegylated interferon treatment; and
- 3 Patient has IL-28B genotype CT or TT; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 5 Patient is hepatitis C protease inhibitor treatment-naïve; and
- 6 Maximum of 44 weeks therapy.

**Initial application — (chronic hepatitis C - genotype 1, second-line)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has received pegylated interferon treatment; and
- 3 Any of the following:
  - 3.1 Patient was a responder relapser; or
  - 3.2 Patient was a partial responder; or
  - 3.3 Patient received pegylated interferon prior to 2004; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Maximum of 44 weeks therapy.

Notes:

- Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count < 100 x10<sup>9</sup> /l or Albumin <35 g/l
- The wastage rule applies to boceprevir to allow dispensing to occur more frequently than monthly

## Antiretrovirals

### ►SA1364 Special Authority for Subsidy

**Initial application — (Confirmed HIV)** only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:
      - 2.3.2.1 CD4 counts < 1000 cells/mm<sup>3</sup>; or
      - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
      - 2.3.2.3 Viral load counts > 100000 copies per ml; or
  - 2.4 Both:
    - 2.4.1 Patient aged 6 years and over; and
    - 2.4.2 CD4 counts < 500 cells/mm<sup>3</sup>.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

**Renewal — (Confirmed HIV)** only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

**Initial application — (Prevention of maternal transmission)** only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued. . .

- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

**Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV)** only from a named specialist.

Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

**Renewal — (second or subsequent post-exposure prophylaxis)** only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initial application — (Percutaneous exposure)** only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

**Renewal — (Second or subsequent percutaneous exposure)** only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Non-nucleosides Reverse Transcriptase Inhibitors</b>				
<b>EFAVIRENZ – Special Authority see SA1364 on page 108 – Retail pharmacy</b>				
Tab 50 mg .....	63.38	30	✓	<b>Stocrin</b> <sup>S29</sup>
Stocrin to be Sole Supply on 1 October 2015				
Tab 200 mg .....	190.15	90	✓	<b>Stocrin</b>
Stocrin to be Sole Supply on 1 October 2015				
Tab 600 mg .....	63.38	30	✓	<b>Stocrin</b>
Stocrin to be Sole Supply on 1 October 2015				
Oral liq 30 mg per ml .....	145.79	180 ml OP	✓	<b>Stocrin</b> <sup>S29</sup>
<b>ETRAVIRINE – Special Authority see SA1364 on page 108 – Retail pharmacy</b>				
Tab 200 mg .....	770.00	60	✓	<b>Intelence</b>
<b>NEVIRAPINE – Special Authority see SA1364 on page 108 – Retail pharmacy</b>				
Tab 200 mg – Brand switch fee payable (Pharmacode 2433265) - see page 204 for details .....	95.94	60	✓	<b>Nevirapine</b> <b>Alphapharm</b>
Oral suspension 10 mg per ml .....	134.55	240 ml	✓	<b>Viramune</b> <b>Suspension</b>
<b>Nucleosides Reverse Transcriptase Inhibitors</b>				
<b>ABACAIR SULPHATE – Special Authority see SA1364 on page 108 – Retail pharmacy</b>				
Tab 300 mg .....	229.00	60	✓	<b>Ziagen</b>
Oral liq 20 mg per ml .....	256.31	240 ml OP	✓	<b>Ziagen</b>
<b>ABACAIR SULPHATE WITH LAMIVUDINE – Special Authority see SA1364 on page 108 – Retail pharmacy</b>				
Note: abacavir with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.				
Tab 600 mg with lamivudine 300 mg .....	630.00	30	✓	<b>Kivexa</b>
<b>DIDANOSINE [DDI] – Special Authority see SA1364 on page 108 – Retail pharmacy</b>				
Cap 125 mg .....	115.05	30	✓	<b>Videx EC</b>
Cap 200 mg .....	184.08	30	✓	<b>Videx EC</b>
Cap 250 mg .....	230.10	30	✓	<b>Videx EC</b>
Cap 400 mg .....	368.16	30	✓	<b>Videx EC</b>
<b>EFAVIRENZ WITH ETRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE – Special Authority see SA1364 on page 108 – Retail pharmacy</b>				
Note: Efavirenz with emtricitabine and tenofovir disoproxil fumarate counts as three anti-retroviral medications for the purposes of the anti-retroviral Special Authority				
Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg .....	1,313.19	30	✓	<b>Atripla</b>
<b>EMTRICITABINE – Special Authority see SA1364 on page 108 – Retail pharmacy</b>				
Cap 200 mg .....	307.20	30	✓	<b>Emtriva</b>
<b>EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE – Special Authority see SA1364 on page 108 – Retail pharmacy</b>				
Note: Emtricitabine with tenofovir disoproxil fumarate counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority				
Tab 200 mg with tenofovir disoproxil fumarate 300 mg .....	838.20	30	✓	<b>Truvada</b>
<b>LAMIVUDINE – Special Authority see SA1364 on page 108 – Retail pharmacy</b>				
Tab 150 mg .....	52.50	60	✓	<b>Lamivudine</b> <b>Alphapharm</b>
Oral liq 10 mg per ml .....	102.50	240 ml OP	✓	<b>3TC</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
STAVUDINE [D4T] – Special Authority see SA1364 on page 108 – Retail pharmacy				
Cap 40 mg .....	503.80	60	✓	Zerit
Powder for oral soln 1 mg per ml .....	100.76	200 ml OP	✓	Zerit <sup>§29</sup>
ZIDOVUDINE [AZT] – Special Authority see SA1364 on page 108 – Retail pharmacy				
Cap 100 mg .....	152.25	100	✓	Retrovir
Oral liq 10 mg per ml .....	30.45	200 ml OP	✓	Retrovir
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see SA1364 on page 108 – Retail pharmacy				
Note: zidovudine [AZT] with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.				
Tab 300 mg with lamivudine 150 mg .....	44.00	60	✓	Alphapharm

## Protease Inhibitors

ATAZANAVIR SULPHATE – Special Authority see SA1364 on page 108 – Retail pharmacy				
Cap 150 mg .....	568.34	60	✓	Reyataz
Cap 200 mg .....	757.79	60	✓	Reyataz
DARUNAVIR – Special Authority see SA1364 on page 108 – Retail pharmacy				
Tab 400 mg .....	837.50	60	✓	Prezista
Tab 600 mg .....	1,190.00	60	✓	Prezista
INDINAVIR – Special Authority see SA1364 on page 108 – Retail pharmacy				
Cap 200 mg .....	519.75	360	✓	Crixivan
Cap 400 mg .....	519.75	180	✓	Crixivan
LOPINAVIR WITH RITONAVIR – Special Authority see SA1364 on page 108 – Retail pharmacy				
Tab 100 mg with ritonavir 25 mg .....	183.75	60	✓	Kaletra
Tab 200 mg with ritonavir 50 mg .....	735.00	120	✓	Kaletra
Oral liq 80 mg with ritonavir 20 mg per ml .....	735.00	300 ml OP	✓	Kaletra
RITONAVIR – Special Authority see SA1364 on page 108 – Retail pharmacy				
Tab 100 mg .....	43.31	30	✓	Norvir
Oral liq 80 mg per ml .....	103.98	90 ml OP	✓	Norvir

## Strand Transfer Inhibitors

RALTEGRAVIR POTASSIUM – Special Authority see SA1364 on page 108 – Retail pharmacy				
Tab 400 mg .....	1,090.00	60	✓	Isentress

## Antiretrovirals - Additional Therapies

### HIV Fusion Inhibitors

ENFUVIRTIDE – Special Authority see SA0845 below – Retail pharmacy				
Powder for inj 90 mg per ml × 60 .....	2,380.00	1	✓	Fuzeon

#### ►SA0845 Special Authority for Subsidy

**Initial application** only from a named specialist. Approvals valid for 3 months for applications meeting the following criteria:  
All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
  - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
  - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
  - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
  - 5.3 Previous treatment with a protease inhibitor has failed.

**Renewal** only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Evidence of at least a 10 fold reduction in viral load at 12; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

## Immune Modulators

### Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects.

Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

### Criteria for Treatment

#### a) Diagnosis

- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.

### Exclusion Criteria

- a) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
- b) Pregnancy.
- c) Neutropenia ( $<2.0 \times 10^9$ ) and/or thrombocytopenia.
- d) Continuing alcohol abuse and/or continuing intravenous drug users.

### Dosage

The current recommended dosage is 3 million units of interferon alfa-2a or interferon alfa-2b administered subcutaneously 3 times a week for 52 weeks (twelve months)

### Exit Criteria

The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

### INTERFERON ALFA-2A – PCT – Retail pharmacy-Specialist

a) See prescribing guideline above

b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist

Inj 3 m iu prefilled syringe .....	31.32	1	✓ <b>Roferon-A</b>
------------------------------------	-------	---	--------------------

### INTERFERON ALFA-2B – PCT – Retail pharmacy-Specialist

a) See prescribing guideline above

b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist

Inj 18 m iu, 1.2 ml multidose pen .....	206.71	1	✓ <b>Intron-A</b>
---	--------	---	-------------------

Inj 30 m iu, 1.2 ml multidose pen .....	344.52	1	✓ <b>Intron-A</b>
---	--------	---	-------------------

Inj 60 m iu, 1.2 ml multidose pen .....	689.04	1	✓ <b>Intron-A</b>
---	--------	---	-------------------



	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PEGYLATED INTERFERON ALFA-2A – Special Authority see SA1400 below – Retail pharmacy				
See prescribing guideline on the previous page				
Inj 135 mcg prefilled syringe .....	1,448.00	4	✓	<u>Pegasys</u>
Inj 180 mcg prefilled syringe .....	900.00	4	✓	<u>Pegasys</u>
Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 .....	1,799.68	1 OP	✓	<u>Pegasys RBV Combination Pack</u>
Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 .....	1,975.00	1 OP	✓	<u>Pegasys RBV Combination Pack</u>
Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 .....	1,159.84	1 OP	✓	<u>Pegasys RBV Combination Pack</u>
Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 .....	1,290.00	1 OP	✓	<u>Pegasys RBV Combination Pack</u>

►SA1400 Special Authority for Subsidy

**Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant)** from any specialist. Approvals valid for 18 months for applications meeting the following criteria:

Both:

- Any of the following:
  - Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
  - Patient has chronic hepatitis C and is co-infected with HIV; or
  - Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and
- Maximum of 48 weeks therapy.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

**Renewal — (Chronic hepatitis C - genotype 1 infection)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- Patient has chronic hepatitis C, genotype 1; and
- Patient has had previous treatment with pegylated interferon and ribavirin; and
- Either:
  - Patient has responder relapsed; or
  - Patient was a partial responder; and
- Patient is to be treated in combination with boceprevir; and
- Maximum of 48 weeks therapy.

**Initial application — (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- Patient has chronic hepatitis C, genotype 1; and
- Patient has had previous treatment with pegylated interferon and ribavirin; and
- Any of the following:

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3.1 Patient has responder relapsed; or
- 3.2 Patient was a partial responder; or
- 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

**Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV)** from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

**Initial application — (Hepatitis B)** only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naïve; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
  - 5.1 HBeAg positive; or
  - 5.2 serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

- Approved dose is 180 mcg once weekly.
- The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alfa 2a dose should be reduced to 135 mcg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alfa 2a is not approved for use in children.

## Urinary Tract Infections

### HEXAMINE HIPPURATE

* Tab 1 g .....	18.40	100	
	(38.10)		Hiprex

### NITROFURANTOIN

* Tab 50 mg – For nitrofurantoin oral liquid formulation refer, page 207 .....	22.20	100	✓ Nifuran
* Tab 100 mg .....	37.50	100	✓ Nifuran

### NORFLOXACIN

Tab 400 mg – Subsidy by endorsement .....	13.50	100	✓ <u>Arrow-Norfloxacine</u>
---	-------	-----	-----------------------------

Only if prescribed for a patient with an uncomplicated urinary tract infection that is unresponsive to a first line agent or with proven resistance to first line agents and the prescription is endorsed accordingly.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Anticholinesterases</b>				
NEOSTIGMINE METILSULFATE				
Inj 2.5 mg per ml, 1 ml ampoule .....	98.00	50	✓	<u>AstraZeneca</u>
PYRIDOSTIGMINE BROMIDE				
▲ Tab 60 mg .....	38.90	100	✓	<u>Mestinon</u>
<b>Non-Steroidal Anti-Inflammatory Drugs</b>				
DICLOFENAC SODIUM				
* Tab EC 25 mg .....	4.00	100	✓	<u>Apo-Diclo</u>
* Tab 50 mg dispersible .....	1.50	20	✓	<u>Voltaren D</u>
* Tab EC 50 mg .....	16.00	500	✓	<u>Apo-Diclo</u>
* Tab long-acting 75 mg .....	24.52	500	✓	<u>Dicla SR</u>
* Tab long-acting 100 mg .....	42.25	500	✓	<u>Dicla SR</u>
* Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO .....	13.20	5	✓	<u>Voltaren</u>
* Suppos 12.5 mg .....	2.04	10	✓	<u>Voltaren</u>
* Suppos 25 mg .....	2.44	10	✓	<u>Voltaren</u>
* Suppos 50 mg – Up to 10 supp available on a PSO .....	4.22	10	✓	<u>Voltaren</u>
* Suppos 100 mg .....	7.00	10	✓	<u>Voltaren</u>
IBUPROFEN				
* Tab 200 mg .....	9.45	1,000	✓	<u>Ibugesic</u>
* Tab long-acting 800 mg .....	7.99	30	✓	<u>Brufen SR</u>
* Oral liq 20 mg per ml .....	1.89	200 ml	✓	<u>Fenpaed</u>
KETOPROFEN				
* Cap long-acting 200 mg .....	12.07	28	✓	<u>Oruvail SR</u>
MEFENAMIC ACID				
* Cap 250 mg .....	0.50 (5.60) 1.25 (9.16)	20  50		Ponstan  Ponstan
NAPROXEN				
* Tab 250 mg .....	18.06	500	✓	<u>Noflam 250</u>
Noflam 250 to be Sole Supply on 1 October 2015				
* Tab 500 mg .....	18.91	250	✓	<u>Noflam 500</u>
Noflam 500 to be Sole Supply on 1 October 2015				
* Tab long-acting 750 mg .....	18.00	90	✓	<u>Naprosyn SR 750</u>
* Tab long-acting 1 g .....	21.00	90	✓	<u>Naprosyn SR 1000</u>
SULINDAC				
* Tab 100 mg .....	8.55	50	✓	<u>Aclin</u>
* Tab 200 mg .....	15.10	50	✓	<u>Aclin</u>
TENOXICAM				
* Tab 20 mg .....	3.05	20	✓	<u>Reutenox</u>
* Inj 20 mg vial .....	9.95	1	✓	<u>AFT</u>
<b>NSAIDs Other</b>				
MELOXICAM – Special Authority see SA1034 on the next page – Retail pharmacy				
* Tab 7.5 mg .....	11.50	30	✓	<u>Arrow-Meloxicam</u>

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## ►SA1034 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and
- 2 The patient has haemophilic arthropathy; and
- 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated.

## Topical Products for Joint and Muscular Pain

### CAPSAICIN

Crm 0.025% – Special Authority see SA1289 below – Retail			
pharmacy .....	6.95	25 g OP	✓ Zostrix
	9.95	45 g OP	✓ Zostrix

## ►SA1289 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

## Antirheumatoid Agents

### AURANOFIN

Tab 3 mg .....	68.99	60	✓ Ridaura s29 s29
----------------	-------	----	-------------------

### HYDROXYCHLOROQUINE

* Tab 200 mg .....	10.50	100	✓ Plaquenil
--------------------	-------	-----	-------------

Plaquenil to be Sole Supply on 1 October 2015

### LEFLUNOMIDE

Tab 10 mg .....	55.00	30	✓ Arava
Tab 20 mg .....	76.00	30	✓ Arava
Tab 100 mg .....	54.44	3	✓ Arava

### PENICILLAMINE

Tab 125 mg .....	61.93	100	✓ D-Penamine
Tab 250 mg .....	98.98	100	✓ D-Penamine

### SODIUM AUROTHIOMALATE

Inj 10 mg in 0.5 ml ampoule .....	76.87	10	✓ Myocrisin
Inj 20 mg in 0.5 ml ampoule .....	113.17	10	✓ Myocrisin
Inj 50 mg in 0.5 ml ampoule .....	217.23	10	✓ Myocrisin

## Drugs Affecting Bone Metabolism

### Alendronate for Osteoporosis

## ►SA1039 Special Authority for Subsidy

**Initial application — (Underlying cause – Osteoporosis)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq 2.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -2.5$ ) (see Note); or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued. . .

- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score  $\leq -3.0$  (see Note); or
- 5 A 10-year risk of hip fracture  $\geq 3\%$ , calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or raloxifene.

**Initial application — (Underlying cause – glucocorticosteroid therapy)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is receiving systemic glucocorticosteroid therapy ( $\geq 5$  mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
  - 2.1 The patient has documented BMD  $\geq 1.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -1.5$ ) (see Note); or
  - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
  - 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause - glucocorticosteroid therapy) or raloxifene.

**Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy)** from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteroid therapy ( $\geq 5$  mg per day prednisone equivalents).

**Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq 2.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -2.5$ ) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score  $\leq -3.0$  (see Note); or
- 5 A 10-year risk of hip fracture  $\geq 3\%$ , calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - Osteoporosis' criteria) or raloxifene.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\leq -2.5$  and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ALENDRONATE SODIUM – Special Authority see SA1039 on page 116 – Retail pharmacy				
* Tab 70 mg .....	12.90	4	✓	<b>Fosamax</b>
ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA1039 on page 116 – Retail pharmacy				
* Tab 70 mg with cholecalciferol 5,600 iu .....	12.90	4	✓	<b>Fosamax Plus</b>

## Alendronate for Paget's Disease

### ►SA0949 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:  
Both:

- 1 Paget's disease; and
- 2 Any of the following:
  - 2.1 Bone or articular pain; or
  - 2.2 Bone deformity; or
  - 2.3 Bone, articular or neurological complications; or
  - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
  - 2.5 Preparation for orthopaedic surgery.

**Renewal** from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

ALENDRONATE SODIUM – Special Authority see SA0949 above – Retail pharmacy

* Tab 40 mg .....	133.00	30	✓	<b>Fosamax</b>
-------------------	--------	----	---	----------------

## Other Treatments

ETIDRONATE DISODIUM – See prescribing guideline below

* Tab 200 mg .....	13.50	100	✓	<b>Arrow-Etidronate</b>
--------------------	-------	-----	---	-------------------------

Arrow-Etidronate to be Sole Supply on 1 October 2015

### Prescribing Guidelines

Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water.

PAMIDRONATE DISODIUM

Inj 3 mg per ml, 10 ml vial .....	6.80	1	✓	<b>Pamisol</b>
Inj 6 mg per ml, 10 ml vial .....	13.20	1	✓	<b>Pamisol</b>
Inj 9 mg per ml, 10 ml vial .....	19.20	1	✓	<b>Pamisol</b>

RALOXIFENE HYDROCHLORIDE – Special Authority see SA1138 below – Retail pharmacy

* Tab 60 mg .....	53.76	28	✓	<b>Evista</b>
-------------------	-------	----	---	---------------

### ►SA1138 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq 2.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -2.5$ ) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score  $\leq -3.0$  (see Notes); or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 5 A 10-year risk of hip fracture  $\geq 3\%$ , calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or alendronate (Underlying cause - Osteoporosis).

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\leq -2.5$  and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

#### RISEDRONATE SODIUM

Tab 35 mg ..... 4.00 4 ✓ Risedronate Sandoz

#### TERIPARATIDE – Special Authority see SA1139 below – Retail pharmacy

Inj 250 mcg per ml, 2.4 ml ..... 490.00 1 ✓ Forteo

#### ►SA1139 | Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

#### ZOLEDRONIC ACID

Inj 0.05 mg per ml, 100 ml, vial – Special Authority see

SA1187 on the next page – Retail pharmacy ..... 600.00 100 ml OP ✓ Aclasta

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time

if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## ►SA1187 Special Authority for Subsidy

**Initial application — (Paget's disease)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
  - 2.1 Bone or articular pain; or
  - 2.2 Bone deformity; or
  - 2.3 Bone, articular or neurological complications; or
  - 2.4 Asymptomatic disease, but risk of complications; or
  - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

**Initial application — (Underlying cause - Osteoporosis)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
  - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq$  2.5 standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq$  -2.5) (see Note); or
  - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
  - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
  - 1.4 Documented T-Score  $\leq$  -3.0 (see Note); or
  - 1.5 A 10-year risk of hip fracture  $\geq$  3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
  - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

**Initial application — (Underlying cause - glucocorticosteroid therapy)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy ( $\geq$  5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
  - 2.1 The patient has documented BMD  $\geq$  1.5 standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq$  -1.5) (see Note); or
  - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
  - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) or raloxifene; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

**Renewal — (Paget's disease)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
  - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
  - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
  - 1.3 Symptomatic disease (prescriber determined); and

continued...



Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued. . .

- The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

**Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- The patient is continuing systemic glucocorticosteroid therapy ( $\geq 5$  mg per day prednisone equivalents); and
- The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

**Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- Any of the following:
  - History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq 2.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -2.5$ ) (see Note); or
  - History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
  - History of two significant osteoporotic fractures demonstrated radiologically; or
  - Documented T-Score  $\leq -3.0$  (see Note); or
  - A 10-year risk of hip fracture  $\geq 3\%$ , calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
  - Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - Osteoporosis' criteria) or raloxifene; and
- The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\leq -2.5$  and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

## Hyperuricaemia and Antigout

### ALLOPURINOL

* Tab 100 mg .....	15.11	1,000	✓ <b>Apo-Allopurinol</b>
* Tab 300 mg – For allopurinol oral liquid formulation refer, page 207 .....	15.91	500	✓ <b>Apo-Allopurinol</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
BENZBROMARONE – Special Authority see SA1537 below – Retail pharmacy				
Tab 100 mg .....	45.00	100	✓	<b>Benzbromaron AL</b> 100 <small>\$29</small>

## ►SA1537 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
  - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
  - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
  - 2.3 Both:
    - 2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Notes); and
    - 2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
  - 2.4 All of the following:
    - 2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
    - 2.4.2 Allopurinol is contraindicated; and
    - 2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
- 3 The patient is receiving monthly liver function tests.

**Renewal** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefitting from the treatment; and
- 2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity.

In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at [www.rheumatology.org.nz/downloads/Benzbromarone-prescriber-information-NZRA-V2.pdf](http://www.rheumatology.org.nz/downloads/Benzbromarone-prescriber-information-NZRA-V2.pdf)

## COLCHICINE

* Tab 500 mcg .....	10.08	100	✓	<b>Colgout</b>
---------------------	-------	-----	---	----------------

FEBUXOSTAT – Special Authority see SA1538 on the next page – Retail pharmacy

Tab 80 mg .....	39.50	28	✓	<b>Adenuric</b>
Tab 120 mg .....	39.50	28	✓	<b>Adenuric</b>

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1538 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
  - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
  - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
  - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note).

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from treatment.

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID

\* Tab 500 mg .....55.00 100 ✓ Probenecid-AFT

**Muscle Relaxants**

BACLOFEN

\* Tab 10 mg – For baclofen oral liquid formulation refer, page 207 .....3.85 100 ✓ Pacifen

Inj 0.05 mg per ml, 1 ml ampoule – Subsidy by endorsement.....11.55 1 ✓ Lioresal Intrathecal

a) Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.

b) Lioresal Intrathecal to be Sole Supply on 1 October 2015

Inj 2 mg per ml, 5 ml ampoule – Subsidy by endorsement.....209.29 1 ✓ Lioresal Intrathecal

Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.

DANTROLENE

\* Cap 25 mg .....65.00 100 ✓ Dantrium

\* Cap 50 mg .....77.00 100 ✓ Dantrium

ORPHENADRINE CITRATE

Tab 100 mg .....18.54 100 ✓ Norflex

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

## Agents for Parkinsonism and Related Disorders

### Dopamine Agonists and Related Agents

#### AMANTADINE HYDROCHLORIDE

▲ Cap 100 mg .....	38.24	60	✓ <u>Symmetrel</u>
--------------------	-------	----	--------------------

#### APOMORPHINE HYDROCHLORIDE

▲ Inj 10 mg per ml, 2 ml ampoule .....	119.00	5	✓ <u>Apomine</u>
--	--------	---	------------------

#### BROMOCRIPTINE MESYLATE

* Tab 2.5 mg .....	32.08	100	✓ <u>Apo-Bromocriptine</u>
--------------------	-------	-----	----------------------------

#### ENTACAPONE

▲ Tab 200 mg .....	28.00	100	✓ <u>Entapone</u>
--------------------	-------	-----	-------------------

Entapone to be Sole Supply on 1 October 2015

#### LEVODOPA WITH BENSERAZIDE

* Tab dispersible 50 mg with benserazide 12.5 mg .....	10.00	100	✓ <u>Madopar Rapid</u>
* Cap 50 mg with benserazide 12.5 mg .....	8.00	100	✓ <u>Madopar 62.5</u>
* Cap 100 mg with benserazide 25 mg .....	12.50	100	✓ <u>Madopar 125</u>
* Cap long-acting 100 mg with benserazide 25 mg .....	17.00	100	✓ <u>Madopar HBS</u>
* Cap 200 mg with benserazide 50 mg .....	25.00	100	✓ <u>Madopar 250</u>

#### LEVODOPA WITH CARBIDOPA

* Tab 100 mg with carbidopa 25 mg – For levodopa with carbidopa oral liquid formulation refer, page 207 .....	20.00	100	✓ <u>Kinson</u> ✓ <u>Sinemet</u>
* Tab long-acting 200 mg with carbidopa 50 mg .....	47.50	100	✓ <u>Sinemet CR</u>
* Tab 250 mg with carbidopa 25 mg .....	40.00	100	✓ <u>Sinemet</u>

#### LISURIDE HYDROGEN MALEATE

▲ Tab 200 mcg .....	25.00	30	✓ <u>Dopergin</u>
---------------------	-------	----	-------------------

#### PRAMIPEXOLE HYDROCHLORIDE

▲ Tab 0.25 mg .....	7.20	100	✓ <u>Ramipex</u>
▲ Tab 1 mg .....	24.39	100	✓ <u>Ramipex</u>

#### ROPINIROLE HYDROCHLORIDE

▲ Tab 0.25 mg .....	2.36	100	✓ <u>Apo-Ropinirole</u>
▲ Tab 1 mg .....	5.32	100	✓ <u>Apo-Ropinirole</u>
▲ Tab 2 mg .....	7.72	100	✓ <u>Apo-Ropinirole</u>
▲ Tab 5 mg .....	14.48	100	✓ <u>Apo-Ropinirole</u>

#### SELEGILINE HYDROCHLORIDE

* Tab 5 mg .....	16.06	100	✓ <u>Apo-Selegiline</u> ✓ <u>Apo-Selegiline</u>
------------------	-------	-----	--

S29 S29

#### TOLCAPONE

▲ Tab 100 mg .....	126.20	100	✓ <u>Tasmar</u>
--------------------	--------	-----	-----------------

Subsidy  
(Manufacturer's Price)  
\$

Per

Fully  
Subsidised  
✓

Brand or  
Generic  
Manufacturer

## Anticholinergics

### BENZTROPINE MESYLATE

Tab 2 mg .....	7.99	60	✓ Benztrop
Inj 1 mg per ml, 2 ml .....	95.00	5	✓ Cogentin
a) Up to 5 inj available on a PSO			
b) Only on a PSO			

### PROCYCLIDINE HYDROCHLORIDE

Tab 5 mg .....	7.40	100	✓ Kemadrin
----------------	------	-----	------------

## Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – Special Authority see SA1403 below – Retail pharmacy

Wastage claimable – see rule 3.3.2 on page 13

Tab 50 mg .....	400.00	56	✓ Rilutek
-----------------	--------	----	-----------

### ►SA1403 Special Authority for Subsidy

**Initial application** only from a neurologist or respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
  - 5.1 The patient is ambulatory; or
  - 5.2 The patient is able to use upper limbs; or
  - 5.3 The patient is able to swallow.

**Renewal** from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
  - 3.1 The patient is ambulatory; or
  - 3.2 The patient is able to use upper limbs; or
  - 3.3 The patient is able to swallow.

### TETRABENAZINE

Tab 25 mg .....	118.00	112	✓ Motetis
-----------------	--------	-----	-----------

## Anaesthetics

### Local

#### LIDOCAINE [LIGNOCAINE]

Gel 2%, 10 ml urethral syringe – Subsidy by endorsement.....	43.26	10	✓ Pfizer
a) Up to 5 each available on a PSO			
b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE</b>				
Oral (viscous) soln 2% .....	55.00	200 ml	✓	<b>Xylocaine Viscous</b>
Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO .....	8.75	25	✓	<b>Lidocaine-Clarix</b>
	17.50	50		
	(35.00)			Xylocaine
Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO .....	6.90	25	✓	<b>Lidocaine-Clarix</b>
Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO .....	2.40	1	✓	<b>Lidocaine-Clarix</b>
	12.00	5		
	(20.00)			Xylocaine
Inj 2%, 20 ml ampoule – Up to 5 inj available on a PSO .....	2.40	1	✓	<b>Lidocaine-Clarix</b>
<b>LIDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE</b>				
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes –				
Subsidy by endorsement .....	43.26	10	✓	<b>Pfizer</b>
a) Up to 5 each available on a PSO				
b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.				

## Topical Local Anaesthetics

### ►SA0906 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

LIDOCAINE [LIGNOCAINE] – Special Authority see SA0906 above – Retail pharmacy

Crm 4% .....	27.00	30 g OP	✓	<b>LMX4</b>
Crm 4% (5 g tubes) .....	27.00	5	✓	<b>LMX4</b>

LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE – Special Authority see SA0906 above – Retail pharmacy

Crm 2.5% with prilocaine 2.5% .....	45.00	30 g OP	✓	<b>EMLA</b>
Crm 2.5% with prilocaine 2.5% (5 g tubes) .....	45.00	5	✓	<b>EMLA</b>

## Analgesics

For Anti-inflammatory NSAIDs refer to MUSCULOSKELETAL, page 115

### Non-opioid Analgesics

For aspirin & chloroform application refer Standard Formulae, page 210

#### ASPIRIN

* Tab EC 300 mg .....	2.00	100		
	(8.50)			Aspec 300
* Tab dispersible 300 mg – Up to 30 tab available on a PSO .....	2.55	100	✓	<b>Ethics Aspirin</b>

#### CAPSAICIN – Subsidy by endorsement

Subsidised only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy and the prescription is endorsed accordingly.

Crm 0.075% .....	12.50	45 g OP	✓	<b>Zostrix HP</b>
------------------	-------	---------	---	-------------------

#### NEFOPAM HYDROCHLORIDE

Tab 30 mg .....	23.40	90	✓	<b>Acupan</b>
-----------------	-------	----	---	---------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>PARACETAMOL</b>				
* Tab 500 mg – Up to 30 tab available on a PSO.....	8.47	1,000	✓	<b>Pharmacare</b>
*‡ Oral liq 120 mg per 5 ml .....	4.15	1,000 ml	✓	<b>Paracare</b>
a) Up to 200 ml available on a PSO				
b) Not in combination				
*‡ Oral liq 250 mg per 5 ml .....	4.35	1,000 ml	✓	<b>Paracare Double Strength</b>
a) Up to 100 ml available on a PSO				
b) Not in combination				
* Suppos 125 mg .....	7.49	20	✓	<b>Panadol</b>
* Suppos 250 mg .....	14.40	20	✓	<b>Panadol</b>
* Suppos 500 mg .....	20.70	50	✓	<b>Paracare</b>
<b>Opioid Analgesics</b>				
<b>CODEINE PHOSPHATE – Safety medicine; prescriber may determine dispensing frequency</b>				
Tab 15 mg .....	4.75	100	✓	<b>PSM</b>
Tab 30 mg .....	5.80	100	✓	<b>PSM</b>
Tab 60 mg .....	12.50	100	✓	<b>PSM</b>
<b>DIHYDROCODEINE TARTRATE</b>				
Tab long-acting 60 mg .....	13.64	60	✓	<b>DHC Continus</b>
<b>FENTANYL</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Inj 50 mcg per ml, 2 ml ampoule .....	3.95	10	✓	<b>Boucher and Muir</b>
Boucher and Muir to be Sole Supply on 1 October 2015				
Inj 50 mcg per ml, 10 ml ampoule .....	10.45	10	✓	<b>Boucher and Muir</b>
Boucher and Muir to be Sole Supply on 1 October 2015				
Patch 12.5 mcg per hour .....	2.92	5	✓	<b>Fentanyl Sandoz</b>
Patch 25 mcg per hour .....	3.66	5	✓	<b>Fentanyl Sandoz</b>
Patch 50 mcg per hour .....	6.64	5	✓	<b>Fentanyl Sandoz</b>
Patch 75 mcg per hour .....	9.18	5	✓	<b>Fentanyl Sandoz</b>
Patch 100 mcg per hour .....	11.29	5	✓	<b>Fentanyl Sandoz</b>
<b>METHADONE HYDROCHLORIDE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
d) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).				
e) For methadone hydrochloride oral liquid refer Standard Formulae, page 210				
Tab 5 mg .....	1.85	10	✓	<b>Methatabs</b>
Methatabs to be Sole Supply on 1 October 2015				
‡ Oral liq 2 mg per ml .....	5.55	200 ml	✓	<b>Biodone</b>
Biodone to be Sole Supply on 1 October 2015				
‡ Oral liq 5 mg per ml .....	5.00	200 ml	✓	<b>Biodone Forte</b>
Biodone Forte to be Sole Supply on 1 October 2015				
‡ Oral liq 10 mg per ml .....	6.55	200 ml	✓	<b>Biodone Extra Forte</b>
Biodone Extra Forte to be Sole Supply on 1 October 2015				
Inj 10 mg per ml, 1 ml .....	61.00	10	✓	<b>AFT</b>

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>MORPHINE HYDROCHLORIDE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
‡ Oral liq 1 mg per ml ..... 8.84	200 ml	✓	RA-Morph	
RA-Morph to be Sole Supply on 1 November 2015				
‡ Oral liq 2 mg per ml ..... 14.00	200 ml	✓	RA-Morph	
RA-Morph to be Sole Supply on 1 November 2015				
‡ Oral liq 5 mg per ml ..... 18.00	200 ml	✓	RA-Morph	
RA-Morph to be Sole Supply on 1 November 2015				
‡ Oral liq 10 mg per ml ..... 26.00	200 ml	✓	RA-Morph	
RA-Morph to be Sole Supply on 1 November 2015				
<b>MORPHINE SULPHATE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Tab immediate-release 10 mg ..... 2.80	10	✓	Sevredol	
Tab long-acting 10 mg ..... 1.95	10	✓	Arrow-Morphine LA	
Tab immediate-release 20 mg ..... 5.52	10	✓	Sevredol	
Tab long-acting 30 mg ..... 2.98	10	✓	Arrow-Morphine LA	
Tab long-acting 60 mg ..... 5.75	10	✓	Arrow-Morphine LA	
Tab long-acting 100 mg ..... 6.45	10	✓	Arrow-Morphine LA	
Cap long-acting 10 mg ..... 1.70	10	✓	m-Eslon	
Cap long-acting 30 mg ..... 2.50	10	✓	m-Eslon	
Cap long-acting 60 mg ..... 5.40	10	✓	m-Eslon	
Cap long-acting 100 mg ..... 6.38	10	✓	m-Eslon	
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO ..... 12.48	5	✓	DBL Morphine Sulphate	
Inj 10 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO ..... 9.09	5	✓	DBL Morphine Sulphate	
Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO ..... 9.77	5	✓	DBL Morphine Sulphate	
Inj 30 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO ..... 12.43	5	✓	DBL Morphine Sulphate	
<b>MORPHINE TARTRATE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Inj 80 mg per ml, 1.5 ml ..... 35.60	5	✓	Hospira	
Inj 80 mg per ml, 5 ml ..... 107.67	5	✓	Hospira	



	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>OXYCODONE HYDROCHLORIDE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Tab controlled-release 5 mg .....	7.51	20	✓	OxyContin
Tab controlled-release 10 mg .....	6.75	20	✓	Oxycodone ControlledRelease Tablets(BNM)
Tab controlled-release 20 mg .....	11.50	20	✓	Oxycodone ControlledRelease Tablets(BNM)
Tab controlled-release 40 mg .....	18.50	20	✓	Oxycodone ControlledRelease Tablets(BNM)
Tab controlled-release 80 mg .....	34.00	20	✓	Oxycodone ControlledRelease Tablets(BNM)
Cap immediate-release 5 mg .....	1.98	20	✓	OxyNorm
OxyNorm to be Sole Supply on 1 November 2015				
Cap immediate-release 10 mg .....	3.91	20	✓	OxyNorm
OxyNorm to be Sole Supply on 1 November 2015				
Cap immediate-release 20 mg .....	6.84	20	✓	OxyNorm
OxyNorm to be Sole Supply on 1 November 2015				
‡ Oral liq 5 mg per 5 ml .....	11.20	250 ml	✓	OxyNorm
Inj 10 mg per ml, 1 ml .....	10.08	5	✓	Oxycodone Orion
Inj 10 mg per ml, 2 ml .....	19.87	5	✓	Oxycodone Orion
Inj 50 mg per ml, 1 ml .....	60.00	5	✓	OxyNorm
<b>PARACETAMOL WITH CODEINE</b> – Safety medicine; prescriber may determine dispensing frequency				
* Tab paracetamol 500 mg with codeine phosphate 8 mg .....	21.06	1,000	✓	<u>Paracetamol + Codeine (Relieve)</u>
<b>PETHIDINE HYDROCHLORIDE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Tab 50 mg .....	3.95	10	✓	PSM
Tab 100 mg .....	5.80	10	✓	PSM
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	5.51	5	✓	<u>DBL Pethidine Hydrochloride</u>
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	5.83	5	✓	<u>DBL Pethidine Hydrochloride</u>
<b>TRAMADOL HYDROCHLORIDE</b>				
Tab sustained-release 100 mg .....	2.00	20	✓	<u>Tramal SR 100</u>
Tab sustained-release 150 mg .....	3.00	20	✓	<u>Tramal SR 150</u>
Tab sustained-release 200 mg .....	4.00	20	✓	<u>Tramal SR 200</u>
Cap 50 mg – For tramadol hydrochloride oral liquid formula- tion refer, page 207.....	2.50	100	✓	<u>Arrow-Tramadol</u>

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time  
if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy  
(Manufacturer's Price)  
\$

Fully  
Subsidised  
✓

Brand or  
Generic  
Manufacturer

## Antidepressants

### Cyclic and Related Agents

AMITRIPTYLINE – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg .....	1.68	100	✓ <u>Arrow Amitriptyline</u>
Tab 25 mg .....	1.68	100	✓ <u>Arrow-Amitriptyline</u>
Tab 50 mg .....	2.82	100	✓ <u>Arrow-Amitriptyline</u>

CLOMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg .....	12.60	100	✓ <u>Apo-Clomipramine</u>
Apo-Clomipramine to be Sole Supply on 1 October 2015			
Tab 25 mg .....	8.68	100	✓ <u>Apo-Clomipramine</u>
Apo-Clomipramine to be Sole Supply on 1 October 2015			

DOTHIEPIN HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 75 mg .....	10.50	100	✓ <u>Dopress</u>
Cap 25 mg .....	6.17	100	✓ <u>Dopress</u>

DOXEPIN HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Cap 10 mg .....	6.30	100	✓ <u>Anten</u>
Cap 25 mg .....	6.86	100	✓ <u>Anten</u>
Cap 50 mg .....	8.55	100	✓ <u>Anten</u>

IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg .....	6.58	60	✓ <u>Tofranil s29</u> <sup>s29</sup>
	5.48	50	✓ <u>Tofranil</u>
	10.96	100	✓ <u>Tofranil</u>
Tab 25 mg .....	8.80	50	✓ <u>Tofranil</u>

MAPROTILINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 25 mg .....	7.52	30	✓ <u>Ludiomil</u>
	12.53	50	✓ <u>Ludiomil</u>
	25.06	100	✓ <u>Ludiomil</u>
Tab 75 mg .....	14.01	20	✓ <u>Ludiomil</u>
	21.01	30	✓ <u>Ludiomil</u>

MIANSERIN HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 30 mg – Subsidy by endorsement .....	24.86	30	✓ <u>Tolvon</u>
--	-------	----	-----------------

Subsidised for patients who were taking mianserin hydrochloride prior to 1 July 2014 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of mianserin hydrochloride. Note that supply of mianserin hydrochloride is being discontinued in New Zealand and it is anticipated that there will be no stock of mianserin available beyond November 2015.

NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg .....	4.00	100	✓ <u>Norpress</u>
Tab 25 mg .....	9.00	180	✓ <u>Norpress</u>

### Monoamine-Oxidase Inhibitors (MAOIs) - Non Selective

PHENELZINE SULPHATE

* Tab 15 mg .....	95.00	100	✓ <u>Nardil</u>
-------------------	-------	-----	-----------------

TRANLYCYPROMINE SULPHATE

* Tab 10 mg .....	22.94	50	✓ <u>Parnate</u>
-------------------	-------	----	------------------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Monoamine-Oxidase Type A Inhibitors

### MOCLOBEMIDE

Note: There is a significant cost differential between moclobemide and fluoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with fluoxetine first before considering prescribing moclobemide.

* Tab 150 mg .....	85.10	500	✓ Apo-Moclobemide
Apo-Moclobemide to be Sole Supply on 1 November 2015			
* Tab 300 mg .....	30.70	100	✓ Apo-Moclobemide
Apo-Moclobemide to be Sole Supply on 1 November 2015			

## Selective Serotonin Reuptake Inhibitors

### CITALOPRAM HYDROBROMIDE

* Tab 20 mg .....	2.34	84	✓ Arrow-Citalopram
-------------------	------	----	--------------------

### ESCITALOPRAM

* Tab 10 mg .....	1.40	28	✓ Air Flow Products ✓ Loxalate
Air Flow Products to be Sole Supply on 1 October 2015			
* Tab 20 mg .....	2.40	28	✓ Air Flow Products ✓ Loxalate

Air Flow Products to be Sole Supply on 1 October 2015

(Loxalate Tab 10 mg to be delisted 1 October 2015)

(Loxalate Tab 20 mg to be delisted 1 October 2015)

### FLUOXETINE HYDROCHLORIDE

* Tab dispersible 20 mg, scored – Subsidy by endorsement .....	2.50	30	✓ <u>Arrow-Fluoxetine</u>
Subsidised by endorsement			
1) When prescribed for a patient who cannot swallow whole tablets or capsules and the prescription is endorsed accordingly; or			
2) When prescribed in a daily dose that is not a multiple of 20 mg in which case the prescription is deemed to be endorsed.			
Note: Tablets should be combined with capsules to facilitate incremental 10 mg doses.			

* Cap 20 mg .....	1.74	90	✓ <u>Arrow-Fluoxetine</u>
-------------------	------	----	---------------------------

### PAROXETINE HYDROCHLORIDE

* Tab 20 mg .....	4.32	90	✓ <u>Loxamine</u>
-------------------	------	----	-------------------

### SERTRALINE

* Tab 50 mg .....	3.64	90	✓ <u>Arrow-Sertraline</u>
* Tab 100 mg .....	6.28	90	✓ <u>Arrow-Sertraline</u>

## Other Antidepressants

### MIRTAZAPINE – Special Authority see SA0994 on the next page – Retail pharmacy

Tab 30 mg .....	8.78	30	✓ Avanza
Tab 45 mg .....	13.95	30	✓ Avanza

## ►SA0994 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has a severe major depressive episode; and
- 2 Either:
  - 2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or
  - 2.2 Both:
    - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
    - 2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

### VENLAFAXINE

Tab 37.5 mg .....	5.06	28	✓ Arrow-Venlafaxine XR
Tab 75 mg .....	6.44	28	✓ Arrow-Venlafaxine XR
Tab 150 mg .....	8.86	28	✓ Arrow-Venlafaxine XR
Tab 225 mg .....	14.34	28	✓ Arrow-Venlafaxine XR
Cap 37.5 mg – Special Authority see SA1061 below – Retail pharmacy .....	5.69	28	✓ Efexor XR
Cap 75 mg – Special Authority see SA1061 below – Retail pharmacy .....	11.40	28	✓ Efexor XR
Cap 150 mg – Special Authority see SA1061 below – Retail pharmacy .....	13.98	28	✓ Efexor XR

## ►SA1061 Special Authority for Subsidy

**Initial application** only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has 'treatment-resistant' depression; and
- 2 Either:
  - 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or
  - 2.2 Both:
    - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
    - 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

**Renewal** from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

## Antiepilepsy Drugs

### Agents for Control of Status Epilepticus

CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Inj 1 mg per ml, 1 ml .....	19.00	5	✓ Rivotril
-----------------------------	-------	---	------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>DIAZEPAM</b> – Safety medicine; prescriber may determine dispensing frequency				
Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement.....	11.83	5	✓	Hospira
a) Up to 5 inj available on a PSO				
b) Only on a PSO				
c) PSO must be endorsed “not for anaesthetic procedures”.				
Rectal tubes 5 mg – Up to 5 tube available on a PSO .....	25.05	5	✓	Stesolid
Rectal tubes 10 mg – Up to 5 tube available on a PSO .....	30.50	5	✓	Stesolid
<b>PARALDEHYDE</b>				
* Inj 5 ml .....	1,500.00	5	✓	AFT
<b>PHENYTOIN SODIUM</b>				
* Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO .....	88.63	5	✓	Hospira
Hospira to be Sole Supply on 1 November 2015				
* Inj 50 mg per ml, 5 ml ampoule – Up to 5 inj available on a PSO .....	133.92	5	✓	Hospira
Hospira to be Sole Supply on 1 November 2015				

## Control of Epilepsy

<b>CARBAMAZEPINE</b>				
* Tab 200 mg .....	14.53	100	✓	Tegretol
* Tab long-acting 200 mg .....	16.98	100	✓	Tegretol CR
* Tab 400 mg .....	34.58	100	✓	Tegretol
* Tab long-acting 400 mg .....	39.17	100	✓	Tegretol CR
*‡ Oral liq 20 mg per ml .....	26.37	250 ml	✓	Tegretol
<b>CLOBAZAM</b> – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg .....	9.12	50	✓	Frisium
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
<b>CLONAZEPAM</b> – Safety medicine; prescriber may determine dispensing frequency				
‡ Oral drops 2.5 mg per ml .....	7.38	10 ml OP	✓	Rivotril
<b>ETHOSUXIMIDE</b>				
* Cap 250 mg .....	32.90	200	✓	Zarontin
*‡ Oral liq 250 mg per 5 ml .....	13.60	200 ml	✓	Zarontin
<b>GABAPENTIN</b> – Special Authority see SA1477 below – Retail pharmacy				
▲ Cap 100 mg .....	7.16	100	✓	Arrow-Gabapentin
			✓	Nupentin
▲ Cap 300 mg – For gabapentin oral liquid formulation refer, page 207 .....	11.00	100	✓	Arrow-Gabapentin
			✓	Nupentin
▲ Cap 400 mg .....	13.75	100	✓	Arrow-Gabapentin
			✓	Nupentin

### ►SA1477 Special Authority for Subsidy

**Initial application — (Epilepsy)** from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

continued...

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time

if endorsed “certified exemption” by the prescriber or pharmacist.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

**Initial application — (Neuropathic pain or Chronic Kidney Disease associated pruritus)** from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 The patient has been diagnosed with neuropathic pain; or
- 2 Both:
  - 2.1 The patient has Chronic Kidney Disease Stage 5-associated pruritus\* where no other cause for pruritus can be identified (e.g. scabies, allergy); and
  - 2.2 The patient has persistent pruritus not relieved with a trial of emollient/moisturising creams alone.

**Renewal — (Epilepsy)** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

**Renewal — (Neuropathic pain or Chronic Kidney Disease associated pruritus)** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain or itch (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Note: Indications marked with \* are Unapproved Indications (see Interpretations and Definitions). Dosage adjustment of gabapentin is recommended for patients with renal impairment.

**GABAPENTIN (NEURONTIN) — Special Authority see SA0973 below — Retail pharmacy**

▲ Tab 600 mg .....	67.50	100	✓ Neurontin
▲ Cap 100 mg .....	13.26	100	✓ Neurontin
▲ Cap 300 mg — For gabapentin (neurontin) oral liquid formulation refer, page 207 .....	39.76	100	✓ Neurontin
▲ Cap 400 mg .....	53.01	100	✓ Neurontin

## ►SA0973 Special Authority for Subsidy

Notes: Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 August 2009.

**LACOSAMIDE — Special Authority see SA1125 below — Retail pharmacy**

▲ Tab 50 mg .....	25.04	14	✓ Vimpat
▲ Tab 100 mg .....	50.06	14	✓ Vimpat
	200.24	56	✓ Vimpat
▲ Tab 150 mg .....	75.10	14	✓ Vimpat
	300.40	56	✓ Vimpat
▲ Tab 200 mg .....	400.55	56	✓ Vimpat

## ►SA1125 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

**Renewal** from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

#### LAMOTRIGINE

▲ Tab dispersible 2 mg .....	6.74	30	✓ Lamictal
▲ Tab dispersible 5 mg .....	9.64	30	✓ Lamictal
	15.00	56	✓ Arrow-Lamotrigine
▲ Tab dispersible 25 mg .....	19.38	56	✓ Logem
	20.40		✓ Arrow-Lamotrigine
			✓ Mogine
	29.09		✓ Lamictal
▲ Tab dispersible 50 mg .....	32.97	56	✓ Logem
	34.70		✓ Arrow-Lamotrigine
			✓ Mogine
	47.89		✓ Lamictal
▲ Tab dispersible 100 mg .....	56.91	56	✓ Logem
	59.90		✓ Arrow-Lamotrigine
			✓ Mogine
	79.16		✓ Lamictal

#### LEVETIRACETAM

Tab 250 mg .....	24.03	60	✓ Levetiracetam-Rex
Tab 500 mg – For levetiracetam oral liquid formulation refer, page 207 .....	28.71	60	✓ Levetiracetam-Rex
Tab 750 mg .....	45.23	60	✓ Levetiracetam-Rex

#### PHENOBARBITONE

For phenobarbitone oral liquid refer Standard Formulae, page 210

* Tab 15 mg .....	28.00	500	✓ PSM
* Tab 30 mg .....	29.00	500	✓ PSM

#### PHENYTOIN SODIUM

* Tab 50 mg .....	50.51	200	✓ Dilantin Infatab
* Cap 30 mg .....	22.00	200	✓ Dilantin
* Cap 100 mg .....	19.79	200	✓ Dilantin
*‡ Oral liq 30 mg per 5 ml .....	22.03	500 ml	✓ Dilantin

#### PRIMIDONE

* Tab 250 mg .....	17.25	100	✓ Apo-Primidone
--------------------	-------	-----	-----------------

#### SODIUM VALPROATE

* Tab 100 mg .....	13.65	100	✓ Epilim Crushable
* Tab 200 mg EC .....	27.44	100	✓ Epilim
* Tab 500 mg EC .....	52.24	100	✓ Epilim
*‡ Oral liq 200 mg per 5 ml .....	20.48	300 ml	✓ Epilim S/F Liquid
			✓ Epilim Syrup
* Inj 100 mg per ml, 4 ml .....	41.50	1	✓ Epilim IV

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
STIRIPENTOL – Special Authority see SA1330 below – Retail pharmacy				
Cap 250 mg .....	509.29	60	✓	Diacomit \$29
Powder for oral liq 250 mg sachet .....	509.29	60	✓	Diacomit \$29

## ►SA1330 Special Authority for Subsidy

**Initial application** only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

**Renewal** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

### TOPIRAMATE

▲ Tab 25 mg .....	11.07	60	✓	Arrow-Topiramate
	26.04		✓	Topiramate Actavis
			✓	Topamax
▲ Tab 50 mg .....	18.81	60	✓	Arrow-Topiramate
	44.26		✓	Topiramate Actavis
			✓	Topamax
▲ Tab 100 mg .....	31.99	60	✓	Arrow-Topiramate
	75.25		✓	Topiramate Actavis
			✓	Topamax
▲ Tab 200 mg .....	55.19	60	✓	Arrow-Topiramate
	129.85		✓	Topiramate Actavis
			✓	Topamax
▲ Sprinkle cap 15 mg .....	20.84	60	✓	Topamax
▲ Sprinkle cap 25 mg .....	26.04	60	✓	Topamax

### VIGABATRIN – Special Authority see SA1072 below – Retail pharmacy

▲ Tab 500 mg .....	119.30	100	✓	Sabril
--------------------	--------	-----	---	--------

## ►SA1072 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

- 1 Either:
  - 1.1 Patient has infantile spasms; or
  - 1.2 Both:
    - 1.2.1 Patient has epilepsy; and
    - 1.2.2 Either:
      - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
      - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
- 2 Either:
  - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
  - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

continued...



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued. . .

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

**Renewal** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Both:
- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
  - 2 Either:

- 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
- 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

## Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 115

### Acute Migraine Treatment

#### ERGOTAMINE TARTRATE WITH CAFFEINE

Tab 1 mg with caffeine 100 mg .....	31.00	100	✓ <b>Cafergot</b>
-------------------------------------	-------	-----	-------------------

#### RIZATRIPTAN

Tab orodispersible 10 mg .....	8.10	30	✓ <b>Rizamelt</b>
--------------------------------	------	----	-------------------

#### SUMATRIPTAN

Tab 50 mg .....	29.80	100	✓ <b>Arrow-Sumatriptan</b>
-----------------	-------	-----	----------------------------

Tab 100 mg .....	54.80	100	✓ <b>Arrow-Sumatriptan</b>
------------------	-------	-----	----------------------------

Inj 12 mg per ml, 0.5 ml cartridge – Maximum of 10 inj per prescription .....	13.80	2 OP	✓ <b>Arrow-Sumatriptan</b>
---	-------	------	----------------------------

### Prophylaxis of Migraine

For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTEM, page 52

#### PIZOTIFEN

* Tab 500 mcg .....	23.21	100	✓ <b>Sandomigran</b>
---------------------	-------	-----	----------------------

Sandomigran to be Sole Supply on 1 October 2015

### Antinausea and Vertigo Agents

For Antispasmodics refer to ALIMENTARY TRACT, page 22

#### APREPITANT – Special Authority see SA0987 below – Retail pharmacy

Cap 2 × 80 mg and 1 × 125 mg .....	100.00	3 OP	✓ <b>Emend Tri-Pack</b>
------------------------------------	--------	------	-------------------------

#### ►SA0987 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

**Renewal** from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

#### BETAHISTINE DIHYDROCHLORIDE

* Tab 16 mg .....	4.95	84	✓ <b>Vergo 16</b>
-------------------	------	----	-------------------

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>CYCLIZINE HYDROCHLORIDE</b>				
Tab 50 mg .....	0.59	10	✓	<b>Nausicalm</b>
<b>CYCLIZINE LACTATE</b>				
Inj 50 mg per ml, 1 ml .....	14.95	5	✓	<b>Nausicalm</b>
<b>DOMPERIDONE</b>				
* Tab 10 mg – For domperidone oral liquid formulation refer, page 207 .....	3.25	100	✓	<b>Prokinex</b>
<b>GRANISETRON</b>				
* Tab 1 mg .....	5.98	50	✓	<b>Granirex</b>
<b>HYOSCINE HYDROBROMIDE</b>				
* Inj 400 mcg per ml, 1 ml ampoule .....	46.50	5	✓	<b>Hospira</b>
	93.00	10	✓	<b>Martindale</b> <small>S29</small>
Patch 1.5 mg – Special Authority see SA1387 below – Retail pharmacy .....	11.95	2	✓	<b>Scopoderm TTS</b>
<b>►SA1387 Special Authority for Subsidy</b>				
<b>Initial application</b> from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:				
1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or				
2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective.				
<b>Renewal</b> from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.				
<b>METOCLOPRAMIDE HYDROCHLORIDE</b>				
* Tab 10 mg – For metoclopramide hydrochloride oral liquid formulation refer, page 207.....	1.82	100	✓	<b>Metamide</b>
* Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO .....	4.50	10	✓	<b>Pfizer</b>
<b>ONDANSETRON</b>				
* Tab 4 mg .....	5.51	50	✓	<b>Onrex</b>
* Tab disp 4 mg .....	1.00	10	✓	<b>Dr Reddy's Ondansetron</b>
* Tab 8 mg .....	6.19	50	✓	<b>Onrex</b>
* Tab disp 8 mg .....	1.50	10	✓	<b>Ondansetron ODT-DRLA</b>
<b>PROCHLORPERAZINE</b>				
* Tab 3 mg buccal .....	5.97 (15.00)	50		Buccastem
* Tab 5 mg – Up to 30 tab available on a PSO.....	9.75	500	✓	<b>Antinaus</b>
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	25.81	10	✓	<b>Stemetil</b>
* Suppos 25 mg .....	23.87	5	✓	<b>Stemetil</b>
<b>PROMETHAZINE THEOCLATE</b>				
* Tab 25 mg .....	1.20 (6.24)	10		Avomine

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## Antipsychotics

### Guidelines for the use of atypical antipsychotic agents

Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

### General

AMISULPRIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 100 mg .....	6.22	30	✓ <b>Solian</b>
Tab 200 mg .....	21.92	60	✓ <b>Solian</b>
Tab 400 mg .....	44.52	60	✓ <b>Solian</b>
Oral liq 100 mg per ml .....	52.50	60 ml	✓ <b>Solian</b>

ARIPRAZOLE – Special Authority see SA1539 below – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency			
Tab 10 mg .....	123.54	30	✓ <b>Abilify</b>
Tab 15 mg .....	175.28	30	✓ <b>Abilify</b>
Tab 20 mg .....	213.42	30	✓ <b>Abilify</b>
Tab 30 mg .....	260.07	30	✓ <b>Abilify</b>

#### ►SA1539 | Special Authority for Subsidy

**Initial application — (Schizophrenia or related psychoses)** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

- Both:
- 1 Patient is suffering from schizophrenia or related psychoses; and
  - 2 Either:
    - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
    - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

**Initial application — (Autism spectrum disorder\*)** only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has been diagnosed with an autism spectrum disorder\* and has symptoms of severe irritability; and
- 2 An effective dose of risperidone has been trialled and has been discontinued because of unacceptable side effects or inadequate response; and
- 3 The patient is aged less than 18 years.

**Renewal — (Schizophrenia or related psychoses)** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**Renewal — (Autism spectrum disorder\*)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Indications marked with \* are Unapproved Indications

CHLORPROMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg – Up to 30 tab available on a PSO.....	12.36	100	✓ <b>Largactil</b>
Tab 25 mg – Up to 30 tab available on a PSO.....	13.02	100	✓ <b>Largactil</b>
Tab 100 mg – Up to 30 tab available on a PSO.....	30.61	100	✓ <b>Largactil</b>
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	25.66	10	✓ <b>Largactil</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time

if endorsed "certified exemption" by the prescriber or pharmacist.

# NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>CLOZAPINE – Hospital pharmacy [HP4]</b>				
Safety medicine; prescriber may determine dispensing frequency				
Tab 25 mg .....	5.69	50	✓	<u>Clozaril</u>
	11.36	100	✓	<u>Clozaril</u>
	6.69	50	✓	<u>Clopine</u>
	13.37	100	✓	<u>Clopine</u>
Tab 50 mg .....	8.67	50	✓	<u>Clopine</u>
	17.33	100	✓	<u>Clopine</u>
Tab 100 mg .....	14.73	50	✓	<u>Clozaril</u>
	29.45	100	✓	<u>Clozaril</u>
	17.33	50	✓	<u>Clopine</u>
	34.65	100	✓	<u>Clopine</u>
Tab 200 mg .....	34.65	50	✓	<u>Clopine</u>
	69.30	100	✓	<u>Clopine</u>
Suspension 50 mg per ml .....	17.33	100 ml	✓	<u>Clopine</u>
<b>HALOPERIDOL – Safety medicine; prescriber may determine dispensing frequency</b>				
Tab 500 mcg – Up to 30 tab available on a PSO .....	6.23	100	✓	<u>Serenace</u>
Tab 1.5 mg – Up to 30 tab available on a PSO .....	9.43	100	✓	<u>Serenace</u>
Tab 5 mg – Up to 30 tab available on a PSO .....	29.72	100	✓	<u>Serenace</u>
Oral liq 2 mg per ml – Up to 200 ml available on a PSO .....	23.84	100 ml	✓	<u>Serenace</u>
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	21.55	10	✓	<u>Serenace</u>
<b>LEVOMEPROMAZINE MALEATE – Safety medicine; prescriber may determine dispensing frequency</b>				
Tab 25 mg .....	16.93	100	✓	<u>Nozinan</u>
Tab 100 mg .....	43.96	100	✓	<u>Nozinan</u>
Inj 25 mg per ml, 1 ml .....	73.68	10	✓	<u>Nozinan</u>
<b>LITHIUM CARBONATE – Safety medicine; prescriber may determine dispensing frequency</b>				
Tab 250 mg .....	34.30	500	✓	<u>Lithicarb FC</u>
Lithicarb FC to be Sole Supply on 1 October 2015				
Tab 400 mg .....	12.83	100	✓	<u>Lithicarb FC</u>
Lithicarb FC to be Sole Supply on 1 October 2015				
Tab long-acting 400 mg .....	19.20	100	✓	<u>Priadel</u>
Cap 250 mg .....	9.42	100	✓	<u>Douglas</u>
<b>OLANZAPINE – Safety medicine; prescriber may determine dispensing frequency</b>				
Tab 2.5 mg .....	0.75	28	✓	<u>Zypine</u>
Tab 5 mg .....	1.65	28	✓	<u>Zypine</u>
Tab orodispersible 5 mg .....	1.75	28	✓	<u>Zypine ODT</u>
Tab 10 mg .....	2.55	28	✓	<u>Zypine</u>
Tab orodispersible 10 mg .....	3.05	28	✓	<u>Zypine ODT</u>
<b>PERICYZINE – Safety medicine; prescriber may determine dispensing frequency</b>				
Tab 2.5 mg .....	12.49	100	✓	<u>Neulactil</u>
Tab 10 mg .....	44.45	100	✓	<u>Neulactil</u>
<b>QUETIAPINE – Safety medicine; prescriber may determine dispensing frequency</b>				
Tab 25 mg .....	2.10	90	✓	<u>Quetapel</u>
Tab 100 mg .....	4.20	90	✓	<u>Quetapel</u>
Tab 200 mg .....	7.20	90	✓	<u>Quetapel</u>
Tab 300 mg .....	12.00	90	✓	<u>Quetapel</u>

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

**RISPERIDONE** – Safety medicine; prescriber may determine dispensing frequency

Tab orodispersible 0.5 mg – Special Authority see SA0927			
below – Retail pharmacy .....	21.42	28	✓ <b>Risperdal Quicklet</b>
Tab 0.5 mg .....	1.90	60	✓ <b>Actavis</b>
Tab 1 mg .....	2.10	60	✓ <b>Actavis</b>
Tab orodispersible 1 mg – Special Authority see SA0927 be-			
low – Retail pharmacy .....	42.84	28	✓ <b>Risperdal Quicklet</b>
Tab 2 mg .....	2.34	60	✓ <b>Actavis</b>
Tab orodispersible 2 mg – Special Authority see SA0927 be-			
low – Retail pharmacy .....	85.71	28	✓ <b>Risperdal Quicklet</b>
Tab 3 mg .....	2.55	60	✓ <b>Actavis</b>
Tab 4 mg .....	3.50	60	✓ <b>Actavis</b>
Oral liq 1 mg per ml .....	9.75	30 ml	✓ <b>Risperon</b>

►SA0927 Special Authority for Subsidy

**Initial application — (Acute situations)** from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

**Initial application — (Chronic situations)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

**Renewal** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary.

**TRIFLUOPERAZINE HYDROCHLORIDE** – Safety medicine; prescriber may determine dispensing frequency

Tab 1 mg .....	9.83	100	✓ <b>Stelazine</b>
Tab 2 mg .....	14.64	100	✓ <b>Stelazine</b>
Tab 5 mg .....	16.66	100	✓ <b>Stelazine</b>

**ZIPRASIDONE** – Subsidy by endorsement

a) Safety medicine; prescriber may determine dispensing frequency			
b) Ziprasidone is subsidised for patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone or quetiapine that has been discontinued, or is in the process of being discontinued, because of unacceptable side effects or inadequate response, and the prescription is endorsed accordingly.			
Cap 20 mg .....	87.88	60	✓ <b>Zeldox</b>
Cap 40 mg .....	164.78	60	✓ <b>Zeldox</b>
Cap 60 mg .....	247.17	60	✓ <b>Zeldox</b>
Cap 80 mg .....	329.56	60	✓ <b>Zeldox</b>

**ZUCLOPENTHIXOL HYDROCHLORIDE** – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg .....	31.45	100	✓ <b>Clopixol</b>
-----------------	-------	-----	-------------------

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

## Depot Injections

**FLUPENTHIXOL DECANOATE** – Safety medicine; prescriber may determine dispensing frequency

Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	13.14	5	✓	Fluanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	20.90	5	✓	Fluanxol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	40.87	5	✓	Fluanxol

**FLUPHENAZINE DECANOATE** – Safety medicine; prescriber may determine dispensing frequency

Inj 12.5 mg per 0.5 ml, 0.5 ml – Up to 5 inj available on a PSO .....	17.60	5	✓	Modectate
Inj 25 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	27.90	5	✓	Modectate
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	154.50	5	✓	Modectate

**HALOPERIDOL DECANOATE** – Safety medicine; prescriber may determine dispensing frequency

Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	28.39	5	✓	Haldol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	55.90	5	✓	Haldol Concentrate

**OLANZAPINE** – Special Authority see SA1428 below – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 210 mg vial .....	280.00	1	✓	Zyprexa Relprevv
Inj 300 mg vial .....	460.00	1	✓	Zyprexa Relprevv
Inj 405 mg vial .....	560.00	1	✓	Zyprexa Relprevv

### ►SA1428 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:  
Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia; and
  - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
  - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

**Renewal** from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

**PALIPERIDONE** – Special Authority see SA1429 below – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg syringe .....	194.25	1	✓	Invega Sustenna
Inj 50 mg syringe .....	271.95	1	✓	Invega Sustenna
Inj 75 mg syringe .....	357.42	1	✓	Invega Sustenna
Inj 100 mg syringe .....	435.12	1	✓	Invega Sustenna
Inj 150 mg syringe .....	435.12	1	✓	Invega Sustenna

### ►SA1429 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:  
Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia or other psychotic disorder; and
  - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
  - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

**Renewal** from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Paliperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialling paliperidone depot injection.

PIPTHIAZINE PALMITATE – Subsidy by endorsement

a) Safety medicine; prescriber may determine dispensing frequency		
b) Subsidised for patients who were taking pipothiazine palmitate prior to 1 August 2014 and the prescription or PSO is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of pipothiazine palmitate.		
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	178.48	10 ✓ Piportil
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	353.32	10 ✓ Piportil

RISPERIDONE – Special Authority see SA1427 below – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency		
Inj 25 mg vial .....	135.98	1 ✓ Risperdal Consta
Inj 37.5 mg vial .....	178.71	1 ✓ Risperdal Consta
Inj 50 mg vial .....	217.56	1 ✓ Risperdal Consta

#### ▶SA1427 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia or other psychotic disorder; and
  - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
  - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

**Renewal** from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialling risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	19.80	5 ✓ Clopixol
--	-------	--------------

### Anxiolytics

ALPRAZOLAM – Safety medicine; prescriber may determine dispensing frequency

Tab 250 mcg .....	2.50	50 ✓ Xanax
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Tab 500 mcg .....	3.25	50 ✓ Xanax
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Tab 1 mg .....	5.00	50 ✓ Xanax
‡ Safety cap for extemporaneously compounded oral liquid preparations.		

BUSPIRONE HYDROCHLORIDE

* Tab 5 mg .....	28.00	100 ✓ Pacific Buspirone
* Tab 10 mg .....	17.00	100 ✓ Pacific Buspirone

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time

if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>CLONAZEPAM</b> – Safety medicine; prescriber may determine dispensing frequency				
Tab 500 mcg .....	7.53	100	✓	<b>Paxam</b>
Tab 2 mg .....	14.37	100	✓	<b>Paxam</b>
<b>DIAZEPAM</b> – Safety medicine; prescriber may determine dispensing frequency				
Tab 2 mg .....	11.44	500	✓	<b>Arrow-Diazepam</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 5 mg .....	13.71	500	✓	<b>Arrow-Diazepam</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
<b>LORAZEPAM</b> – Safety medicine; prescriber may determine dispensing frequency				
Tab 1 mg .....	10.79	250	✓	<b>Ativan</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 2.5 mg .....	13.88	100	✓	<b>Ativan</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
<b>OXAZEPAM</b> – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg .....	6.17	100	✓	<b>Ox-Pam</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 15 mg .....	8.53	100	✓	<b>Ox-Pam</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				

## Multiple Sclerosis Treatments

**FINGOLIMOD** – Special Authority see SA1487 below – Retail pharmacy

Wastage claimable – see rule 3.3.2 on page 13

Cap 0.5 mg .....	2,650.00	28	✓	<b>Gilenya</b>
------------------	----------	----	---	----------------

### ►SA1487 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: <a href="mailto:mstaccoordinator@pharmac.govt.nz">mstaccoordinator@pharmac.govt.nz</a>
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

### Entry Criteria

- Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- patients must have:
  - EDSS score 0 - 4.0 and:
    - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
    - Evidence of MRI activity on a scan within the past 24 months (either a contrast enhancing lesion or with new T2 lesions(s) compared with a previous scan); and
- A significant relapse must:
  - be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);

continued...



Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
- c) last at least one week;
- d) start at least one month after the onset of a previous relapse;
- e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
- f) be distinguishable from the effects of general fatigue; and
- g) not be associated with a fever ( $T > 37.5^{\circ}\text{C}$ ); and
- e) applications must be made by the patient's neurologist or general physician; and
- f) patients must have no previous history of lack of response to fingolimod; and
- g) patients must have not previously had intolerance to fingolimod; and
- h) patient must not be co-prescribed beta interferon or glatiramer acetate.

### Stopping Criteria

#### Any of the following:

- a) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:
  - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
  - b) 1.0 to 3.0; or
  - c) 1.5 to 3.5; or
  - d) 2.0 to 4.0; or
  - e) 2.5 to 4.5; or
  - f) 3.0 to 4.5; or
  - g) 3.5 to 4.5; or
  - h) 4.0 to 4.5.
- b) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) intolerance to fingolimod; or
- d) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab and fingolimod is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

NATALIZUMAB – Special Authority see SA1496 below – Retail pharmacy

Inj 20 mg per ml, 15 ml vial ..... 1,750.00 1 ✓ Tysabri

### ▶SA1496 | Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: <a href="mailto:mstaccoordinator@pharmac.govt.nz">mstaccoordinator@pharmac.govt.nz</a>
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

### Entry Criteria

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

continued...

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
  - a) EDSS score 0 – 4.0 and:
    - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
    - Evidence of MRI activity on a scan within the past 24 months (either a contrast enhancing lesion or with new T2 lesions(s) compared with a previous scan); and
- d) A significant relapse must:
  - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
  - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
  - c) last at least one week;
  - d) start at least one month after the onset of a previous relapse;
  - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
  - f) be distinguishable from the effects of general fatigue; and
  - g) not be associated with a fever ( $T > 37.5^{\circ}\text{C}$ ); and
- e) applications must be made by the patient's neurologist or general physician; and
- f) treatment must be initiated and supervised by a neurologist who is registered in the Tysabri Australasian Prescribing Programme operated by the supplier; and
- g) patients must have no previous history of lack of response to natalizumab; and
- h) patients must have not previously had intolerance to natalizumab; and
- i) either
  - a) Patient is JC virus negative, or
  - b) Patient is JC virus positive and has given written informed consent acknowledging an understanding of the risk of progressive multifocal leucoencephalopathy (PML) associated with natalizumab
- j) patient will not be co-prescribed beta interferon or glatiramer acetate.

## Stopping Criteria

### Any of the following:

- a) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:
  - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
  - b) 1.0 to 3.0; or
  - c) 1.5 to 3.5; or
  - d) 2.0 to 4.0; or
  - e) 2.5 to 4.5; or
  - f) 3.0 to 4.5; or
  - g) 3.5 to 4.5; or
  - h) 4.0 to 4.5.
- b) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) intolerance to natalizumab; or
- d) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier. Switching between natalizumab and fingolimod is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the EDSS stopping criteria are not met.

If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## Other Multiple Sclerosis Treatments

### ►SA1484 | Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: <a href="mailto:mstaccoordinator@pharmac.govt.nz">mstaccoordinator@pharmac.govt.nz</a>
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

### Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
  - a) EDSS score 0 - 4.0 and:
    - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
    - Evidence of MRI activity on a scan within the past 24 months (either a contrast enhancing lesion or with new T2 lesions(s) compared with a previous scan); and
- d) A significant relapse must:
  - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
  - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
  - c) last at least one week;
  - d) start at least one month after the onset of a previous relapse;
  - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
  - f) be distinguishable from the effects of general fatigue; and
  - g) not be associated with a fever ( $T > 37.5^{\circ}\text{C}$ ); and
- e) applications must be made by the patient's neurologist; and
- f) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate; and
- g) patients must have either:
  - a) intolerance to both natalizumab and fingolimod; or
  - b) treatment with both natalizumab and fingolimod is considered clinically inappropriate; and
- h) patient will not be co-prescribed natalizumab or fingolimod.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

## Stopping Criteria

### Any of the following:

- Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as progress by any of the following EDDSS Points:
  - from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
  - 1.0 to 3.0; or
  - 1.5 to 3.5; or
  - 2.0 to 4.0; or
  - 2.5 to 4.5; or
  - 3.0 to 4.5; or
  - 3.5 to 4.5; or
  - 4.0 to 4.5.
- increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- non-compliance with treatment, including refusal to undergo annual assessment.

Note: Treatment with interferon beta -1-beta, interferon beta-1-alpha and glatiramer acetate, is permitted only if treatment with both natalizumab and fingolimod is not tolerated or treatment with both would be clinically inappropriate. Beta-interferon or glatiramer acetate will not be funded as second line treatments if EDSS progression has occurred on treatment with natalizumab or fingolimod. Patients who have an increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet the EDSS Stopping Criteria at annual review may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa for increased relapses only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to increasing relapse rate over 12 months of treatment). If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur. In this setting anti-JCV antibody positive status may be accepted as a clinically inappropriate reason for treatment with natalizumab.

### Entry Criteria for patients with an EDSS of 4.5-5.5 who have not had an application for funding considered prior to 1 November 2014

- Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis should as a rule include MRI confirmation. For patients diagnosed before MRI was widely utilised in New Zealand, confirmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and
- patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- patients must have:
  - EDSS score 4.5-5.5 with 2+ relapses:
    - Experienced at least 2 significant relapses of MS in the previous 12 months, and
    - An EDSS score of between 4.5-5.5; and
- Each relapse must:
  - be confirmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
  - be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
  - last at least one week;
  - follow a period of stability of at least one month;
  - be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point;
  - be distinguishable from the effects of general fatigue; and

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- g) not be associated with a fever ( $T > 37.5^{\circ}\text{C}$ ); and
- e) applications must be made at least four weeks after the date of the onset of the last known relapse; and
- f) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping).
- g) applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient's neurologist or a general physician; and
- h) patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and
- i) patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate.

**Stopping Criteria for patients with an EDSS of 4.5-5.5 who have not had an application for funding considered prior to 1 November 2014**

**Any of the following:**

- a) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as progress by any of the following:
  - a) an increase of 1 EDSS point where starting EDSS 3.5 or greater; or
  - b) an increase in EDSS score to 6.0 or more; or
- b) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) pregnancy and/or lactation; or
- d) within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- e) non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC; or
- f) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate.

Note: Patients who have a stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet any of the other Stopping Criteria at annual review may switch to a different class of funded treatment (i.e. patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa). Patients may switch classes of treatment for this reason only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to stable or increasing relapse rate over 12 months of treatment).

GLATIRAMER ACETATE – Special Authority see SA1484 on page 147 – [Xpharm]

Inj 20 mg prefilled syringe .....	1,089.25	28	✓ Copaxone
-----------------------------------	----------	----	------------

INTERFERON BETA-1-ALPHA – Special Authority see SA1484 on page 147 – [Xpharm]

Inj 6 million iu prefilled syringe .....	1,170.00	4	✓ Avonex
Injection 6 million iu per 0.5 ml pen injector .....	1,170.00	4	✓ Avonex Pen
Inj 6 million iu per vial .....	1,170.00	4	✓ Avonex

INTERFERON BETA-1-BETA – Special Authority see SA1484 on page 147 – [Xpharm]

Inj 8 million iu per 1 ml .....	1,322.89	15	✓ Betaferon
---------------------------------	----------	----	-------------

## Sedatives and Hypnotics

LORMETAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Tab 1 mg .....	3.11	30	Noctamid
	(23.50)		

‡ Safety cap for extemporaneously compounded oral liquid preparations.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

# NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>MIDAZOLAM</b> – Safety medicine; prescriber may determine dispensing frequency				
Inj 1 mg per ml, 5 ml .....	10.00	10	✓ Pfizer	
	10.75		✓ Hypnovel	
Inj 5 mg per ml, 3 ml .....	11.90	5	✓ Hypnovel	
			✓ Pfizer	
<b>NITRAZEPAM</b> – Safety medicine; prescriber may determine dispensing frequency				
Tab 5 mg .....	5.22	100	✓ Nitrados	
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
<b>PHENOBARBITONE SODIUM</b> – Special Authority see SA1386 below – Retail pharmacy				
Inj 200 mg per ml, 1 ml ampoule .....	46.20	10	✓ Martindale	\$29

## ►SA1386 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 For the treatment of terminal agitation that is unresponsive to other agents; and
- 2 The applicant is part of a multidisciplinary team working in palliative care.

<b>TEMAZEPAM</b> – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg .....	1.27	25	✓ Normison	
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
<b>TRIAZOLAM</b> – Safety medicine; prescriber may determine dispensing frequency				
Tab 125 mcg .....	5.10	100		Hypam
	(7.25)			
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 250 mcg .....	4.10	100		Hypam
	(8.70)			
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
<b>ZOPICLONE</b> – Safety medicine; prescriber may determine dispensing frequency				
Tab 7.5 mg .....	11.90	500	✓ Apo-Zopiclone	

## Stimulants/ADHD Treatments

### Stimulants/ADHD treatments

<b>ATOMOXETINE</b> – Special Authority see SA1416 below – Retail pharmacy				
Cap 10 mg .....	107.03	28	✓ Strattera	
Cap 18 mg .....	107.03	28	✓ Strattera	
Cap 25 mg .....	107.03	28	✓ Strattera	
Cap 40 mg .....	107.03	28	✓ Strattera	
Cap 60 mg .....	107.03	28	✓ Strattera	
Cap 80 mg .....	139.11	28	✓ Strattera	
Cap 100 mg .....	139.11	28	✓ Strattera	

## ►SA1416 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
- 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
- 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
- 3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

DEXAMFETAMINE SULFATE – Special Authority see SA1149 below – Retail pharmacy

- a) Only on a controlled drug form
- b) Safety medicine; prescriber may determine dispensing frequency

Tab 5 mg ..... 16.50 100 ✓ PSM

#### ►SA1149 Special Authority for Subsidy

**Initial application — (ADHD in patients 5 or over)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
  - 3.1 Applicant is a paediatrician or psychiatrist; or
  - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

**Initial application — (ADHD in patients under 5)** only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

**Initial application — (Narcolepsy)** only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

**Renewal — (ADHD in patients 5 or over)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 Applicant is a paediatrician or psychiatrist; or
  - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
<b>Renewal — (ADHD in patients under 5)</b> only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.				
<b>Renewal — (Narcolepsy)</b> only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.				
<b>METHYLPHENIDATE HYDROCHLORIDE</b> – Special Authority see SA1150 below – Retail pharmacy				
a) Only on a controlled drug form				
b) Safety medicine; prescriber may determine dispensing frequency				
Tab immediate-release 5 mg .....	3.20	30	✓	Rubifen
Tab immediate-release 10 mg .....	3.00	30	✓	Ritalin
			✓	Rubifen
Tab immediate-release 20 mg .....	7.85	30	✓	Rubifen
Tab sustained-release 20 mg .....	10.95	30	✓	Rubifen SR
	50.00	100	✓	Ritalin SR

## ►SA1150 Special Authority for Subsidy

**Initial application — (ADHD in patients 5 or over)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- Diagnosed according to DSM-IV or ICD 10 criteria; and
- Either:
  - Applicant is a paediatrician or psychiatrist; or
  - Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

**Initial application — (ADHD in patients under 5)** only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- Diagnosed according to DSM-IV or ICD 10 criteria.

**Initial application — (Narcolepsy)** only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

**Renewal — (ADHD in patients 5 or over)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

Both:

- The treatment remains appropriate and the patient is benefiting from treatment; and
- Either:
  - Applicant is a paediatrician or psychiatrist; or
  - Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

**Renewal — (ADHD in patients under 5)** only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

**Renewal — (Narcolepsy)** only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

**METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE** – Special Authority see SA1151 below – Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab extended-release 18 mg .....	58.96	30	✓ Concerta
Tab extended-release 27 mg .....	65.44	30	✓ Concerta
Tab extended-release 36 mg .....	71.93	30	✓ Concerta
Tab extended-release 54 mg .....	86.24	30	✓ Concerta
Cap modified-release 10 mg .....	15.60	30	✓ Ritalin LA
Cap modified-release 20 mg .....	20.40	30	✓ Ritalin LA
Cap modified-release 30 mg .....	25.52	30	✓ Ritalin LA
Cap modified-release 40 mg .....	30.60	30	✓ Ritalin LA

▶▶SA1151 Special Authority for Subsidy

**Initial application** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
  - 3.1 Applicant is a paediatrician or psychiatrist; or
  - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and
- 4 Either:
  - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
  - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

**Renewal** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 Applicant is a paediatrician or psychiatrist; or
  - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

**MODAFINIL** – Special Authority see SA1126 below – Retail pharmacy

Tab 100 mg .....	72.50	30	✓ Modavigil
------------------	-------	----	-------------

▶▶SA1126 Special Authority for Subsidy

**Initial application** only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
  - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
  - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

3 Either:

3.1 An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or

3.2 Methylphenidate and dexamphetamine are contraindicated.

**Renewal** only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

## Treatments for Dementia

### DONEPEZIL HYDROCHLORIDE

* Tab 5 mg .....	5.48	90	✓ <b>Donepezil-Rex</b>
* Tab 10 mg .....	10.51	90	✓ <b>Donepezil-Rex</b>

### RIVASTIGMINE – Special Authority see SA1488 below – Retail pharmacy

Patch 4.6 mg per 24 hour .....	90.00	30	✓ <b>Exelon</b>
Patch 9.5 mg per 24 hour .....	90.00	30	✓ <b>Exelon</b>

#### ►SA1488 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

**Renewal** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

## Treatments for Substance Dependence

### BUPRENORPHINE WITH NALOXONE – Special Authority see SA1203 below – Retail pharmacy

a) No patient co-payment payable

b) Safety medicine; prescriber may determine dispensing frequency

Tab sublingual 2 mg with naloxone 0.5 mg .....	57.40	28	✓ <b>Suboxone</b>
Tab sublingual 8 mg with naloxone 2 mg .....	166.00	28	✓ <b>Suboxone</b>

#### ►SA1203 Special Authority for Subsidy

**Initial application — (Detoxification)** from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health.

**Initial application — (Maintenance treatment)** from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued. . .

**Renewal — (Detoxification)** from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

**Renewal — (Maintenance treatment)** from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

**Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification)** from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

#### BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg .....	4.97	30	✓ <u>Zyban</u>
-----------------------------------	------	----	----------------

#### DISULFIRAM

Tab 200 mg .....	24.30	100	✓ <u>Antabuse</u>
------------------	-------	-----	-------------------

#### NALTREXONE HYDROCHLORIDE – Special Authority see SA1408 below – Retail pharmacy

Tab 50 mg .....	76.00	30	✓ <u>Nalttraccord</u>
-----------------	-------	----	-----------------------

#### ►SA1408 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

**Renewal** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
  - 2.1 Patient is still unstable and requires further treatment; or
  - 2.2 Patient achieved significant improvement but requires further treatment; or
  - 2.3 Patient is well controlled but requires maintenance therapy.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>NICOTINE</b>				
Nicotine will not be funded under the Dispensing Frequency Rule in amounts less than 4 weeks of treatment.				
Patch 7 mg – Up to 28 patch available on a PSO .....	10.57	28	✓	<b>Habitrol</b>
Patch 14 mg – Up to 28 patch available on a PSO .....	11.31	28	✓	<b>Habitrol</b>
Patch 21 mg – Up to 28 patch available on a PSO .....	11.95	28	✓	<b>Habitrol</b>
Lozenge 1 mg – Up to 216 loz available on a PSO .....	12.91	216	✓	<b>Habitrol</b>
Lozenge 2 mg – Up to 216 loz available on a PSO .....	14.14	216	✓	<b>Habitrol</b>
Gum 2 mg (Classic) – Up to 384 piece available on a PSO .....	22.26	384	✓	<b>Habitrol</b>
Gum 2 mg (Fruit) – Up to 384 piece available on a PSO .....	22.26	384	✓	<b>Habitrol</b>
Gum 2 mg (Mint) – Up to 384 piece available on a PSO .....	22.26	384	✓	<b>Habitrol</b>
Gum 4 mg (Classic) – Up to 384 piece available on a PSO .....	25.67	384	✓	<b>Habitrol</b>
Gum 4 mg (Fruit) – Up to 384 piece available on a PSO .....	25.67	384	✓	<b>Habitrol</b>
Gum 4 mg (Mint) – Up to 384 piece available on a PSO .....	25.67	384	✓	<b>Habitrol</b>

## VARENICLINE TARTRATE – Special Authority see SA1161 below – Retail pharmacy

- a) Varenicline will not be funded under the Dispensing Frequency Rule in amounts less than 2 weeks of treatment.  
b) A maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

Tab 1 mg .....	67.74	28	✓	<b>Champix</b>
	135.48	56	✓	<b>Champix</b>
Tab 0.5 mg × 11 and 1 mg × 14 .....	60.48	25 OP	✓	<b>Champix</b>

### ►SA1161 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- Either:
  - The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
  - The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- The patient has not used funded varenicline in the last 12 months; and
- Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- The patient is not pregnant; and
- The patient will not be prescribed more than 3 months' funded varenicline (see note).

**Renewal** from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- The patient has not used funded varenicline in the last 12 months; and
- Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- The patient is not pregnant; and
- The patient will not be prescribed more than 3 months' funded varenicline (see note).

The patient must not have had an approval in the past 12 months.

Note: a maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Chemotherapeutic Agents

### Alkylating Agents

<b>BUSULPHAN – PCT – Retail pharmacy-Specialist</b>			
Tab 2 mg .....	59.50	100	✓ Myleran
<b>CARBOPLATIN – PCT only – Specialist</b>			
Inj 10 mg per ml, 5 ml vial .....	15.07	1	✓ DBL Carboplatin
	20.00		✓ Carboplatin Ebewe
Inj 10 mg per ml, 15 ml vial .....	14.05	1	✓ DBL Carboplatin
	19.50		✓ Carbaccord
	22.50		✓ Carboplatin Ebewe
Inj 10 mg per ml, 45 ml vial .....	32.59	1	✓ DBL Carboplatin
	48.50		✓ Carbaccord
	50.00		✓ Carboplatin Ebewe
Inj 10 mg per ml, 100 ml vial .....	105.00	1	✓ Carboplatin Ebewe
Inj 1 mg for ECP .....	0.13	1 mg	✓ Baxter
<i>(Carboplatin Ebewe Inj 10 mg per ml, 100 ml vial to be delisted 1 September 2015)</i>			
<b>CARMUSTINE – PCT only – Specialist</b>			
Inj 100 mg vial .....	532.00	1	✓ BiCNU
Inj 100 mg for ECP .....	532.00	100 mg OP	✓ Baxter
<b>CHLORAMBUCIL – PCT – Retail pharmacy-Specialist</b>			
Tab 2 mg .....	29.06	25	✓ Leukeran FC
<b>CISPLATIN – PCT only – Specialist</b>			
Inj 1 mg per ml, 50 ml .....	15.00	1	✓ Cisplatin Ebewe
			✓ Hospira
Inj 1 mg per ml, 100 ml .....	21.00	1	✓ Cisplatin Ebewe
			✓ Hospira
Inj 1 mg for ECP .....	0.27	1 mg	✓ Baxter
<b>CYCLOPHOSPHAMIDE</b>			
Tab 50 mg – PCT – Retail pharmacy-Specialist.....	79.00	50	✓ Endoxan S29
	158.00	100	✓ Procytox S29
Wastage claimable – see rule 3.3.2 on page 13			
Inj 1 g vial – PCT – Retail pharmacy-Specialist .....	35.03	1	✓ Endoxan
	127.80	6	✓ Cytosan
Inj 2 g vial – PCT only – Specialist .....	70.06	1	✓ Endoxan
Inj 1 mg for ECP – PCT only – Specialist .....	0.04	1 mg	✓ Baxter
<b>IFOSFAMIDE – PCT only – Specialist</b>			
Inj 1 g .....	96.00	1	✓ Holoxan
Inj 2 g .....	180.00	1	✓ Holoxan
Inj 1 mg for ECP .....	0.10	1 mg	✓ Baxter
<b>LOMUSTINE – PCT – Retail pharmacy-Specialist</b>			
Cap 10 mg .....	132.59	20	✓ CeeNU
Cap 40 mg .....	399.15	20	✓ CeeNU
<b>MELPHALAN</b>			
Tab 2 mg – PCT – Retail pharmacy-Specialist.....	40.70	25	✓ Alkeran
Inj 50 mg – PCT only – Specialist.....	67.80	1	✓ Alkeran

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>OXALIPLATIN – PCT only – Specialist</b>				
Inj 50 mg .....	15.32	1	✓	<b>Oxaliplatin Actavis 50</b>
	55.00		✓	<b>Oxaliplatin Ebewe</b>
	200.00		✓	<b>Eloxatin</b>
Inj 100 mg .....	25.01	1	✓	<b>Oxaliplatin Actavis 100</b>
	110.00		✓	<b>Oxaliplatin Ebewe</b>
	400.00		✓	<b>Eloxatin</b>
Inj 1 mg for ECP .....	0.28	1 mg	✓	<b>Baxter</b>
<b>THIOTEPA – PCT only – Specialist</b>				
Inj 15 mg .....	CBS	1	✓	<b>Bedford</b> <sup>S29</sup>
			✓	<b>THIO-TEPA</b> <sup>S29</sup>
			✓	<b>Tepadina</b> <sup>S29</sup>

## Antimetabolites

**AZACITIDINE – PCT only – Specialist – Special Authority see SA1467 below**

Inj 100 mg vial .....	605.00	1	✓	<b>Vidaza</b>
Inj 1 mg for ECP .....	6.66	1 mg	✓	<b>Baxter</b>

### ►SA1467 Special Authority for Subsidy

**Initial application** only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- Any of the following:
  - The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
  - The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
  - The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
- The patient has performance status (WHO/ECOG) grade 0-2; and
- The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
- The patient has an estimated life expectancy of at least 3 months.

**Renewal** only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- No evidence of disease progression; and
- The treatment remains appropriate and patient is benefitting from treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>CALCIUM FOLINATE</b>				
Tab 15 mg – PCT – Retail pharmacy-Specialist.....	82.45	10	✓	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist .....	17.10	5	✓	Hospira
Inj 50 mg – PCT – Retail pharmacy-Specialist.....	18.25	5	✓	Calcium Folate Ebewe
Inj 100 mg – PCT only – Specialist.....	7.33	1	✓	Calcium Folate Ebewe
Inj 300 mg – PCT only – Specialist.....	22.51	1	✓	Calcium Folate Ebewe
Inj 1 g – PCT only – Specialist.....	67.51	1	✓	Calcium Folate Ebewe
Inj 1 mg for ECP – PCT only – Specialist.....	0.06	1 mg	✓	Baxter
<b>CAPECITABINE – Retail pharmacy-Specialist</b>				
Tab 150 mg .....	30.00	60	✓	Capecitabine Winthrop
Tab 500 mg .....	120.00	120	✓	Capecitabine Winthrop
<b>CLADRIBINE – PCT only – Specialist</b>				
Inj 1 mg per ml, 10 ml .....	5,249.72	7	✓	Leustatin
Inj 10 mg for ECP .....	749.96	10 mg OP	✓	Baxter
<b>CYTARABINE</b>				
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist .....	55.00	5	✓	Pfizer
	80.00		✓	Hospira
Inj 500 mg – PCT – Retail pharmacy-Specialist.....	18.15	1	✓	Pfizer
	95.36	5	✓	Hospira
Inj 100 mg per ml, 10 ml vial – PCT – Retail pharmacy- Specialist .....	8.83	1	✓	Pfizer
	42.65		✓	Hospira
Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy- Specialist .....	17.65	1	✓	Pfizer
	34.47		✓	Hospira
Inj 1 mg for ECP – PCT only – Specialist.....	0.11	10 mg	✓	Baxter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist .....	11.00	100 mg OP	✓	Baxter
<b>FLUDARABINE PHOSPHATE</b>				
Tab 10 mg – PCT – Retail pharmacy-Specialist.....	412.00	20	✓	Fludara Oral
Fludara Oral to be Sole Supply on 1 October 2015				
Inj 50 mg – PCT only – Specialist.....	525.00	5	✓	Fludarabine Ebewe
	1,430.00		✓	Fludara
Inj 50 mg for ECP – PCT only – Specialist .....	105.00	50 mg OP	✓	Baxter
<b>FLUOROURACIL</b>				
Inj 50 mg per ml, 10 ml vial – PCT only – Specialist .....	26.25	5	✓	Fluorouracil Ebewe
Inj 50 mg per ml, 20 ml vial – PCT only – Specialist .....	10.00	1	✓	Fluorouracil Ebewe
Inj 25 mg per ml, 100 ml vial – PCT only – Specialist .....	13.55	1	✓	Hospira
Inj 50 mg per ml, 50 ml vial – PCT only – Specialist .....	17.00	1	✓	Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml vial – PCT only – Specialist .....	30.00	1	✓	Fluorouracil Ebewe
Inj 1 mg for ECP – PCT only – Specialist.....	0.66	100 mg	✓	Baxter

(Fluorouracil Ebewe Inj 50 mg per ml, 10 ml vial to be delisted 1 November 2015)

(Hospira Inj 25 mg per ml, 100 ml vial to be delisted 1 November 2015)

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time

if endorsed "certified exemption" by the prescriber or pharmacist.

# ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>GEMCITABINE HYDROCHLORIDE – PCT only – Specialist</b>				
Inj 1 g .....	15.89	1	✓	Gemcitabine Ebewe
	62.50		✓	DBL Gemcitabine
	349.20		✓	Gemzar
Inj 200 mg .....	8.36	1	✓	Gemcitabine Ebewe
	78.00		✓	Gemzar
Inj 1 mg for ECP .....	0.02	1 mg	✓	Baxter
<b>IRINOTECAN HYDROCHLORIDE – PCT only – Specialist</b>				
Inj 20 mg per ml, 2 ml vial .....	11.50	1	✓	Irinotecan Actavis 40
	41.00		✓	Camptosar
			✓	Irinotecan-Rex
Inj 20 mg per ml, 5 ml vial .....	17.80	1	✓	Irinotecan Actavis 100
	100.00		✓	Camptosar
			✓	Irinotecan-Rex
Inj 1 mg for ECP .....	0.19	1 mg	✓	Baxter
<b>MERCAPTOPURINE – PCT – Retail pharmacy-Specialist</b>				
Tab 50 mg .....	49.41	25	✓	Puri-nethol
<b>METHOTREXATE</b>				
* Tab 2.5 mg – PCT – Retail pharmacy-Specialist .....	3.18	30	✓	Trexate
Trexate to be Sole Supply on 1 October 2015				
* Tab 10 mg – PCT – Retail pharmacy-Specialist .....	21.00	50	✓	Trexate
Trexate to be Sole Supply on 1 October 2015				
* Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist .....	23.65	5	✓	Hospira
* Inj 7.5 mg prefilled syringe .....	17.19	1	✓	Methotrexate Sandoz
* Inj 10 mg prefilled syringe .....	17.25	1	✓	Methotrexate Sandoz
* Inj 15 mg prefilled syringe .....	17.38	1	✓	Methotrexate Sandoz
* Inj 20 mg prefilled syringe .....	17.50	1	✓	Methotrexate Sandoz
* Inj 25 mg prefilled syringe .....	17.63	1	✓	Methotrexate Sandoz
* Inj 30 mg prefilled syringe .....	17.75	1	✓	Methotrexate Sandoz
* Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist .....	20.20	5	✓	Hospira
* Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist .....	27.78	1	✓	Hospira
* Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist .....	25.00	1	✓	Methotrexate Ebewe
* Inj 100 mg per ml, 50 ml – PCT – Retail pharmacy-Specialist .....	99.99	1	✓	Methotrexate Ebewe
* Inj 1 mg for ECP – PCT only – Specialist .....	0.10	1 mg	✓	Baxter
* Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist .....	4.73	5 mg OP	✓	Baxter
<b>THIOGUANINE – PCT – Retail pharmacy-Specialist</b>				
Tab 40 mg .....	126.31	25	✓	Lanvis



	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Other Cytotoxic Agents</b>				
<b>AMSACRINE – PCT only – Specialist</b>				
Inj 50 mg per ml, 1.5 ml ampoule .....	1,500.00	6	✓	<b>Amsidine</b> <sup>\$29</sup>
Inj 75 mg .....	1,250.00	5	✓	<b>AmsaLyo</b> <sup>\$29</sup>
<b>ANAGRELIDE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist</b>				
Cap 0.5 mg .....	CBS	100	✓	<b>Agrylin</b> <sup>\$29</sup>
			✓	<b>Teva</b> <sup>\$29</sup>
<b>ARSENIC TRIOXIDE – PCT only – Specialist</b>				
Inj 10 mg .....	4,817.00	10	✓	<b>AFT</b> <sup>\$29</sup>
<b>BLEOMYCIN SULPHATE – PCT only – Specialist</b>				
Inj 15,000 iu (10 mg), vial .....	150.48	1	✓	<b>DBL Bleomycin Sulfate</b>
Inj 1,000 iu for ECP .....	11.64	1,000 iu	✓	<b>Baxter</b>
<b>BORTEZOMIB – PCT only – Specialist – Special Authority see SA1127 below</b>				
Inj 1 mg .....	540.70	1	✓	<b>Velcade</b>
Inj 3.5 mg .....	1,892.50	1	✓	<b>Velcade</b>
Inj 1 mg for ECP .....	594.77	1 mg	✓	<b>Baxter</b>

➡SA1127 Special Authority for Subsidy

**Initial application — (Treatment naïve multiple myeloma/amyloidosis)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:

Both:

- 1 Either:
  - 1.1 The patient has treatment-naïve symptomatic multiple myeloma; or
  - 1.2 The patient has treatment-naïve symptomatic systemic AL amyloidosis \*; and
- 2 Maximum of 9 treatment cycles.

Note: Indications marked with \* are Unapproved Indications.

**Initial application — (Relapsed/refractory multiple myeloma/amyloidosis)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

All of the following:

- 1 Either:
  - 1.1 The patient has relapsed or refractory multiple myeloma; or
  - 1.2 The patient has relapsed or refractory systemic AL amyloidosis \*; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 treatment cycles.

Note: Indications marked with \* are Unapproved Indications.

**Renewal — (Relapsed/refractory multiple myeloma/amyloidosis)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

Both:

- 1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
- 2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

- a) a known therapeutic chemotherapy regimen and supportive treatments; or
- b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time

if endorsed "certified exemption" by the prescriber or pharmacist.

# ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>COLASPASE [L-ASPARAGINASE] – PCT only – Specialist</b>				
Inj 10,000 iu .....	102.32	1	✓	<b>Leunase</b>
Inj 10,000 iu for ECP .....	102.32	10,000 iu OP	✓	<b>Baxter</b>
<b>DACARBAZINE – PCT only – Specialist</b>				
Inj 200 mg vial .....	51.84	1	✓	<b>Hospira</b>
Inj 200 mg for ECP .....	51.84	200 mg OP	✓	<b>Baxter</b>
<b>DACTINOMYCIN [ACTINOMYCIN D] – PCT only – Specialist</b>				
Inj 0.5 mg vial .....	145.00	1	✓	<b>Cosmegen</b>
Inj 0.5 mg for ECP .....	145.00	0.5 mg OP	✓	<b>Baxter</b>
<b>DAUNORUBICIN – PCT only – Specialist</b>				
Inj 2 mg per ml, 10 ml .....	118.72	1	✓	<b>Pfizer</b>
Inj 20 mg for ECP .....	118.72	20 mg OP	✓	<b>Baxter</b>
<b>DOCETAXEL – PCT only – Specialist</b>				
Inj 20 mg .....	13.70	1	✓	<b>DBL Docetaxel</b>
	48.75		✓	<b>Docetaxel Sandoz</b>
Inj 20 mg per ml, 1 ml .....	48.75	1	✓	<b>Taxotere</b>
Inj 20 mg per ml, 4 ml .....	195.00	1	✓	<b>Taxotere</b>
Inj 80 mg .....	29.99	1	✓	<b>DBL Docetaxel</b>
	195.00		✓	<b>Docetaxel Sandoz</b>
Inj 1 mg for ECP .....	0.61	1 mg	✓	<b>Baxter</b>
<b>DOXORUBICIN – PCT only – Specialist</b>				
Inj 10 mg .....	10.00	1	✓	<b>Doxorubicin Ebewe</b>
Inj 50 mg .....	17.00	1	✓	<b>Arrow-Doxorubicin</b>
	40.00		✓	<b>DBL Doxorubicin</b>
			✓	<b>DBL Doxorubicin</b>
			<b>S29 <sup>S29</sup></b>	
			✓	<b>Doxorubicin Ebewe</b>
Inj 100 mg .....	80.00	1	✓	<b>Doxorubicin Ebewe</b>
Inj 200 mg .....	65.00	1	✓	<b>Arrow-Doxorubicin</b>
	150.00		✓	<b>Adriamycin</b>
			✓	<b>Doxorubicin Ebewe</b>
Inj 1 mg for ECP .....	0.37	1 mg	✓	<b>Baxter</b>
<b>EPIRUBICIN – PCT only – Specialist</b>				
Inj 2 mg per ml, 5 ml .....	25.00	1	✓	<b>Epirubicin Ebewe</b>
Inj 2 mg per ml, 25 ml .....	39.38	1	✓	<b>DBL Epirubicin</b>
	87.50		✓	<b>Epirubicin Ebewe</b>
Inj 2 mg per ml, 50 ml .....	58.20	1	✓	<b>DBL Epirubicin</b>
				<b>Hydrochloride</b>
	125.00		✓	<b>Epirubicin Ebewe</b>
Inj 2 mg per ml, 100 ml .....	94.50	1	✓	<b>DBL Epirubicin</b>
				<b>Hydrochloride</b>
	210.00		✓	<b>Epirubicin Ebewe</b>
Inj 1 mg for ECP .....	0.82	1 mg	✓	<b>Baxter</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ETOPOSIDE</b>				
Cap 50 mg – PCT – Retail pharmacy-Specialist .....	340.73	20	✓	Vepesid
Cap 100 mg – PCT – Retail pharmacy-Specialist .....	340.73	10	✓	Vepesid
Inj 20 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist .....	25.00	1	✓	Hospira
	612.20	10	✓	Vepesid
Inj 1 mg for ECP – PCT only – Specialist .....	0.30	1 mg	✓	Baxter
<b>ETOPOSIDE PHOSPHATE – PCT only – Specialist</b>				
Inj 100 mg (of etoposide base) .....	40.00	1	✓	Etopophos
Inj 1 mg (of etoposide base) for ECP .....	0.47	1 mg	✓	Baxter
<b>HYDROXYUREA – PCT – Retail pharmacy-Specialist</b>				
Cap 500 mg .....	31.76	100	✓	Hydrea
<b>IDARUBICIN HYDROCHLORIDE</b>				
Inj 5 mg – PCT only – Specialist .....	100.00	1	✓	Zavedos
Inj 10 mg – PCT only – Specialist .....	200.00	1	✓	Zavedos
Inj 1 mg for ECP – PCT only – Specialist .....	22.20	1 mg	✓	Baxter
<b>LENALIDOMIDE – Retail pharmacy-Specialist – Special Authority see SA1468 below</b>				
Wastage claimable – see rule 3.3.2 on page 13				
Cap 10 mg .....	6,207.00	21	✓	Revlimid
Cap 25 mg .....	7,627.00	21	✓	Revlimid
<b>►SA1468 Special Authority for Subsidy</b>				
<b>Initial application — (Relapsed/refractory disease)</b> only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:				
All of the following:				
1 Patient has relapsed or refractory multiple myeloma with progressive disease; and				
2 Either:				
2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; and				
2.2 Both:				
2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and				
2.2.2 The patient has experienced severe (grade ≥ 3), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and				
3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.				
<b>Renewal</b> only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:				
Both:				
1 No evidence of disease progression; and				
2 The treatment remains appropriate and patient is benefitting from treatment.				
Note: Indication marked with * is an Unapproved Indication (refer to Interpretations and Definitions). A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.				
<b>MESNA</b>				
Tab 400 mg – PCT – Retail pharmacy-Specialist .....	227.50	50	✓	Uromitexan
Tab 600 mg – PCT – Retail pharmacy-Specialist .....	339.50	50	✓	Uromitexan
Inj 100 mg per ml, 4 ml ampoule – PCT only – Specialist .....	148.05	15	✓	Uromitexan
Inj 100 mg per ml, 10 ml ampoule – PCT only – Specialist .....	339.90	15	✓	Uromitexan
Inj 1 mg for ECP – PCT only – Specialist .....	2.47	100 mg	✓	Baxter

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

# ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>MITOMYCIN C – PCT only – Specialist</b>				
Inj 5 mg vial .....	79.75	1	✓	<b>Arrow</b>
Inj 1 mg for ECP .....	16.43	1 mg	✓	<b>Baxter</b>
<b>MITOZANTRONE – PCT only – Specialist</b>				
Inj 2 mg per ml, 5 ml vial .....	110.00	1	✓	<b>Mitozantrone Ebewe</b>
Inj 2 mg per ml, 10 ml vial .....	97.50	1	✓	<b>Mitozantrone Ebewe</b>
Inj 2 mg per ml, 12.5 ml vial .....	407.50	1		
	(413.21)			Onkotrone
Inj 1 mg for ECP .....	5.51	1 mg	✓	<b>Baxter</b>
<i>(Mitozantrone Ebewe Inj 2 mg per ml, 5 ml vial to be delisted 1 January 2016)</i>				
<i>(Onkotrone Inj 2 mg per ml, 12.5 ml vial to be delisted 1 January 2016)</i>				
<b>PACLITAXEL – PCT only – Specialist</b>				
Inj 30 mg .....	45.00	5	✓	<b>Paclitaxel Ebewe</b>
Inj 100 mg .....	19.02	1	✓	<b>Paclitaxel Ebewe</b>
	91.67		✓	<b>Paclitaxel Actavis</b>
Inj 150 mg .....	26.69	1	✓	<b>Paclitaxel Ebewe</b>
	137.50		✓	<b>Anzatax</b>
			✓	<b>Paclitaxel Actavis</b>
Inj 300 mg .....	36.53	1	✓	<b>Paclitaxel Ebewe</b>
	275.00		✓	<b>Anzatax</b>
			✓	<b>Paclitaxel Actavis</b>
Inj 600 mg .....	73.06	1	✓	<b>Paclitaxel Ebewe</b>
Inj 1 mg for ECP .....	0.17	1 mg	✓	<b>Baxter</b>
<b>PEGASPARGASE – PCT only – Special Authority see SA1325 below</b>				
Inj 3,750 IU per 5 ml .....	3,005.00	1	✓	<b>Oncaspar</b> <sup>S29</sup>
<b>►SA1325 Special Authority for Subsidy</b>				
<b>Initial application</b> only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:				
All of the following:				
1 The patient has newly diagnosed acute lymphoblastic leukaemia; and				
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and				
3 Treatment is with curative intent.				
<b>Renewal</b> only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:				
All of the following:				
1 The patient has relapsed acute lymphoblastic leukaemia; and				
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and				
3 Treatment is with curative intent.				
<b>PENTOSTATIN [DEOXYCOFORMYCIN] – PCT only – Specialist</b>				
Inj 10 mg .....	CBS	1	✓	<b>Nipent</b> <sup>S29</sup>
<b>PROCARBAZINE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist</b>				
Cap 50 mg .....	498.00	50	✓	<b>Natulan</b> <sup>S29</sup>
<b>TEMOZOLOMIDE – Special Authority see SA1063 on the next page – Retail pharmacy</b>				
Cap 5 mg .....	8.00	5	✓	<b>Temaccord</b>
Cap 20 mg .....	36.00	5	✓	<b>Temaccord</b>
Cap 100 mg .....	175.00	5	✓	<b>Temaccord</b>
Cap 250 mg .....	410.00	5	✓	<b>Temaccord</b>

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1063 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria:  
All of the following:

- 1 Either:
  - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
  - 1.2 Patient has newly diagnosed anaplastic astrocytoma\*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m<sup>2</sup>.

Notes: Indication marked with a \* is an Unapproved Indication. Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved.

Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

THALIDOMIDE – PCT only – Specialist – Special Authority see SA1124 below

Cap 50 mg .....	378.00	28	✓ Thalomid
Cap 100 mg .....	756.00	28	✓ Thalomid

►SA1124 Special Authority for Subsidy

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:  
Either:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis\*.

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period.  
Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with \* is an Unapproved Indication.

TRETINOIN

Cap 10 mg – PCT – Retail pharmacy-Specialist .....	479.50	100	✓ Vesanoïd
--	--------	-----	------------

VINBLASTINE SULPHATE

Inj 1 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist .....	37.29	1	✓ Hospira
	186.46	5	✓ Hospira
Inj 1 mg for ECP – PCT only – Specialist .....	4.14	1 mg	✓ Baxter

VINCISTINE SULPHATE

Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist .....	64.80	5	✓ Hospira
Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist .....	69.60	5	✓ Hospira
Inj 1 mg for ECP – PCT only – Specialist .....	9.45	1 mg	✓ Baxter

VINORELBINE – PCT only – Specialist

Inj 10 mg per ml, 1 ml vial .....	8.00	1	✓ Navelbine
	42.00		✓ Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml vial .....	40.00	1	✓ Navelbine
	210.00		✓ Vinorelbine Ebewe
Inj 1 mg for ECP .....	0.90	1 mg	✓ Baxter

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
<b>Protein-tyrosine Kinase Inhibitors</b>			
DASATINIB – Special Authority see SA0976 below – [Xpharm]			
Tab 20 mg .....	3,774.06	60	✓ Sprycel
Tab 50 mg .....	6,214.20	60	✓ Sprycel
Tab 70 mg .....	7,692.58	60	✓ Sprycel
Tab 100 mg .....	6,214.20	30	✓ Sprycel

## ►SA0976 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz>, and prescriptions should be sent to:

The CML/GIST Co-ordinator      Phone: (04) 460 4990  
 PHARMAC                              Facsimile: (04) 916 7571  
 PO Box 10 254                      Email: [cmlgistcoordinator@pharmac.govt.nz](mailto:cmlgistcoordinator@pharmac.govt.nz)  
 Wellington

### Special Authority criteria for CML - access by application

- Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- Subsidised for use as monotherapy only.
- Initial approvals valid seven months.
- Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

### Guideline on discontinuation of treatment for patients with CML

- Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
  - complete haematologic response (as characterised by an absolute neutrophil count (ANC)  $> 1.5 \times 10^9/L$ , platelets  $> 100 \times 10^9/L$ , absence of peripheral blood (PB) blasts, bone marrow (BM) blasts  $< 5\%$  (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
  - no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC)  $> 1.0 \times 10^9/L$ , platelets  $> 20 \times 10^9/L$ , absence of peripheral blood (PB) blasts, bone marrow (BM) blasts  $< 5\%$  (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
  - return to chronic phase (as characterised by BM and PB blasts  $< 15\%$ , BM and PB blasts and promyelocytes  $< 30\%$ , PB basophils  $< 20\%$  and absence of extramedullary disease other than spleen and liver).
- Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

ERLOTINIB – Retail pharmacy-Specialist – Special Authority see SA1519 on the next page

Tab 100 mg .....	1,000.00	30	✓ Tarceva
Tab 150 mg .....	1,500.00	30	✓ Tarceva

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1519 Special Authority for Subsidy

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
  - 1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
  - 1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
  - 1.3 Any of the following:
    - 1.3.1 Patient is treatment naive; or
    - 1.3.2 Both:
      - 1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
      - 1.3.2.2 Patient has not received prior treatment with gefitinib; or
    - 1.3.3 Both:
      - 1.3.3.1 The patient has discontinued gefitinib within 6 weeks of starting treatment due to intolerance; and
      - 1.3.3.2 The cancer did not progress while on gefitinib; and
  - 1.4 Erlotinib is to be given for a maximum of 3 months; or
- 2 The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB – Retail pharmacy-Specialist

Tab 250 mg – Special Authority see SA1520 below ..... 1,700.00      30      ✓ Iressa

►SA1520 Special Authority for Subsidy

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Either:
  - 2.1 Patient is treatment naive; or
  - 2.2 Both:
    - 2.2.1 The patient has discontinued erlotinib within 6 weeks of starting treatment due to intolerance; and
    - 2.2.2 The cancer did not progress whilst on erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
- 4 Gefitinib is to be given for a maximum of 3 months.

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

Tab 100 mg – Special Authority see SA1460 on the next page

– [Xpharm].....	2,400.00	60	✓ Glivec
* Cap 100 mg .....	298.90	60	✓ Imatinib-AFT
* Cap 400 mg .....	597.80	30	✓ Imatinib-AFT

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## ►SA1460 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz>, and prescriptions should be sent to:

The CML/GIST Co-ordinator      Phone: (04) 460 4990  
 PHARMAC                              Facsimile: (04) 916 7571  
 PO Box 10 254                      Email: [cmlgistcoordinator@pharmac.govt.nz](mailto:cmlgistcoordinator@pharmac.govt.nz)  
 Wellington

## Special Authority criteria for GIST – access by application

Funded for patients:

- With a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST).
- Maximum dose of 400 mg/day.
- Applications to be made and subsequent prescriptions can be written by an oncologist.
- Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

LAPATINIB DITOSYLATE – Special Authority see SA1191 below – Retail pharmacy

Tab 250 mg .....	1,899.00	70	✓ Tykerb
------------------	----------	----	----------

## ►SA1191 Special Authority for Subsidy

**Initial application — (metastatic breast cancer)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- All of the following:
  - The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
  - Lapatinib not to be given in combination with trastuzumab; and
  - Lapatinib to be discontinued at disease progression; or
- All of the following:
  - The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
  - The cancer did not progress whilst on trastuzumab; and
  - Lapatinib not to be given in combination with trastuzumab; and
  - Lapatinib to be discontinued at disease progression.

**Renewal — (metastatic breast cancer)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
- Lapatinib not to be given in combination with trastuzumab; and
- Lapatinib to be discontinued at disease progression.

NILOTINIB – Special Authority see SA1489 on the next page – Retail pharmacy

Wastage claimable – see rule 3.3.2 on page 13

Cap 150 mg .....	4,680.00	120	✓ Tasigna
Cap 200 mg .....	6,532.00	120	✓ Tasigna



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

►SA1489 Special Authority for Subsidy

**Initial application** only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
- 2 Either:
  - 2.1 Patient has documented CML treatment failure\* with imatinib; or
  - 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: \*treatment failure as defined by Leukaemia Net Guidelines.

**Renewal** only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

PAZOPANIB – Special Authority see SA1190 below – Retail pharmacy

Tab 200 mg .....	1,334.70	30	✓ Votrient
Tab 400 mg .....	2,669.40	30	✓ Votrient

►SA1190 Special Authority for Subsidy

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
  - 2.1 The patient is treatment naive; or
  - 2.2 The patient has only received prior cytokine treatment; or
  - 2.3 Both:
    - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
    - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and  
The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
  - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
  - 5.2 Haemoglobin level < lower limit of normal; or
  - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
  - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
  - 5.5 Karnofsky performance score of ≤ 70; or
  - 5.6 ≥ 2 sites of organ metastasis; and
- 6 Pazopanib to be used for a maximum of 3 months.

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

SUNITINIB – Special Authority see SA1266 below – Retail pharmacy

Cap 12.5 mg .....	2,315.38	28	✓	Sutent
Cap 25 mg .....	4,630.77	28	✓	Sutent
Cap 50 mg .....	9,261.54	28	✓	Sutent

## ►SA1266 Special Authority for Subsidy

**Initial application — (RCC)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
  - 2.1 The patient is treatment naive; or
  - 2.2 The patient has only received prior cytokine treatment; or
  - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
  - 2.4 Both:
    - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
    - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and  
The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
  - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
  - 5.2 Haemoglobin level < lower limit of normal; or
  - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
  - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
  - 5.5 Karnofsky performance score of ≤ 70; or
  - 5.6 ≥ 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

**Initial application — (GIST)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
  - 2.1 The patient's disease has progressed following treatment with imatinib; or
  - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

**Renewal — (RCC)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued. . .

Notes: Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6

**Renewal — (GIST)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
- The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:
    - 1 Any of the following:
      - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
      - 1.2 The patient has had a partial response (a decrease in size of  $\geq 10\%$  or decrease in tumour density in Hounsfield Units (HU) of  $\geq 15\%$  on CT and no new lesions and no obvious progression of non measurable disease); or
      - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
    - 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of  $\geq 10\%$  and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

## Endocrine Therapy

For GnRH ANALOGUES – refer to HORMONE PREPARATIONS, Tropic Hormones, page 85

ABIRATERONE ACETATE – Retail pharmacy-Specialist – Special Authority see SA1515 below

Wastage claimable – see rule 3.3.2 on page 13

Tab 250 mg ..... 4,276.19 120 ✓ Zytiga

### ►SA1515 | Special Authority for Subsidy

**Initial application** only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:
  - 4.1 All of the following:
    - 4.1.1 Patient is symptomatic; and
    - 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
    - 4.1.3 Patient has ECOG performance score of 0-1; and
    - 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
  - 4.2 All of the following:
    - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
    - 4.2.2 Patient has ECOG performance score of 0-2; and
    - 4.2.3 Patient has not had prior treatment with abiraterone.

**Renewal — (abiraterone acetate)** only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

continued. . .

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time

if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
1 Significant decrease in serum PSA from baseline; and				
2 No evidence of clinical disease progression; and				
3 No initiation of taxane chemotherapy with abiraterone; and				
4 The treatment remains appropriate and the patient is benefiting from treatment.				
<b>BICALUTAMIDE</b>				
Tab 50 mg .....	4.90	28	✓	<b>Bicalaccord</b>
<b>FLUTAMIDE – Retail pharmacy-Specialist</b>				
Tab 250 mg .....	16.50	30	✓	<b>Flutamin S29</b>
	55.00	100	✓	<b>Flutamin</b>
<b>MEGESTROL ACETATE – Retail pharmacy-Specialist</b>				
Tab 160 mg .....	54.30	30	✓	<b>Apo-Megestrol</b>
Apo-Megestrol to be Sole Supply on 1 November 2015				
<b>OCTREOTIDE</b>				
Inj 50 mcg per ml, 1 ml vial .....	13.50	5	✓	<b>DBL</b>
Inj 100 mcg per ml, 1 ml vial .....	22.40	5	✓	<b>DBL</b>
Inj 500 mcg per ml, 1 ml vial .....	89.40	5	✓	<b>DBL</b>
<b>OCTREOTIDE LAR (SOMATOSTATIN ANALOGUE) – Special Authority see SA1016 below – Retail pharmacy</b>				
Inj LAR 10 mg prefilled syringe .....	1,772.50	1	✓	<b>Sandostatin LAR</b>
Inj LAR 20 mg prefilled syringe .....	2,358.75	1	✓	<b>Sandostatin LAR</b>
Inj LAR 30 mg prefilled syringe .....	2,951.25	1	✓	<b>Sandostatin LAR</b>

## ►SA1016 Special Authority for Subsidy

**Initial application — (Malignant Bowel Obstruction)** from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea\* and vomiting\* due to malignant bowel obstruction\*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with \* are Unapproved Indications.

**Renewal — (Malignant Bowel Obstruction)** from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

**Initial application — (Acromegaly)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
  - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
  - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
  - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

**Renewal — (Acromegaly)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

**Initial application — (Other Indications)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
  - 2.1 Gastrinoma; and
  - 2.2 Either:
    - 2.2.1 Patient has failed surgery; or
    - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
  - 3.1 Insulinomas; and
  - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
  - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
  - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

**Renewal — (Other Indications)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

#### TAMOXIFEN CITRATE

* Tab 10 mg .....	17.50	100	✓ Genox
* Tab 20 mg .....	2.63	30	✓ Genox
	8.75	100	✓ Genox

### Aromatase Inhibitors

#### ANASTROZOLE

* Tab 1 mg .....	26.55	30	✓ Aremed
			✓ Arimidex
			✓ DP-Anastrozole

#### EXEMESTANE

* Tab 25 mg .....	14.50	30	✓ <u>Aromasin</u>
-------------------	-------	----	-------------------

#### LETROZOLE

* Tab 2.5 mg .....	4.85	30	✓ Letraccord
--------------------	------	----	--------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

## Immunosuppressants

### Cytotoxic Immunosuppressants

AZATHIOPRINE – Retail pharmacy-Specialist

* Tab 25 mg .....	8.28	60	✓	<b>Azamun</b>
* Tab 50 mg – For azathioprine oral liquid formulation refer, page 207 .....	13.22	100	✓	<b>Azamun</b>
* Inj 50 mg .....	126.00	1	✓	<b>Imuran</b>

MYCOPHENOLATE MOFETIL

Tab 500 mg .....	25.00	50	✓	<b>Cellcept</b>
Cap 250 mg .....	25.00	100	✓	<b>Cellcept</b>
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement .....	187.25	165 ml OP	✓	<b>Cellcept</b>

Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

### Fusion Proteins

ETANERCEPT – Special Authority see SA1478 below – Retail pharmacy

Inj 25 mg .....	949.96	4	✓	<b>Enbrel</b>
Inj 50 mg autoinjector .....	1,899.92	4	✓	<b>Enbrel</b>
Inj 50 mg prefilled syringe .....	1,899.92	4	✓	<b>Enbrel</b>

#### ►SA1478 Special Authority for Subsidy

**Initial application — (juvenile idiopathic arthritis)** only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
  - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
  - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or

2 All of the following:

- 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
- 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m<sup>2</sup> weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 2.5 Both:
  - 2.5.1 Either:
    - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
    - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
  - 2.5.2 Physician's global assessment indicating severe disease.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

**Initial application — (rheumatoid arthritis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
    - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
  - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
  - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
  - 2.5 Any of the following:
    - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
    - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
    - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
  - 2.6 Either:
    - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
    - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
  - 2.7 Either:
    - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
    - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Initial application — (severe chronic plaque psoriasis)** only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
    - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
  - 2.1 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Initial application — (ankylosing spondylitis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
- 1.2 Either:
  - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
  - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or

2 All of the following:

- 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
- 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
- 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
- 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
- 2.5 Either:
  - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
  - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
- 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

continued...



Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

**Initial application — (psoriatic arthritis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or

2 All of the following:

2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and

2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and

2.4 Either:

2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or

2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:

2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or

2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Initial application — (pyoderma gangrenosum)** only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Patient has pyoderma gangrenosum\*; and

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, cyclosporine, azathioprine, or methotrexate) and not received an adequate response; and

3 A maximum of 4 doses.

Note: Indications marked with \* are Unapproved Indications (refer to Interpretations and Definitions).

**Initial application — (adult-onset Still's disease)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 1 Both:
  - 1.1 Either:
    - 1.1.1 The patient has had an initial Special Authority approval for adalimumab for adult-onset Still's disease (AOSD); or
    - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or tocilizumab; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
  - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
  - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
  - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Renewal — (juvenile idiopathic arthritis)** only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
  - 1.1 Applicant is a named specialist or rheumatologist; or
  - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
  - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
  - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

**Renewal — (rheumatoid arthritis)** only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
  - 1.1 Applicant is a rheumatologist; or
  - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
  - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

**Renewal — (severe chronic plaque psoriasis)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
  - 1.1 Applicant is a dermatologist; or
  - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
  - 2.1 Both:
    - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
    - 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
  - 2.2 Both:
    - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
    - 2.2.2 Either:
      - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
      - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

**Renewal — (ankylosing spondylitis)** only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
  - 1.1 Applicant is a rheumatologist; or
  - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

**Renewal — (psoriatic arthritis)** only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
  - 1.1 Applicant is a rheumatologist; or
  - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued. . .

2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and

3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

**Renewal — (pyoderma gangrenosum)** only from a dermatologist or Practitioner on the recommendation of a dermatologist.

Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

**Renewal — (adult-onset Still's disease)** only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
  - 1.1 Applicant is a rheumatologist; or
  - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

## Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist

Inj 50 mg per ml, 5 ml .....	2,351.25	5	✓ ATGAM
------------------------------	----------	---	---------

BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist

Subsidised only for bladder cancer.

Inj 2-8 × 100 million CFU .....	149.37	1	✓ OncoTICE
---------------------------------	--------	---	------------

Inj 40 mg per ml, vial .....	149.37	3	✓ SII-Onco-BCG <sup>\$29</sup>
------------------------------	--------	---	--------------------------------

## Monoclonal Antibodies

ADALIMUMAB – Special Authority see SA1479 below – Retail pharmacy

Inj 20 mg per 0.4 ml prefilled syringe .....	1,799.92	2	✓ Humira
Inj 40 mg per 0.8 ml prefilled pen .....	1,799.92	2	✓ HumiraPen
Inj 40 mg per 0.8 ml prefilled syringe .....	1,799.92	2	✓ Humira

### ►SA1479 Special Authority for Subsidy

**Initial application — (rheumatoid arthritis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
    - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
  - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

continued. . .

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 2.5 Any of the following:
  - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
  - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
  - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 2.6 Either:
  - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
  - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
  - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Initial application — (Crohn's disease)** only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
  - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
  - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
  - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
  - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

**Initial application — (severe chronic plaque psoriasis)** only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
    - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
  - 2.1 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Initial application — (ankylosing spondylitis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
- 1.2 Either:
  - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
  - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or

2 All of the following:

- 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
- 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
- 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
- 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
- 2.5 Either:
  - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
  - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
- 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

**Initial application — (psoriatic arthritis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept; or

1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or

2 All of the following:

2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and

2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and

2.4 Either:

2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or

2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:

2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or

2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Initial application — (juvenile idiopathic arthritis)** only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept; or

1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for juvenile idiopathic arthritis; or

2 All of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.2 Patient diagnosed with JIA; and
- 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m<sup>2</sup> weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 2.5 Both:
  - 2.5.1 Either:
    - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
    - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
  - 2.5.2 Physician's global assessment indicating severe disease.

**Initial application — (fistulising Crohn's disease)** only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
  - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
  - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application; and
- 4 The patient will be assessed for response to treatment after 4 months' adalimumab treatment (see Note).

Note: A maximum of 4 months' adalimumab will be subsidised on an initial Special Authority approval for fistulising Crohn's disease.

**Initial application — (pyoderma gangrenosum)** only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum\*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Note: Indications marked with \* are Unapproved Indications (refer to (Interpretations and Definitions).

**Initial application — (adult-onset Still's disease)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
  - 1.1 Either:
    - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
    - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:

continued...



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
- 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
- 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Renewal — (rheumatoid arthritis)** only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
  - 1.1 Applicant is a rheumatologist; or
  - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
  - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Either:
  - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
  - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

**Renewal — (Crohn's disease)** only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
  - 1.1 Applicant is a gastroenterologist; or
  - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
  - 2.1 Either:
    - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
    - 2.1.2 CDAI score is 150 or less; or
  - 2.2 Both:
    - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
    - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Renewal — (severe chronic plaque psoriasis)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
  - 1.1 Applicant is a dermatologist; or
  - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

## 2 Either:

### 2.1 Both:

- 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or

### 2.2 Both:

- 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

### 2.2.2 Either:

- 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
- 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and

## 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

**Renewal — (ankylosing spondylitis)** only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

## 1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

## 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and

## 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

## 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Renewal — (psoriatic arthritis)** only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

## 1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

## 2 Either:

- 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and

## 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Renewal — (juvenile idiopathic arthritis)** only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

## 1 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 1.1 Applicant is a named specialist or rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
  - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
  - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

**Renewal — (fistulising Crohn's disease)** only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
- 1 Either:
    - 1.1 Applicant is a gastroenterologist; or
    - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
  - 2 Either:
    - 2.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
    - 2.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

**Renewal — (pyoderma gangrenosum)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

- All of the following:
- 1 Patient has shown clinical improvement; and
  - 2 Patient continues to require treatment; and
  - 3 A maximum of 4 doses.

**Renewal — (adult-onset Still's disease)** only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
- 1 Either:
    - 1.1 Applicant is a rheumatologist; or
    - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
  - 2 The patient has a sustained improvement in inflammatory markers and functional status.

OMALIZUMAB – Special Authority see SA1490 below – Retail pharmacy

Inj 150 mg vial .....	500.00	1	✓ Xolair
-----------------------	--------	---	----------

►SA1490 Special Authority for Subsidy

**Initial application** only from a respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
- 1 Patient is over the age of 6; and
  - 2 Patient has a diagnosis of severe, life threatening asthma; and
  - 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
  - 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and

continued...

continued...

- 5 Proven compliance with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or formoterol 12 micrograms bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; and
- 7 At least four admissions to hospital for a severe asthma exacerbation over the previous 24 months with at least one of those being in the previous 12 months; and
- 8 An Asthma Control Questionnaire (ACQ-5) score of at least 3.0 as assessed in the previous month.

**Renewal** only from a respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Hospital admissions have been reduced as a result of treatment; and
- 2 A reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 1.0 from baseline; and
- 3 A reduction in the maintenance oral corticosteroid dose of at least 50% from baseline.

**RITUXIMAB** – PCT only – Specialist – Special Authority see SA1152 below

Inj 100 mg per 10 ml vial .....	1,075.50	2	✓ Mabthera
Inj 500 mg per 50 ml vial .....	2,688.30	1	✓ Mabthera
Inj 1 mg for ECP .....	5.64	1 mg	✓ Baxter

## ►SA1152 Special Authority for Subsidy

**Initial application — (Post-transplant)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder\*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with \* are Unapproved Indications.

**Initial application — (Indolent, Low-grade lymphomas)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
  - 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
  - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
  - 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
  - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenström macroglobulinaemia.

**Initial application — (Aggressive CD20 positive NHL)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
  - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
  - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
  - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
  - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

**Initial application — (Chronic Lymphocytic Leukaemia)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
  - 3.1 The patient is chemotherapy treatment naive; or
  - 3.2 Both:
    - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
    - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance  $\geq 30$  ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

**Renewal — (Post-transplant)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder\*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with \* are Unapproved Indications.

**Renewal — (Indolent, Low-grade lymphomas)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenström macroglobulinaemia.

**Renewal — (Aggressive CD20 positive NHL)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TRASTUZUMAB – PCT only – Specialist – Special Authority see SA1521 below				
Inj 150 mg vial .....	1,350.00	1	✓	Herceptin
Inj 440 mg vial .....	3,875.00	1	✓	Herceptin
Inj 1 mg for ECP .....	9.36	1 mg	✓	Baxter

## ►SA1521 Special Authority for Subsidy

**Initial application — (metastatic breast cancer)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
  - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
  - 1.3 Trastuzumab not to be given in combination with lapatinib; and
  - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
  - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
  - 2.3 The cancer did not progress whilst on lapatinib; and
  - 2.4 Trastuzumab not to be given in combination with lapatinib; and
  - 2.5 Trastuzumab to be discontinued at disease progression.

**Renewal — (metastatic breast cancer)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

**Initial application — (early breast cancer)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
  - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
  - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
  - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
  - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
  - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

**Renewal — (early breast cancer\*)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
  - 3.1 All of the following:
    - 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
    - 3.1.2 Trastuzumab not to be given in combination with lapatinib; and
    - 3.1.3 Trastuzumab to be discontinued at disease progression; or
  - 3.2 All of the following:
    - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
    - 3.2.2 The cancer did not progress whilst on lapatinib; and
    - 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
    - 3.2.4 Trastuzumab to be discontinued at disease progression; or
  - 3.3 All of the following:
    - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
    - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
    - 3.3.3 Trastuzumab to be discontinued at disease progression.

Note: \* For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

## Other Immunosuppressants

### CICLOSPORIN

Cap 25 mg .....	44.63	50	✓ Neoral
Cap 50 mg .....	88.91	50	✓ Neoral
Cap 100 mg .....	177.81	50	✓ Neoral
Oral liq 100 mg per ml .....	198.13	50 ml OP	✓ Neoral

### EVEROLIMUS – Special Authority see SA1491 below – Retail pharmacy

Wastage claimable – see rule 3.3.2 on page 13

Tab 5 mg .....	4,555.76	30	✓ Afinitor
Tab 10 mg .....	6,512.29	30	✓ Afinitor

### ►SA1491 Special Authority for Subsidy

**Initial application** only from a neurologist or oncologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has tuberous sclerosis; and
- 2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

**Renewal** only from a neurologist or oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

### SIROLIMUS – Special Authority see SA0866 on the next page – Retail pharmacy

Tab 1 mg .....	813.00	100	✓ Rapamune
Tab 2 mg .....	1,626.00	100	✓ Rapamune
Oral liq 1 mg per ml .....	487.80	60 ml OP	✓ Rapamune

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>►SA0866 Special Authority for Subsidy</b>				
<b>Initial application</b> from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.				
Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:				
<ul style="list-style-type: none"> <li>• GFR&lt;30 ml/min; or</li> <li>• Rapidly progressive transplant vasculopathy; or</li> <li>• Rapidly progressive obstructive bronchiolitis; or</li> <li>• HUS or TTP; or</li> <li>• Leukoencephalopathy; or</li> <li>• Significant malignant disease</li> </ul>				
TACROLIMUS – Special Authority see SA1540 below – Retail pharmacy				
Cap 0.5 mg .....	85.60	100	✓	<u>Tacrolimus Sandoz</u>
Cap 1 mg .....	171.20	100	✓	<u>Tacrolimus Sandoz</u>
Cap 5 mg – For tacrolimus oral liquid formulation refer, page 207 .....	428.00	50	✓	<u>Tacrolimus Sandoz</u>

<b>►SA1540 Special Authority for Subsidy</b>				
<b>Initial application — (organ transplant)</b> only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.				
<b>Initial application — (steroid-resistant nephrotic syndrome*)</b> only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:				
Either:				
1 The patient is a child with steroid-resistant nephrotic syndrome* (SRNS) where ciclosporin has been trialled in combination with prednisone and discontinued because of unacceptable side effects or inadequate clinical response; or				
2 All of the following:				
2.1 The patient is an adult with SRNS; and				
2.2 Ciclosporin has been trialled in combination with prednisone and discontinued because of unacceptable side effects or inadequate clinical response; and				
2.3 Cyclophosphamide or mycophenolate have been trialled and discontinued because of unacceptable side effects or inadequate clinical response, or these treatments are contraindicated.				
Note: Indications marked with * are Unapproved Indications				
Note: Subsidy applies for either primary or rescue therapy.				



Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## Antiallergy Preparations

### ▶SA1367 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:  
Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

**Renewal** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**BEE VENOM ALLERGY TREATMENT** – Special Authority see SA1367 above – Retail pharmacy

Maintenance kit - 6 vials 120 mcg freeze dried venom, 6 diluent 1.8 ml .....	285.00	1 OP	✓ Albay
--	--------	------	---------

Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml .....	305.00	1 OP	✓ Albey
---	--------	------	---------

(Albay Maintenance kit - 6 vials 120 mcg freeze dried venom, 6 diluent 1.8 ml to be delisted 1 February 2016)

**WASP VENOM ALLERGY TREATMENT** – Special Authority see SA1367 above – Retail pharmacy

Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml .....	305.00	1 OP	✓ Albey
---	--------	------	---------

Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze dried vesputa venom, 1 diluent 9 ml, 1 diluent 1.8 ml .....	305.00	1 OP	✓ Albey
---	--------	------	---------

## Antihistamines

### CETIRIZINE HYDROCHLORIDE

* Tab 10 mg .....	1.59	100	✓ Zetop
*‡ Oral liq 1 mg per ml .....	2.99	200 ml	✓ Histaclear

### CHLORPHENIRAMINE MALEATE

*‡ Oral liq 2 mg per 5 ml .....	8.06	500 ml	✓ Histafen
---------------------------------	------	--------	------------

### DEXTROCHLORPHENIRAMINE MALEATE

* Tab 2 mg .....	1.01	20	
	(5.99)		Polaramine
	2.02	40	Polaramine
	(8.40)		
*‡ Oral liq 2 mg per 5 ml .....	1.77	100 ml	
	(10.29)		Polaramine

### FEXOFENADINE HYDROCHLORIDE

* Tab 60 mg .....	4.34	20	
	(11.53)		Telfast
* Tab 120 mg .....	4.74	10	
	(11.53)		Telfast
	14.22	30	
	(29.81)		Telfast

### LORATADINE

* Tab 10 mg .....	1.30	100	✓ Lorafix
* Oral liq 1 mg per ml .....	4.25	200 ml	✓ LoraPaed

# RESPIRATORY SYSTEM AND ALLERGIES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>PROMETHAZINE HYDROCHLORIDE</b>				
* Tab 10 mg .....	1.78	50	✓	Allersoothe
Allersoothe to be Sole Supply on 1 October 2015				
* Tab 25 mg .....	1.99	50	✓	Allersoothe
Allersoothe to be Sole Supply on 1 October 2015				
* ‡ Oral liq 1 mg per 1 ml .....	2.59	100 ml	✓	Allersoothe
Allersoothe to be Sole Supply on 1 October 2015				
* Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO .....	11.99	5	✓	Hospira
<b>TRIMEPAZINE TARTRATE</b>				
‡ Oral liq 30 mg per 5 ml .....	2.79 (8.06)	100 ml OP		Vallergan Forte

## Inhaled Corticosteroids

<b>BECLOMETHASONE DIPROPIONATE</b>				
Aerosol inhaler, 50 mcg per dose .....	9.30	200 dose OP	✓	Qvar
Aerosol inhaler, 50 mcg per dose CFC-free .....	8.54	200 dose OP	✓	Beclazone 50
Aerosol inhaler, 100 mcg per dose .....	15.50	200 dose OP	✓	Qvar
Aerosol inhaler, 100 mcg per dose CFC-free .....	12.50	200 dose OP	✓	Beclazone 100
Aerosol inhaler, 250 mcg per dose CFC-free .....	22.67	200 dose OP	✓	Beclazone 250
<b>BUDESONIDE</b>				
Powder for inhalation, 100 mcg per dose .....	17.00	200 dose OP	✓	Pulmicort Turbuhaler
Powder for inhalation, 200 mcg per dose .....	19.00	200 dose OP	✓	Pulmicort Turbuhaler
Powder for inhalation, 400 mcg per dose .....	32.00	200 dose OP	✓	Pulmicort Turbuhaler
<b>FLUTICASONE</b>				
Aerosol inhaler, 50 mcg per dose CFC-free .....	7.50	120 dose OP	✓	Flixotide
Powder for inhalation, 50 mcg per dose .....	7.50	60 dose OP	✓	Flixotide Accuhaler
Powder for inhalation, 100 mcg per dose .....	7.50	60 dose OP	✓	Flixotide Accuhaler
Aerosol inhaler, 125 mcg per dose CFC-free .....	13.60	120 dose OP	✓	Flixotide
Aerosol inhaler, 250 mcg per dose CFC-free .....	27.20	120 dose OP	✓	Flixotide
Powder for inhalation, 250 mcg per dose .....	13.60	60 dose OP	✓	Flixotide Accuhaler

## Inhaled Long-acting Beta-adrenoceptor Agonists

<b>EFORMOTEROL FUMARATE</b>				
Powder for inhalation, 6 mcg per dose, breath activated .....	10.32 (16.90)	60 dose OP		Oxis Turbuhaler
Powder for inhalation, 12 mcg per dose, and monodose de- vice .....	20.64 (35.80)	60 dose		Foradil
<b>INDACATEROL</b>				
Powder for inhalation 150 mcg .....	61.00	30 dose OP	✓	Onbrez Breezhaler
Powder for inhalation 300 mcg .....	61.00	30 dose OP	✓	Onbrez Breezhaler
<b>SALMETEROL</b>				
Aerosol inhaler CFC-free, 25 mcg per dose .....	26.46	120 dose OP	✓	Serevent
Powder for inhalation, 50 mcg per dose, breath activated .....	26.46	60 dose OP	✓	Serevent Accuhaler

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

**BUDESONIDE WITH EFORMOTEROL** – Special Authority see SA1179 below – Retail pharmacy

Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg .....	26.49	120 dose OP	✓ <b>Vannair</b>
Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg .....	55.00	120 dose OP	✓ <b>Symbicort Turbuhaler 100/6</b>
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg .....	31.25	120 dose OP	✓ <b>Vannair</b>
Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg .....	60.00	120 dose OP	✓ <b>Symbicort Turbuhaler 200/6</b>
Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg – No more than 2 dose per day .....	60.00	60 dose OP	✓ <b>Symbicort Turbuhaler 400/12</b>

### ►SA1179 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 All of the following:
  - 1.1 Patient is a child under the age of 12; and
  - 1.2 Has been treated with inhaled corticosteroids of at least 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone; and
  - 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- 2 All of the following:
  - 2.1 Patient is over the age of 12; and
  - 2.2 Has been treated with inhaled corticosteroids of at least 800 mcg per day beclomethasone or budesonide, or 500 mcg per day fluticasone; and
  - 2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

## FLUTICASONE WITH SALMETEROL

Aerosol inhaler 50 mcg with salmeterol 25 mcg .....	37.48	120 dose OP	✓ <b>Seretide</b>
Aerosol inhaler 125 mcg with salmeterol 25 mcg .....	49.69	120 dose OP	✓ <b>Seretide</b>
Powder for inhalation 100 mcg with salmeterol 50 mcg – No more than 2 dose per day .....	37.48	60 dose OP	✓ <b>Seretide Accuhaler</b>
Powder for inhalation 250 mcg with salmeterol 50 mcg – No more than 2 dose per day .....	49.69	60 dose OP	✓ <b>Seretide Accuhaler</b>

## Beta-Adrenoceptor Agonists

### SALBUTAMOL

‡ Oral liq 400 mcg per ml .....	2.06	150 ml	✓ <b>Ventolin</b>
Infusion 1 mg per ml, 5 ml .....	118.38 (130.21)	10	Ventolin
Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO .....	12.90	5	✓ <b>Ventolin</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time  
if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Inhaled Beta-Adrenoceptor Agonists</b>				
<b>SALBUTAMOL</b>				
Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO .....	3.80	200 dose OP	✓	<b>Respigen</b>
	(6.00)		✓	<b>Salamol</b> Ventolin
Nebuliser soln, 1 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO .....	3.19	20	✓	<b>Asthalin</b>
Asthalin to be Sole Supply on 1 October 2015				
Nebuliser soln, 2 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO .....	3.29	20	✓	<b>Asthalin</b>
Asthalin to be Sole Supply on 1 October 2015				
<b>TERBUTALINE SULPHATE</b>				
Powder for inhalation, 250 mcg per dose, breath activated .....	22.00	200 dose OP	✓	<b>Bricanyl Turbuhaler</b>

## Anticholinergic Agents

<b>IPRATROPIUM BROMIDE</b>				
Aerosol inhaler, 20 mcg per dose CFC-free .....	16.20	200 dose OP	✓	<b>Atrovent</b>
Nebuliser soln, 250 mcg per ml, 1 ml – Up to 40 neb available on a PSO .....	3.26	20	✓	<b>Univent</b>
Nebuliser soln, 250 mcg per ml, 2 ml – Up to 40 neb available on a PSO .....	3.37	20	✓	<b>Univent</b>

## Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents

<b>SALBUTAMOL WITH IPRATROPIUM BROMIDE</b>				
Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free .....	12.19	200 dose OP	✓	<b>Duolin HFA</b>
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule – Up to 20 neb available on a PSO .....	3.59	20	✓	<b>Duolin</b>
Duolin to be Sole Supply on 1 October 2015				

## Long-Acting Muscarinic Antagonists

### ►SA1485 Special Authority for Subsidy

**Initial application** only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialled a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and
- 3 Either:

The patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:

- 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or
- 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and

- 4 All of the following:

Applicant must state recent measurement of:

- 4.1 Actual FEV<sub>1</sub> (litres); and

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 4.2 Predicted FEV<sub>1</sub> (litres); and
- 4.3 Actual FEV<sub>1</sub> as a % of predicted (must be below 60%); and
- 5 Either:
  - 5.1 Patient is not a smoker (for reporting purposes only); or
  - 5.2 Patient is a smoker and has been offered smoking cessation counselling; and
- 6 The patient has been offered annual influenza immunisation.

**Renewal** only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined); and
- 3 All of the following:
 

Applicant must state recent measurement of:

  - 3.1 Actual FEV<sub>1</sub> (litres); and
  - 3.2 Predicted FEV<sub>1</sub> (litres); and
  - 3.3 Actual FEV<sub>1</sub> as a % of predicted.

**GLYCOPYRRONIUM** – Special Authority see SA1485 on the previous page – Retail pharmacy

Glycopyrronium treatment will not be subsidised if patient is also receiving treatment with subsidised tiotropium.

Powder for inhalation 50 mcg per dose .....61.00 30 dose OP ✓ **Seebri Breezhaler**

**TIOTROPIUM BROMIDE** – Special Authority see SA1485 on the previous page – Retail pharmacy

Tiotropium treatment will not be subsidised if patient is also receiving treatment with subsidised glycopyrronium.

Powder for inhalation, 18 mcg per dose .....70.00 30 dose ✓ **Spiriva**

## Leukotriene Receptor Antagonists

**MONTELUKAST** – Special Authority see SA1421 below – Retail pharmacy

Prescribing Guideline: Clinical evidence indicates that the effectiveness of montelukast is strongest when montelukast is used in short treatment courses.

Tab 4 mg .....	18.48	28	✓ <b>Singulair</b>
Tab 5 mg .....	18.48	28	✓ <b>Singulair</b>
Tab 10 mg .....	18.48	28	✓ <b>Singulair</b>

### ►SA1421 Special Authority for Subsidy

**Initial application — (Pre-school wheeze)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and
- 2 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

**Renewal — (Pre-school wheeze)** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**Initial application — (exercise-induced asthma)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been trialled with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
- 2 Patient continues to receive optimal inhaled corticosteroid therapy; and

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

# RESPIRATORY SYSTEM AND ALLERGIES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

**Initial application — (aspirin desensitisation)** only from a clinical immunologist or allergist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a Clinical Immunologist or Allergist; and
- 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
- 3 Nasal polyposis, confirmed radiologically or surgically; and
- 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

## Mast Cell Stabilisers

### NEDOCROMIL

Aerosol inhaler, 2 mg per dose CFC-free .....28.07 112 dose OP ✓ **Tilade**

### SODIUM CROMOGLYCATE

Powder for inhalation, 20 mg per dose .....17.94 50 dose ✓ **Intal Spincaps**  
Aerosol inhaler, 5 mg per dose CFC-free .....28.07 112 dose OP ✓ **Intal Forte CFC Free**

## Methylxanthines

### AMINOPHYLLINE

\* Inj 25 mg per ml, 10 ml ampoule – Up to 5 inj available on a  
PSO .....118.25 5 ✓ **DBL Aminophylline**

### THEOPHYLLINE

\* Tab long-acting 250 mg .....21.51 100 ✓ **Nuelin-SR**  
\*<sub>‡</sub> Oral liq 80 mg per 15 ml .....15.50 500 ml ✓ **Nuelin**

## Mucolytics

### DORNASE ALFA – Special Authority see SA0611 below – Retail pharmacy

Nebuliser soln, 2.5 mg per 2.5 ml ampoule .....250.00 6 ✓ **Pulmozyme**

### ►SA0611 Special Authority for Subsidy

Special Authority approved by the Cystic Fibrosis Advisory Panel

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Co-ordinator, Cystic Fibrosis Advisory Panel Phone: (04) 460 4990  
PHARMAC, PO Box 10 254 Facsimile: (04) 916 7571  
Wellington Email: [CFPanel@pharmac.govt.nz](mailto:CFPanel@pharmac.govt.nz)

Prescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.

### SODIUM CHLORIDE

Not funded for use as a nasal drop.  
Soln 7% .....23.50 90 ml OP ✓ **Biomed**

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Nasal Preparations

### Allergy Prophylactics

#### BECLOMETHASONE DIPROPIONATE

Metered aqueous nasal spray, 50 mcg per dose .....	2.35 (4.85)	200 dose OP	Alanase
Metered aqueous nasal spray, 100 mcg per dose .....	2.46 (5.75)	200 dose OP	Alanase

#### BUDESONIDE

Metered aqueous nasal spray, 50 mcg per dose .....	2.35 (4.85)	200 dose OP	Butacort Aqueous
Metered aqueous nasal spray, 100 mcg per dose .....	2.61 (5.75)	200 dose OP	Butacort Aqueous

#### FLUTICASONE PROPIONATE

Metered aqueous nasal spray, 50 mcg per dose .....	2.18	120 dose OP	✓ Flixonase Hayfever & Allergy
--	------	-------------	--------------------------------

Flixonase Hayfever & Allergy to be Sole Supply on 1 October 2015

#### IPRATROPIUM BROMIDE

Aqueous nasal spray, 0.03% .....	3.95	15 ml OP	✓ Univent
----------------------------------	------	----------	-----------

## Respiratory Devices

#### MASK FOR SPACER DEVICE

a) Up to 20 dev available on a PSO			
b) Only on a PSO			
c) Only for children aged six years and under			
Size 2 .....	2.99	1	✓ EZ-fit Paediatric Mask

#### PEAK FLOW METER

a) Up to 10 dev available on a PSO			
b) Only on a PSO			
Low range .....	11.44	1	✓ Breath-Alert
Normal range .....	11.44	1	✓ Breath-Alert

#### SPACER DEVICE

a) Up to 20 dev available on a PSO			
b) Only on a PSO			
230 ml (single patient) .....	4.72	1	✓ Space Chamber Plus
800 ml .....	8.50	1	✓ Volumatic

#### SPACER DEVICE AUTOCLAVABLE

a) Up to 5 dev available on a PSO			
b) Only on a PSO			
230 ml (autoclavable) – Subsidy by endorsement.....	11.60	1	✓ Space Chamber

Available where the prescriber requires a spacer device that is capable of sterilisation in an autoclave and the PSO is endorsed accordingly.

## Respiratory Stimulants

#### CAFFEINE CITRATE

Oral liq 20 mg per ml (10 mg base per ml) .....	14.85	25 ml OP	✓ Biomed
---	-------	----------	----------

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## Ear Preparations

### ACETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BENZETHONIUM

For Vosol ear drops with hydrocortisone powder refer Standard Formulae, page 210

Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02% .....	6.97	35 ml OP	✓ Vosol
--	------	----------	---------

### FLUMETASONE PIVALATE

Ear drops 0.02% with clioquinol 1% .....	4.46	7.5 ml OP	✓ Locacorten-Viaform ED's ✓ Locorten-Vioform
--	------	-----------	--

### TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN

Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g .....	5.16	7.5 ml OP	✓ Kenacomb
--	------	-----------	------------

## Ear/Eye Preparations

### DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN

Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml .....	4.50 (9.27)	8 ml OP	Sofradex
---	----------------	---------	----------

### FRAMYCETIN SULPHATE

Ear/Eye drops 0.5% .....	4.13 (8.65)	8 ml OP	Soframycin
--------------------------	----------------	---------	------------

## Eye Preparations

Eye preparations are only funded for use in the eye, unless explicitly stated otherwise.

## Anti-Infective Preparations

### ACICLOVIR

* Eye oint 3% .....	37.53	4.5 g OP	✓ Zovirax
---------------------	-------	----------	-----------

### CHLORAMPHENICOL

Eye oint 1% .....	2.76	4 g OP	✓ Chlorsig
Eye drops 0.5% .....	0.98	10 ml OP	✓ Chlorafast

a) Funded for use in the ear\*. Indications marked with \* are Unapproved Indications.  
b) Chlorafast to be Sole Supply on 1 October 2015

### CIPROFLOXACIN

Eye Drops 0.3% .....	12.43	5 ml OP	✓ Ciloxan
----------------------	-------	---------	-----------

For treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol.

### FUSIDIC ACID

Eye drops 1% .....	4.50	5 g OP	✓ Fucithalmic
--------------------	------	--------	---------------

### GANCICLOVIR

Eye gel 0.15% .....	37.53	5 g OP	✓ Virgan <sup>\$29</sup>
---------------------	-------	--------	--------------------------

### GENTAMICIN SULPHATE

Eye drops 0.3% .....	11.40	5 ml OP	✓ Genoptic
----------------------	-------	---------	------------

### PROPAMIDINE ISETHIONATE

* Eye drops 0.1% .....	2.97 (7.99)	10 ml OP	Brolene
------------------------	----------------	----------	---------



	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>TOBRAMYCIN</b>				
Eye oint 0.3% .....	10.45	3.5 g OP	✓	<b>Tobrex</b>
Eye drops 0.3% .....	11.48	5 ml OP	✓	<b>Tobrex</b>
<b>Corticosteroids and Other Anti-Inflammatory Preparations</b>				
<b>DEXAMETHASONE</b>				
* Eye oint 0.1% .....	5.86	3.5 g OP	✓	<b>Maxidex</b>
* Eye drops 0.1% .....	4.50	5 ml OP	✓	<b>Maxidex</b>
<b>DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE</b>				
* Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g .....	5.39	3.5 g OP	✓	<b>Maxitrol</b>
* Eye drops 0.1% with neomycin sulphate 0.35% and polymy- xin b sulphate 6,000 u per ml .....	4.50	5 ml OP	✓	<b>Maxitrol</b>
<b>DICLOFENAC SODIUM</b>				
* Eye drops 0.1% .....	13.80	5 ml OP	✓	<b>Voltaren Ophtha</b>
<b>FLUOROMETHOLONE</b>				
* Eye drops 0.1% .....	3.09	5 ml OP	✓	<b>FML</b>
	3.80		✓	<b>Flucon</b>
<b>LEVOCABASTINE</b>				
Eye drops 0.5 mg per ml .....	8.71	4 ml OP		
	(10.34)			Livostin
<b>LODOXAMIDE</b>				
Eye drops 0.1% .....	8.71	10 ml OP	✓	<b>Lomide</b>
<b>PREDNISOLONE ACETATE</b>				
* Eye drops 0.12% .....	4.50	5 ml OP	✓	<b>Pred Mild</b>
* Eye drops 1% .....	4.50	5 ml OP	✓	<b>Pred Forte</b>
<b>SODIUM CROMOGLYCATE</b>				
Eye drops 2% .....	1.18	5 ml OP	✓	<b>Rexacrom</b>
<b>Glaucoma Preparations - Beta Blockers</b>				
<b>BETAXOLOL</b>				
* Eye drops 0.25% .....	11.80	5 ml OP	✓	<b>Betoptic S</b>
* Eye drops 0.5% .....	7.50	5 ml OP	✓	<b>Betoptic</b>
<b>LEVOBUNOLOL</b>				
* Eye drops 0.5% .....	7.00	5 ml OP	✓	<b>Betagan</b>
<b>TIMOLOL</b>				
* Eye drops 0.25% .....	1.45	5 ml OP	✓	<b>Arrow-Timolol</b>
* Eye drops 0.25%, gel forming .....	3.30	2.5 ml OP	✓	<b>Timoptol XE</b>
* Eye drops 0.5% .....	1.45	5 ml OP	✓	<b>Arrow-Timolol</b>
* Eye drops 0.5%, gel forming .....	3.78	2.5 ml OP	✓	<b>Timoptol XE</b>
<b>Glaucoma Preparations - Carbonic Anhydrase Inhibitors</b>				
<b>ACETAZOLAMIDE</b>				
* Tab 250 mg – For acetazolamide oral liquid formulation refer, page 207 .....	17.03	100	✓	<b>Diamox</b>
<b>BRINZOLAMIDE</b>				
* Eye Drops 1% .....	9.77	5 ml OP	✓	<b>Azopt</b>

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time

if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>DORZOLAMIDE HYDROCHLORIDE</b>				
* Eye drops 2% .....	9.77 (17.44)	5 ml OP		Trusopt
<b>DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE</b>				
* Eye drops 2% with timolol maleate 0.5% .....	15.50	5 ml OP	✓	Cosopt
<b>Glaucoma Preparations - Prostaglandin Analogues</b>				
<b>BIMATOPROST</b>				
* Eye drops 0.03% .....	18.50	3 ml OP	✓	Lumigan
<b>LATANOPROST</b>				
* Eye drops 0.005% .....	1.50	2.5 ml OP	✓	Hysite
Hysite to be Sole Supply on 1 October 2015				
<b>TRAVOPROST</b>				
* Eye drops 0.004% .....	19.50	2.5 ml OP	✓	Travatan
<b>Glaucoma Preparations - Other</b>				
<b>BRIMONIDINE TARTRATE</b>				
* Eye drops 0.2% .....	4.32	5 ml OP	✓	Arrow-Brimonidine
<b>BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE</b>				
* Eye drops 0.2% with timolol maleate 0.5% .....	18.50	5 ml OP	✓	Combigan
<b>PILOCARPINE HYDROCHLORIDE</b>				
* Eye drops 1% .....	4.26	15 ml OP	✓	Isopto Carpine
* Eye drops 2% .....	5.35	15 ml OP	✓	Isopto Carpine
* Eye drops 4% .....	7.99	15 ml OP	✓	Isopto Carpine
Subsidised for oral use pursuant to the Standard Formulae.				
* Eye drops 2% single dose – Special Authority see SA0895				
below – Retail pharmacy .....	31.95 (32.72)	20 dose		Minims

## ►SA0895 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:  
Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be “tools of trade” and are not approved as special authority items.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

## Mydriatics and Cycloplegics

<b>ATROPINE SULPHATE</b>				
* Eye drops 1% .....	17.36	15 ml OP	✓	Atropt
<b>CYCLOPENTOLATE HYDROCHLORIDE</b>				
* Eye drops 1% .....	8.76	15 ml OP	✓	Cyclogyl
<b>TROPICAMIDE</b>				
* Eye drops 0.5% .....	7.15	15 ml OP	✓	Mydriacyl
* Eye drops 1% .....	8.66	15 ml OP	✓	Mydriacyl

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## Preparations for Tear Deficiency

For acetylcysteine eye drops refer Standard Formulae, page 210

### HYPROMELLOSE

* Eye drops 0.5% .....	2.00	15 ml OP	
	(3.92)		Methopt

### HYPROMELLOSE WITH DEXTRAN

* Eye drops 0.3% with dextran 0.1% .....	2.30	15 ml OP	✓ Poly-Tears
--	------	----------	--------------

### POLYVINYL ALCOHOL

* Eye drops 1.4% .....	2.68	15 ml OP	✓ Vistil
* Eye drops 3% .....	3.75	15 ml OP	✓ Vistil Forte

## Preservative Free Ocular Lubricants

### ▶SA1388 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Confirmed diagnosis by slit lamp of severe secretory dry eye; and
- 2 Either:
  - 2.1 Patient is using eye drops more than four times daily on a regular basis; or
  - 2.2 Patient has had a confirmed allergic reaction to preservative in eye drop.

**Renewal** from any relevant practitioner. Approvals valid for 24 months where the patient continues to require lubricating eye drops and has benefited from treatment.

CARBOMER – Special Authority see SA1388 above – Retail pharmacy

Ophthalmic gel 0.3%, 0.5 g .....	8.25	30	✓ Poly-Gel
----------------------------------	------	----	------------

MACROGOL 400 AND PROPYLENE GLYCOL – Special Authority see SA1388 above – Retail pharmacy

Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml .....	4.30	24	✓ Systane Unit Dose
--	------	----	---------------------

SODIUM HYALURONATE [HYALURONIC ACID] – Special Authority see SA1388 above – Retail pharmacy

Eye drops 1 mg per ml .....	22.00	10 ml OP	✓ Hylo-Fresh
-----------------------------	-------	----------	--------------

Hylo-Fresh has a 6 month expiry after opening. The Pharmacy Procedures Manual restriction allowing one bottle per month is not relevant and therefore only the prescribed dosage to the nearest OP may be claimed.

## Other Eye Preparations

### NAPHAZOLINE HYDROCHLORIDE

* Eye drops 0.1% .....	4.15	15 ml OP	✓ Naphcon Forte
------------------------	------	----------	-----------------

### OLOPATADINE

Eye drops 0.1% .....	17.00	5 ml OP	✓ Patanol
----------------------	-------	---------	-----------

### PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN

* Eye oint with soft white paraffin .....	3.63	3.5 g OP	✓ Refresh Night Time
---	------	----------	----------------------

### PARAFFIN LIQUID WITH WOOL FAT

* Eye oint 3% with wool fat 3% .....	3.63	3.5 g OP	✓ Poly-Visc
--------------------------------------	------	----------	-------------

### RETINOL PALMITATE

Eye oint 138 mcg per g .....	3.80	5 g OP	✓ Vita-POS
------------------------------	------	--------	------------

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Agents Used in the Treatment of Poisonings

### Antidotes

ACETYL CYSTEINE – Retail pharmacy-Specialist

Inj 200 mg per ml, 10 ml ampoule .....	78.34	10	✓ DBL Acetylcysteine
	178.00		✓ Martindale

Inj 200 mg per ml, 30 ml .....	219.00	4	✓ Acetadote
--------------------------------	--------	---	-------------

NALOXONE HYDROCHLORIDE

a) Up to 5 inj available on a PSO

b) Only on a PSO

* Inj 400 mcg per ml, 1 ml ampoule .....	48.84	5	✓ Hospira
--	-------	---	-----------

### Removal and Elimination

CHARCOAL

* Oral liq 50 g per 250 ml .....	43.50	250 ml OP	✓ Carbosorb-X
a) Up to 250 ml available on a PSO			
b) Only on a PSO			

DEFERASIROX – Special Authority see SA1492 below – Retail pharmacy

Wastage claimable – see rule 3.3.2 on page 13

Tab 125 mg dispersible .....	276.00	28	✓ Exjade
------------------------------	--------	----	----------

Tab 250 mg dispersible .....	552.00	28	✓ Exjade
------------------------------	--------	----	----------

Tab 500 mg dispersible .....	1,105.00	28	✓ Exjade
------------------------------	----------	----	----------

#### ►SA1492 Special Authority for Subsidy

**Initial application** only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
- 2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
- 3 Any of the following:
  - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2\*; or
  - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
  - 3.3 Treatment with deferiprone has resulted in arthritis; or
  - 3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per  $\mu$ L) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per  $\mu$ L).

**Renewal** only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2\* and liver MRI T2\* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2\* and liver MRI T2\* levels.

DEFERIPRONE – Special Authority see SA1480 on the next page – Retail pharmacy

Tab 500 mg .....	533.17	100	✓ Ferriprox
------------------	--------	-----	-------------

Oral liq 100 mg per 1 ml .....	266.59	250 ml OP	✓ Ferriprox
--------------------------------	--------	-----------	-------------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

►SA1480 | Special Authority for Subsidy

**Initial application** only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; or
- 2 The patient has been diagnosed with chronic iron overload due to acquired red cell aplasia.

DEFERRIOXAMINE MESYLATE

* Inj 500 mg vial .....	109.89	10	✓ Hospira
-------------------------	--------	----	-----------

SODIUM CALCIUM EDETATE

* Inj 200 mg per ml, 5 ml .....	53.31 (156.71)	6	Calcium Disodium Versenate
---------------------------------	-------------------	---	-------------------------------

## INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The “Standard Formulae”.
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
  - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
  - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacy-specialist).
  - c) Menthol crystals only in the following bases:  
 Aqueous cream  
 Urea cream 10%  
 Wool fat with mineral oil lotion  
 Hydrocortisone 1% with wool fat and mineral oil lotion  
 Glycerol, paraffin and cetyl alcohol lotion.

## Glossary

**Dermatological base:** The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Hydrocortisone with wool fat and mineral oil lotion
- Oil in water emulsion
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

**Dermatological galenical:** Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution - up to 10%
- Hydrocortisone powder - up to 5%
- Menthol crystals
- Salicylic acid powder
- Sulphur precipitated powder

**Standard formulae:** Standard formulae are a list of formulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

## Explanatory notes

### Oral liquid mixtures

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored.

The Emixt website [www.pharminfotech.co.nz](http://www.pharminfotech.co.nz) has evidence-based formulations which are intended to standardise compounded oral liquids within New Zealand.

### Pharmaceuticals with standardised formula for compounding in Ora products

Acetazolamide 25 mg/ml	Gabapentin 100 mg/ml	Sildenafil 2 mg/ml
Allopurinol 20 mg/ml	Gabapentin (Neurontin) 100 mg/ml	Sotalol 5 mg/ml
Amlodipine 1 mg/ml	Hydrocortisone 1 mg/ml	Sulphasalazine 100 mg/ml
Azathioprine 50 mg/ml	Labetalol 10 mg/ml	Tacrolimus 1 mg/ml
Baclofen 10 mg/ml	Levetiracetam 100 mg/ml	Terbinafine 25 mg/ml
Carvedilol 1 mg/ml	Levodopa with carbidopa (5 mg levodopa + 1.25 mg carbidopa)/ml	Tramadol 10 mg/ml
Clopidogrel 5 mg/ml	Metoclopramide 1 mg/ml	Ursodeoxycholic acid 50 mg/ml
Diltiazem hydrochloride 12 mg/ml	Metoprolol tartrate 10 mg/ml	Valganciclovir 60 mg/ml*
Dipyridamole 10 mg/ml	Nitrofurantoin 10 mg/ml	Verapamil hydrochloride 50 mg/ml
Domperidone 1 mg/ml	Pyrazinamide 100 mg/ml	
Enalapril 1 mg/ml	Rifabutin 20 mg/ml	
Flecainide 20 mg/ml		

\*Note this is a DCS formulation

PHARMAC endorses the recommendations of the Emixt website and encourages New Zealand pharmacists to use these formulations when compounding is appropriate. The Emixt website also provides stability and expiry data for compounded products. For the majority of products compounded with Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet or Ora-Sweet SF a four week expiry is appropriate.

Please note that no oral liquid mixture will be eligible for Subsidy unless all the requirements of Section B and C of the Schedule applicable to that pharmaceutical are met.

Some community pharmacies may not have appropriate equipment to compound all of the listed products, please use appropriate clinical judgement.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

or	
Solid dose form	qs
Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF	to 100%

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent.

- Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and Ora-Sweet SF when used correctly are an appropriate preservative and suspending agent.
- Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Where a Standard Formula exists in the Pharmaceutical Schedule for a solid dose form, compounding the solid dose form in Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF.
- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

### **Standard formulae**

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

### **Dermatological Preparations**

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 206) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).

One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.


The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on the next page may assist you in deciding whether or not a dermatological ECP is subsidised.



# Dermatological ECPs

## Is it subsidised?



## Standard Formulae

### ACETYLCYSTEINE EYE DROPS

Acetylcysteine inj 200 mg per ml, 10 ml	qs
Suitable eye drop base	qs

### ASPIRIN AND CHLOROFORM APPLICATION

Aspirin Soluble tabs 300 mg	12 tabs
Chloroform	to 100 ml

### CODEINE LINCTUS PAEDIATRIC (3 mg per 5 ml)

Codeine phosphate	60 mg
Glycerol	40 ml
Preservative	qs
Water	to 100 ml

### CODEINE LINCTUS DIABETIC (15 mg per 5 ml)

Codeine phosphate	300 mg
Glycerol	40 ml
Preservative	qs
Water	to 100 ml

### FOLINIC MOUTHWASH

Calcium folinate 15 mg tab	1 tab
Preservative	qs
Water	to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

### MAGNESIUM HYDROXIDE 8% MIXTURE

Magnesium hydroxide paste 29%	275 g
Methyl hydroxybenzoate	1.5 g
Water	to 1,000 ml

### METHADONE MIXTURE

Methadone powder	qs
Glycerol	qs
Water	to 100 ml

### METHYL HYDROXYBENZOATE 10% SOLUTION

Methyl hydroxybenzoate	10 g
Propylene glycol	to 100 ml

(Use 1 ml of the 10% solution per 100 ml of oral liquid mixture)

### OMEPRAZOLE SUSPENSION

Omeprazole capules or powder	qs
Sodium bicarbonate powder BP	8.4 g
Water	to 100 ml

### PHENOBARBITONE ORAL LIQUID

Phenobarbitone Sodium	1 g
Glycerol BP	70 ml
Water	to 100 ml

### PHENOBARBITONE SODIUM PAEDIATRIC ORAL LIQUID (10 mg per ml)

Phenobarbitone Sodium	400 mg
Glycerol BP	4 ml
Water	to 40 ml

### PILOCARPINE ORAL LIQUID

Pilocarpine 4% eye drops	qs
Preservative	qs
Water	to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days.)

### SALIVA SUBSTITUTE FORMULA

Methylcellulose	5 g
Preservative	qs
Water	to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

### SODIUM CHLORIDE ORAL LIQUID

Sodium chloride inj 23.4%, 20 ml	qs
Water	qs

(Only funded if prescribed for treatment of hyponatraemia)

### VANCOMYCIN ORAL SOLUTION (50 mg per ml)

Vancomycin 500 mg injection	10 vials
Glycerol BP	40 ml
Water	to 100 ml

(Only funded if prescribed for treatment of Clostridium difficile following metronidazole failure)

### VOSOL EAR DROPS

#### WITH HYDROCORTISONE POWDER 1%

Hydrocortisone powder	1%
Vosol Ear Drops	to 35 ml

Subsidy  
(Manufacturer's Price)  
\$ Per Fully  
Subsidised  
✓ Brand or  
Generic  
Manufacturer

## Extemporaneously Compounded Preparations and Galenicals

### BENZOIN

Tincture compound BP .....	2.44	50 ml	
	(5.10)		Pharmacy Health
	24.42	500 ml	
	(39.90)		Pharmacy Health
	2.44	50 ml	
	(5.93)		Home Essentials

(Home Essentials Tincture compound BP to be delisted 1 December 2015)

### CHLOROFORM – Only in combination

Only in aspirin and chloroform application.

Chloroform BP .....	25.50	500 ml	✓ PSM
---------------------	-------	--------	-------

### CODEINE PHOSPHATE – Safety medicine; prescriber may determine dispensing frequency

Powder – Only in combination .....	12.62	5 g	
	(25.46)		Douglas
	63.09	25 g	
	(90.09)		Douglas

a) Only in extemporaneously compounded codeine linctus diabetic or codeine linctus paediatric.

b) ‡ Safety cap for extemporaneously compounded oral liquid preparations.

### COLLODION FLEXIBLE

Collodion flexible .....	19.30	100 ml	✓ PSM
--------------------------	-------	--------	-------

### COMPOUND HYDROXYBENZOATE – Only in combination

Only in extemporaneously compounded oral mixtures.

Soln .....	30.00	100 ml	✓ Midwest
	34.18		✓ David Craig

### GLYCERIN WITH SODIUM SACCHARIN – Only in combination

Only in combination with Ora-Plus.

Suspension .....	35.50	473 ml	✓ Ora-Sweet SF
------------------	-------	--------	----------------

### GLYCERIN WITH SUCROSE – Only in combination

Only in combination with Ora-Plus.

Suspension .....	35.50	473 ml	✓ Ora-Sweet
------------------	-------	--------	-------------

### GLYCEROL

* Liquid – Only in combination .....	3.71	500 ml	✓ <u>healthE Glycerol BP</u>
--------------------------------------	------	--------	------------------------------

Only in extemporaneously compounded oral liquid preparations.

### MAGNESIUM HYDROXIDE

Paste 29% .....	22.61	500 g	✓ PSM
-----------------	-------	-------	-------

### METHADONE HYDROCHLORIDE

a) Only on a controlled drug form

b) No patient co-payment payable

c) Safety medicine; prescriber may determine dispensing frequency

d) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).

Powder .....	7.84	1 g	✓ AFT
--------------	------	-----	-------

‡ Safety cap for extemporaneously compounded oral liquid preparations.

### METHYL HYDROXYBENZOATE

Powder .....	8.00	25 g	✓ PSM
	8.98		✓ Midwest

# EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>METHYLCELLULOSE</b>				
Powder .....	36.95	100 g	✓	<b>MidWest</b>
Suspension – Only in combination .....	35.50	473 ml	✓	<b>Ora-Plus</b>
<b>METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN – Only in combination</b>				
Suspension .....	35.50	473 ml	✓	<b>Ora-Blend SF</b>
<b>METHYLCELLULOSE WITH GLYCERIN AND SUCROSE – Only in combination</b>				
Suspension .....	35.50	473 ml	✓	<b>Ora-Blend</b>
<b>PHENOBARBITONE SODIUM</b>				
Powder – Only in combination .....	52.50	10 g	✓	<b>MidWest</b>
	325.00	100 g	✓	<b>MidWest</b>
a) Only in children up to 12 years				
b) ‡ Safety cap for extemporaneously compounded oral liquid preparations.				
<b>PROPYLENE GLYCOL</b>				
Only in extemporaneously compounded methyl hydroxybenzoate 10% solution.				
Liq .....	10.50	500 ml	✓	<b>PSM</b>
	11.25		✓	<b>Midwest</b>
<b>SODIUM BICARBONATE</b>				
Powder BP – Only in combination .....	8.95	500 g	✓	<b>Midwest</b>
	9.80			
	(29.50)			David Craig
Only in extemporaneously compounded omeprazole and lansoprazole suspension.				
<b>SYRUP (PHARMACEUTICAL GRADE) – Only in combination</b>				
Only in extemporaneously compounded oral liquid preparations.				
Liq .....	21.75	2,000 ml	✓	<b>Midwest</b>
<b>WATER</b>				
Tap – Only in combination .....	0.00	1 ml	✓	<b>Tap water</b>

## EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

### Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

### Who can apply for Special Authority?

*Initial Applications:* Only from a dietitian, relevant specialist or a vocationally registered general practitioner.

*Reapplications:* Only from a dietitian, relevant specialist or a vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or a vocationally registered general practitioner. Other general practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

All applications must be made on an official form available from the PHARMAC website [www.pharmac.govt.nz](http://www.pharmac.govt.nz). All applications must include specific details as requested on the form relating to the application. Applications must be forwarded to:

Ministry of Health Sector Services  
Private Bag 3015  
WHANGANUI 4540  
Freefax 0800 100 131

### Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

### Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

### Definitions

*Failure to thrive* An inability to gain or maintain weight resulting in physiological impairment.  
*Growth deficiency* Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

**Dietitian Prescribing**

Prescriptions from Dietitians will be only valid for subsidy where they are for special foods, as listed in this section, or where they are for the following products:

**ASCORBIC ACID**

- ✓ Tab 100 mg

**CALCIUM CARBONATE**

- ✓ Tab eff 1.75 g (1 g elemental)
- ✓ Tab 1.25 g (500 mg elemental)

**COMPOUND ELECTROLYTES**

- ✓ Powder for oral soln

**DEXTROSE WITH ELECTROLYTES**

- ✓ Soln with electrolytes

**FERROUS FUMARATE**

- ✓ Tab 200 mg (65 mg elemental)

**FERROUS FUMARATE WITH FOLIC ACID**

- ✓ Tab 310 mg (100 mg elemental) with folic acid 350 mcg

**FERROUS SULPHATE**

- ✓ Tab long-acting 325 mg (105 mg elemental)
- ✓ Oral liq 30 mg (6 mg elemental) per 1 ml

**FERROUS SULPHATE WITH FOLIC ACID**

- Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg

**FOLIC ACID**

- ✓ Tab 0.8 mg

**MULTIVITAMINS**

- ✓ Powder

**PANCREATIC ENZYME**

- ✓ Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease

**PHOSPHORUS**

- ✓ Tab eff 500 mg (16 mmol)

**POTASSIUM CHLORIDE**

- Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)
- ✓ Tab long-acting 600 mg (8 mmol)

**POTASSIUM IODATE**

- ✓ Tab 253 mcg (150 mcg elemental iodine)

**PYRIDOXINE HYDROCHLORIDE**

- ✓ Tab 25 mg
- ✓ Tab 50 mg

**SODIUM CHLORIDE**

- ✓ Inj 23.4%, 20 ml ampoule

**SODIUM FLUORIDE**

- ✓ Tab 1.1 mg (0.5 mg elemental)

**THIAMINE HYDROCHLORIDE**

- ✓ Tab 50 mg

**VITAMIN A WITH VITAMINS D AND C**

- ✓ Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops

**VITAMIN B COMPLEX**

- ✓ Tab, strong, BPC

**VITAMINS**

- ✓ Tab (BPC cap strength)
- ✓ Cap (fat soluble vitamins A, D, E, K)

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## Nutrient Modules

### Carbohydrate

#### ►SA1522 Special Authority for Subsidy

**Initial application — (Cystic fibrosis or kidney disease)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Either:

- 1 cystic fibrosis; or
- 2 chronic kidney disease.

**Initial application — (Indications other than cystic fibrosis or renal failure)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 faltering growth in an infant/child; or
- 4 bronchopulmonary dysplasia; or
- 5 premature and post premature infant; or
- 6 inborn errors of metabolism; or
- 7 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**Renewal — (Cystic fibrosis or renal failure)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

**Renewal — (Indications other than cystic fibrosis or renal failure)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT – Special Authority see SA1522 above – Hospital pharmacy [HP3]

Powder ..... 5.29      400 g OP      ✓ Polycal

### Carbohydrate And Fat

#### ►SA1376 Special Authority for Subsidy

**Initial application — (Cystic fibrosis)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 Infant or child aged four years or under; and
- 2 cystic fibrosis.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

**Initial application — (Indications other than cystic fibrosis)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 infant or child aged four years or under; and
- 2 Any of the following:
  - 2.1 cancer in children; or
  - 2.2 faltering growth; or
  - 2.3 bronchopulmonary dysplasia; or
  - 2.4 premature and post premature infants.

**Renewal — (Cystic fibrosis)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

**Renewal — (Indications other than cystic fibrosis)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

**CARBOHYDRATE AND FAT SUPPLEMENT** – Special Authority see SA1376 on the previous page – Hospital pharmacy [HP3]

Powder (neutral) .....	60.31	400 g OP	✓ Duocal Super Soluble Powder
------------------------	-------	----------	-------------------------------

## Fat

### ►SA1523 Special Authority for Subsidy

**Initial application — (Inborn errors of metabolism)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

**Initial application — (Indications other than inborn errors of metabolism)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 faltering growth in an infant/child; or
- 2 bronchopulmonary dysplasia; or
- 3 fat malabsorption; or
- 4 lymphangiectasia; or
- 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliary atresia; or
- 8 for use in a ketogenic diet; or
- 9 chyle leak; or
- 10 acites; or
- 11 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

continued...



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**Renewal — (Inborn errors of metabolism)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner.

Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

**Renewal — (Indications other than inborn errors of metabolism)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT – Special Authority see SA1523 on the previous page – Hospital pharmacy [HP3]

Emulsion (neutral) .....	12.30	200 ml OP	✓ Calogen
	30.75	500 ml OP	✓ Calogen
Emulsion (strawberry) .....	12.30	200 ml OP	✓ Calogen
Oil .....	30.00	500 ml OP	✓ MCT oil (Nutricia)
Oil, 250 ml .....	114.92	4 OP	✓ Liquigen

## Protein

### ►SA1524 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT – Special Authority see SA1524 above – Hospital pharmacy [HP3]

Powder .....	7.90	225 g OP	✓ Protifar
	8.95	227 g OP	✓ Resource Beneprotein
Powder (vanilla) .....	12.90	275 g OP	✓ Promod

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

### Respiratory Products

#### ►SA1094 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia, defined as a CO<sub>2</sub> value exceeding 55 mmHg.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CORD ORAL FEED 1.5KCAL/ML – Special Authority see SA1094 above – Hospital pharmacy [HP3]

Liquid .....	1.66	237 ml OP	✓ Pulmocare
--------------	------	-----------	-------------

### Diabetic Products

#### ►SA1095 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1095 above – Hospital pharmacy [HP3]

Liquid .....	7.50	1,000 ml OP	✓ Diason RTH ✓ Glucerna Select RTH
--------------	------	-------------	--

DIABETIC ORAL FEED 1KCAL/ML – Special Authority see SA1095 above – Hospital pharmacy [HP3]

Liquid (strawberry) .....	1.50	200 ml OP	✓ Diasip
Liquid (vanilla) .....	1.50	200 ml OP	✓ Diasip
	1.88	250 ml OP	✓ Glucerna Select
	1.78	237 ml OP	
	(2.10)		Resource Diabetic
	(2.10)		Sustagen Diabetic

### Fat Modified Products

#### ►SA1525 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued. . .

- 3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED – Special Authority see SA1525 on the previous page – Hospital pharmacy [HP3]

Powder ..... 60.48      400 g OP      ✓ **Monogen**

## High Protein Products

### ▶▶SA1378 | Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 decompensating liver disease without encephalopathy; or
- 2 protein losing gastro-enteropathy.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

HIGH PROTEIN ORAL FEED 1KCAL/ML – Special Authority see SA1378 above – Hospital pharmacy [HP3]

Liquid ..... 1.90      200 ml OP      ✓ **Fortimel Regular**

(Fortimel Regular Liquid to be delisted 1 September 2015)

## Paediatric Products For Children Awaiting Liver Transplant

### ▶▶SA1098 | Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1098 above – Hospital pharmacy [HP3]

Powder (unflavoured) ..... 78.97      400 g OP      ✓ **Heparon Junior**

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## Paediatric Products For Children With Chronic Renal Failure

### ►SA1099 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1099 above – Hospital pharmacy [HP3]

Liquid .....	54.00	400 g OP	✓ <b>Kindergen</b>
--------------	-------	----------	--------------------

## Paediatric Products

### ►SA1379 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
  - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
  - 2.2 any condition causing malabsorption; or
  - 2.3 faltering growth in an infant/child; or
  - 2.4 increased nutritional requirements; or
  - 2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]

Liquid .....	2.68	500 ml OP	✓ <b>Nutrini RTH</b> ✓ <b>Pediasure RTH</b>
--------------	------	-----------	--

PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]

Liquid .....	6.00	500 ml OP	✓ <b>Nutrini Energy Multi Fibre</b> ✓ <b>Nutrini Energy RTH</b>
--------------	------	-----------	--

PAEDIATRIC ORAL FEED – Special Authority see SA1379 above – Hospital pharmacy [HP3]

Powder (vanilla) .....	20.00	850 g OP	✓ <b>Pediasure</b>
------------------------	-------	----------	--------------------

PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]

Liquid (strawberry) .....	1.60	200 ml OP	✓ <b>Fortini</b>
Liquid (vanilla) .....	1.60	200 ml OP	✓ <b>Fortini</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid (chocolate) .....	1.07	200 ml OP	✓	Pediasure
Liquid (strawberry) .....	1.07	200 ml OP	✓	Pediasure
Liquid (vanilla) .....	1.07	200 ml OP	✓	Pediasure
	1.34	250 ml OP	✓	Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid (chocolate) .....	1.60	200 ml OP	✓	Fortini Multi Fibre
Liquid (strawberry) .....	1.60	200 ml OP	✓	Fortini Multi Fibre
Liquid (vanilla) .....	1.60	200 ml OP	✓	Fortini Multi Fibre

## Renal Products

### ►SA1101 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic kidney disease.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
  - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

RENAL ENTERAL FEED 1.8 KCAL/ML – Special Authority see SA1101 above – Hospital pharmacy [HP3]

Liquid .....	6.08	500 ml OP	✓	Nepro HP RTH
--------------	------	-----------	---	--------------

RENAL ORAL FEED 1.8 KCAL/ML – Special Authority see SA1101 above – Hospital pharmacy [HP3]

Liquid .....	2.67	220 ml OP	✓	Nepro HP (strawberry)
			✓	Nepro HP (vanilla)

RENAL ORAL FEED 2 KCAL/ML – Special Authority see SA1101 above – Hospital pharmacy [HP3]

Liquid .....	2.88	237 ml OP		
	(3.31)			NovaSource Renal
Liquid (apricot) 125 ml .....	11.52	4 OP	✓	Renilon 7.5
Liquid (caramel) 125 ml .....	11.52	4 OP	✓	Renilon 7.5

## Specialised And Elemental Products

### ►SA1377 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
- 4 eosinophilic oesophagitis; or
- 5 inflammatory bowel disease; or
- 6 patients with multiple food allergies requiring enteral feeding.

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

continued. . .

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA1377 on the previous page – Hospital pharmacy [HP3]

Powder .....	4.40	79 g OP	✓ <b>Vital HN</b>
	7.50	76 g OP	✓ <b>Alitraq</b>

ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see SA1377 on the previous page – Hospital pharmacy [HP3]

Liquid (grapefruit), 250 ml carton .....	171.00	18 OP	✓ <b>Elemental 028 Extra</b>
Liquid (pineapple & orange), 250 ml carton .....	171.00	18 OP	✓ <b>Elemental 028 Extra</b>
Liquid (summer fruits), 250 ml carton .....	171.00	18 OP	✓ <b>Elemental 028 Extra</b>

ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA1377 on the previous page – Hospital pharmacy [HP3]

Powder (unflavoured) .....	4.50	80.4 g OP	✓ <b>Vivonex TEN</b>
----------------------------	------	-----------	----------------------

SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authority see SA1377 on the previous page – Hospital pharmacy [HP3]

Liquid .....	12.04	1,000 ml OP	✓ <b>Peptisorb</b>
--------------	-------	-------------	--------------------

## Paediatric Products For Children With Low Energy Requirements

### ►►SA1196 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML – Special Authority see SA1196 above – Hospital pharmacy [HP3]

Liquid .....	4.00	500 ml OP	✓ <b>Nutrini Low Energy Multi Fibre</b>
--------------	------	-----------	---

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

## Standard Supplements

### ►SA1228 | Special Authority for Subsidy

**Initial application — (Children)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
  - 2.1 The patient has a condition causing malabsorption; or
  - 2.2 The patient has failure to thrive; or
  - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

**Renewal — (Children)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

**Initial application — (Adults)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 

Patient is Malnourished

  - 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m<sup>2</sup>; or
  - 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
  - 1.3 Patient has a BMI of less than 20 kg/m<sup>2</sup> and unintentional weight loss greater than 5% within the last 3-6 months; and
- 2 Any of the following:
 

Patient has not responded to first-line dietary measures over a 4 week period by:

  - 2.1 Increasing their food intake frequency (eg snacks between meals); or
  - 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
  - 2.3 Using over the counter supplements (e.g. Complan); and
- 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

**Renewal — (Adults)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 2 Any of the following:
 

Patient is Malnourished

  - 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m<sup>2</sup>; or
  - 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
  - 2.3 Patient has a BMI of less than 20 kg/m<sup>2</sup> and unintentional weight loss greater than 5% within the last 3-6 months.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

**Initial application — (Adults transitioning from hospital Discretionary Community Supply)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has had up to a 30 day supply of a 1.0 or a 1.5 kcal/ml Standard Oral Supplement; and
- 2 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 3 Any of the following:
  - Patient is Malnourished
  - 3.1 Patient has a body mass index (BMI) of less than 18.5 kg/m<sup>2</sup>; or
  - 3.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
  - 3.3 Patient has a BMI of less than 20 kg/m<sup>2</sup> and unintentional weight loss greater than 5% within the last 3-6 months.

**Initial application — (Short-term medical condition)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
  - 5.1 Pregnant; and
  - 5.2 Any of the following:
    - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
    - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
    - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

**Renewal — (Short-term medical condition)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
  - 5.1 Pregnant; and
  - 5.2 Any of the following:
    - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
    - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
    - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

continued...



Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

**Initial application — (Long-term medical condition)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions; or
- 10 Epidermolysis bullosa; or
- 11 AIDS (CD4 count < 200 cells/mm<sup>3</sup>); or
- 12 Chronic pancreatitis.

**Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1228 on page 223 – Hospital pharmacy [HP3]

Liquid .....	7.00	1,000 ml OP	✓ <b>Nutrison Energy</b>
--------------	------	-------------	--------------------------

ENTERAL FEED 1KCAL/ML – Special Authority see SA1228 on page 223 – Hospital pharmacy [HP3]

Liquid .....	1.24	250 ml OP	✓ <b>Isosource Standard</b>
			✓ <b>Osmolite</b>
	5.29	1,000 ml OP	✓ <b>Isosource Standard RTH</b>
			✓ <b>Nutrison Standard RTH</b>
	2.65	500 ml OP	✓ <b>Osmolite RTH</b>
	5.29	1,000 ml OP	✓ <b>Osmolite RTH</b>

ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1228 on page 223 – Hospital pharmacy [HP3]

Liquid .....	1.32	237 ml OP	✓ <b>Jevity</b>
	2.65	500 ml OP	✓ <b>Jevity RTH</b>
	5.29	1,000 ml OP	✓ <b>Jevity RTH</b>
			✓ <b>Nutrison Multi Fibre</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1228 on page 223 – Hospital pharmacy [HP3]				
Liquid .....	1.75	250 ml OP	✓	<b>Ensure Plus HN</b>
	7.00	1,000 ml OP	✓	<b>Ensure Plus RTH</b>
			✓	<b>Jevity HiCal RTH</b>
			✓	<b>Nutrison Energy Multi Fibre</b>
ORAL FEED (POWDER) – Special Authority see SA1228 on page 223 – Hospital pharmacy [HP3]				
Note: Higher subsidy for Sustagen Hospital Formula will only be reimbursed for patients with both a valid Special Authority number and an appropriately endorsed prescription.				
Powder (chocolate) – Higher subsidy of up to \$14.90 per				
900 g with Endorsement.....	13.00	850 g OP	✓	<b>Ensure</b>
	10.22	900 g OP		
	(14.90)			Sustagen Hospital Formula
Additional subsidy by endorsement is available for patients with fat malabsorption, fat intolerance or chyle leak. The prescription must be endorsed accordingly.				
Powder (vanilla) – Higher subsidy of up to \$14.90 per 900 g				
with Endorsement.....	3.67	350 g OP	✓	<b>Fortisip</b>
	13.00	850 g OP	✓	<b>Ensure</b>
	10.22	900 g OP		
	(14.90)			Sustagen Hospital Formula
Additional subsidy by endorsement is available for patients with fat malabsorption, fat intolerance or chyle leak. The prescription must be endorsed accordingly.				

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

# ORAL FEED 1.5KCAL/ML – Special Authority see SA1228 on page 223 – Hospital pharmacy [HP3]

Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.

Liquid (banana) – Higher subsidy of \$1.26 per 200 ml with

Endorsement .....	0.72	200 ml OP	
	(1.26)		Ensure Plus
	(1.26)		Fortisip

Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 ml

with Endorsement.....	0.72	200 ml OP	
	(1.26)		Ensure Plus
	0.85	237 ml OP	
	(1.33)		Ensure Plus
	0.72	200 ml OP	
	(1.26)		Fortisip

Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml

with Endorsement.....	0.72	200 ml OP	
	(1.26)		Ensure Plus

Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with

Endorsement .....	0.72	200 ml OP	
	(1.26)		Ensure Plus
	(1.26)		Fortisip

Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with

Endorsement .....	0.72	200 ml OP	
	(1.26)		Fortisip

Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml

with Endorsement.....	0.72	200 ml OP	
	(1.26)		Fortisip

Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml

with Endorsement.....	0.72	200 ml OP	
	(1.26)		Ensure Plus
	0.85	237 ml OP	
	(1.33)		Ensure Plus
	0.72	200 ml OP	
	(1.26)		Fortisip

*(Fortisip Liquid (toffee) to be delisted 1 September 2015)*

*(Fortisip Liquid (tropical fruit) to be delisted 1 September 2015)*

# ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1228 on page 223 – Hospital pharmacy [HP3]

Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.

Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with

Endorsement .....	0.72	200 ml OP	
	(1.26)		Fortisip Multi Fibre

Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with

Endorsement .....	0.72	200 ml OP	
	(1.26)		Fortisip Multi Fibre

Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml with

Endorsement.....	0.72	200 ml OP	
	(1.26)		Fortisip Multi Fibre

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## High Calorie Products

### ►SA1195 Special Authority for Subsidy

**Initial application — (Cystic fibrosis)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

**Initial application — (Indications other than cystic fibrosis)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
  - 1.1 any condition causing malabsorption; or
  - 1.2 faltering growth in an infant/child; or
  - 1.3 increased nutritional requirements; or
  - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

**Renewal — (Cystic fibrosis)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

**Renewal — (Indications other than cystic fibrosis)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL FEED 2 KCAL/ML – Special Authority see SA1195 above – Hospital pharmacy [HP3]

Liquid .....	5.50	500 ml OP	✓ <b>Nutrison Concentrated</b>
	11.00	1,000 ml OP	✓ <b>Two Cal HN RTH</b>

ORAL FEED 2 KCAL/ML – Special Authority see SA1195 above – Hospital pharmacy [HP3]

Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.

Liquid (vanilla) – Higher subsidy of \$1.90 per 200 ml with		
Endorsement .....	0.96 (1.90)	200 ml OP  Two Cal HN

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## Food Thickeners

### ▶▶SA1106 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
  - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FOOD THICKENER – Special Authority see SA1106 above – Hospital pharmacy [HP3]

Powder .....	6.53	300 g OP	✓ Nutilis
	7.25	380 g OP	✓ Feed Thickener Karicare Aptamil

## Gluten Free Foods

The funding of gluten free foods is no longer being actively managed by PHARMAC from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.

### ▶▶SA1107 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Either:
- 1 Gluten enteropathy has been diagnosed by biopsy; or
  - 2 Patient suffers from dermatitis herpetiformis.

GLUTEN FREE BAKING MIX – Special Authority see SA1107 above – Hospital pharmacy [HP3]

Powder .....	2.81	1,000 g OP	Healthieries Simple Baking Mix
	(5.15)		

GLUTEN FREE BREAD MIX – Special Authority see SA1107 above – Hospital pharmacy [HP3]

Powder .....	3.93	1,000 g OP	NZB Low Gluten Bread Mix
	(7.32)		
	4.77		Bakels Gluten Free Health Bread Mix
	(8.71)		
	3.51		Horleys Bread Mix
	(10.87)		

GLUTEN FREE FLOUR – Special Authority see SA1107 above – Hospital pharmacy [HP3]

Powder .....	5.62	2,000 g OP	Horleys Flour
	(18.10)		

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
GLUTEN FREE PASTA – Special Authority see SA1107 on the previous page – Hospital pharmacy [HP3]				
Buckwheat Spirals .....	2.00 (3.11)	250 g OP		Orgran
Corn and Vegetable Shells .....	2.00 (2.92)	250 g OP		Orgran
Corn and Vegetable Spirals .....	2.00 (2.92)	250 g OP		Orgran
Rice and Corn Lasagne Sheets .....	1.60 (3.82)	200 g OP		Orgran
Rice and Corn Macaroni .....	2.00 (2.92)	250 g OP		Orgran
Rice and Corn Penne .....	2.00 (2.92)	250 g OP		Orgran
Rice and Maize Pasta Spirals .....	2.00 (2.92)	250 g OP		Orgran
Rice and Millet Spirals .....	2.00 (3.11)	250 g OP		Orgran
Rice and corn spaghetti noodles .....	2.00 (2.92)	375 g OP		Orgran
Vegetable and Rice Spirals .....	2.00 (2.92)	250 g OP		Orgran
Italian long style spaghetti .....	2.00 (3.11)	220 g OP		Orgran

## Foods And Supplements For Inborn Errors Of Metabolism

### ►SA1108 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Dietary management of homocystinuria; or
- 2 Dietary management of maple syrup urine disease; or
- 3 Dietary management of phenylketonuria (PKU); or
- 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

## Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA1108 above – Hospital pharmacy [HP3]  
Powder .....461.94 500 g OP ✓ **XMET Maxamum**

## Supplements For MSUD

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA1108 above – Hospital pharmacy [HP3]  
Powder .....300.54 500 g OP ✓ **MSUD Maxamaid**  
437.22 ✓ **MSUD Maxamum**

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

## Supplements For PKU

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 on the previous page – Hospital pharmacy [HP3]

Tabs .....	99.00	75 OP	✓ Phlexy 10
Powder (unflavoured) 29 g sachets .....	330.12	30	✓ PKU Anamix Junior
Infant formula .....	174.72	400 g OP	✓ PKU Anamix Infant
Powder (orange) .....	221.00	500 g OP	✓ XP Maxamaid
	320.00		✓ XP Maxamum
Powder (unflavoured) .....	221.00	500 g OP	✓ XP Maxamaid
	320.00		✓ XP Maxamum
Liquid (berry) .....	13.10	125 ml OP	✓ PKU Anamix Junior LQ
Liquid (orange) .....	13.10	125 ml OP	✓ PKU Anamix Junior LQ
Liquid (unflavoured) .....	13.10	125 ml OP	✓ PKU Anamix Junior LQ
Liquid (forest berries), 250 ml carton .....	540.00	18 OP	✓ Easiphen Liquid
Liquid (juicy berries) 62.5 ml .....	939.00	60 OP	✓ PKU Lophlex LQ 10
Liquid (juicy citrus) 62.5 ml .....	939.00	60 OP	✓ PKU Lophlex LQ 10
Liquid (juicy orange) 62.5 ml .....	939.00	60 OP	✓ PKU Lophlex LQ 10
Liquid (juicy berries) 125 ml .....	936.00	30 OP	✓ PKU Lophlex LQ 20
Liquid (juicy citrus) 125 ml .....	936.00	30 OP	✓ PKU Lophlex LQ 20
Liquid (juicy orange) 125 ml .....	936.00	30 OP	✓ PKU Lophlex LQ 20

## Foods

LOW PROTEIN BAKING MIX – Special Authority see SA1108 on the previous page – Hospital pharmacy [HP3]

Powder .....	8.22	500 g OP	✓ Loprofin Mix
--------------	------	----------	----------------

LOW PROTEIN PASTA – Special Authority see SA1108 on the previous page – Hospital pharmacy [HP3]

Animal shapes .....	11.91	500 g OP	✓ Loprofin
Lasagne .....	5.95	250 g OP	✓ Loprofin
Low protein rice pasta .....	11.91	500 g OP	✓ Loprofin
Macaroni .....	5.95	250 g OP	✓ Loprofin
Penne .....	11.91	500 g OP	✓ Loprofin
Spaghetti .....	11.91	500 g OP	✓ Loprofin
Spirals .....	11.91	500 g OP	✓ Loprofin

## Infant Formulae

### For Premature Infants

PRETERM POST-DISCHARGE INFANT FORMULA – Special Authority see SA1198 on the next page – Hospital pharmacy [HP3]

Powder .....	15.25	400 g OP	✓ S-26 Gold Premgro
--------------	-------	----------	---------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

## ►SA1198 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth; and
- 2 Either:
  - 2.1 The infant has faltering growth (downward crossing of percentiles); or
  - 2.2 The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula.

## For Williams Syndrome

## ►SA1110 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA – Special Authority see SA1110 above – Hospital pharmacy [HP3]

Powder .....	44.40	400 g OP	✓ Locasol
--------------	-------	----------	-----------

## Gastrointestinal and Other Malabsorptive Problems

AMINO ACID FORMULA – Special Authority see SA1219 below – Hospital pharmacy [HP3]

Powder .....	6.00	48.5 g OP	✓ Vivonex Pediatric
	53.00	400 g OP	✓ Neocate LCP
Powder (unflavoured) .....	53.00	400 g OP	✓ Elecare
			✓ Elecare LCP
			✓ Neocate Advance
			✓ Neocate Gold
Powder (vanilla) .....	53.00	400 g OP	✓ Elecare
			✓ Neocate Advance

## ►SA1219 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

Note: A reasonable trial is defined as a 2-4 week trial.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

continued...



Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

EXTENSIVELY HYDROLYSED FORMULA – Special Authority see SA1380 below – Hospital pharmacy [HP3]

Powder ..... 15.21 450 g OP ✓ **Pepti Junior Gold**  
**Karicare Aptamil**

#### ►SA1380 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
  - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
  - 1.2 Either:
    - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
    - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malabsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure.

Note: A reasonable trial is defined as a 2-4 week trial.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

**Renewal — (Step Down from Amino Acid Formula)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The infant is currently receiving funded amino acid formula; and
- 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

## Ketogenic Diet

### ►SA1197 Special Authority for Subsidy

**Initial application** only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

**Renewal** only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA – Special Authority see SA1197 above – Retail pharmacy

Powder (unflavoured) .....	35.50	300 g OP	✓ KetoCal 4:1
Powder (vanilla) .....	35.50	300 g OP	✓ Ketocal 3:1
			✓ KetoCal 4:1

### Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order

<b>ADRENALINE</b>	
✓ Inj 1 in 1,000, 1 ml ampoule.....	5
✓ Inj 1 in 10,000, 10 ml ampoule.....	5
<b>AMINOPHYLLINE</b>	
✓ Inj 25 mg per ml, 10 ml ampoule .....	5
<b>AMIODARONE HYDROCHLORIDE</b>	
✓ Inj 50 mg per ml, 3 ml ampoule .....	6
<b>AMOXICILLIN</b>	
✓ Cap 250 mg .....	30
✓ Cap 500 mg .....	30
✓ Grans for oral liq 125 mg per 5 ml .....	200 ml
✓ Grans for oral liq 250 mg per 5 ml .....	300 ml
✓ Inj 1 g vial.....	5
<b>AMOXICILLIN WITH CLAVULANIC ACID</b>	
✓ Tab 500 mg with clavulanic acid 125 mg .....	30
✓ Grans for oral liq amoxicillin 125 mg with clavulanic acid 31.25 mg per 5 ml.....	200 ml
✓ Grans for oral liq amoxicillin 250 mg with clavulanic acid 62.5 mg per 5 ml .....	200 ml
<b>ASPIRIN</b>	
✓ Tab dispersible 300 mg.....	30
<b>ATROPINE SULPHATE</b>	
✓ Inj 600 mcg per ml, 1 ml ampoule.....	5
<b>AZITHROMYCIN</b>	
✓ Tab 500 mg – See note on page 92.....	8
<b>BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]</b>	
✓ Tab 2.5 mg – See note on page 56.....	150
<b>BENZATHINE BENZYLPENICILLIN</b>	
✓ Inj 900 mg (1.2 million units) in 2.3 ml syringe.....	5
<b>BENZTROPINE MESYLATE</b>	
✓ Inj 1 mg per ml, 2 ml .....	5
<b>BENZYLPENICILLIN SODIUM (PENICILLIN G)</b>	
✓ Inj 600 mg (1 million units) vial .....	5
<b>BLOOD GLUCOSE DIAGNOSTIC TEST METER</b>	
✓ Meter with 50 lancets, a lancing device and 10 diagnostic test strips – Subsidy by endorsement – See note on page 26 .....	1
<b>BLOOD GLUCOSE DIAGNOSTIC TEST STRIP</b>	
✓ Blood glucose test strips – See note on page 26 .....	50 test
<b>BLOOD KETONE DIAGNOSTIC TEST METER</b>	
✓ Meter – See note on page 25 .....	1
<b>CEFTRIAXONE</b>	
✓ Inj 500 mg vial – Subsidy by endorsement – See note on page 91 .....	5
✓ Inj 1 g vial – Subsidy by endorsement – See note on page 91 .....	5
<b>CHARCOAL</b>	
✓ Oral liq 50 g per 250 ml .....	250 ml
<b>CHLORPROMAZINE HYDROCHLORIDE</b>	
✓ Tab 10 mg .....	30
✓ Tab 25 mg .....	30
✓ Tab 100 mg .....	30
✓ Inj 25 mg per ml, 2 ml .....	5
<b>CIPROFLOXACIN</b>	
✓ Tab 250 mg – See note on page 95.....	5
✓ Tab 500 mg – See note on page 95.....	5
<b>CO-TRIMOXAZOLE</b>	
✓ Tab trimethoprim 80 mg and sulphamethoxazole 400 mg.....	30
✓ Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml.....	200 ml
<b>COMPOUND ELECTROLYTES</b>	
✓ Powder for oral soln .....	10
<b>CONDOMS</b>	
✓ 49 mm.....	144
✓ 52 mm.....	144
✓ 52 mm extra strength .....	144
✓ 53 mm.....	144
✓ 53 mm (chocolate) .....	144
✓ 53 mm (strawberry).....	144
54 mm, shaped.....	144
✓ 55 mm.....	144
✓ 56 mm.....	144
✓ 56 mm, shaped.....	144
✓ 60 mm.....	144
<b>CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL</b>	
✓ Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs.....	168
<b>DEXAMETHASONE</b>	
✓ Tab 1 mg – Retail pharmacy-Specialist .....	30
✓ Tab 4 mg – Retail pharmacy-Specialist .....	30
<b>DEXAMETHASONE PHOSPHATE</b>	
✓ Inj 4 mg per ml, 1 ml ampoule – See note on page 79 .....	5

continued...

(continued)

- ✓ Inj 4 mg per ml, 2 ml ampoule – See note on page 79 ..... 5

## DIAPHRAGM

- ✓ 65 mm – See note on page 73 ..... 1
- ✓ 70 mm – See note on page 73 ..... 1
- ✓ 75 mm – See note on page 73 ..... 1
- ✓ 80 mm – See note on page 73 ..... 1

## DIAZEPAM

- ✓ Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement – See note on page 133 ..... 5
- ✓ Rectal tubes 5 mg ..... 5
- ✓ Rectal tubes 10 mg ..... 5

## DICLOFENAC SODIUM

- ✓ Inj 25 mg per ml, 3 ml ampoule ..... 5
- ✓ Suppos 50 mg ..... 10

## DIGOXIN

- ✓ Tab 62.5 mcg ..... 30
- ✓ Tab 250 mcg ..... 30

## DOXYCYCLINE

- Tab 50 mg ..... 30
- ✓ Tab 100 mg ..... 30

## ERGOMETRINE MALEATE

- ✓ Inj 500 mcg per ml, 1 ml ampoule ..... 5

## ERYTHROMYCIN ETHYL SUCCINATE

- ✓ Tab 400 mg ..... 20
- ✓ Grans for oral liq 200 mg per 5 ml ..... 300 ml
- ✓ Grans for oral liq 400 mg per 5 ml ..... 200 ml

## ERYTHROMYCIN STEARATE

- Tab 250 mg ..... 30

## ETHINYLLOESTRADIOL WITH DESOGESTREL

- Tab 20 mcg with desogestrel 150 mcg and 7 inert tab ..... 84
- Tab 30 mcg with desogestrel 150 mcg and 7 inert tab ..... 84

## ETHINYLLOESTRADIOL WITH LEVONORGESTREL

- ✓ Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab ..... 84
- ✓ Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab ..... 84
- Tab 30 mcg with levonorgestrel 150 mcg ..... 63
- ✓ Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab ..... 84

## ETHINYLLOESTRADIOL WITH NORETHISTERONE

- ✓ Tab 35 mcg with norethisterone 1 mg ..... 63

- ✓ Tab 35 mcg with norethisterone 1 mg and 7 inert tab ..... 84
- ✓ Tab 35 mcg with norethisterone 500 mcg ..... 63
- ✓ Tab 35 mcg with norethisterone 500 mcg and 7 inert tab ..... 84

## FLUCLOXACILLIN

- ✓ Cap 250 mg ..... 30
- ✓ Grans for oral liq 25 mg per ml ..... 200 ml
- ✓ Grans for oral liq 50 mg per ml ..... 200 ml
- ✓ Inj 1 g vial ..... 10

## FLUPENTHIXOL DECANOATE

- ✓ Inj 20 mg per ml, 1 ml ..... 5
- ✓ Inj 20 mg per ml, 2 ml ..... 5
- ✓ Inj 100 mg per ml, 1 ml ..... 5

## FLUPHENAZINE DECANOATE

- ✓ Inj 12.5 mg per 0.5 ml, 0.5 ml ..... 5
- ✓ Inj 25 mg per ml, 1 ml ..... 5
- ✓ Inj 100 mg per ml, 1 ml ..... 5

## FUROSEMIDE [FRUSEMIDE]

- ✓ Tab 40 mg ..... 30
- ✓ Inj 10 mg per ml, 2 ml ampoule ..... 5

## GLUCAGON HYDROCHLORIDE

- ✓ Inj 1 mg syringe kit ..... 5

## GLUCOSE [DEXTROSE]

- ✓ Inj 50%, 10 ml ampoule ..... 5
- ✓ Inj 50%, 90 ml bottle ..... 5

## GLYCERYL TRINITRATE

- ✓ Tab 600 mcg ..... 100
- ✓ Oral pump spray, 400 mcg per dose ..... 250 dose
- ✓ Oral spray, 400 mcg per dose ..... 250 dose

## GLYCOPYRRONIUM BROMIDE

- ✓ Inj 200 mcg per ml, 1 ml ampoule ..... 10

## HALOPERIDOL

- ✓ Tab 500 mcg ..... 30
- ✓ Tab 1.5 mg ..... 30
- ✓ Tab 5 mg ..... 30
- ✓ Oral liq 2 mg per ml ..... 200 ml
- ✓ Inj 5 mg per ml, 1 ml ..... 5

## HALOPERIDOL DECANOATE

- ✓ Inj 50 mg per ml, 1 ml ..... 5
- ✓ Inj 100 mg per ml, 1 ml ..... 5

## HYDROCORTISONE

- ✓ Inj 100 mg vial ..... 5

## HYDROXOCOBALAMIN

- ✓ Inj 1 mg per ml, 1 ml ampoule ..... 6

continued...

(continued)

<b>HYOSCIINE N-BUTYLBROMIDE</b>	
✓ Inj 20 mg, 1 ml .....	5
<b>INTRA-UTERINE DEVICE</b>	
✓ IUD 29.1 mm length × 23.2 mm width .....	40
✓ IUD 33.6 mm length × 29.9 mm width .....	40
<b>IPRATROPIUM BROMIDE</b>	
✓ Nebuliser soln, 250 mcg per ml, 1 ml .....	40
✓ Nebuliser soln, 250 mcg per ml, 2 ml .....	40
<b>IVERMECTIN</b>	
✓ Tab 3 mg – See note on page 68 .....	100
<b>KETONE BLOOD BETA-KETONE ELECTRODES</b>	
✓ Test strip .....	10
<b>LEVONORGESTREL</b>	
Tab 30 mcg .....	84
✓ Tab 1.5 mg .....	5
<b>LIDOCAINE [LIGNOCAINE]</b>	
✓ Gel 2%, 10 ml urethral syringe – Subsidy by endorsement – See note on page 125 .....	5
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE</b>	
✓ Inj 1%, 5 ml ampoule .....	25
✓ Inj 2%, 5 ml ampoule .....	5
✓ Inj 1%, 20 ml ampoule .....	5
✓ Inj 2%, 20 ml ampoule .....	5
<b>LIDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE</b>	
✓ Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Subsidy by endorsement – See note on page 126 .....	5
<b>LOPERAMIDE HYDROCHLORIDE</b>	
✓ Tab 2 mg .....	30
✓ Cap 2 mg .....	30
<b>MASK FOR SPACER DEVICE</b>	
✓ Size 2 – See note on page 199 .....	20
<b>MEDROXYPROGESTERONE ACETATE</b>	
✓ Inj 150 mg per ml, 1 ml syringe .....	5
<b>METOCLOPRAMIDE HYDROCHLORIDE</b>	
✓ Inj 5 mg per ml, 2 ml ampoule .....	5
<b>METRONIDAZOLE</b>	
✓ Tab 200 mg .....	30
<b>MORPHINE SULPHATE</b>	
✓ Inj 5 mg per ml, 1 ml ampoule – Only on a controlled drug form .....	5
✓ Inj 10 mg per ml, 1 ml ampoule – Only on a controlled drug form .....	5

✓ Inj 15 mg per ml, 1 ml ampoule – Only on a controlled drug form .....	5
✓ Inj 30 mg per ml, 1 ml ampoule – Only on a controlled drug form .....	5
<b>NALOXONE HYDROCHLORIDE</b>	
✓ Inj 400 mcg per ml, 1 ml ampoule .....	5
<b>NICOTINE</b>	
✓ Patch 7 mg – See note on page 156 .....	28
✓ Patch 14 mg – See note on page 156 .....	28
✓ Patch 21 mg – See note on page 156 .....	28
✓ Lozenge 1 mg – See note on page 156 .....	216
✓ Lozenge 2 mg – See note on page 156 .....	216
✓ Gum 2 mg (Classic) – See note on page 156 .....	384
✓ Gum 2 mg (Fruit) – See note on page 156 .....	384
✓ Gum 2 mg (Mint) – See note on page 156 .....	384
✓ Gum 4 mg (Classic) – See note on page 156 .....	384
✓ Gum 4 mg (Fruit) – See note on page 156 .....	384
✓ Gum 4 mg (Mint) – See note on page 156 .....	384
<b>NORETHISTERONE</b>	
✓ Tab 350 mcg .....	84
✓ Tab 5 mg .....	30
<b>OXYTOCIN</b>	
✓ Inj 5 iu per ml, 1 ml ampoule .....	5
✓ Inj 10 iu per ml, 1 ml ampoule .....	5
<b>OXYTOCIN WITH ERGOMETRINE MALEATE</b>	
✓ Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml .....	5
<b>PARACETAMOL</b>	
✓ Tab 500 mg .....	30
✓ Oral liq 120 mg per 5 ml .....	200 ml
✓ Oral liq 250 mg per 5 ml .....	100 ml
<b>PEAK FLOW METER</b>	
✓ Low range .....	10
✓ Normal range .....	10
<b>PETHIDINE HYDROCHLORIDE</b>	
✓ Inj 50 mg per ml, 1 ml – Only on a controlled drug form .....	5
✓ Inj 50 mg per ml, 2 ml – Only on a controlled drug form .....	5
<b>PHENOXYMETHYLPENICILLIN (PENICILLIN V)</b>	
✓ Cap 250 mg .....	30
✓ Cap 500 mg .....	20
✓ Grans for oral liq 125 mg per 5 ml .....	200 ml
✓ Grans for oral liq 250 mg per 5 ml .....	300 ml
<b>PHENYTOIN SODIUM</b>	
✓ Inj 50 mg per ml, 2 ml ampoule .....	5
✓ Inj 50 mg per ml, 5 ml ampoule .....	5

continued. .

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

(continued)

## PHYTOMENADIONE

- ✓ Inj 2 mg per 0.2 ml ..... 5
- ✓ Inj 10 mg per ml, 1 ml ..... 5

## PIPOTHIAZINE PALMITATE

- ✓ Inj 50 mg per ml, 1 ml – Subsidy by endorsement – See note on page 143 ..... 5
- ✓ Inj 50 mg per ml, 2 ml – Subsidy by endorsement – See note on page 143 ..... 5

## PREDNISOLONE

- ✓ Oral liq 5 mg per ml – See note on page 80 ..... 30 ml

## PREDNISONE

- ✓ Tab 5 mg ..... 30

## PREGNANCY TESTS - HCG URINE

- ✓ Cassette ..... 200 test

## PROCAINE PENICILLIN

- ✓ Inj 1.5 g in 3.4 ml syringe ..... 5

## PROCHLORPERAZINE

- ✓ Tab 5 mg ..... 30
- ✓ Inj 12.5 mg per ml, 1 ml ..... 5

## PROMETHAZINE HYDROCHLORIDE

- ✓ Inj 25 mg per ml, 2 ml ampoule ..... 5

## SALBUTAMOL

- ✓ Inj 500 mcg per ml, 1 ml ..... 5
- ✓ Aerosol inhaler, 100 mcg per dose CFC free ..... 1000 dose
- ✓ Nebuliser soln, 1 mg per ml, 2.5 ml ampoule ..... 30
- ✓ Nebuliser soln, 2 mg per ml, 2.5 ml ampoule ..... 30

## SALBUTAMOL WITH IPRATROPIUM BROMIDE

- ✓ Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule ..... 20

## SILVER SULPHADIAZINE

- ✓ Crm 1% ..... 250 g

## SODIUM BICARBONATE

- ✓ Inj 8.4%, 50 ml ..... 5
- ✓ Inj 8.4%, 100 ml ..... 5

## SODIUM CHLORIDE

- ✓ Inf 0.9% – See note on page 47 ..... 2000 ml
- ✓ Inj 0.9%, 5 ml – See note on page 47 ..... 5
- ✓ Inj 0.9%, 10 ml – See note on page 47 ..... 5

## SPACER DEVICE

- ✓ 230 ml (single patient) ..... 20
- ✓ 800 ml ..... 20

## SPACER DEVICE AUTOCLAVABLE

- ✓ 230 ml (autoclavable) – Subsidy by endorsement – See note on page 199 ..... 5

## TRIMETHOPRIM

- ✓ Tab 300 mg ..... 30

## VERAPAMIL HYDROCHLORIDE

- ✓ Inj 2.5 mg per ml, 2 ml ampoule ..... 5

## WATER

- ✓ Purified for inj, 5 ml – See note on page 47 ..... 5
- ✓ Purified for inj, 10 ml – See note on page 47 ..... 5
- ✓ Purified for inj, 20 ml – See note on page 47 ..... 5

## ZUCLOPENTHIXOL DECANOATE

- ✓ Inj 200 mg per ml, 1 ml ..... 5

## Rural Areas for Practitioner's Supply Orders

### NORTH ISLAND

#### Northland DHB

Dargaville  
Hikurangi  
Kaeo  
Kaikohe  
Kaitiaki  
Kawakawa  
Kerikeri  
Mangonui  
Maungaturoto  
Moerewa  
Ngunguru  
Paihia  
Rawene  
Ruakaka  
Russell  
Tutukaka  
Waipu  
Whangaroa

#### Waitemata DHB

Helensville  
Huapai  
Kumeu  
Snells Beach  
Waimauku  
Warkworth  
Wellsford

#### Auckland DHB

Great Barrier Island  
Oneroa  
Ostend

#### Counties Manukau DHB

Tuakau  
Waiuku

#### Waikato DHB

Coromandel  
Huntly  
Kawhia  
Matamata  
Morrinsville  
Ngatea  
Otorohanga  
Paeroa  
Pauanui Beach  
Putaruru  
Raglan

Tairua  
Taumarunui  
Te Aroha  
Te Kauwhata  
Te Kuiti  
Tokoroa  
Waihi  
Whangamata  
Whitianga

#### Bay of Plenty DHB

Edgecumbe  
Katikati  
Kawerau  
Murupara  
Opotiki  
Taneatua  
Te Kaha  
Waihi Beach  
Whakatane

#### Lakes DHB

Mangakino  
Turangi

#### Tairāwhiti DHB

Ruatoria  
Te Araroa  
Te Karaka  
Te Puia Springs  
Tikitiki  
Tokomaru Bay  
Tolaga Bay

#### Taranaki DHB

Eltham  
Inglewood  
Manaia  
Oakura  
Okato  
Opunake  
Patea  
Stratford  
Waverley

#### Hawkes Bay DHB

Chatham Islands  
Waipawa  
Waipukurau  
Wairoa

#### Whanganui DHB

Bulls

Marton  
Ohakune  
Raetihi  
Taihape  
Waiouru

#### MidCentral DHB

Dannevirke  
Foxton  
Levin  
Otaki  
Pahiatua  
Shannon  
Woodville

#### Wairarapa DHB

Carteron  
Featherston  
Greytown  
Martinborough

### SOUTH ISLAND

#### Nelson/Marlborough DHB

Havelock  
Mapua  
Motueka  
Murchison  
Picton  
Takaka  
Wakefield

#### West Coast DHB

Dobson  
Greymouth  
Hokitika  
Karamea  
Reefton  
South Westland  
Westport  
Whataroa

#### Canterbury DHB

Akaroa  
Amberley  
Amuri  
Cheviot  
Darfield  
Diamond Harbour  
Hanmer Springs  
Kaikoura

Leeston  
Lincoln  
Methven  
Oxford  
Rakaia  
Rolleston  
Rotherham  
Templeton  
Waikari

#### South Canterbury DHB

Fairlie  
Geraldine  
Pleasant Point  
Temuka  
Twizel  
Waimate

#### Southern DHB

Alexandra  
Balclutha  
Cromwell  
Gore  
Kurow  
Lawrence  
Lumsden  
Mataura  
Milton  
Oamaru  
Oban  
Otautau  
Outram  
Owaka  
Palmerston  
Queenstown  
Ranfurly  
Riverton  
Roxburgh  
Tapanui  
Te Anau  
Tokonui  
Tuatapere  
Wanaka  
Winton

## SECTION F:

### COMMUNITY PHARMACEUTICALS DISPENSING PERIOD EXEMPTIONS

#### SECTION F: PART I

A Community Pharmaceutical identified with a \* within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is under the Dispensing Frequency Rule.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a \* within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is under the Dispensing Frequency Rule.

#### SECTION F: PART II:

#### CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a \* within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

- a) the Community Pharmaceutical is identified with a ▲ within the other sections of the Pharmaceutical Schedule and the prescriber/pharmacist has endorsed/annotated the Prescription item(s) on the Prescription to which the exemption applies "certified exemption".

In endorsing/annotating the Prescription items for a certified exemption, the prescriber/pharmacist is certifying that:

- i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
- ii) the patient has been stabilised on the same medicine for a reasonable period of time; and
- iii) the prescriber/pharmacist has reason to believe the patient will continue on the medicine and is compliant.

- b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:

- i) have limited physical mobility;
- ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- iii) are relocating to another area;
- iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

#### SECTION F: PART III:

#### FLEXIBLE AND VARIABLE DISPENSING PERIODS FOR PHARMACY

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a \* within the other sections of the Pharmaceutical Schedule, may be dispensed in variable dispensing periods under the following conditions:

- a) for stock management where the original pack(s) result in dispensing greater than 30 days supply,
- b) to synchronise a patients medication where multiple medicines result in uneven supply periods, note if dispensing a medicine other than a Pharmaceutical identified with a \* please refer to Section F; Part II

Note – the total quantity and dispensing period can not exceed the total quantity and period prescribed on the prescription.



The following Community Pharmaceuticals are identified with a ▲ within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

**ALIMENTARY TRACT AND METABOLISM**

INSULIN ASPART

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

INSULIN GLARGINE

INSULIN GLULISINE

INSULIN ISOPHANE

INSULIN ISOPHANE WITH INSULIN NEUTRAL

INSULIN LISPRO

INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE

INSULIN NEUTRAL

**CARDIOVASCULAR SYSTEM**

AMIODARONE HYDROCHLORIDE

Tab 100 mg	Cordarone-X
Tab 200 mg	Cordarone-X

DISOPYRAMIDE PHOSPHATE

FLECAINIDE ACETATE

Tab 50 mg	Tambocor
Tab 100 mg	Tambocor
Cap long-acting 100 mg	Tambocor CR
Cap long-acting 200 mg	Tambocor CR

MEXILETINE HYDROCHLORIDE

MINOXIDIL

NICORANDIL

PROPAFENONE HYDROCHLORIDE

**HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES**

DESMOPRESSIN ACETATE

Nasal drops 100 mcg Minirin  
per mlNasal spray 10 mcg per Dosemopressin-PH&T  
dose**MUSCULOSKELETAL SYSTEM**

PYRIDOSTIGMINE BROMIDE

**NERVOUS SYSTEM**

AMANTADINE HYDROCHLORIDE

APOMORPHINE HYDROCHLORIDE

ENTACAPONE

GABAPENTIN

GABAPENTIN (NEURONTIN)

LACOSAMIDE

LAMOTRIGINE

LISURIDE HYDROGEN MALEATE

PRAMIPEXOLE HYDROCHLORIDE

ROPINIROLE HYDROCHLORIDE

TOLCAPONE

TOPIRAMATE

VIGABATRIN

## SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

### Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

### Reimbursement

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

### Safety Caps (NZS 5825:1991)

20 mm.....	<i>Clic-Loc</i> , United Closures & Plastics PLC, England <i>Kerr</i> , Cormack Packaging, Sydney, under licence to Kerr USA
24 mm.....	<i>Clic-Loc</i> , United Closures & Plastics PLC, England <i>Clic-Loc</i> , ACI Closures under license to Owens-Illinois <i>Kerr</i> , Cormack Packaging, Sydney, under licence to Kerr USA
28 mm.....	<i>Clic-Loc</i> , United Closures & Plastics PLC, England <i>Clic-Loc</i> , ACI Closures under license to Owens-Illinois <i>Kerr</i> , Cormack Packaging, Sydney, under licence to Kerr USA <i>PDL Squeezlok</i> <i>PDL FG</i>

**ALIMENTARY TRACT AND METABOLISM****FERROUS SULPHATE**

Oral liq 30 mg (6 mg elemental) per 1 ml      Ferodan

**CARDIOVASCULAR SYSTEM****AMILORIDE HYDROCHLORIDE**

Oral liq 1 mg per ml      Biomed

**CAPTOPRIL**

Oral liq 5 mg per ml      Capoten

**CHLOROTHIAZIDE**

Oral liq 50 mg per ml      Biomed

**DIGOXIN**

Oral liq 50 mcg per ml      Lanoxin

**FUROSEMIDE [FRUSEMIDE]**

Oral liq 10 mg per ml      Lasix

**SPIRONOLACTONE**

Oral liq 5 mg per ml      Biomed

**HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES****LEVOTHYROXINE**

Tab 25 mcg      Synthroid  
Tab 50 mcg      Eltroxin  
Synthroid  
Tab 100 mcg      Eltroxin  
Synthroid

*(Extemporaneously compounded oral liquid preparations)*

**LEVOTHYROXINE (MERCURY PHARMA)**

Tab 50 mcg      Mercury Pharma  
Tab 100 mcg      Mercury Pharma

*(Extemporaneously compounded oral liquid preparations)*

**INFECTIONS - AGENTS FOR SYSTEMIC USE****QUININE SULPHATE**

Tab 300 mg      Q 300

*(Extemporaneously compounded oral liquid preparations)*

**NERVOUS SYSTEM****ALPRAZOLAM**

Tab 250 mcg      Xanax  
Tab 500 mcg      Xanax  
Tab 1 mg      Xanax

*(Extemporaneously compounded oral liquid preparations)*

**CARBAMAZEPINE**

Oral liq 20 mg per ml      Tegretol

**CLOBAZAM**

Tab 10 mg

Frisium

*(Extemporaneously compounded oral liquid preparations)*

**CLONAZEPAM**

Oral drops 2.5 mg per ml      Rivotril

**DIAZEPAM**

Tab 2 mg      Arrow-Diazepam  
Tab 5 mg      Arrow-Diazepam

*(Extemporaneously compounded oral liquid preparations)*

**ETHOSUXIMIDE**

Oral liq 250 mg per 5 ml      Zarontin

**LORAZEPAM**

Tab 1 mg      Ativan  
Tab 2.5 mg      Ativan

*(Extemporaneously compounded oral liquid preparations)*

**LORMETAZEPAM**

Tab 1 mg      Noctamid

*(Extemporaneously compounded oral liquid preparations)*

**METHADONE HYDROCHLORIDE**

Oral liq 2 mg per ml      Biodone  
Oral liq 5 mg per ml      Biodone Forte  
Oral liq 10 mg per ml      Biodone Extra Forte

**MORPHINE HYDROCHLORIDE**

Oral liq 1 mg per ml      RA-Morph  
Oral liq 2 mg per ml      RA-Morph  
Oral liq 5 mg per ml      RA-Morph  
Oral liq 10 mg per ml      RA-Morph

**NITRAZEPAM**

Tab 5 mg      Nitrados

*(Extemporaneously compounded oral liquid preparations)*

**OXAZEPAM**

Tab 10 mg      Ox-Pam  
Tab 15 mg      Ox-Pam

*(Extemporaneously compounded oral liquid preparations)*

**OXYCODONE HYDROCHLORIDE**

Oral liq 5 mg per 5 ml      OxyNorm

**PARACETAMOL**

Oral liq 120 mg per 5 ml      Paracare  
Oral liq 250 mg per 5 ml      Paracare Double Strength

**PHENYTOIN SODIUM**

Oral liq 30 mg per 5 ml      Dilantin

## SODIUM VALPROATE

Oral liq 200 mg per 5 ml    Epilim S/F Liquid  
   Epilim Syrup

## TEMAZEPAM

Tab 10 mg                                    Normison

*(Extemporaneously compounded oral liquid preparations)*

## TRIAZOLAM

Tab 125 mcg                                Hypam  
Tab 250 mcg                                Hypam

*(Extemporaneously compounded oral liquid preparations)*

**RESPIRATORY SYSTEM AND ALLERGIES**

## CETIRIZINE HYDROCHLORIDE

Oral liq 1 mg per ml                    Histaclear

## CHLORPHENIRAMINE MALEATE

Oral liq 2 mg per 5 ml                Histafen

## DEXTROCHLORPHENIRAMINE MALEATE

Oral liq 2 mg per 5 ml                Polaramine

## PROMETHAZINE HYDROCHLORIDE

Oral liq 1 mg per 1 ml                Allersoothe

## SALBUTAMOL

Oral liq 400 mcg per ml                Ventolin

## THEOPHYLLINE

Oral liq 80 mg per 15 ml                Nuelin

## TRIMEPAZINE TARTRATE

Oral liq 30 mg per 5 ml                Vallergran Forte

**EXTEMPORANEOUSLY COMPOUNDED  
PREPARATIONS AND GALENICALS**

## CODEINE PHOSPHATE

Powder                                        Douglas

*(Extemporaneously compounded oral liquid preparations)*

## METHADONE HYDROCHLORIDE

Powder                                        AFT

*(Extemporaneously compounded oral liquid preparations)*

## PHENOBARBITONE SODIUM

Powder                                        MidWest

*(Extemporaneously compounded oral liquid preparations)*

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## Vaccinations

### ADULT DIPHTHERIA AND TETANUS VACCINE – [Xpharm]

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml .....	0.00	1	✓ <b>ADT Booster</b>
		5	✓ <b>ADT Booster</b>

Any of the following:

- 1) For vaccination of patients aged 45 and 65 years old; or
- 2) For vaccination of previously unimmunised or partially immunised patients; or
- 3) For revaccination following immunosuppression; or
- 4) For boosting of patients with tetanus-prone wounds; or
- 5) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

### BACILLUS CALMETTE-GUERIN VACCINE – [Xpharm]

For infants at increased risk of tuberculosis. Increased risk is defined as:

- 1) living in a house or family with a person with current or past history of TB; or
- 2) having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or
- 3) during their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000

Note a list of countries with high rates of TB are available at [www.health.govt.nz/tuberculosis](http://www.health.govt.nz/tuberculosis) (search for downloads) or [www.bcgatlas.org/](http://www.bcgatlas.org/)

Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent .....	0.00	1	✓ <b>BCG Vaccine</b>
		10	✓ <b>BCG Vaccine</b>

### DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – [Xpharm]

Funded for any of the following criteria:

- 1) A single vaccine for pregnant woman between gestational weeks 28 and 38; or
- 2) A course of up to four vaccines is funded for children from age 7 up to the age of 18 years inclusive to complete full primary immunisation; or
- 3) An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens.

Notes: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg per- tussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe .....	0.00	1	✓ <b>Boostrix</b>
		10	✓ <b>Boostrix</b>

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
<b>DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – [Xpharm]</b>			
Funded for any of the following:			
1) A single dose for children up to the age of 7 who have completed primary immunisation; or			
2) A course of four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or			
3) An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or			
4) Five doses will be funded for children requiring solid organ transplantation.			
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.			
Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units			
poliomyelitis virus in 0.5ml syringe .....	0.00	1	✓ <u>Infanrix IPV</u>
		10	✓ <u>Infanrix IPV</u>
<b>DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – [Xpharm]</b>			
Funded for patients meeting any of the following criteria:			
1) Up to four doses for children up to and under the age of 10 for primary immunisation; or			
2) An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or			
3) Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.			
Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.			
Inj 30IU diphtheriattoxoid with 40IU tetanustoxoid, 25mcg pertussistoxoid, 25mcg pertussisfilamentoushaemagglutinin, 8 mcg pertactin, 80 D-AgUpoliiovirus, 10mcghepatitisB-surfaceantigen in 0.5ml syringe .....	0.00	1	✓ <u>Infanrix-hexa</u>
		10	✓ <u>Infanrix-hexa</u>
<b>HAEMOPHILUS INFLUENZAE TYPE B VACCINE – [Xpharm]</b>			
One dose for patients meeting any of the following:			
1) For primary vaccination in children; or			
2) An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or			
3) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.			
Inj 10 mcg vial with diluent syringe .....	0.00	1	✓ <u>Act-HIB</u>
<b>HEPATITIS A VACCINE – [Xpharm]</b>			
Funded for patients meeting any of the following criteria:			
1) Two vaccinations for use in transplant patients; or			
2) Two vaccinations for use in children with chronic liver disease; or			
3) One dose of vaccine for close contacts of known hepatitis A cases.			
Inj 1440 ELISA units in 1 ml syringe .....	0.00	1	✓ <u>Havrix</u>
Inj 720 ELISA units in 0.5 ml syringe .....	0.00	1	✓ <u>Havrix Junior</u>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>HEPATITIS B RECOMBINANT VACCINE – [Xpharm]</b>				
Inj 5 mcg per 0.5 ml vial .....	0.00	1	✓	<b>HBvaxPRO</b>
Funded for patients meeting any of the following criteria:				
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or				
2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or				
3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or				
4) for HIV positive patients; or				
5) for hepatitis C positive patients; or				
6) for patients following non-consensual sexual intercourse; or				
7) for patients following immunosuppression; or				
8) for transplant patients; or				
9) following needle stick injury.				
Inj 10 mcg per 1 ml vial .....	0.00	1	✓	<b>HBvaxPRO</b>
Funded for patients meeting any of the following criteria:				
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or				
2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or				
3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or				
4) for HIV positive patients; or				
5) for hepatitis C positive patients; or				
6) for patients following non-consensual sexual intercourse; or				
7) for patients following immunosuppression; or				
8) for transplant patients; or				
9) following needle stick injury.				
Inj 40 mcg per 1 ml vial .....	0.00	1	✓	<b>HBvaxPRO</b>
Funded for any of the following criteria:				
1) for dialysis patients; or				
2) for liver or kidney transplant patient.				
<b>HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] – [Xpharm]</b>				
Maximum of three doses for patient meeting any of the following criteria:				
1) Females aged under 20 years old; or				
2) Patients aged under 26 years old with confirmed HIV infection; or				
3) For use in transplant (including stem cell) patients; or				
4) An additional dose for patients under 26 years of age post chemotherapy.				
Inj 120 mcg in 0.5 ml syringe .....	0.00	1 10	✓ ✓	<b>Gardasil</b> <b>Gardasil</b>

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
<b>INFLUENZA VACCINE – [Xpharm]</b>			
A) is available each year for patients who meet the following criteria, as set by PHARMAC:			
a) all people 65 years of age and over; or			
b) people under 65 years of age who:			
i) have any of the following cardiovascular diseases:			
a) ischaemic heart disease, or			
b) congestive heart failure, or			
c) rheumatic heart disease, or			
d) congenital heart disease, or			
e) cerebro-vascular disease; or			
ii) have either of the following chronic respiratory diseases:			
a) asthma, if on a regular preventative therapy, or			
b) other chronic respiratory disease with impaired lung function; or			
iii) have diabetes; or			
iv) have chronic renal disease; or			
v) have any cancer, excluding basal and squamous skin cancers if not invasive; or			
vi) have any of the following other conditions:			
a) autoimmune disease, or			
b) immune suppression or immune deficiency, or			
c) HIV, or			
d) transplant recipients, or			
e) neuromuscular and CNS diseases/disorders, or			
f) haemoglobinopathies, or			
g) are children on long term aspirin, or			
h) have a cochlear implant, or			
i) errors of metabolism at risk of major metabolic decompensation, or			
j) pre and post splenectomy, or			
k) down syndrome, or			
vii) are pregnant; or			
c) children aged four years and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness;			
Unless meeting the criteria set out above, the following conditions are excluded from funding:			
a) asthma not requiring regular preventative therapy,			
b) hypertension and/or dyslipidaemia without evidence of end-organ disease.			
B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.			
C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor, or			
D) Stock of the seasonal influenza vaccine is typically available from February until late July with suppliers being required to ensure supply until at least 30 June. Exact start and end dates for each season will be notified each year.			
Inj 45 mcg in 0.5 ml syringe .....	90.00	10	✓ Fluorix ✓ Influvac



Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## MEASLES, MUMPS AND RUBELLA VACCINE – [Xpharm]

A maximum of two doses for any patient meeting the following criteria:

- 1) For primary vaccination in children; or
- 2) For revaccination following immunosuppression; or
- 3) For any individual susceptible to measles, mumps or rubella; or
- 4) A maximum of three doses for children who have had their first dose prior to 12 months.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000

TCID50 rubella vial with diluent 0.5 ml vial	0.00	1	✓ <b>M-M-R II</b>
		10	✓ <b>M-M-R II</b>

## MENINGOCOCCAL (GROUPS A, C, Y AND W-135) CONJUGATE VACCINE – [Xpharm]

Any of the following:

- 1) Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
- 2) One dose for close contacts of meningococcal cases; or
- 3) A maximum of two doses for bone marrow transplant patients; or
- 4) A maximum of two doses for patients following immunosuppression\*.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

\*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 4 mcg of each meningococcal polysaccharide conjugated  
to a total of approximately 48 mcg of diphtheria toxoid  
carrier per 0.5 ml vial

..... 0.00	1	✓ <b>Menactra</b>
------------	---	-------------------

## MENINGOCOCCAL C CONJUGATED VACCINE – [Xpharm]

Any of the following:

- 1) Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
- 2) One dose for close contacts of meningococcal cases; or
- 3) A maximum of two doses for bone marrow transplant patients; or
- 4) A maximum of two doses for patients following immunosuppression\*.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

\*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 10 mcg in 0.5 ml syringe	0.00	1	✓ <b>Neisvac-C</b>
		10	✓ <b>Neisvac-C</b>

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
<b>PNEUMOCOCCAL (PCV13) VACCINE – [Xpharm]</b>			
Any of the following:			
1) A primary course of four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or			
2) Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV10; or			
3) One dose is funded for high risk children (over the age of 17 months and up to the age of 18) who have previously received four doses of PCV10; or			
4) Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients with HIV, for patients post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or			
5) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.			
Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes			
Inj 30.8 mcg in 0.5 ml syringe .....	0.00	1	✓ <b>Prevenar 13</b>
		10	✓ <b>Prevenar 13</b>
<b>PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – [Xpharm]</b>			
Either of the following:			
1) Up to three doses for patients pre- or post-splenectomy or with functional asplenia; or			
2) Up to two doses are funded for high risk children to the age of 18.			
Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pneumococcal serotype) .....	0.00	1	✓ <b>Pneumovax 23</b>
Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) .....	0.00	1	✓ <b>Pneumovax 23</b>
<i>(Pneumovax 23 Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pneumococcal serotype) to be delisted 1 December 2015)</i>			
<b>POLIOMYELITIS VACCINE – [Xpharm]</b>			
Up to three doses for patients meeting either of the following:			
1) For partially vaccinated or previously unvaccinated individuals; or			
2) For revaccination following immunosuppression.			
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch-up programmes.			
Inj 80D antigen units in 0.5 ml syringe .....	0.00	1	✓ <b>IPOL</b>
<b>ROTAVIRUS LIVE REASSORTANT ORAL VACCINE – [Xpharm]</b>			
Maximum of three doses for patients meeting the following:			
1) first dose to be administered in infants aged under 15 weeks of age; and			
2) no vaccination being administered to children aged 8 months or over.			
Oral susp G1, G2, G3, G4, P1(8)11.5 million CCID50 units per 2 ml, tube .....	0.00	10	✓ <b>RotaTaq</b>

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
VARICELLA VACCINE [CHICKEN POX VACCINE] – [Xpharm]			
Maximum of two doses for any of the following:			
1) For non-immune patients:			
a) with chronic liver disease who may in future be candidates for transplantation; or			
b) with deteriorating renal function before transplantation; or			
c) prior to solid organ transplant; or			
d) prior to any elective immunosuppression*.			
2) For patients at least 2 years after bone marrow transplantation, on advice of their specialist.			
3) For patients at least 6 months after completion of chemotherapy, on advice of their specialist.			
4) For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist.			
5) For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella.			
6) For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.			
7) For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.			
* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days			
Inj 2000 PFU vial with diluent .....	0.00	1	✓ <u>Varilrix</u>

**- Symbols -**

3TC .....	110
50X 3.0 Reservoir .....	32

**- A -**

A-Scabies .....	70	vaccine .....	245	Amsidine .....	161
Abacavir sulphate .....	110	Advantan .....	66	Amyl nitrite .....	59
Abacavir sulphate with lamivudine .....	110	Advate .....	42	Anaesthetics .....	125
Abilify .....	139	Afinitor .....	191	Anagrelide hydrochloride .....	161
Abiraterone acetate .....	171	AFT-Pyrazinamide .....	102	Analgesics .....	126
ABM Hydroxocobalamin .....	37	Agents Affecting the Renin-Angiotensin System .....	49	Anastrozole .....	173
Acarbose .....	25	Agents for Parkinsonism and Related Disorders .....	124	Andriol Testocaps .....	81
Accarb .....	25	Agents Used in the Treatment of Poisonings .....	204	Androderm .....	81
Accu-Chek Ketur-Test .....	25	Agrylin .....	161	Animas Battery Cap .....	28
Accu-Chek Performa .....	26	Alanase .....	199	Animas Cartridge .....	32
Accuretic 10 .....	50	Albay .....	193	Animas Vibe .....	28
Accuretic 20 .....	50	Albendazole .....	91	Antabuse .....	155
Acetadote .....	204	Albey .....	193	Antacids and Antiflatulants .....	20
Acetazolamide .....	201	Albustix .....	78	Anten .....	130
Acetic acid with 1, 2- propanediol diacetate and benzethonium .....	200	Alendronate sodium .....	118	Anthelmintics .....	91
Acetic acid with hydroxyquinoline and ricinoleic acid .....	76	Alendronate sodium with cholecalciferol .....	118	Antiacne Preparations .....	62
Acetylcysteine .....	204	Alfacalcidol .....	37	Antiallergy Preparations .....	193
Aci-Jel .....	76	Alginic acid .....	20	Antianaemics .....	40
Aciclovir .....	104	Alitraq .....	222	Antiandrogen Oral Contraceptives .....	76
Infection .....	104	Alkeran .....	157	Antiarrhythmics .....	51
Sensory .....	200	Allersoothe .....	194	Antibacterials .....	91
Acidex .....	20	Allopurinol .....	121	Antibacterials Topical .....	63
Acipimox .....	56	Alpha Adrenoceptor Blockers .....	49	Anticholinergic Agents .....	196
Acitretin .....	70	Alpha-Keri Lotion .....	67	Anticholinesterases .....	115
Aclasta .....	119	Alphamox .....	93	Antidepressants .....	130
Aclin .....	115	Alprazolam .....	143	Antidiarrhoeals .....	20
Act-HIB .....	246	Alu-Tab .....	20	Antiepilepsy Drugs .....	132
Actavis .....	141	Aluminium hydroxide .....	20	Antifibrinolytics, Haemostatics and Local Sclerosants .....	41
Actinomycin D .....	162	Amantadine hydrochloride .....	124	Antifungals .....	98
Actrapid .....	24	Ambrisentan .....	60	Antifungals Topical .....	63
Actrapid Penfill .....	24	Amiloride hydrochloride .....	55	Antihistamines .....	193
Acupan .....	126	Amiloride hydrochloride with furosemide .....	56	Antihypotensives .....	52
Adalat 10 .....	54	Amiloride hydrochloride with hydrochlorothiazide .....	56	Antimalarials .....	100
Adalimumab .....	180	Aminophylline .....	198	Antimigraine Preparations .....	137
Adapalene .....	62	Amiodarone hydrochloride .....	51	Antinaus .....	138
Adefin XL .....	54	Amisulpride .....	139	Antinausea and Vertigo Agents .....	137
Adefovir dipivoxil .....	102	Amitriptyline .....	130	Antiparasitics .....	100
Adenuric .....	122	Amlodipine .....	54	Antipruritic Preparations .....	64
ADR Cartridge 1.8 .....	32	Amorolfine .....	63	Antipsychotics .....	139
ADR Cartridge 3.0 .....	32	Amoxicillin .....	93	Antiretrovirals .....	108
Adrenaline .....	59	Amoxicillin Actavis .....	93	Antiretrovirals - Additional Therapies .....	111
Adriamycin .....	162	Amoxicillin with clavulanic acid .....	93	Antirheumatoid Agents .....	116
ADT Booster .....	245	Amphotericin B .....	36	Antispasmodics and Other Agents Altering Gut Motility .....	22
Adult diphtheria and tetanus		Amsacrine .....	161	Antithrombotic Agents .....	43
		AmsaLyo .....	161	Antithymocyte globulin (equine) .....	180



[Bendroflumazide] .....	56	Bisoprolol fumarate .....	52	- C -	
BeneFIX .....	42	BK Lotion .....	67	Cabergoline .....	89
Benhex .....	68	Bleomycin sulphate .....	161	Cafergot .....	137
Benzathine benzylpenicillin .....	93	Blood Colony-stimulating Factors .....	46	Caffeine citrate .....	199
Benzbromaron AL 100 .....	122	Blood glucose diagnostic test meter .....	26	Cal-d-Forte .....	37
Benzbromarone .....	122	Blood glucose diagnostic test strip .....	26	Calamine .....	64
Benzooin .....	211	Blood glucose test strips (visually impaired) .....	27	Calcipotriol .....	71
Benztrap .....	125	Blood ketone diagnostic test meter .....	25	Calcitonin .....	79
Benztropine mesylate .....	125	BNM		Calcitriol .....	37
Benzydamine hydrochloride .....	36	Cardiovascular .....	49	Calcitriol-AFT .....	37
Benzylpenicillin sodium (penicillin G) .....	94	Genito-Urinary .....	76	Calcium carbonate .....	20, 38
Beta Adrenoceptor Blockers .....	52	Boceprevir .....	107	Calcium Channel Blockers .....	54
Beta Cream .....	65	Bonjela .....	36	Calcium Disodium Versenate .....	205
Beta Ointment .....	65	Boostrix .....	245	Calcium folinate .....	159
Beta Scalp .....	71	Bortezomib .....	161	Calcium Folate Ebewe .....	159
Beta-Adrenoceptor Agonists .....	195	Bosentan .....	60	Calcium gluconate .....	38
Betadine .....	68	Bosvate .....	52	Calcium Homeostasis .....	79
Betadine Skin Prep .....	68	Bplex .....	37	Calcium polystyrene sulphonate .....	47
Betaferon .....	149	Breath-Alert .....	199	Calcium Resonium .....	47
Betagan .....	201	Brevinor 1/21 .....	75	Calogen .....	217
Betahistine dihydrochloride .....	137	Brevinor 1/28 .....	75	Calsource .....	38
Betamethasone dipropionate .....	65	Brevinor 21 .....	75	Camptosar .....	160
Betamethasone dipropionate with calcipotriol .....	70	Bricanyl Turbuhaler .....	196	Candesartan cilexetil .....	50
Betamethasone sodium phosphate with betamethasone acetate .....	79	Briliinta .....	43	Candestar .....	50
Betamethasone valerate .....	65, 71	Brimonidine tartrate .....	202	Canesten .....	63
Betamethasone valerate with clioquinol .....	66	Brimonidine tartrate with timolol maleate .....	202	Capecitabine .....	159
Betamethasone valerate with fusidic acid .....	66	Brinzolamide .....	201	Capecitabine Winthrop .....	159
Betaxolol .....	201	Brolene .....	200	Capoten .....	49
Betnovate .....	65	Bromocriptine mesylate .....	124	Capsaicin Musculoskeletal System .....	116
Betnovate-C .....	66	Brufen SR .....	115	Nervous .....	126
Betoptic .....	201	Buccastem .....	138	Captopril .....	49
Betoptic S .....	201	Budesonide		Carafate .....	23
Bezafibrate .....	56	Alimentary .....	20	Carbaccord .....	157
Bezalip .....	56	Respiratory .....	194, 199	Carbamazepine .....	133
Bezalip Retard .....	56	Budesonide with eformoterol .....	195	Carbimazole .....	84
Bicalaccord .....	172	Bumetanide .....	55	Carbomer .....	203
Bicalutamide .....	172	Buprenorphine with naloxone .....	154	Carboplatin .....	157
Bicillin LA .....	93	Bupropion hydrochloride .....	155	Carboplatin Ebewe .....	157
BICNU .....	157	Burinex .....	55	Carbosorb-X .....	204
Bile and Liver Therapy .....	23	Buscopan .....	22	Cardinol LA .....	53
Biltricide .....	91	Buspirone hydrochloride .....	143	Cardizem CD .....	54
Bimatoprost .....	202	Busulphan .....	157	CareSens .....	26
Biodone .....	127	Butacort Aqueous .....	199	CareSens II .....	26
Biodone Extra Forte .....	127			CareSens N .....	26
Biodone Forte .....	127			CareSens N POP .....	26
Bisacodyl .....	35			Carmustine .....	157
Bismuth trioxide .....	23			Carvedilol .....	52

Catapres-TTS-2 .....	55	Cilicaine VK .....	94	Colaspase [L-asparaginase] .....	162
Catapres-TTS-3 .....	55	Ciloxan .....	200	Colchicine .....	122
CeeNU .....	157	Cimetidine .....	22	Colestid .....	56
Cefaclor monohydrate .....	91	Cipflox .....	95	Colestipol hydrochloride .....	56
Cefalexin .....	91	Ciprofloxacin .....	95	Colgout .....	122
Cefalexin Sandoz .....	91	Infection .....	95	Colifoam .....	21
Cefazolin .....	91	Sensory .....	200	Colistin sulphomethate .....	95
Ceftriaxone .....	91	Cisplatin .....	157	Colistin-Link .....	95
Ceftriaxone-AFT .....	91	Cisplatin Ebewe .....	157	Collodion flexible .....	211
Cefuroxime axetil .....	92	Citalopram hydrobromide .....	131	Colofac .....	22
Celestone Chronodose .....	79	Cladribine .....	159	Coloxyl .....	34
Celiprolol .....	52	Clarithromycin .....		Combigan .....	202
Cellcept .....	174	Alimentary .....	22	Comfort .....	30
Celol .....	52	Infection .....	92	Comfort Short .....	30
Centrally-Acting Agents .....	55	Clexane .....	44	Compound electrolytes .....	47
Cephalexin ABM .....	91	Climara 100 .....	82	Compound	
Cerezyme .....	35	Climara 50 .....	82	hydroxybenzoate .....	211
Cetirizine hydrochloride .....	193	Clindamycin .....	95	Concerta .....	153
Cetomacrogol .....	67	Clindamycin ABM .....	95	Condoms .....	73
Cetomacrogol with glycerol .....	67	Clobazam .....	133	Condyline .....	72
Champix .....	156	Clobetasol BNM .....	65	Contact-D .....	29
Charcoal .....	204	Clobetasol propionate .....	65, 71	Contraceptives - Hormonal .....	74
Chemotherapeutic Agents .....	157	Clobetasone butyrate .....	65	Contraceptives -	
Chicken pox vaccine .....	250	Clofazimine .....	101	Non-hormonal .....	73
Chlorafast .....	200	Clomazol .....		Copaxone .....	149
Chlorambucil .....	157	Dermatological .....	63	Cordarone-X .....	51
Chloramphenicol .....	200	Genito-Urinary .....	76	Corticosteroids and Related	
Chlorhexidine gluconate		Clomiphene citrate .....	90	Agents for Systemic Use .....	79
Alimentary .....	36	Clomipramine hydrochloride .....	130	Corticosteroids Topical .....	65
Dermatological .....	66	Clonazepam .....	132-133, 144	Cosmegen .....	162
Chloroform .....	211	Clonidine .....	55	Cosopt .....	202
Chlorothiazide .....	56	Clonidine BNM .....	55	Coumadin .....	46
Chlorpheniramine maleate .....	193	Clonidine hydrochloride .....	55	Creon 10000 .....	33
Chlorpromazine		Clopidogrel .....	43	Creon 25000 .....	33
hydrochloride .....	139	Clopine .....	140	Crixivan .....	111
Chlorsig .....	200	Clopixol .....	141, 143	Crotamiton .....	64
Chlortalidone		Clotrimazole .....		Crystaderm .....	63
[Chlorthalidone] .....	56	Dermatological .....	63	Curam .....	93
Chlorthalidone .....	56	Genito-Urinary .....	76	Curam Duo .....	93
Chlorvescent .....	48	Clozapine .....	140	Cvite .....	37
Choice TT380 Short .....	73	Clozaril .....	140	Cyclizine hydrochloride .....	138
Choice TT380 Standard .....	73	Co-Renitec .....	50	Cyclizine lactate .....	138
Cholecalciferol .....	37	Co-trimoxazole .....	95	Cyclogyl .....	202
Cholestyramine .....	56	Coal tar .....	71	Cyclopentolate	
Choline salicylate with		Coal tar with allantoin, menthol,		hydrochloride .....	202
cetalkonium chloride .....	36	phenol and sulphur .....	71	Cyclophosphamide .....	157
Cholvaslin .....	57	Coal tar with salicylic acid and		Cycloserine .....	101
Ciclopirox olamine .....	63	sulphur .....	71	Cyklokapon .....	42
Ciclosporin .....	191	Coco-Scalp .....	71	Cyproterone acetate .....	81
Cilazapril .....	49	Codeine phosphate .....		Cyproterone acetate with	
Cilazapril with		Extemporaneous .....	211	ethinyloestradiol .....	76
hydrochlorothiazide .....	50	Nervous .....	127	Cytarabine .....	159
Cilicaine .....	94	Cogentin .....	125	Cytotec .....	22

Cytoxan .....	157	Dermol .....	65, 71	Dipentum .....	21
- D -		Desferrioxamine mesylate .....	205	Diphtheria, tetanus and pertussis vaccine .....	245
D-Penamine .....	116	Desmopressin acetate .....	89	Diphtheria, tetanus, pertussis and polio vaccine .....	246
d4T .....	110	Desmopressin-PH&T .....	89	Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine .....	246
Dabigatran .....	45	Detection of Substances in Urine .....	78	Diprosone .....	65
Dacarbazine .....	162	Dexamethasone		Diprosone OV .....	65
Dactinomycin [Actinomycin D] .....	162	Hormone .....	79	Dipyridamole .....	43
Daivobet .....	70	Sensory .....	201	Disinfecting and Cleansing Agents .....	66
Daivonex .....	71	Dexamethasone phosphate .....	79	Disopyramide phosphate .....	51
Daktarin .....	64	Dexamethasone with framycetin and gramicidin .....	200	Disulfiram .....	155
Dalacin C .....	95	Dexamethasone with neomycin sulphate and polymyxin B sulphate .....	201	Diuretics .....	55
Dalteparin sodium .....	44	Dexamethasone-hameln .....	79	Diurin 40 .....	55
Danazol .....	90	Dexamfetamine sulfate .....	151	Docetaxel .....	162
Dantrium .....	123	Dextrochlorpheniramine maleate .....	193	Docetaxel Sandoz .....	162
Dantrolene .....	123	Dextrose .....	47	Docusate sodium .....	34
Daonil .....	25	Dextrose with electrolytes .....	48	Docusate sodium with sennosides .....	34
Dapa-Tabs .....	56	DHC Continus .....	127	Domperidone .....	138
Dapsone .....	101	Diabetes .....	23	Donepezil hydrochloride .....	154
Daraprim .....	97	Diabetes Management .....	25	Donepezil-Rex .....	154
Darunavir .....	111	Diacomit .....	136	Dopergin .....	124
Dasatinib .....	166	Diamide Relief .....	20	Dopress .....	130
Daunorubicin .....	162	Diamox .....	201	Dornase alfa .....	198
DBL Acetylcysteine .....	204	Diaphragm .....	73	Dorzolamide hydrochloride .....	202
DBL Aminophylline .....	198	Diasip .....	218	Dorzolamide hydrochloride with timolol maleate .....	202
DBL Bleomycin Sulfate .....	161	Diason RTH .....	218	Dostinex .....	89
DBL Carboplatin .....	157	Diazepam .....	133, 144	Dothiepin hydrochloride .....	130
DBL Docetaxel .....	162	Diazoxide .....	23	Doxazosin .....	49
DBL Doxorubicin .....	162	Dicarz .....	52	Doxepin hydrochloride .....	130
DBL Doxorubicin S29 .....	162	Diclax SR .....	115	Doxine .....	94
DBL Epirubicin Hydrochloride .....	162	Diclofenac sodium		Doxorubicin .....	162
DBL Ergometrine .....	76	Musculoskeletal System .....	115	Doxorubicin Ebewe .....	162
DBL Flucloxacillin .....	94	Sensory .....	201	Doxy-50 .....	94
DBL Gemcitabine .....	160	Didanosine [DDI] .....	110	Doxycycline .....	94
DBL Leucovorin Calcium .....	159	Differin .....	62	DP Fusidic Acid Cream .....	63
DBL Morphine Sulphate .....	128	Diffiam .....	36	DP Lotion .....	67
DBL Pethidine Hydrochloride .....	129	Diflucan .....	98	DP Lotn HC .....	65
DBL Tobramycin .....	97	Diflucan S29 .....	98	DP-Anastrozole .....	173
DDI .....	110	Diflucortolone valerate .....	65	Dr Reddy's Omeprazole .....	23
De Nol .....	23	Digestives Including Enzymes .....	33	Dr Reddy's Ondansetron .....	138
De-Worm .....	91	Digoxin .....	51	Dr Reddy's Terbinafine .....	99
Decozol .....	36	Dihydrocodeine tartrate .....	127	Drugs Affecting Bone Metabolism .....	116
Deferasirox .....	204	Dilantin .....	135	Dulcolax .....	35
Deferiprone .....	204	Dilantin Infatab .....	135	Duocal Super Soluble Powder .....	216
Deoxycoformycin .....	164	Dilatrend .....	52		
Depo-Medrol .....	80	Diltiazem hydrochloride .....	54		
Depo-Medrol with Lidocaine .....	80	Dilzem .....	54		
Depo-Provera .....	75	Dimethicone .....	67		
Depo-Testosterone .....	81				
Deprim .....	95				



Duolin .....	196
Duolin HFA .....	196
Durex Confidence .....	73
Durex Extra Safe .....	73
Durex Select Flavours .....	73
Duride .....	59
Dynacirc-SRO .....	54

**- E -**

E-Mycin .....	92
Ear Preparations .....	200
Ear/Eye Preparations .....	200
Easiphen Liquid .....	231
EasyCheck .....	77
Econazole nitrate .....	64
Efavirenz .....	110
Efavirenz with emtricitabine and tenofovir disoproxil fumarate .....	110
Efexor XR .....	132
Effient .....	43
Eformoterol fumarate .....	194
Efudix .....	72
Egopsoryl TA .....	71
Elecare .....	232
Elecare LCP .....	232
Elemental 028 Extra .....	222
Eligard .....	89
Elocon .....	66
Eloxatin .....	158
Eltrombopag .....	41
Eltroxin .....	84
Emend Tri-Pack .....	137
EMLA .....	126
Emtricitabine .....	110
Emtricitabine with tenofovir disoproxil fumarate .....	110
Emtriva .....	110
Emulsifying ointment .....	67
Enalapril maleate .....	49
Enalapril maleate with hydrochlorothiazide .....	50
Enbrel .....	174
Endocrine Therapy .....	171
Endoxan .....	157
Enerlyte .....	47
Enfuvirtide .....	111
Enoxaparin sodium .....	44
Ensure .....	226
Ensure Plus .....	227
Ensure Plus HN .....	226
Ensure Plus RTH .....	226
Entacapone .....	124

Entapone .....	124
Entecavir .....	103
Entocort CIR .....	20
Epilim .....	135
Epilim Crushable .....	135
Epilim IV .....	135
Epilim S/F Liquid .....	135
Epilim Syrup .....	135
Epirubicin .....	162
Epirubicin Ebewe .....	162
Epoetin alfa [Erythropoietin alfa] .....	41
Eprex .....	41
Eptacog alfa [Recombinant factor VIIa] .....	41
ERA .....	92
Ergometrine maleate .....	76
Ergotamine tartrate with caffeine .....	137
Erlotinib .....	166
Erythrocin IV .....	92
Erythromycin ethyl succinate .....	92
Erythromycin lactobionate .....	92
Erythromycin stearate .....	92
Erythropoietin alfa .....	40
Escitalopram .....	131
Eskazole .....	91
Estradot .....	82
Estrofem .....	82
Etanercept .....	174
Ethambutol hydrochloride .....	101
Ethics Aspirin .....	126
Ethics Aspirin EC .....	43
Ethics Enalapril .....	49
Ethinylestradiol .....	83
Ethinylestradiol with desogestrel .....	74
Ethinylestradiol with levonorgestrel .....	74
Ethinylestradiol with norethisterone .....	75
Ethosuximide .....	133
Etidronate disodium .....	118
Etopophos .....	163
Etoposide .....	163
Etoposide phosphate .....	163
Etravirine .....	110
Eumovate .....	65
Everolimus .....	191
Evista .....	118
Exelon .....	154
Exemestane .....	173
Exjade .....	204

Extemporaneously Compounded Preparations and Galenicals .....	211
Eye Preparations .....	200
EZ-fit Paediatric Mask .....	199
Ezemibe .....	57
Ezetimibe .....	57
Ezetimibe with simvastatin .....	58
Ezetrol .....	57

**- F -**

Factor eight inhibitors bypassing agent .....	42
Febuxostat .....	122
Feed Thickener Karicare Aptamil .....	229
FEIBA .....	42
Felodipine .....	54
Fenpaed .....	115
Fentanyl .....	127
Fentanyl Sandoz .....	127
Ferodan .....	38
Feriprox .....	204
Ferro-F-Tabs .....	38
Ferro-tab .....	38
Ferrograd .....	38
Ferrograd F .....	38
Ferrous fumarate .....	38
Ferrous fumarate with folic acid .....	38
Ferrous sulphate .....	38
Ferrous sulphate with folic acid .....	38
Ferrum H .....	38
Fexofenadine hydrochloride .....	193
Fibro-vein .....	42
Filgrastim .....	46
Finasteride .....	77
Fingolimod .....	144
Finpro .....	77
Flagyl .....	100
Flagyl-S .....	100
Flamazine .....	63
Flecainide acetate .....	51
Fleet Phosphate Enema .....	35
Flixonase Hayfever & Allergy .....	199
Flixotide .....	194
Flixotide Accuhaler .....	194
Florinef .....	79
Fluanxol .....	142
Fluarix .....	248
Flucloxacillin .....	94
Flucloxin .....	94

Flucon .....201	Furosemide [Frusemide] .....55	Gold Knight .....73
Fluconazole .....98	Fusidic acid	Gopten .....50
Fludara .....159	Dermatological .....63	Goserelin acetate .....88
Fludara Oral .....159	Infection .....95	Granirex .....138
Fludarabine Ebewe .....159	Sensory .....200	Granisetron .....138
Fludarabine phosphate .....159	Fuzeon .....111	Gutron .....52
Fludrocortisone acetate .....79		Gynaecological
Fluids and Electrolytes .....47	<b>- G -</b>	Anti-infectives .....76
Flumetasone pivalate .....200	Gabapentin .....133	<b>- H -</b>
Fluocortolone caproate with	Gabapentin (Neurontin) .....134	Habitrol .....156
fluocortolone pivalate and	Gamma benzene	Haemophilus influenzae type B
cinchocaine .....21	hexachloride .....68	vaccine .....246
Fluorometholone .....201	Ganciclovir .....200	Haldol .....142
Fluorouracil .....159	Gardasil .....247	Haldol Concentrate .....142
Fluorouracil Ebewe .....159	Gastrosoothe .....22	Haloperidol .....140
Fluorouracil sodium .....72	Gaviscon Double Strength .....20	Haloperidol decanoate .....142
Fluoxetine hydrochloride .....131	Gaviscon Infant .....20	Hamilton Sunscreen .....72
Flupenthixol decanoate .....142	Gefitinib .....167	Havrix .....246
Fluphenazine decanoate .....142	Gemcitabine Ebewe .....160	Havrix Junior .....246
Flutamide .....172	Gemcitabine hydrochloride .....160	HBvaxPRO .....247
Flutamin .....172	Gemfibrozil .....56	healthE Dimethicone 5% .....67
Flutamin S29 .....172	Gemzar .....160	healthE Fatty Cream .....67
Fluticasone .....194	Genoptic .....200	healthE Glycerol BP .....211
Fluticasone propionate .....199	Genox .....173	healthE Urea Cream .....67
Fluticasone with salmeterol .....195	Gentamicin sulphate	Healtheries Simple Baking
FML .....201	Infection .....96	Mix .....229
Foban .....63	Sensory .....200	Hemastix .....78
Folic acid .....41	Gilenya .....144	Heparin sodium .....45
Food Thickeners .....229	Ginet .....76	Heparinised saline .....45
Foods And Supplements For	Glatiramer acetate .....149	Heparon Junior .....219
Inborn Errors Of	Glibenclamide .....25	Hepatitis A vaccine .....246
Metabolism .....230	Gliclazide .....25	Hepatitis B recombinant
Foradil .....194	Glipizide .....25	vaccine .....247
Forteo .....119	Glivec .....167	Hepsera .....102
Fortimel Regular .....219	Glizide .....25	Herceptin .....190
Fortini .....220	Glucagen Hypokit .....24	Hexamine hippurate .....114
Fortini Multi Fibre .....221	Glucagon hydrochloride .....24	Hiprex .....114
Fortisip .....226, 227	Glucerna Select .....218	Histaclear .....193
Fortisip Multi Fibre .....227	Glucerna Select RTH .....218	Histafen .....193
Fosamax .....118	Glucobay .....25	Holoxan .....157
Fosamax Plus .....118	Glucose [Dextrose] .....47	Horleys Bread Mix .....229
Fragmin .....44	Gluten Free Foods .....229	Horleys Flour .....229
Framycetin sulphate .....200	Glycerin with sodium	Hormone Replacement Therapy -
Freestyle Optium .....25, 26	saccharin .....211	Systemic .....81
Freestyle Optium Ketone .....25	Glycerin with sucrose .....211	HPV .....247
Frisium .....133	Glycerol	Humalog .....25
Frumil .....56	Alimentary .....34	Humalog Mix 25 .....24
Frusemide .....55	Extemporaneous .....211	Humalog Mix 50 .....24
Frusemide-Clarix .....55	Glyceryl trinitrate	Human papillomavirus (6, 11, 16
Fucicort .....66	Alimentary .....22	and 18) vaccine [HPV] .....247
Fucidin .....95	Cardiovascular .....59	Humatin .....96
Fucithalmic .....200	Glycopyrronium .....197	Humira .....180
Fungilin .....36	Glycopyrronium bromide .....22	HumiraPen .....180
	Glytrin .....59	

Humulin 30/70 .....	24	Immunosuppressants .....	174	Interferon beta-1-alpha .....	149
Humulin NPH .....	24	Imuran .....	174	Interferon beta-1-beta .....	149
Humulin R .....	24	Indacaterol .....	194	Intra-uterine device .....	73
Hyaluronic acid .....	203	Indapamide .....	56	Intron-A .....	112
Hybloc .....	52	Indinavir .....	111	Invega Sustenna .....	142
Hydralazine .....	59	Infanrix IPV .....	246	IPOL .....	250
Hydralazine hydrochloride .....	59	Infanrix-hexa .....	246	Ipratropium bromide .....	196, 199
Hydrea .....	163	Infant Formulae .....	231	Iressa .....	167
Hydrocortisone .....		Influenza vaccine .....	248	Irinotecan Actavis 100 .....	160
Dermatological .....	65	Influvac .....	248	Irinotecan Actavis 40 .....	160
Hormone .....	80	Inhaled Corticosteroids .....	194	Irinotecan hydrochloride .....	160
Hydrocortisone acetate .....	21	Inhaled Long-acting		Irinotecan-Rex .....	160
Hydrocortisone and paraffin		Beta-adrenoceptor		Iron polymaltose .....	38
liquid and lanolin .....	65	Agonists .....	194	Isentress .....	111
Hydrocortisone butyrate .....	66, 71	Innovacon hCG One Step		Ismo 20 .....	59
Hydrocortisone with		Pregnancy Test .....	77	Ismo 40 Retard .....	59
cinchocaine .....	22	Inset 30 .....	30	Isoniazid .....	101
Hydrocortisone with		Inset II .....	31	Isoprenaline .....	59
miconazole .....	66	Insulin aspart .....	24	Isoptin .....	54
Hydrocortisone with natamycin		Insulin aspart with insulin aspart		Isopto Carpine .....	202
and neomycin .....	66	protamine .....	24	Isosorbide mononitrate .....	59
Hydrogen peroxide .....		Insulin glargine .....	24	Isosource Standard .....	225
Alimentary .....	36	Insulin glulisine .....	25	Isosource Standard RTH .....	225
Dermatological .....	63	Insulin isophane .....	24	Isotretinoin .....	62
Hydroxocobalamin .....	37	Insulin isophane with insulin		Ispaghula (psyllium) husk .....	34
Hydroxychloroquine .....	116	neutral .....	24	Isradipine .....	54
Hydroxyurea .....	163	Insulin lispro .....	25	Isuprel .....	59
Hygroton .....	56	Insulin lispro with insulin lispro		Itch-Soothe .....	64
Hylo-Fresh .....	203	protamine .....	24	Itraconazole .....	98
Hyoscine hydrobromide .....	138	Insulin neutral .....	24	Itrazole .....	98
Hyoscine N-butylbromide .....	22	Insulin pen needles .....	27	Ivermectin .....	68
Hypam .....	150	Insulin pump .....	28		
Hyperuricaemia and		Insulin pump accessories .....	28	<b>- J -</b>	
Antigout .....	121	Insulin pump infusion set (steel		Jadelle .....	75
Hypnovel .....	150	cannula) .....	29	Jevity .....	225
Hypromellose .....	203	Insulin pump infusion set (teflon		Jevity HiCal RTH .....	226
Hypromellose with Dextran .....	203	cannula, angle insertion with		Jevity RTH .....	225
Hysite .....	202	insertion device) .....	30	<b>- K -</b>	
<b>- I -</b>		Insulin pump infusion set (teflon		Kaletra .....	111
Ibiamox .....	93	cannula, angle insertion) .....	30	Kemadrin .....	125
Ibugesic .....	115	Insulin pump infusion set (teflon		Kenacomb .....	200
Ibuprofen .....	115	cannula, straight insertion with		Kenacort-A 10 .....	80
Idarubicin hydrochloride .....	163	insertion device) .....	31	Kenacort-A 40 .....	80
Ifosfamide .....	157	Insulin pump infusion set (teflon		Kenalog in Orabase .....	36
Ikorel .....	60	cannula, straight insertion) .....	32	Ketocal 3:1 .....	234
Iloprost .....	61	Insulin pump reservoir .....	32	KetoCal 4:1 .....	234
Imatinib mesilate .....	167	Insulin syringes, disposable with		Ketoconazole .....	
Imatinib-AFT .....	167	attached needle .....	27	Dermatological .....	71
Imiglucerase .....	35	Intal Forte CFC Free .....	198	Infection .....	99
Imipramine hydrochloride .....	130	Intal Spincaps .....	198	Ketogenic Diet .....	234
Imiquimod .....	72	Intelence .....	110	Ketone blood beta-ketone	
Immune Modulators .....	112	Interferon alfa-2a .....	112	electrodes .....	25
		Interferon alfa-2b .....	112	Ketoprofen .....	115

Ketostix .....	25	Levonorgestrel .....		Lormetazepam .....	149
Kindergen .....	220	Genito-Urinary .....	75–76	Losartan Actavis .....	51
Kinson .....	124	Hormone .....	83	Losartan potassium .....	51
Kivexa .....	110	Levothyroxine .....	84	Losartan potassium with	
Klacid .....	92	Levothyroxine (mercury		hydrochlorothiazide .....	51
Kliogest .....	83	pharma) .....	84	Lovir .....	104
Kliovance .....	83	Lidocaine .....		Loxalate .....	131
Kogenate FS .....	42	[Lignocaine] .....	125–126	Loxamine .....	131
Konakion MM .....	42	Lidocaine [Lignocaine]		Lucrin Depot PDS .....	89
Konsyl-D .....	34	hydrochloride .....	126	Ludiomil .....	130
<b>- L -</b>					
L-asparaginase .....	161	Lidocaine [Lignocaine] with		Lumigan .....	202
Labetalol .....	52	chlorhexidine .....	126	Lycinate .....	59
Lacosamide .....	134	Lidocaine [Lignocaine] with		Lyderm .....	70
Lactulose .....	34	prilocaine .....	126	<b>- M -</b>	
Laevolac .....	34	Lidocaine-Clarix .....	126	m-Eslon .....	128
Lamictal .....	135	Lifestyles Flared .....	73	M-M-R II .....	249
Lamivudine .....	103, 110	Lignocaine .....	80, 125, 126	m-Mometasone .....	66
Lamivudine Alphapharm .....	110	Hormone .....	80	Mabthera .....	188
Lamotrigine .....	135	Nervous .....	125, 126	Macrogol 3350 with potassium	
Lamprene .....	101	Link Healthcare .....	99	chloride, sodium bicarbonate	
Lanoxin .....	51	Lioresal Intrathecal .....	123	and sodium chloride .....	34
Lanoxin PG .....	51	Lipazil .....	56	Macrogol 400 and propylene	
Lansoprazole .....	23	Lipid-Modifying Agents .....	56	glycol .....	203
Lantus .....	24	Lipitor .....	57	Madopar 125 .....	124
Lantus SoloStar .....	24	Liquigen .....	217	Madopar 250 .....	124
Lanvis .....	160	Lisinopril .....	49	Madopar 62.5 .....	124
Lapatinib ditosylate .....	168	Lisuride hydrogen maleate .....	124	Madopar HBS .....	124
Lagactil .....	139	Lithicarb FC .....	140	Madopar Rapid .....	124
Lasix .....	55	Lithium carbonate .....	140	Magnesium hydroxide .....	211
Latanoprost .....	202	Livostin .....	201	Magnesium sulphate .....	39
Lax-Sachets .....	34	LMX4 .....	126	Malathion with permethrin and	
Lax-Tab .....	35	Locacorten-Viaform ED's .....	200	piperonyl butoxide .....	70
Laxatives .....	34	Local preparations for Anal and		Maprotiline hydrochloride .....	130
Laxsol .....	34	Rectal Disorders .....	21	Marevan .....	46
Leflunomide .....	116	Locasol .....	232	Marine Blue Lotion SPF 50+ .....	72
Lenalidomide .....	163	Locoid .....	66, 71	Marquis Black .....	73
Letracord .....	173	Locoid Crelo .....	66	Marquis Conforma .....	73
Letrozole .....	173	Locoid Lipocream .....	66	Marquis Protecta .....	73
Leukeran FC .....	157	Locorten-Vioform .....	200	Marquis Selecta .....	73
Leukotriene Receptor		Lodoxamide .....	201	Marquis Sensolite .....	73
Antagonists .....	197	Logem .....	135	Marquis Supalite .....	73
Leunase .....	162	Lomide .....	201	Marquis Titillata .....	73
Leuprorelin .....	89	Lomustine .....	157	MarquisTantiliza .....	73
Leustatin .....	159	Loniten .....	59	Martindale Acetylcysteine .....	204
Levetiracetam .....	135	Loperamide hydrochloride .....	20	Marvelon 28 .....	74
Levetiracetam-Rex .....	135	Lopinavir with ritonavir .....	111	Mask for spacer device .....	199
Levobunolol .....	201	Lopresor .....	53	Mast Cell Stabilisers .....	198
Levocabastine .....	201	Loprofin .....	231	Maxidex .....	201
Levodopa with benserazide .....	124	Loprofin Mix .....	231	Maxitrol .....	201
Levodopa with carbidopa .....	124	Lorafix .....	193	MCT oil (Nutricia) .....	217
Levomepromazine maleate .....	140	LoraPaed .....	193	Measles, mumps and rubella	
		Loratadine .....	193	vaccine .....	249
		Lorazepam .....	144	Mebendazole .....	91

Mebeverine hydrochloride .....	22	hydrochloride .....	138	Morphine tartrate .....	128
Medrol .....	80	Metolazone .....	55	Motetis .....	125
Medroxyprogesterone acetate		Metopirone .....	90	Mouth and Throat .....	36
Genito-Urinary .....	75	Metoprolol - AFT CR .....	53	Moxifloxacin .....	96
Hormone .....	82, 84	Metoprolol succinate .....	53	MSUD Maxamaid .....	230
Mefenamic acid .....	115	Metoprolol tartrate .....	53	MSUD Maxamum .....	230
Megestrol acetate .....	172	Metronidazole .....	100	Mucilaginous laxatives with	
Meloxicam .....	115	Metyrapone .....	90	stimulants .....	34
Melphalan .....	157	Mexiletine hydrochloride .....	51	Mucolytics .....	198
Menactra .....	249	Mexiletine Hydrochloride		Multiple Sclerosis	
Meningococcal (groups A, C, Y		USP .....	51	Treatments .....	144
and W-135) conjugate		Miacalcic .....	79	Multivitamins .....	37
vaccine .....	249	Mianserin hydrochloride .....	130	Mupirocin .....	63
Meningococcal c conjugated		Micolette .....	35	Muscle Relaxants .....	123
vaccine .....	249	Miconazole .....	36	Mvite .....	38
Menthol .....	64	Miconazole nitrate		Myambutol .....	101
Mercaptopurine .....	160	Dermatological .....	64	Mycobutin .....	102
Mercilon 28 .....	74	Genito-Urinary .....	76	MycosNail .....	63
Mesalazine .....	21	Micreme .....	76	Mycophenolate mofetil .....	174
Mesna .....	163	Micreme H .....	66	Mycostatin .....	64
Mestinon .....	115	Microgynon 30 .....	74	Mydriacyl .....	202
Metabolic Disorder Agents .....	35	Microgynon 50 ED .....	74	Mylan Atenolol .....	52
Metamide .....	138	Microlut .....	75	Mylan-Bosentan .....	60
Metformin hydrochloride .....	25	Midazolam .....	150	Mylanta P .....	20
Methadone hydrochloride		Midodrine .....	52	Myleran .....	157
Extemporaneous .....	211	Minerals .....	38	Myocrisin .....	116
Nervous .....	127	Minidiab .....	25	Myometrial and Vaginal Hormone	
Methatabs .....	127	Minirin .....	89	Preparations .....	76
Methopt .....	203	Mino-tabs .....	94		
Methotrexate .....	160	Minocycline hydrochloride .....	94	<b>- N -</b>	
Methotrexate Ebewe .....	160	Minomycin .....	94	Nadolol .....	53
Methotrexate Sandoz .....	160	Minor Skin Infections .....	68	Nalcrom .....	21
Methyl hydroxybenzoate .....	211	Minoxidil .....	59	Naloxone hydrochloride .....	204
Methylcellulose .....	212	Mirena .....	83	Naltraccord .....	155
Methylcellulose with glycerin and		Mirtazapine .....	131	Naltrexone hydrochloride .....	155
sodium saccharin .....	212	Misoprostol .....	22	Naphazoline hydrochloride .....	203
Methylcellulose with glycerin and		Mitomycin C .....	164	Naphcon Forte .....	203
sucrose .....	212	Mitozantrone .....	164	Naprosyn SR 1000 .....	115
Methylidopa .....	55	Mitozantrone Ebewe .....	164	Naprosyn SR 750 .....	115
Methylphenidate		Mixtard 30 .....	24	Naproxen .....	115
hydrochloride .....	152	Moclobemide .....	131	Nardil .....	130
Methylphenidate hydrochloride		Modafinil .....	153	Nasal Preparations .....	199
extended-release .....	153	Modavigil .....	153	Natalizumab .....	145
Methylprednisolone .....	80	Moderate .....	142	Natulan .....	164
Methylprednisolone (as sodium		Moduretic .....	56	Nausicalm .....	138
succinate) .....	80	Mogine .....	135	Navelbine .....	165
Methylprednisolone		Mometasone furoate .....	66	Nedocromil .....	198
aceponate .....	66	Monogen .....	219	Nefopam hydrochloride .....	126
Methylprednisolone acetate .....	80	Montelukast .....	197	Neisvac-C .....	249
Methylprednisolone acetate with		Moroctocog alfa [Recombinant		Neo-B12 .....	37
lidocaine [Lignocaine] .....	80	factor VIII] .....	42	Neo-Mercazole .....	84
Methylxanthines .....	198	Morphine hydrochloride .....	128	Neocate Advance .....	232
Metoclopramide		Morphine sulphate .....	128	Neocate Gold .....	232
				Neocate LCP .....	232

Neoral .....	191	NovoRapid .....	24	Onbrez Breezhaler .....	194
Neostigmine metilsulfate .....	115	NovoRapid FlexPen .....	24	Oncaspar .....	164
Nepro HP (strawberry) .....	221	NovoRapid Penfill .....	24	OncoTICE .....	180
Nepro HP (vanilla) .....	221	NovoSeven RT .....	41	Ondansetron .....	138
Nepro HP RTH .....	221	Noxafil .....	99	Ondansetron ODT-DRLA .....	138
Nerisone .....	65	Nozinan .....	140	One-Alpha .....	37
Neulactil .....	140	Nuelin .....	198	Onelink .....	59
Neulastim .....	46	Nuelin-SR .....	198	Onkotrone .....	164
Neurontin .....	134	Nupentin .....	133	Onrex .....	138
NeuroTabs .....	38	Nutilis .....	229	Ora-Blend .....	212
Nevirapine .....	110	Nutrient Modules .....	215	Ora-Blend SF .....	212
Nevirapine Alphapharm .....	110	Nutrini Energy Multi Fibre .....	220	Ora-Plus .....	212
Nicorandil .....	60	Nutrini Energy RTH .....	220	Ora-Sweet .....	211
Nicotine .....	156	Nutrini Low Energy Multi Fibre .....	222	Ora-Sweet SF .....	211
Nicotinic acid .....	56	Nutrini RTH .....	220	Orabase .....	36
Nifedipine .....	54	Nutrison Concentrated .....	228	Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed) .....	218
Nifuran .....	114	Nutrison Energy .....	225	Oratane .....	62
Nilotinib .....	168	Nutrison Energy Multi Fibre .....	226	Orgran .....	230
Nilstat		Nutrison Multi Fibre .....	225	Ornidazole .....	100
Alimentary .....	36	Nutrison Standard RTH .....	225	Orphenadrine citrate .....	123
Genito-Urinary .....	76	Nyefax Retard .....	54	Ortho All-flex .....	73
Infection .....	99	Nystatin		Ortho-tolidine .....	78
Nipent .....	164	Alimentary .....	36	Oruvail SR .....	115
Nitrados .....	150	Dermatological .....	64	Osmolite .....	225
Nitrates .....	59	Genito-Urinary .....	76	Osmolite RTH .....	225
Nitrazepam .....	150	Infection .....	99	Other Endocrine Agents .....	89
Nitroderm TTS .....	59	NZB Low Gluten Bread Mix .....	229	Other Oestrogen Preparations .....	83
Nitrofurantoin .....	114			Other Progestogen Preparations .....	83
Nitrolingual Pump Spray .....	59			Other Skin Preparations .....	72
Nizoral .....	99			Ovestin	
Noctamid .....	149			Genito-Urinary .....	76
Nodia .....	20			Hormone .....	83
Noflam 250 .....	115			Ox-Pam .....	144
Noflam 500 .....	115			Oxalipatin .....	158
Non-Steroidal Anti-Inflammatory Drugs .....	115			Oxalipatin Actavis 100 .....	158
Nonacog alfa [Recombinant factor IX] .....	42			Oxalipatin Actavis 50 .....	158
Norethisterone				Oxalipatin Ebewe .....	158
Genito-Urinary .....	75			Oxazepam .....	144
Hormone .....	84			Oxis Turbuhaler .....	194
Norflex .....	123			Oxpentifylline .....	60
Norfloxacin .....	114			Oxybutynin .....	77
Noriday 28 .....	75			Oxycodone ControlledRelease Tablets(BNM) .....	129
Norimin .....	75			Oxycodone hydrochloride .....	129
Normacol Plus .....	34			Oxycodone Orion .....	129
Normison .....	150			OxyContin .....	129
Norpress .....	130			OxyNorm .....	129
Nortriptyline hydrochloride .....	130			Oxytocin .....	76
Norvir .....	111			Oxytocin BNM .....	76
NovaSource Renal .....	221				
Novatrein .....	70				
NovoMix 30 FlexPen .....	24				

## - O -

Oxytocin with ergometrine maleate .....	76	MMT-368 .....	30	Peptisorb .....	222
Ozole .....	98	Paradigm Silhouette MMT-377 .....	30	Perhexiline maleate .....	54
<b>- P -</b>					
Pacifen .....	123	Paradigm Silhouette MMT-378 .....	30	Pericyazine .....	140
Pacific Buspirone .....	143	Paradigm Silhouette MMT-381 .....	30	Perindopril .....	49
Paclitaxel .....	164	Paradigm Silhouette MMT-382 .....	30	Permethrin .....	70
Paclitaxel Actavis .....	164	Paradigm Silhouette MMT-383 .....	30	Persantin .....	43
Paclitaxel Ebewe .....	164	Paradigm Silhouette MMT-384 .....	30	Peteha .....	101
Paediatric Seravit .....	37	Paradigm Sure-T MMT-864 .....	29	Pethidine hydrochloride .....	129
Paliperidone .....	142	Paradigm Sure-T MMT-866 .....	29	Pevaryl .....	64
Pamidronate disodium .....	118	Paradigm Sure-T MMT-874 .....	29	Pexsig .....	54
Pamisol .....	118	Paradigm Sure-T MMT-876 .....	29	Pharmacare .....	127
Panadol .....	127	Paradigm Sure-T MMT-884 .....	29	Phenelzine sulphate .....	130
Pancreatic enzyme .....	33	Paradigm Sure-T MMT-886 .....	29	Phenobarbitone .....	135
Pantoprazole .....	23	Paraffin .....	68	Phenobarbitone sodium	
Pantoprazole Actavis 20 .....	23	Paraffin liquid with soft white paraffin .....	203	Extemporaneous .....	212
Pantoprazole Actavis 40 .....	23	Paraffin liquid with wool fat .....	203	Nervous .....	150
Panzytrat .....	33	Paraldehyde .....	133	Phenoxybenzamine hydrochloride .....	49
Papaverine hydrochloride .....	60	Parasiticial Preparations .....	68	Phenoxymethylpenicillin (Penicillin V) .....	94
Para Plus .....	70	Parnate .....	130	Phenytion sodium .....	133, 135
Para-amino salicylic acid .....	101	Paromomycin .....	96	Phlexy 10 .....	231
Paracare .....	127	Paroxetine hydrochloride .....	131	Phosphate-Sandoz .....	48
Paracare Double Strength .....	127	Paser .....	101	Phosphorus .....	48
Paracetamol .....	127	Patanol .....	203	Phytomenadione .....	42
Paracetamol + Codeine (Relieve) .....	129	Paxam .....	144	Pilocarpine hydrochloride .....	202
Paracetamol with codeine .....	129	Pazopanib .....	169	Pimafucort .....	66
Paradigm 1.8 Reservoir .....	32	Peak flow meter .....	199	Pindolol .....	53
Paradigm 3.0 Reservoir .....	32	Pedialyte - Bubblegum .....	48	Pinetarsol .....	71
Paradigm 522 .....	28	Pediasure .....	220, 221	Pioglitazone .....	25
Paradigm 722 .....	28	Pediasure RTH .....	220	Piportil .....	143
Paradigm Mio MMT-921 .....	31	Pegasparase .....	164	Pipothiazine palmitate .....	143
Paradigm Mio MMT-923 .....	31	Pegasys .....	113	Pizaccord .....	25
Paradigm Mio MMT-925 .....	31	Pegasys RBV Combination Pack .....	113	Pizotifen .....	137
Paradigm Mio MMT-941 .....	31	Pegfilgrastim .....	46	PKU Anamix Infant .....	231
Paradigm Mio MMT-943 .....	31	Pegylated interferon alfa-2a .....	113	PKU Anamix Junior .....	231
Paradigm Mio MMT-945 .....	31	Penicillamine .....	116	PKU Anamix Junior LQ .....	231
Paradigm Mio MMT-965 .....	31	PenMix 30 .....	24	PKU Lophlex LQ 10 .....	231
Paradigm Mio MMT-975 .....	31	PenMix 40 .....	24	PKU Lophlex LQ 20 .....	231
Paradigm Quick-Set MMT-386 .....	32	PenMix 50 .....	24	Plaquenil .....	116
Paradigm Quick-Set MMT-387 .....	32	Pentasa .....	21	Plendil ER .....	54
Paradigm Quick-Set MMT-396 .....	32	Pentostatin [Deoxycofomycin] .....	164	pms-Bosentan .....	60
Paradigm Quick-Set MMT-397 .....	32	Pentoxifylline [Oxpentifylline] .....	60	Pneumococcal (PCV13) vaccine .....	250
Paradigm Quick-Set MMT-398 .....	32	Pepti Junior Gold Karicare Aptamil .....	233	Pneumococcal (PPV23) polysaccharide vaccine .....	250
Paradigm Quick-Set MMT-399 .....	32	Peptisoothe .....	22	Pneumovax 23 .....	250
Paradigm Silhouette .....				Podophyllotoxin .....	72
				Polaramine .....	193
				Poliomyelitis vaccine .....	250
				Poloxamer .....	34
				Poly-Gel .....	203
				Poly-Tears .....	203

## Generic Chemicals and Brands

Poly-Visc .....	203	Propylene glycol .....	212	Renilon 7.5 .....	221
Polycal .....	215	Propylthiouracil .....	85	Resonium-A .....	48
Polyvinyl alcohol .....	203	Protamine sulphate .....	45	Resource Beneprotein .....	217
Ponstan .....	115	Protaphane .....	24	Resource Diabetic .....	218
Posaconazole .....	99	Protaphane Penfill .....	24	Respigen .....	196
Postinor-1 .....	76	Protifar .....	217	Respiratory Devices .....	199
Potassium chloride .....	47–48	Protonamide .....	101	Respiratory Stimulants .....	199
Potassium citrate .....	77	Provera .....	82, 84	Retinol palmitate .....	203
Potassium iodate .....	38	PSO .....	235–238	ReTrieve .....	62
Povidone iodine .....	68	Psoriasis and Eczema Preparations .....	70	Retrovir .....	11
Pradaxa .....	45	PTU .....	85	Reutenox .....	115
Pramipexole hydrochloride .....	124	Pulmicort Turbuhaler .....	194	Revimid .....	163
Prasugrel .....	43	Pulmocare .....	218	Revolade .....	41
Pravastatin .....	57	Pulmozyme .....	198	Rexacrom .....	201
Praziquantel .....	91	Puri-nethol .....	160	Reyataz .....	111
Prazosin .....	49	Pyrazinamide .....	102	Ridaura s29 .....	116
Pred Forte .....	201	Pyridostigmine bromide .....	115	Rifabutin .....	102
Pred Mild .....	201	Pyridoxine hydrochloride .....	37	Rifadin .....	102
Prednisolone .....	80	Pyrimethamine .....	97	Rifampicin .....	102
Prednisolone acetate .....	201	Pytazen SR .....	43	Rifaximin .....	23
Prednisone .....	80	- Q -		Rifinah .....	101
Pregnancy Tests - hCG Urine .....	77	Q 300 .....	100	Rilutek .....	125
Premarin .....	82	Questran-Lite .....	56	Riluzole .....	125
Premia 2.5 Continuous .....	83	Quetapel .....	140	Riodine .....	68
Premia 5 Continuous .....	83	Quetiapine .....	140	Risedronate Sandoz .....	119
Prevenir 13 .....	250	Quick-Set MMT-390 .....	32	Risedronate sodium .....	119
Prezista .....	111	Quick-Set MMT-391 .....	32	Risperdal Consta .....	143
Priadel .....	140	Quick-Set MMT-392 .....	32	Risperdal Quicklet .....	141
Primacin .....	100	Quick-Set MMT-393 .....	32	Risperidone .....	141, 143
Primaquine phosphate .....	100	Quinapril .....	49	Risperon .....	141
Primidone .....	135	Quinapril with hydrochlorothiazide .....	50	Ritalin .....	152
Primolut N .....	84	Quinine sulphate .....	100	Ritalin LA .....	153
Probenecid .....	123	Qvar .....	194	Ritalin SR .....	152
Probenecid-AFT .....	123	- R -		Ritonavir .....	111
Procaine penicillin .....	94	RA-Morph .....	128	Rituximab .....	188
Procarbazine hydrochloride .....	164	Raloxifene hydrochloride .....	118	Rivaroxaban .....	45
Prochlorperazine .....	138	Raltegravir potassium .....	111	Rivastigmine .....	154
Proctosedyl .....	22	Ramipex .....	124	Rivotril .....	132, 133
Procur .....	81	Ranbaxy-Cefaclor .....	91	Rizamel t .....	137
Procyclidine hydrochloride .....	125	Ranitidine .....	22	RizatRIPTAN .....	137
Procytox .....	157	Ranitidine Relief .....	22	Roferon-A .....	112
Prodopa .....	55	Ranmoxy .....	93	Ropinirole hydrochloride .....	124
Progesterone .....	84	Rapamune .....	191	RotaTeq .....	250
Proglycem .....	23	Reandron 1000 .....	81	Rotavirus live reassortant oral vaccine .....	250
Proglycem .....	23	Recombinant factor IX .....	42	Roxane .....	53
Prodynova .....	82	Recombinant factor VIIa .....	41	Alimentary Cardiovascular .....	20
Prokinex .....	138	Recombinant factor VIII .....	42	Roxithromycin .....	93
Promethazine hydrochloride .....	194	Rectogesic .....	22	Rubifen .....	152
Promethazine theoclate .....	138	Redipred .....	80	Rubifen SR .....	152
Promod .....	217	Refresh Night Time .....	203	Rythmodan .....	51
Propafenone hydrochloride .....	51			Rytmonorm .....	51
Propamidine isethionate .....	200				
Propranolol .....	53				



**- S -**

S-26 Gold Premgro .....	231	Sodium aurothiomalate .....	116	Stocrin .....	110
Sabril .....	136	Sodium bicarbonate .....		Stomahesive .....	36
Salamol .....	196	Blood .....	47-48	Strattera .....	150
Salazopyrin .....	21	Extemporaneous .....	212	Stromectol .....	68
Salazopyrin EN .....	21	Sodium calcium edetate .....	205	Suboxone .....	154
Salbutamol .....	195-196	Sodium .....		Sucralfate .....	23
Salbutamol with ipratropium		carboxymethylcellulose .....	36	Sulfadiazine sodium .....	97
bromide .....	196	Sodium chloride .....		Sulindac .....	115
Salicylic acid .....	71	Blood .....	47	Sulphasalazine .....	21
Salmeterol .....	194	Respiratory .....	198	Sulphur .....	71
Sandomigran .....	137	Sodium citrate with sodium lauryl		Sumatriptan .....	137
Sandostatin LAR .....	172	sulphoacetate .....	35	Sunitinib .....	170
Scalp Preparations .....	71	Sodium citro-tartrate .....	78	Sunscreens .....	72
Scopoderm TTS .....	138	Sodium cromoglycate .....		Sunscreens, proprietary .....	72
Sebizole .....	71	Alimentary .....	21	Sure-T MMT-863 .....	29
Sedatives and Hypnotics .....	149	Respiratory .....	198	Sure-T MMT-865 .....	29
Seebri Breezhaler .....	197	Sensory .....	201	Sure-T MMT-873 .....	29
Selegiline hydrochloride .....	124	Sodium fluoride .....	38	Sure-T MMT-875 .....	29
Senna .....	35	Sodium hyaluronate [Hyaluronic		Sure-T MMT-883 .....	29
Senokot .....	35	acid] .....	203	Sure-T MMT-885 .....	29
SensoCard .....	27	Sodium nitroprusside .....	25	Sustagen Diabetic .....	218
Serenace .....	140	Sodium polystyrene .....		Sustagen Hospital Formula .....	226
Seretide .....	195	sulphonate .....	48	Sustanon Ampoules .....	81
Seretide Accuhaler .....	195	Sodium tetradecyl sulphate .....	42	Sutent .....	170
Serevent .....	194	Sodium valproate .....	135	Symbicort Turbuhaler 100/6 .....	195
Serevent Accuhaler .....	194	Sofradex .....	200	Symbicort Turbuhaler 200/6 .....	195
Serophene .....	90	Soframycin .....	200	Symbicort Turbuhaler	
Sertraline .....	131	Solian .....	139	400/12 .....	195
Sevredol .....	128	Solifenacin succinate .....	78	Symmetrel .....	124
Sex Hormones Non		Solox .....	23	Sympathomimetics .....	59
Contraceptive .....	81	Solu-Cortef .....	80	Synacthen .....	80
Shield 49 .....	73	Solu-Medrol .....	80	Synacthen Depot .....	80
Shield Blue .....	73	Somatropin (Omnitrope) .....	85	Synthroid .....	84
Shield XL .....	73	Sotacor .....	53	Syntometrine .....	76
SII-Onco-BCG .....	180	Sotalol .....	53	Syrup (pharmaceutical	
Silagra .....	61	Space Chamber .....	199	grade) .....	212
Sildenafil .....	61	Space Chamber Plus .....	199	Systane Unit Dose .....	203
Silhouette MMT-371 .....	30	Spacer device .....	199		
Silhouette MMT-373 .....	30	Spacer device autoclavable .....	199	<b>- T -</b>	
Silver sulphadiazine .....	63	Span-K .....	48	Tacrolimus .....	192
Simethicone .....	20	Spiractin .....	55	Tacrolimus Sandoz .....	192
Simvastatin .....	57	Spiriva .....	197	Tambocor .....	51
Sinemet .....	124	Spirolactone .....	55	Tambocor CR .....	51
Sinemet CR .....	124	Sporanox .....	98	Tamoxifen citrate .....	173
Singulair .....	197	Sprycel .....	166	Tamsulosin hydrochloride .....	77
Sirolimus .....	191	Staphlex .....	94	Tamsulosin-Rex .....	77
Siterone .....	81	Stavudine [d4T] .....	111	Tap water .....	212
Slow-Lopresor .....	53	Stelazine .....	141	Tar with triethanolamine lauryl	
Sodibic .....	48	Stemetil .....	138	sulphate and fluorescein .....	71
Sodium acid phosphate .....	35	Stesolid .....	133	Tarceva .....	166
Sodium alginate .....	20	Stimulants/ADHD		Tasigna .....	168
		Treatments .....	150	Tasmar .....	124
		Stiripentol .....	136	Taxotere .....	162

Tegretol .....	133	Topical Products for Joint and	
Tegretol CR .....	133	Muscular Pain .....	116
Telfast .....	193	Topiramate .....	136
Temacord .....	164	Topiramate Actavis .....	136
Temazepam .....	150	Total parenteral nutrition	
Temozolomide .....	164	(TPN) .....	47
Tenofovir disoproxil		TPN .....	47
fumarate .....	106	Tracleer .....	60
Tenoxicam .....	115	Tramadol hydrochloride .....	129
Tepadina .....	158	Tramal SR 100 .....	129
Terazosin .....	49	Tramal SR 150 .....	129
Terbinafine .....	99	Tramal SR 200 .....	129
Terbutaline sulphate .....	196	Trandate .....	52
Teriparatide .....	119	Trandolapril .....	50
Testosterone .....	81	Tranexamic acid .....	42
Testosterone cypionate .....	81	Tranylcypromine sulphate .....	130
Testosterone esters .....	81	Trastuzumab .....	190
Testosterone undecanoate .....	81	Travatan .....	202
Tetrabenazine .....	125	Travoprost .....	202
Tetrabromophenol .....	78	Treatments for Dementia .....	154
Tetracosactrin .....	80	Treatments for Substance	
Tetracyclin Wolff .....	95	Dependence .....	154
Tetracycline .....	95	Trental 400 .....	60
Teva .....	161	Tretinoin	
Thalidomide .....	165	Dermatological .....	62
Thalomid .....	165	Oncology .....	165
Theophylline .....	198	Trexate .....	160
Thiamine hydrochloride .....	37	Triamcinolone acetonide	
THIO-TEPA .....	158	Alimentary .....	36
Thioguanine .....	160	Dermatological .....	66
Thiotepa .....	158	Hormone .....	80
Thymol glycerin .....	36	Triamcinolone acetonide with	
Thyroid and Antithyroid		gramicidin, neomycin and nystatin	
Agents .....	84	Dermatological .....	66
Ticagrelor .....	43	Sensory .....	200
Tilade .....	198	Triazolam .....	150
Timolol		Trichazole .....	100
Cardiovascular .....	53	Triclosan .....	67
Sensory .....	201	Trifluoperazine	
Timoptol XE .....	201	hydrochloride .....	141
Tiotropium bromide .....	197	Trimeprazine tartrate .....	194
TMP .....	97	Trimethoprim .....	97
TOBI .....	97	Trisequens .....	83
Tobramycin		Trisul .....	95
Infection .....	97	Trophic Hormones .....	85
Sensory .....	201	Tropicamide .....	202
Tobrex .....	201	Trusopt .....	202
Tofranil .....	130	Truvada .....	110
Tofranil s29 .....	130	Two Cal HN .....	228
Tolcapone .....	124	Two Cal HN RTH .....	228
Tolterodine .....	78	Tykerb .....	168
Tolvon .....	130	Tysabri .....	145
Topamax .....	136		

## - U -

Ultraproct .....	21
Univent .....	196, 199
Ural .....	78
Urea .....	67
Urex Forte .....	55
Urinary Agents .....	77
Urinary Tract Infections .....	114
Uromitexan .....	163
Ursodeoxycholic acid .....	33
Ursosan .....	33
Utrogestan .....	84

## - V -

Vaccinations .....	245
Valaciclovir .....	104
Valcyte .....	105
Valganciclovir .....	105
Vallergan Forte .....	194
Valtrex .....	104
Vancomycin .....	97
Vannair .....	195
Varenicline tartrate .....	156
Varicella vaccine [Chicken pox	
vaccine] .....	251
Varilrix .....	251
Vasodilators .....	59
Vasopressin Agonists .....	89
Vedafil .....	61
Velcade .....	161
Venlafaxine .....	132
Ventavis .....	61
Ventolin .....	195, 196
Vepesid .....	163
Verapamil hydrochloride .....	54
Vergo 16 .....	137
Vermox .....	91
Verpamil SR .....	54
Vesanoid .....	165
Vesicare .....	78
Vfend .....	99
Viaderm KC .....	66
Victrelis .....	107
Vidaza .....	158
Videx EC .....	110
Vigabatrin .....	136
Vimpat .....	134
Vinblastine sulphate .....	165
Vincristine sulphate .....	165
Vinorelbine .....	165
Vinorelbine Ebewe .....	165
Viramune Suspension .....	110
Viread .....	106

267



